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Abstract 
Background: Models predicting return to walking after stroke might allow 
accurate prognostication, and planning of rehabilitation. This study aimed to 
construct prognostic models to predict ability to walk 10m or more 
independently at 8weeks and 6months after stroke. 
Method: All participants (N=593) were enrolled in the “Dopamine Augmented 
Rehabilitation in Stroke” trial, and were unable to walk 10m or more 
independently at baseline.  
Imaging predictor variables (from the first available CT scan) included where 
relevant: infarct size and location; vascular territory affected; haematoma 
location and volume; presence of atrophy, white matter hypodensities, old 
stroke lesions, mass effect, or hydrocephalus. Demographic variables 
included age, gender, and Oxford Community Stroke Project syndrome. 
Clinical outcomes recorded at baseline, 8weeks, and 6months included: the 
Rivermead Mobility Index (RMI); the Montreal Cognitive Assessment (MoCA), 
General Health Questionnaire-12; presence of musculoskeletal pain.  
Using forward stepwise binary logistic regression, six models were 
constructed: models 1 and 2 (walking ability after ischaemic stroke); models 
3 and 4 (walking ability after intracerebral haemorrhage); and models 5 and 6 
(walking ability in the whole DARS sample). Models 1-4 utilised imaging, 
demographic, and clinical predictors; models 5 and 6 included demographic 
and clinical predictors only. 
Results: No imaging variables predicted outcome. Baseline RMI was most 
consistently predictive across all models. Baseline MoCA was also predictive, 
but with a smaller effect size than RMI. Only 68%-73% of patients were 
correctly classified by the models. The percentage of variance they explained 
was modest (20-30%). 
Discussion: This exploratory analysis utilised existing data, excluding 
predictors that might have explained additional variance. Within these 
limitations, this study suggests that initial level of mobility offers a more useful 
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prediction of mobility at up to 6months than assessment of structural brain 
impairment on CT.  
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Résumé Français 
Contexte: les modèles prédisent que le retour à la marche après un accident 
vasculaire cérébral pourraient permettre un pronostic précis et la planification 
de la réadaptation. Cette étude visait à construire des modèles pronostiques 
pour prédire la capacité des patients à marcher 10 mètres ou plus 
indépendamment à 8 semaines et 6 mois après un accident vasculaire 
cérébral.  
Méthode: Tous les participants (N = 593) ont été inscrits dans le procès 
"Dopamine Augmented Rehabilitation in Stroke", et ont été incapables de 
marcher 10 mètres indépendamment au départ. Les variables prédictives 
d'imagerie (à partir de la première tomodensitométrie disponible) incluses 
étaient significatives, et, le cas échéant, la taille et l'emplacement de 
l'infarctus; Territoire vasculaire affecté; Emplacement et volume de 
l'hématome; Présence d'atrophie, hyperintensités de la matière blanche, 
vieilles lésions d’accident vasculaire cérébral (AVC), effet de masse ou 
hydrocéphalie. Les variables démographiques comprenaient l'âge, le sexe et 
le syndrome de Oxford Community Stroke Project. Les résultats cliniques 
enregistrés à la ligne de base, 8 semaines et 6 mois comprises: Rivermead 
Mobility Index (RMI); Évaluation cognitive de Montréal (MoCA); Santé 
générale. Questionnaire-12; Présence de douleurs musculo-squelettiques. En 
utilisant la régression logistique binaire progressive par étapes, six modèles 
ont été construits: modèles 1 et 2 (capacité de marche après accident 
vasculaire ischémique); Modèles 3 et 4 (capacité de marche après une 
hémorragie); Et les modèles 5 et 6 (capacité de marche dans l'ensemble de 
l'échantillon DARS). Les modèles 1-4 utilisaient des prédicteurs d'imagerie, 
démographiques et cliniques; Les modèles 5 et 6 incluaient les prédicteurs 
démographiques et cliniques seulement.  
Résultats: aucune variable d'imagerie n'a prédit de résultat. Le RMI de 
référence était la variable prédictive la plus constante dans tous les modèles. 
Le MoCA de base était également prédictif, mais avec une taille d'effet plus 
petite que le RMI. Seulement 68% -73% des patients ont été correctement 
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classés par les modèles. Le pourcentage de variance qu'ils ont expliqué était 
modeste (20 à 30%).  
Discussion: Cette analyse exploratoire a utilisé les données existantes, à 
l'exclusion des prédicteurs qui auraient expliqué une variance 
supplémentaire. Dans le cadre de ces limites, cette étude suggère que le 
niveau initial de mobilité offre une prédiction plus utile de la mobilité jusqu'à 6 
mois que l'évaluation de l'insuffisance cérébrale structurelle sur la 
tomodensitométrie. 
Traduit par Dr Collette Isabel Stadler, Academic Clinical Fellow, University of 
Cambridge. 
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Chapter 1. Introduction 
Part 1.1 Stroke in context 
1.1.1. The epidemiology of stroke 
Every two seconds, someone in the world sustains a stroke for the first time 
(The Stroke Association, 2017c). Around 85% of strokes result from an 
occlusion of an artery, with the remaining 15% resulting from a bleed in to the 
brain parenchyma (Feigin et al., 2014). 
Although the overall incidence of stroke in the UK has reduced by 19% 
between 1990 and 2010, this still equates to around 100,000 new cases a 
year or roughly one person every 5 minutes (The Stroke Association, 2017c). 
Women tend to be slightly older than men at the time of first stroke, with a 
mean age of 80 (versus 74 for men) in England, Wales, and Northern Ireland, 
and 76 (versus 71 for men) in Scotland (The Stroke Association, 2017c). 
However, around 25% of strokes happen in adults of working age. Although 
the peak incidence of stroke remains in the over-70s age group, in England 
the proportion of strokes sustained by those aged 40-69 has risen from 33.7% 
in 2007 to 38.2% in 2016 (Public Health England, 2018). This is significant, as 
those who survive a stroke at a younger age might be expected to spend a 
greater number of years of their lives living with disability and in many cases 
requiring carer support. 
The number of deaths attributable to stroke in the UK have almost halved 
between 1990 and 2010; however, it remains the UK’s fourth largest cause of 
death accounting for 7% of all deaths overall (The Stroke Association, 2017c). 
There are a greater number of stroke-related deaths in women (8% of female 
deaths) than in men (6% of all male deaths); presumably due in part to the 
longer life expectancy of women, and the fact that they tend to be older (and 
thus more frail) at the time of stroke (The Stroke Association, 2017c). The 
greatest mortality from stroke is within the first 30 days, with around one 
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person in eight who has a stroke dying within this time (The Stroke 
Association, 2017c).  
Those who survive a stroke are often left with profound impairments. There 
are 1.2million stroke survivors in the UK, of whom: 75% have arm and/ or leg 
weakness; 50% have problems with bladder control; 45% have swallowing 
problems; 30% have aphasia; and 20% have long-term visual problems (The 
Stroke Association, 2017c). The Auckland Stroke Outcomes Study found that 
after five years, 15% of stroke survivors were living in institutional care (Feigin 
et al., 2010).  
1.1.1.1. The wider impact of stroke 
In 2010, the direct cost of stroke care to the UK’s National Health Service 
(NHS) was estimated at around £3billion annually (Department of Health, 
2010). A more recent study by The Stroke Association (2017a) estimated that 
stroke care cost the NHS £3.5billion in 2015, and forecast that this figure could 
rise to £10.2billion by 2035. The annual cost of stroke care to UK society as a 
whole is £25.6billion (The Stroke Association, 2017b). This equates to an 
average societal cost of £45,409 per patient in the first year, and £24,778 per 
patient per year thereafter (The Stroke Association, 2017b). Around 
£15.8billion of this £25.5billion annual cost is the value of “informal” or unpaid 
care provided to stroke survivors by family members and friends (The Stroke 
Association, 2017b). The cost of lost economic productivity is more modest by 
comparison; around £1.6billion per year (The Stroke Association, 2017b).   
The emotional cost to stroke survivors and their families is, of course, 
substantial. A recent survey of stroke survivors by the Stroke Association 
found that 67% had experienced anxiety and 59% had felt depressed: but two-
thirds did not feel that their emotional needs were adequately addressed (The 
Stroke Association, 2013). A similar proportion of partners reported 
relationship strain, and one-in-ten had either ended their relationship or had 
considered doing so (The Stroke Association, 2013). Rates of anxiety and 
depression amongst carers were comparable to those seen in stroke survivors 
themselves, at 79% and 56% respectively. 
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1.1.1.2. The global impact of stroke 
On a global scale, stroke accounts for 6.7million deaths per year: almost one-
third of the total number of deaths worldwide that are attributable to 
cardiovascular disease (The World Health Organisation, 2014c). Another way 
of conceptualising the impact of stroke is to measure the number of years of 
healthy life lost to this condition each year (either by death, or by survival with 
disability): a concept termed “Disability-Adjusted Life Years” (DALYs;  The 
World Health Organisation (2014b)). Viewed in these terms, in 2012 stroke 
accounted for the loss of over 141million years of healthy life worldwide (The 
World Health Organisation, 2014b). Worryingly, the incidence of stroke is 
projected to increase, due to a general aging of the world population (The 
World Health Organisation, 2014a)  and an increased prevalence of 
modifiable risk factors such as hypertension, diabetes, tobacco use, and 
obesity (Mendis, 2013). 
Internationally, the burden of stroke is not evenly borne. Mortality and disability 
rates vary ten-fold between the most- and least-affected countries (Johnston 
et al., 2009b). Regions with the highest mortality are Eastern Europe, North 
Asia, central Africa, and the South Pacific (Johnston et al., 2009b). The 
countries most profoundly affected are those with low- and middle-incomes, 
which account for 85% of all strokes each year, and which bear 87% of all the 
DALYs lost to stroke (Johnston et al., 2009b). The period between 1970 and 
2008 has seen a 42% fall in stroke incidence in high income countries, but a 
100% increase in incidence in low- and middle-income nations (Johnston et 
al., 2009b). In the absence of effective acute stroke services (as is the case 
in many developing countries), 62% of those who sustain a stroke will be dead 
or dependent at six months (Johnston et al., 2009b). 
1.1.2. Defining “stroke” 
This Thesis is set within the context of a large randomised controlled trial of a 
novel stroke rehabilitation intervention (DARS; Dopamine Augmented 
Rehabilitation in Stroke, ISRCTN99643613) (Bhakta et al., 2014). The 
purpose and methods of this trial will be described later, but at present it must 
be noted that participants were enrolled on the basis of the World Health 
4 
 
Organisation’s clinical criteria (Bhakta et al., 2014), which define “stroke” as 
“rapidly developed clinical signs of focal (or global) disturbance of cerebral 
function, lasting more than 24hours or leading to death, with no apparent 
cause other than of vascular origin” (Aho et al., 1980). Although widely 
adopted, this definition has been criticised (Sacco et al., 2013). Firstly, stroke 
rarely results in “global” cerebral dysfunction (Sacco et al., 2013). Secondly, 
the 24-hour timeframe that distinguishes “stroke” from “transient ischaemic 
attack” was arbitrarily defined (Sacco et al., 2013). As imaging technology has 
matured, it has become apparent that patients with a “transient” clinical deficit 
may have signs of established infarction on scans; conversely, chronic 
ischaemia may cause persistent clinical manifestations in the absence of 
radiographic evidence of an infarct (Sacco et al., 2013). Finally, the WHO 
definition of stroke makes no reference to the underlying pathophysiology of 
this condition. It is therefore important to distinguish between a patient’s 
clinical presentation (“stroke”), and terms that describe pathophysiological 
processes (“ischaemic stroke” or “haemorrhage”) or scan findings (“infarct” or 
“haematoma”). 
The language used in the literature to describe a stroke syndrome attributable 
to haemorrhage is sometimes confusing. The term “intracerebral 
haemorrhage” is sometimes used to cover both spontaneous events and 
parenchymal bleeding due to trauma, and may also encompass subarachnoid 
haemorrhage (Sacco et al., 2013). The alternative expression “haemorrhagic 
stroke” is  ambiguous since it may denote a primary haemorrhage or 
haemorrhagic transformation of an underlying infarct (Sacco et al., 2013). This 
Thesis will adopt the term “intracerebral haemorrhage” (ICH), defined as “a 
focal collection of blood within the brain parenchyma or ventricular system that 
is not caused by trauma” (Sacco et al., 2013). Patients with primary 
subarachnoid haemorrhage will not be considered here. It is important to note 
that the definition of ICH as stated above includes both primary ICH and 
confluent parenchymal haematomas which arise as a result of haemorrhagic 
transformation of an underlying infarct (Sacco et al., 2013). The case for 
including these lesions is that the management of a confluent secondary ICH 
is analogous to a spontaneous primary ICH (Sacco et al., 2013). Although the 
term “intracerebral” strictly refers to a process occurring within the cerebral 
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hemispheres, for simplicity the expression “ICH” will also be used here to 
encompass spontaneous haemorrhage in to the parenchyma of the 
cerebellum or brain stem. 
1.1.3. What constitutes optimal care for people with stroke? 
The care of people with stroke focuses initially upon minimising the extent of 
tissue injury, preventing secondary complications, and identifying and treating 
modifiable risk factors. Subsequently, multidisciplinary rehabilitation seeks to 
restore or compensate for lost functions, with the overall aim of maximising 
independence and autonomy. The principles of rehabilitation will be examined 
in detail below: but first, it is perhaps worth reviewing in brief what constitutes 
“optimal” acute care in stroke. In doing so, reference will be made to the most 
recent UK guidelines for stroke care (The Royal College of Physicians, 2016), 
whilst acknowledging that practice may vary between nations depending upon 
local resources and policies.   
1.1.3.1. Raising public awareness of stroke symptoms 
Optimum care perhaps begins with the patient themselves recognising the 
symptoms of an acute stroke, and presenting promptly to medical services. 
High-profile public health campaigns, such as the UK Department of Health’s 
recent “Act FAST” initiative (Public Health England Campaigns Resource 
Centre, 2009), use multi-media marketing techniques to raise public 
awareness of stroke symptoms and to emphasise the importance of seeking 
medical help promptly (Dombrowski et al., 2013). Nevertheless, a review of 
several such campaigns across a number of countries concluded that there is 
no evidence to suggest that they actually change public behaviour 
(Lecouturier et al., 2010). Although the Act FAST campaign resulted in a short-
term fall in delays in seeking and receiving help in those with suspected stroke 
(Wolters et al., 2015), a survey of general practitioners reported scepticism of 
its longer-term impact on public behaviour  (Dombrowski et al., 2013). Claims 
made by ministers at the time that the campaign saved 642 people from death 
or serious disability were based upon modelling conducted by the advertising 
agency involved in the design of the campaign (Dudley, 2011). These models 
formed part of a cost-effectiveness (“return on marketing investment”) 
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analysis, but have been criticised for assuming firstly that thrombolysis is a 
potentially life-saving intervention (the true aim of this treatment is to prevent 
disability), and secondly that an implausibly-high 56% of patients who 
presented to hospital within three hours of a stroke would be eligible to receive 
this intervention (Dudley, 2011). 
1.1.3.2. Acute investigation and management of ischaemic stroke 
An ischaemic stroke typically consists of a “core” of irreversibly-infarcted 
tissue, surrounded by a zone of less-severe ischaemia. This so-called 
“penumbra” contains tissue that is under oxidative stress, but is potentially 
salvageable with optimum treatment (Iadecola and Anrather, 2011). The basis 
of treatment of ischaemic stroke is therefore firstly to minimise the extent of 
permanent tissue injury, and secondly to maximise salvage of the “ischaemic 
penumbra”.  
The primary purpose of acute imaging in stroke is to differentiate between 
ischaemic stroke and ICH, to exclude other conditions that might mimic stroke 
(The Royal College of Physicians, 2016), but also to identify substantial 
infarcts that carry a greater risk of haemorrhagic transformation (Kaste et al., 
1995, Hacke et al., 1998). Non-contrast computerised tomography (CT) 
scanning performed early after ictus is highly sensitive for acute ICH, and is 
therefore the first-line investigation of choice (Macellari et al., 2014, Sacco et 
al., 2013). National clinical guidelines currently recommend that patients with 
suspected stroke are scanned urgently as soon as possible after presentation, 
within a maximum of one hour of presentation (The Royal College of 
Physicians, 2016).  
For those with ischaemic stroke, intravenous thrombolysis using the 
recombinant tissue plasminogen activator alteplase has been shown to 
reduce the risk of death or dependency at 3-6 months (odds ratio (OR) 0.85, 
95% confidence interval (CI) 0.78-0.93; Wardlaw et al. (2014b)). This 
treatment should be administered as quickly as possible; ideally within 3 hours 
of ictus if the time of onset of symptoms is known, although treatment may be 
considered at up to 4.5 hours on a case-by-case basis (The Royal College of 
Physicians, 2016). Although treatment with alteplase carries an increased risk 
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of both fatal and non-fatal  ICH within the first 7 to 10 days (OR 3.75, CI 3.11-
4.51; Wardlaw et al. (2014b)), mortality at six months does not appear to be 
increased (The Royal College of Physicians, 2016). Furthermore, older 
patients (aged 80 or over) benefitted equally from treatment when compared 
those under 80, particularly when the drug was administered within 3 hours of 
symptom onset (Wardlaw et al., 2014b). Alteplase must be given by staff 
experienced in stroke thrombolysis. Prior to initiation of treatment the patient’s 
blood pressure must be controlled to less than 185/110mmHg. Following 
treatment, patients must be cared for on a dedicated hyper-acute stroke unit 
(The Royal College of Physicians, 2016). 
Historically thrombolysis has been the only available means of restoring brain 
perfusion after ischaemic stroke. However, there is now growing evidence to 
suggest that endovascular clot retrieval (“thrombectomy”) is effective in 
reducing disability after stroke (Berkhemer et al., 2015, Campbell et al., 2015, 
Goyal et al., 2015, Goyal et al., 2016, Jovin et al., 2015, Muir et al., 2017, 
Saver et al., 2015). A meta-analysis of trials enrolling a total of 1287 patients 
with anterior circulation ischaemic stroke found that for every 2.6 patients 
treated, one would achieve a reduction in Modified Rankin Scale (mRS) score 
of at least one point. Treatment effect sizes were similar in several sub-group 
analyses, including patients aged >80, those randomised more than 300 
minutes after symptom onset, and those who were not eligible for intravenous 
alteplase (Goyal et al., 2016). The inclusion criteria for several of these trials 
specified a National Institute of Health Stroke Scale (NIHSS) score of 6 or 
more. The time between symptom onset and thrombectomy varied between 
trials; significantly, all trials that enrolled patients between 6 and 12 hours after 
stroke required evidence of viable penumbral tissue on CT perfusion (The 
Royal College of Physicians, 2016). For patients undergoing thrombectomy 
within 5 hours of symptom onset, demonstration of a large-vessel occlusion 
on CT angiography was regarded as sufficient (The Royal College of 
Physicians, 2016).  
The most recent UK guidelines for stroke care recommend that thrombectomy 
be considered for patients with an NIHSS of 6 or more, who present within 5 
hours of onset of anterior circulation symptoms attributable to a proximal 
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large-vessel thrombus. Patients with anterior circulation symptoms and 
evidence of viable brain tissue on perfusion imaging may be considered for 
thrombectomy up to 12 hours after symptom onset. Those with a large-vessel 
posterior circulation syndrome may be considered for thrombectomy within 24 
hours of ictus. In patients presenting within the time window for thrombolysis 
and with no contraindications to this intervention, a combination of initial 
treatment with intravenous alteplase followed by thrombectomy may be 
offered. For those with known contra-indications to thrombolysis but not to clot 
retrieval, thrombectomy may be considered as a “stand alone” treatment 
within 5 hours of symptom onset. Although thrombectomy is a promising 
development in acute stroke care, delivery of this intervention is dependent 
upon the availability of resources such as operating theatres, interventional 
radiologists skilled in this procedure, and other support staff. At present, there 
remain significant barriers to the widespread introduction of this treatment 
(The Royal College of Physicians, 2016). 
1.1.3.3. Secondary prevention of ischaemic stroke 
In ischaemic stroke it is recommended that, unless otherwise contra-
indicated, high-dose aspirin (300mg) be commenced as soon as possible 
within the first 24 hours and continued thereafter for two weeks (The Royal 
College of Physicians, 2016). In those without underlying atrial fibrillation (AF), 
long term antiplatelet therapy should then be initiated. Clopidogrel 75mg is 
recommended as first line; if this is not tolerated then combination treatment 
with aspirin 75mg and modified-release dipyridamole may be used (The Royal 
College of Physicians, 2016). There is no evidence to support the combined 
use of aspirin and clopidogrel  (The Royal College of Physicians, 2016), nor 
for the use of other antiplatelet agents such as ticlopidine, cilostazol, satigrel, 
sarpolgrelate, KBT 3022, or isbogrel (Sandercock et al., 2014). 
Patients who have sustained an embolic stroke as a result of permanent or 
paroxysmal AF have an annual risk of recurrent stroke of 12% (Anonymous, 
1993). Oral anticoagulants are significantly more effective than antiplatelets in 
preventing stroke in this group, with around a one-third risk reduction when 
compared to aspirin alone (Aguilar et al., 2007). Vitamin K antagonists such 
as warfarin have previously been the drug of choice for stroke prevention in 
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AF. More recently newer drugs which act to inhibit thrombin or factor Xa (non-
vitamin K oral anticoagulants; “NOAC”) have been found to be more effective 
than warfarin in stroke prevention (relative risk 0.87, 95% CI 0.77 to 0.99), 
with a lower risk of intracranial bleeding (relative risk 0.49, 95% CI 0.36 to 
0.66; Miller et al. (2012)). In acute stroke, there is concern that early initiation 
of anticoagulation may increase the risk of haemorrhagic transformation of the 
infarct. Current guidelines therefore recommend a two-week initial course of 
aspirin 300mg, followed  by anticoagulation with either a vitamin K antagonist 
or (in non-valvular AF) a NOAC (The Royal College of Physicians, 2016). 
Every effort should be made to identify and mitigate risk factors for bleeding 
before anticoagulation is initiated. In those judged to be at high risk of 
bleeding, aspirin alone cannot be considered a safer alternative to 
anticoagulation (The Royal College of Physicians, 2016). 
Control of cardiovascular risk factors is crucial in the secondary prevention of 
ischaemic stroke. Aggressive control of hypertension is not recommended in 
the hyperacute stage, due to concerns about further compromising cerebral 
perfusion. Early treatment of hypertension is therefore only recommended if 
there is a definite indication to do so; for example, where there is evidence of 
end-organ injury (hypertensive encephalopathy, nephropathy, or heart 
failure), or in patients who might be eligible for thrombolysis if their blood 
pressure can be reduced to <185/110mmHg. For longer-term secondary 
prevention a target systolic blood pressure (SBP) of <130mmHg is 
recommended, except in those with severe bilateral carotid stenosis in whom 
a target of 140-150mmHg is appropriate (The Royal College of Physicians, 
2016) 
Lipid lowering therapy with atorvastatin 80mg following an ischaemic stroke 
or transient ischaemic attack has been shown to reduce the risk of a 
subsequent stroke by 15%, and that of major coronary events by 35% 
(Amarenco et al., 2006). High-intensity lipid lowering treatment with 
atorvastatin 20mg-80mg should therefore be initiated as soon as possible 
after ischaemic stroke, aiming for a 40% reduction in non-high density 
lipoprotein cholesterol (The Royal College of Physicians, 2016). 
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1.1.3.4. Acute management of ICH 
Patients who sustain an ICH are at risk of deterioration, and must therefore 
be admitted to a hyper-acute stroke unit for monitoring of their conscious level  
(The Royal College of Physicians, 2016). For patients who sustain an ICH, 
treatment aimed at reducing SBP to a target of <140mmHg within the first six 
hours of stroke has been shown to reduce the risk of haematoma expansion 
within the first 72 hours (Anderson et al., 2010). For patients with deep ICH 
involving the basal ganglia, achieving a target SBP of <140mmHg does not 
appear to reduce the risk of  haematoma expansion or death, but there is a 
possible benefit in reducing the final level of disability (defined by the mRS) 
and quality of life (Anderson et al., 2013). A more aggressive target of 110-
139mmHg does not result in any significant benefit in terms of survival or final 
level of disability for those with small deep ICH (Qureshi et al., 2016). For 
those presenting with acute ICH and a SBP>150mmHg, initiation of 
antihypertensive treatment within 6 hours of stroke onset aiming for a target 
of <140mmHg is recommended (The Royal College of Physicians, 2016).  
Those patients who were anticoagulated with warfarin or a NOAC prior to their 
stroke should have their anticoagulation reversed as soon as possible. A 
combination of intravenous vitamin K and prothrombin complex concentrate 
is recommended for those taking vitamin K antagonists. For those taking 
Factor Xa inhibitors, treatment with four-factor prothrombin complex is 
recommended (The Royal College of Physicians, 2016). 
The majority of patients with ICH do not require surgery, and should be 
managed by control of hypertension and reversal of anticoagulation. The 
exceptions are patients with posterior fossa ICH and those who develop 
hydrocephalus, for whom surgical intervention may be considered (The Royal 
College of Physicians, 2016). There is no evidence to suggest that surgical 
evacuation of lobar ICH reduces the rate of death or disability at 6 months 
(Mendelow et al., 2013). 
1.1.3.5. Evidence for management on an acute stroke unit 
For both ischaemic stroke and ICH, the environment in which acute care is 
provided is of crucial importance. The use of dedicated stroke units, staffed 
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by a skilled multidisciplinary team with expertise in the care of stroke patients, 
has been shown to reduce significantly the odds of death at follow-up (median 
1 year; ) OR 0.81, CI 0.69-0.94; p=0.005), death or discharge to institutional 
care (OR 0.78, CI 0.68-0.89; p=0.0003), or death or dependency (OR 0.79, 
0.68-0.90; p=0.0007) when compared with care provided on general medical 
wards or by a “roving” stroke team (Stroke Unit Trialists Collaboration, 2013). 
Admission to a stroke unit is therefore recommended for all patients with an 
acute stroke in England (National Institute for Health and Care Excellence, 
2013, The Royal College of Physicians, 2016). 
1.1.3.6. Recommendations for rehabilitation after stroke 
Following initial stabilisation patients typically require a period of 
multidisciplinary rehabilitation. An initial rehabilitation assessment should be 
completed as soon as possible after admission to hospital. This should focus 
on impairments that might affect adversely the safety or comfort of the patient 
such as swallowing, nutritional status, skin pressure areas, continence, 
cognition, communication, and cognitive function (National Institute for Health 
and Care Excellence, 2016). A more detailed rehabilitation assessment 
should then follow, taking in to account a patient’s previous functional abilities, 
their impairment in bodily structures and functions, activity limitations and 
participation restrictions, and relevant environmental factors (National Institute 
for Health and Care Excellence, 2016). 
A rehabilitation programme should be delivered on a specialist rehabilitation 
ward (National Institute for Health and Care Excellence, 2016). In England, it 
is currently recommended that those who are able to participate should have 
a minimum of 45 minutes per day of each relevant therapy on at least five 
days a week (National Institute for Health and Care Excellence, 2016, The 
Royal College of Physicians, 2016). For selected patients with mild to 
moderate disability, early discharge home from hospital with ongoing 
rehabilitation provided by a dedicated Early Supported Discharge team is 
associated with significantly reduced lengths of stay, a lower risk of requiring 
institutional care, and a greater odds ratio of regaining independence in 
activities of daily living (Early Supported Discharge Trialists, 2009). Discharge 
to such services is therefore recommended for patients who have a safe 
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environment to return to, and who are able to transfer safely from bed to chair 
(National Institute for Health and Care Excellence, 2016, The Royal College 
of Physicians, 2016). Following discharge long-term rehabilitation should be 
provided if necessary, to facilitate participation in social roles such as 
employment, hobbies, and relationships (National Institute for Health and 
Care Excellence, 2016). Patients’ health and social care needs should be 
assessed at six months and twelve months after stroke, then annually 
thereafter, to ensure that they are receiving the care they need (National 
Institute for Health and Care Excellence, 2016)  
1.1.3.7. Current status of stroke services in the UK 
Although evidence-based guidelines are available to support best practice in 
stroke care, there has for some time been disquiet that services in the UK 
compare unfavourably with those of other European nations (Department of 
Health, 2007), despite the UK having one of the largest total healthcare 
expenditures for cardiovascular disease of any of the countries studied (Leal 
et al., 2006). Published in 2007, the National Stroke Strategy (Department of 
Health, 2007) set out ten key priorities for improving acute and long term care 
for those with stroke. Central to these recommendations was early access to 
specialist multi-disciplinary rehabilitation, with intervention beginning in the 
acute phase on an acute stroke unit then continuing through early supported 
discharge to the community and maintained thereafter into the long term 
according to need (Department of Health, 2007). At the time of publication, it 
was estimated that only around 50% of patients were able to access 
appropriate rehabilitation within the first six months after discharge 
(Department of Health, 2007). When progress towards meeting these 
strategic aims was reviewed in 2010, it was clear that development of 
rehabilitation services continued to lag behind that of acute care (Acler et al., 
2009b). Only 36% of hospitals had early supported discharge teams, with no 
consensus on how such  teams would be funded (Acler et al., 2009b). The 
National Sentinel Stroke Audit of 2010 found that around a third of patients 
did not receive therapy of the recommended intensity (Intercollegiate Stroke 
Working Party, 2011).  
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1.1.3.8. Stroke services in developing countries 
Although stroke services in the UK clearly require improvement, it is important 
to bear in mind that what is considered to be “gold standard” care in high-
income countries is beyond the means of most low- and middle-income 
nations to deliver. Unfortunately, these nations are the very ones in which the 
incidence of stroke is rising most rapidly (Feigin et al., 2009, Mendis, 2013). 
There are significant barriers to implementing intravenous thrombolysis in 
such countries, including the significant treatment cost (which is usually borne 
by the patient), delays in accessing medical help (due to lack of awareness of 
stroke symptoms or prolonged transit times to regional medical centres), and 
the paucity of scanning facilities (Mendis, 2010, Kamalakannan et al., 2016). 
There are frequently critical shortages of key health workers, and the costs of 
setting up organised stroke units may be prohibitive (Mendis, 2010). In such 
countries public health measures focusing upon the primary prevention of 
cardiovascular diseases in general may be a more efficient use of limited 
resources (Garbusinski et al., 2005). For those who sustain a stroke in 
developing countries, the focus of treatment remains on early initiation of 
aspirin (World Health Organization, 2009), as well as on the prevention of 
secondary complications such as infections and pressure ulcers (Mendis, 
2010). Multidisciplinary rehabilitation, with its focus upon mitigating disability 
and maximising independence, may have much to offer stroke survivors in 
low-income countries. Although data on the availability of rehabilitation 
services in such countries are sparse, it is probably reasonable to assume 
that there exists a substantial unmet need (The World Health Organisation, 
2011). It is likely, moreover, that many barriers exist to providing rehabilitation 
services including lack of funding for healthcare, lack of appropriately-trained 
personnel, and the centralisation of such rehabilitation services as there are 
in major population centres beyond travelling distance for those in rural 
communities (The World Health Organisation, 2011). Where rehabilitation 
services do exist, the cost of accessing them may be prohibitive, and access 
to appropriate assistive technologies is often limited (Kamalakannan et al., 
2016). The implications of unmet rehabilitation needs in developing countries 
are potentially profound, since a lack of timely and appropriate rehabilitation 
may contribute to long term limitation of activities and restriction of 
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participation, and lead to poorer quality of life and dependency upon others 
for assistance (The World Health Organisation, 2011). Epidemiological data 
on disability after stroke and on access to rehabilitation in developing 
countries are urgently needed if appropriate priorities for development of 
services are to be set (The World Health Organisation, 2011). 
1.1.4. What is “rehabilitation”? 
1.1.4.1. Definition of “rehabilitation” 
The World Health Organisation defines “rehabilitation” as “The use of all 
means aimed at reducing the impact of disabling and handicapping conditions 
and at enabling people with disabilities to achieve optimal social integration” 
(Gutenbrunner et al., 2006). The overall aim of effective rehabilitation is to 
“enable people with disabilities to lead the life that they would wish, given any 
inevitable restrictions imposed on their activities by impairments resulting from 
illness or injury” (Gutenbrunner et al., 2006). The cornerstone of rehabilitation 
practice is the World Health Organisation International Classification of 
Functioning, Disability, and Health (ICF; Figure 1.1.) (World Health 
Organisation, 2001). 
 
 
Figure 1.1. The WHO International Classification of Functioning, Disability, 
and Health (ICF) 
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1.1.4.2. The WHO International Classification of Functioning, Disability, 
and Health 
The WHO-ICF model was published in 2001, and postulates that an 
underlying health condition may cause impairment in bodily structures and 
function, which lead in turn to limitation of activities and restriction of 
participation (The World Health Organisation, 2011). In the context of the ICF, 
a “health condition” is a generic term used to describe any underlying disease 
or disorder: including genetic predispositions, or circumstances such as 
ageing (Gutenbrunner et al., 2006). “Bodily structures” are defined 
anatomically as organs, limbs, and their components (Gutenbrunner et al., 
2006). “Bodily functions” are defined primarily in physiological terms, but also 
include cognitive, mental and psychological functions (Gutenbrunner et al., 
2006). “Activity” is conceptualised as an individual’s ability to execute a tasks 
such as walking, transferring, or personal care (Gutenbrunner et al., 2006). 
“Participation” relates to the individual’s ability to fulfil their role in life situations 
such as employment, leisure pursuits, or relationships (Gutenbrunner et al., 
2006). The spectrum of dysfunction after stroke has been defined by expert 
consensus in a “core set” of ICF codes (Geyh et al., 2004). For example, 
clinically important impairments following stroke include changes in 
intellectual functions, gait pattern, inability to sequence complex movements, 
and alterations in muscle tone and power (Geyh et al., 2004). Activity 
limitations and participation restrictions may include difficulties in problem 
solving, transferring oneself, maintaining family and personal relationships, or 
acquiring and keeping a job (Geyh et al., 2004).   
Important though they are, characteristics intrinsic to the individual (physical 
impairment and limitation of activities) are themselves insufficient to define the 
construct of “disability”. An individual’s functional abilities are often profoundly 
influenced by wider contextual factors (Gutenbrunner et al., 2006), both 
environmental and personal. Environmental factors are external to the 
individual, yet make up the background of their lives (Gutenbrunner et al., 
2006). They comprise not only the built environment, but also legislation (such 
as anti-discrimination laws), and societal attitudes (Gutenbrunner et al., 2006). 
Depending upon circumstances they may serve as barriers to or as facilitators 
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of individual function (Gutenbrunner et al., 2006). Personal factors are intrinsic 
to the individual but not related directly to the underlying health condition 
(Gutenbrunner et al., 2006). They include gender, age, race, and physical 
fitness (Gutenbrunner et al., 2006). 
1.1.4.3. Defining “disability” 
In ICF terms, “disability” is therefore constructed as an “interaction between 
an individual (with a health condition) and that individual’s contextual factors 
(environmental and personal)” [author’s italics] (The World Health 
Organisation, 2011, Dahl, 2002). If the role of rehabilitation professionals is to 
mitigate disability due to an underlying health condition, then rehabilitation 
interventions must comprise a package of measures intervening at multiple 
levels of the ICF. The precise nature of the intervention required, and the ICF 
level upon which efforts will be focused, will vary depending upon the patient’s 
goals, and with the passage of time from stroke. Within the first few hours 
optimum acute care helps to minimise the extent of tissue injury and 
secondary complications (impairment in structure), and therefore maximise 
preservation of function (The Royal College of Physicians, 2010). As planning 
for discharge progresses then environmental assessment and, if necessary, 
provision of assistive technologies (contextual factors) may help to enhance 
safety and personal independence on leaving hospital. In the long term, a 
combination of rehabilitation interventions at impairment (cognition, 
communication, psychological status), activities, and environmental 
(environmental modification, assistive technologies) levels may be necessary 
to address specific goals such as return to work (participation) (National 
Institute for Health and Care Excellence, 2013). Many stroke survivors require 
not only intermittent discrete periods of time-limited rehabilitation to address 
particular functional goals, but also longer term monitoring and support to 
prevent complications and to mitigate the effects of changing disability (such 
as deterioration in mobility due to accelerated joint ageing) (The Royal College 
of Physicians, 2010). 
1.1.4.4. Disability on an international scale 
Article 26 of the United Nations Convention on the Rights of Persons with 
Disabilities calls for signatory nations to develop services to support people 
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with disabilities to attain and maintain maximum independence and full 
participation in all aspects of life (United Nations, 2009). Despite this, in many 
low- and middle-income countries people with disabilities continue to 
experience significant barriers to participating fully in society (The World 
Health Organisation, 2011). These include the lack of access to rehabilitation 
services or to appropriate equipment, inaccessibility of the local environment 
or public amenities including health services, negative attitudes towards 
people with disabilities, and a lack of involvement of people with disabilities in 
shaping legislation and policy (The World Health Organisation, 2011). 
Worldwide, people with disabilities are more likely to be unemployed, and 
those who are employed generally earn less than non-disabled workers (The 
World Health Organisation, 2011). Households with a disabled member are 
more likely to experience poor housing, food insecurity, and a lack of access 
to sanitation or safe water supplies (The World Health Organisation, 2011). 
Since disabled people are more likely to live in poverty, they may lack the 
financial capability to mitigate or overcome barriers to participation in society. 
1.1.5. The trajectory of recovery after stroke 
1.1.5.1. Early recovery 
There is significant heterogeneity in outcomes following stroke: some make a 
near-complete recovery, whilst others are left with profound residual disability 
(Kwakkel and Kollen, 2013). Despite this variability, some interesting patterns 
in recovery may be discerned. The rate of recovery of function tends to be 
maximal within the first few weeks of stroke. This improvement is thought to 
be largely spontaneous (Kwakkel and Kollen, 2013).  
1.1.5.2. Late recovery 
By around eight to ten weeks after stroke the rate of spontaneous recovery 
begins to plateau (Partridge and Morris, 1993). Thereafter recovery occurs 
more slowly, but the final level of ability that a patient attains may nevertheless 
be improved by appropriate rehabilitation (National Institute for Health and 
Care Excellence, 2013). The biological basis of this process will be discussed 
below. The sequence of recovery of activities tends to follow a hierarchical 
pattern: those that may be accomplished by use of compensatory strategies 
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such as grooming tend to be achieved before more complex tasks such as 
climbing stairs (Kwakkel and Kollen, 2013). 
1.1.5.3. Long-term prognosis 
Although considerable effort and money have been invested in early 
rehabilitation services, there is evidence that gains in function achieved in the 
first few months after stroke are not sustained in the long term. A recent multi-
centre longitudinal cohort study that recruited across several European 
rehabilitation services found that motor and functional outcomes all improve 
within the first six months, but this is followed by a progressive decline in 
function over time (Appelros and Viitanen, 2004). By five years outcome 
scores do not differ significantly compared with those recorded at two months 
after stroke (Appelros and Viitanen, 2004). Perhaps it is insufficient to focus 
research effort upon strategies to achieve short-term gains in function, 
important though this is. A survey of stroke survivors conducted in 2012 has 
identified a clear desire to prioritise funding for research in to managing the 
long-term sequelae of stroke at both impairment (motor, cognitive, and speech 
functions), and participation (general confidence, and emotional well-being) 
levels of the ICF (Pollock et al., 2012). 
1.1.6. What rehabilitation interventions are effective after stroke? 
1.1.6.1. Restorative versus compensatory rehabilitation strategies 
Broadly, rehabilitation interventions may be viewed as restorative (for 
example, encouraging use of a hemiplegic limb in functional tasks or attention 
to a neglected side), or compensatory (such as learning to complete tasks one 
handed, or the provision of orthoses, walking aids, or assistive technologies) 
(National Institute for Health and Care Excellence, 2013).  
1.1.6.2. Restorative rehabilitation: motor control approaches 
At an impairment level, a variety of physiotherapy approaches have been 
developed, each based upon differing theories about how patients recover 
from stroke. Prior to the 1940s, the emphasis of stroke rehabilitation was upon 
compensating for lost function and maintaining joint range by passive 
movement (Langhorne et al., 2009). In the 1950s and 1960s, new approaches 
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were developed that incorporated emerging insights in to the neurophysiology 
of motor control (Langhorne et al., 2009). Berta and Karel Bobath based their 
treatment on a detailed assessment of abnormalities in a patient’s postural 
control reflexes, and sought to correct these by intervening upon abnormalities 
in muscle tone (Semans, 1967).  
1.1.6.3. Restorative rehabilitation: feedback on movement performance 
The process of rehabilitation depends upon a patient’s ability to re-learn motor 
skills. Learning may be “explicit”, in which the components of a task are 
committed to declarative memory, or “implicit”, in which a sequence of 
movements is learned and optimised without conscious recognition or recall 
of its component tasks (Subramanian et al., 2010). The biological basis of 
motor learning is a process termed “neuroplasticity”. This will be discussed in 
detail below, but in the context of motor learning it may be defined as the 
reorganisation of movement representations in cortical regions (such as the 
pre-motor cortex and supplementary motor area) resulting from physiological 
changes to synaptic efficacy and remodelling of dendrite spines 
(Subramanian et al., 2010). 
When re-learning movements after stroke, it is common for patients to develop 
inefficient or ineffective movement patterns that, if allowed to persist, may 
compromise their long-term independence (Subramanian et al., 2010). For 
this reason, therapists commonly offer patients feedback on their performance 
during practice of a task (van Vliet and Wulf, 2006, Subramanian et al., 2010). 
Feedback may be intrinsic (the sensory and proprioceptive information 
available to an individual whilst a movement is in progress), or extrinsic (an 
external commentary on the quality of movement performance) (van Vliet and 
Wulf, 2006, Subramanian et al., 2010). Extrinsic feedback may be given 
verbally, or augmented with visual information such as video recording of task 
performance (van Vliet and Wulf, 2006). It may encompass the way in which 
a movement is executed (“knowledge of performance”), or the outcome of that 
movement (“knowledge of results”) (van Vliet and Wulf, 2006, Subramanian 
et al., 2010). Since intrinsic feedback mechanisms may be impaired following 
a stroke, extrinsic feedback may be particularly valuable in improving the 
quality of movement in stroke survivors (van Vliet and Wulf, 2006). Providing 
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extrinsic feedback may also allow stroke patients to utilise declarative memory 
(for facts and events) when learning skills, bypassing impairment in implicit 
learning mechanisms (the learning of motor skills without conscious 
awareness; van Vliet and Wulf (2006)). 
1.1.6.4. The evidence base for different motor rehabilitation strategies 
A recent Cochrane review comparing competing physiotherapy approaches 
to promoting recovery of lower limb function and postural control following 
stroke found that there is no clear evidence to favour any one strategy (Pollock 
et al., 2007). There is, however, some evidence to support specific 
interventions. Langhorne et al. (2009) found modest effect sizes for constraint-
induced movement therapy, electromyographic biofeedback, mental practice 
with motor imagery, and robotic interventions in promoting recovery of arm 
function. However, none of these strategies was of proven benefit in 
enhancing recovery of hand function (Langhorne et al., 2009). Interventions 
to promote recovery of walking included fitness training (both 
cardiorespiratory alone, and combined cardiorespiratory and strength 
training); high-intensity physiotherapy; and repetitive task practice (Langhorne 
et al., 2009). All showed modest effect sizes, but only in the case of 
cardiorespiratory training was the evidence of benefit felt to be strong 
(Langhorne et al., 2009). For standing balance, interventions trialled include 
biofeedback using a force plate, training on a moving platform, and repetitive 
task training. Trials were generally small and of poor quality, and evidence to 
support any one intervention was considered weak (Langhorne et al., 2009). 
For sit-to-stand transfers, only repetitive task training showed a modest effect 
across seven trials. However, this review included a total of only 346 patients 
(Langhorne et al., 2009). A later Cochrane review, of upper limb rehabilitation 
strategies, identified larger numbers of trials; but, once again, of moderate 
quality at best (Pollock et al., 2014). Beneficial effects were shown for 
repetitive task practice (at high doses), mental practice, mirror therapy, 
constraint-induced movement therapy, and interventions for sensory 
impairment (Pollock et al., 2014). 
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1.1.7. The biological basis of rehabilitation 
1.1.7.1. Motor learning: the basis of rehabilitation interventions 
Although evidence is lacking for particular interventions, participation in a 
structured multi-disciplinary rehabilitation programme has been shown to 
improve function and quality of life after stroke, and this complex package of 
interventions therefore remains the cornerstone of treatment for the majority 
of patients (Department of Health, 2007, National Institute for Health and Care 
Excellence, 2013). But what biological processes underpin “rehabilitation”? 
One might say that strategies that aim to restore (as opposed to compensate 
for) loss of function depend fundamentally upon a person’s ability to learn 
skills.  
1.1.7.2. Motor learning after stroke 
The process of learning is itself a complex phenomenon. In healthy 
individuals, learning a new skill depends upon a close interaction between 
spatially distributed and functionally disparate areas of the brain (Doyon et al., 
2009, Hikosaka et al., 2002, Penhune and Steele, 2012). Where brain injury 
has occurred, as in stroke, there is evidence to suggest that areas remote to 
the original injury are activated during task learning: a process that is thought 
to result in partial reorganisation of brain function and the re-location of motor 
representations to spared areas of brain (Hodics et al., 2006). At a cellular 
level, learning is thought to induce the formation of new “hard wired” pathways 
within the brain through re-modelling of axons, changes in the number and 
morphology of dendrites (Dimyan and Cohen, 2011, Ward and Cohen, 2004, 
Gillick and Zirpel, 2012), and long term potentiation or depression of synaptic 
transmission (Gillick and Zirpel, 2012, Ward and Cohen, 2004). These 
processes are enhanced by repetitive practice of a task (French et al., 2007).  
1.1.7.3. Novel rehabilitation interventions to enhance learning 
It is thought that neuroplasticity is enhanced by repetitive practice of a task. 
Thus, more intensive practice, delivered early after stroke, has the potential 
to improve rehabilitation outcomes. For this reason, there has been enormous 
research interest in the development of novel rehabilitation strategies to 
enhance neuroplasticity. For example, the use of robotic systems to assist a 
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patient in active movement of a paretic arm might allow a greater duration and 
intensity of practice than could be provided by a therapist, and may therefore 
enhance recovery of upper limb function (Pollock et al., 2014, Kwakkel et al., 
2008, Sivan et al., 2014). Alternatively, the use of drugs that act to enhance 
neuroplasticity directly might offer a means of amplifying the effectiveness of 
traditional rehabilitation interventions (Chollet et al., 2011, Berends et al., 
2009, Scheidtmann et al., 2001). An understanding of the processes of 
learning in stroke might allow the targeting of emergent rehabilitation 
interventions to those patients most likely to benefit. The biology of learning 
will thus be considered in Part 1.2, below. 
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Part 1.2 Motor learning and recovery from stroke 
1.2.1. Motor learning after stroke 
1.2.1.1. Defining “motor learning” 
Motor learning is fundamental not only to rehabilitation but also to daily life 
(Dayan and Cohen, 2011): from a baby learning to walk to a musician 
practising a symphony. Becoming skilled in a motor task requires us not only 
to learn the correct order of movements, but also to develop an awareness of 
the sensory input that guides decisions such as timing of the movement, 
trajectory, and what force should be applied when manipulating an object 
(Penhune and Steele, 2012). Often, acquiring a skill also requires the learner 
to manipulate or interact with objects in their environment (Doyon et al., 2009). 
Although there is no universally-accepted definition of “motor learning”, it has 
been conceptualised as “a change in motor behaviour, specifically referring to 
the increased use of novel, task-specific joint sequences and combinations, 
resulting from practice and/or repetition” (Nudo, 2008). It is now recognised 
that motor learning, and other cognitive functions, are critically dependent 
upon network interactions between spatially-distributed brain structures. It is 
interesting to consider how a historical understanding of brain function, 
revealed by an understanding of the consequences of direct injury to discrete 
cortical areas, has evolved in to a more modern appreciation of the role of 
neural networks and the connectional anatomy of the brain.   
1.2.1.2. Early theories of motor control 
Many of the early endeavours to understand brain function focused upon 
motor control, rather than cognition. This work has been the subject of a 
historical review by Gross (2007), which will be summarised here in the next 
two paragraphs. As long ago as 1664, Thomas Willis suggested that the 
cortex initiates voluntary movement. Emanuel Schwenbourg (1688-1772) 
proposed that motor function is localised in the cortex in a somatotopic 
manner, with cortical neurones projecting down through the white matter to 
the medulla, and thence to the spinal cord and peripheries. His insight, though 
astonishing to modern eyes, was well ahead of its time and was largely 
ignored by the scientific community of the day. Françoise Pourfour du Petit 
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(1644-1741), a French military surgeon, demonstrated the laterality of motor 
function in a series of experiments with animals which he correlated with 
observations in wounded soldiers. Again, these findings were largely ignored, 
and the prevailing view of the cortex in to the early 18th Century was conveyed 
by the literal translation of the term from Latin: little more than a protective 
“rind”.   
1.2.1.3. The discovery of the cortical localisation of motor control 
Amongst the earliest circumstantial evidence for the localisation of cortical 
function came in 1870, with the observation by John Hughlings Jackson that 
his wife’s seizures showed a distinct pattern of progression (Gross, 2007). He 
recorded twitching that began first in the hand then moved in a stereotyped 
manner up the arm before the seizure become generalised. From this, he 
inferred that distinct muscle groups must be controlled by co-located brain 
areas. He did not, however, directly implicate the cortex as the seat of motor 
function. The first direct experimental evidence for the existence of a “motor 
cortex” came at around this time (1870) when Gustav Fritsch and Edvard 
Hitzig observed reproducible patterns of limb twitching in response to 
“Galvanic“ (electrical) stimulation of the anterior cortex in dogs. Fritsch and 
Hitzig did not themselves cite Jackson’s work, although Jackson’s findings 
were certainly known to David Ferrier who successfully reproduced Fritsch 
and Hitzig’s experiment in 1873. This discovery heralded a growth in interest 
throughout the 19th Century in determining the localisation of brain functions. 
Some of this work, such as Carl Wernicke’s seminal 1874 case series of ten 
patients with the aphasia which now bears his name (Wernicke, 1970), has 
stood the test of time (de Almeida et al., 2014). Other theories have fallen in 
to disrepute. Franz Gall (1758-1828) proposed not only that skills and 
personality traits have their seat in the cortex, but also that the presence of 
these traits in specific individuals would lead to cortical hypertrophy (de 
Almeida et al., 2014). This would in turn result in displacement of the overlying 
skull, and a characteristic pattern of skull prominences from which the 
presence of defined personality characteristics could be inferred (de Almeida 
et al., 2014). Although both flawed in its methodology and erroneous in its 
conclusions, it is worth noting that this theory of “phrenology” was amongst 
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the first attempts to systematically localise cortical functions (de Almeida et 
al., 2014).  
1.2.1.4. Wernicke, and the discovery of network interactions between 
brain structures 
If stroke were a purely “cortical” phenomenon, then predicting recovery would 
be straightforward: the spectrum of impairments, and their ultimate outcome, 
would depend upon the location and extent of the cortical lesion. However, it 
has long been known that the spectrum of impairment seen following a brain 
injury of any nature depends not only upon the pattern of cortical injury, but 
also upon disruption of connections between different brain structures. 
Wernicke described in 1874 how the production of speech depends upon the 
integrity of connections between the superior temporal gyrus and Broca’s area 
in the posterior infrerior frontal gyrus (Wernicke, 1970). This was followed in 
1885 by Ludwig Lichtheim’s description of what he termed a “reflex arc” 
between cortical areas responsible for understanding spoken language and 
those responsible for initiating the motor component of speech (de Almeida et 
al., 2014).  
1.2.1.5. White matter tracts and loop circuits: a contemporary view of 
brain function 
More recently, the existence of extensive networks of white matter projections 
between spatially-distributed structures (both cortical and sub-cortical) has 
been recognised. The basal ganglia are key nodes within these circuits. They 
comprise the striatum (caudate, putamen, and nucleus accumbens), and the 
globus pallidus (Da Cunha et al., 2009, Bolam et al., 2000). The sub-thalamic 
nucleus, substantia nigra and ventral tegmental areas are considered 
associated structures (Da Cunha et al., 2009). Alexander et al. (1986)  
described five loop circuits between the cortex and basal ganglia: the motor, 
occulomotor, dorsolateral prefrontal, lateral orbitofrontal, and anterior 
cingulate. Each arises from different regions of the frontal cortex (Alexander 
et al., 1986), and sends excitatory inputs to the striatum (McHaffie et al., 
2005). Striatal neurones then send a complex web of inhibitory inputs to the 
substantia nigra and the globus pallidus interna, which project in turn to the 
thalamus (McHaffie et al., 2005). The primary output of these circuits is 
26 
 
excitatory efferents from the thalamus to cortical areas (McHaffie et al., 2005). 
(Figure 1.2. adapted from McHaffie et al. (2005)). 
 
Figure 1.2. Schematic illustration of the architecture of the cortico-basal loop 
circuits 
Predominantly excitatory pathways and structures are in red; those with 
predominantly inhibitory output are in blue. Figure taken from (McHaffie 
et al., 2005) 
Similar loop circuits are also now known to exist between subcortical 
structures (McHaffie et al., 2005). In this case, the primary input nucleus is the 
thalamus, which sends excitatory input to the striatum (McHaffie et al., 2005). 
This in turn sends inhibitory projections to the substantia nigra and globus 
pallidus interna, which in turn send inhibitory input back to midbrain and 
hindbrain structures (McHaffie et al., 2005) (Figure 1.3. (McHaffie et al., 
2005)). 
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Figure 1.3. Schematic illustration of the architecture of the subcortical loop 
circuits.  
Predominantly excitatory pathways and structures are in red; those with 
predominantly inhibitory output are in blue. Figure taken from (McHaffie 
et al., 2005) 
1.2.1.6. Neuronal networks and cognitive functioning 
Cortico-basal and subcortical circuits are now known to play a role in a variety 
of cognitive processes. The clinical evidence for this derives in part from 
conditions other than stroke. Huntington’s chorea and Parkinson’s disease are 
both degenerative conditions of the basal ganglia, which have impairment of 
motor control as their primary manifestation. And yet Huntington (1872) also 
described a “tendency towards insanity” in advanced cases, including sexual 
disinhibition. The non-motor manifestations of Parkinson’s disease were not 
at first appreciated: Parkinson (1817) himself noted that the “senses and 
intellects… [are] uninjured”. It was only later that cognitive dysfunction was 
also recognised in the advanced stages of the illness (Louis, 1997). 
Impairment in concentration and attention, strategic planning, procedural 
learning ability, working memory, and verbal fluency are all now recognised 
features of this condition, as are decreased mental flexibility and difficulty in 
switching between cognitive tasks (Schmahmann and Pandya, 2008). More 
recently, studies of discrete stroke lesions in humans have demonstrated a 
similar pattern of cognitive impairment following injury to the basal ganglia 
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(Schmahmann and Pandya, 2008) and cerebellum (Schmahmann et al., 
2009). 
1.2.1.7. Neuronal networks and motor learning 
There has recently been considerable interest in how network interactions 
between disparate brain structures might interact to facilitate the learning of 
motor skills. Advanced imaging techniques may offer insights in to the 
anatomical basis of learning. At the simplest level, techniques such as Voxel-
based mophometry (VBM) or Diffusion Tensor Imaging (DTI) allows detailed 
analysis of the volume of grey matter structures, or visualisation of the white 
matter tracts that link them (Thomas and Baker, 2013). Statistical comparison 
of anatomical differences between trained and untrained individuals, or within 
the same group before and after learning a task, may allow inferences to be 
made about the role of these structures in the learning process (Thomas and 
Baker, 2013). However, VBM and DTI merely provide semi-quantitative 
estimates of structural change: they do not allow real-time visualisation of the 
activation of these brain regions as learning takes place.  
1.2.1.8. Theories of motor learning: evidence from functional magnetic 
resonance imaging (fMRI) 
In contrast to structural imaging, functional imaging techniques allow 
exploration of how patterns of metabolic activity within specific brain regions 
change throughout the learning cycle. Functional MRI (fMRI) relies upon the 
detection of increased levels of deoxygenated haemoglobin in brain regions 
of interest: the Blood Oxygen Level-Dependent (BOLD) signal (Arthurs and 
Boniface, 2002). This is assumed to reflect increased oxygen uptake by 
metabolically active tissue, and therefore increased neuronal activity in that 
area (Arthurs and Boniface, 2002). Several studies have used fMRI to explore 
the process of motor learning. Doyon et al. (2009) suggest that the striatum 
contributes to consolidation of skills, with activity first predominant in the 
associative striatum, but a subsequent shift to the sensorimotor striatum. 
Hikosaka et al. (2002) hypothesised that successful movement requires an 
initial awareness of the body’s spatial position and of the position of 
environmental objects with which it interacts. This requires integration of any 
available spatial information, which is thought to be performed by circuits 
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between the fronto-parietal cortices and the associative striata (Hikosaka et 
al., 2002). This information is then used to generate a series of motor 
coordinates for the planned action prior to execution of a movement: a function 
thought to be performed by loops between the motor cortex, basal ganglia and 
cerebellum (Hikosaka et al., 2002). When learning a new sequence of 
movements, initially each component of that sequence is executed individually 
(Hikosaka et al., 2002). This is an explicit process which requires cognitive 
effort, and results in slow and deliberate movements (Hikosaka et al., 2002). 
The sequence of actions are subsequently optimised, in an implicit process 
requiring no conscious thought (Hikosaka et al., 2002). The end result is fluid 
effortless movement, that retains spatial accuracy (Hikosaka et al., 2002). 
Penhune and Steele (2012) believe that the cerebellum is responsible for the 
construction of an “internal model,” containing the optimum kinematic 
parameters for a planned movement sequence. This representation is then 
compared with proprioceptive feedback whilst the movement is in progress, 
allowing optimisation of movement in real time (Penhune and Steele, 2012). 
The final anatomical localisation of memory traces for learned action is split, 
with the motor, pre-motor, and parietal cortex encoding a representation of a 
learned sequence of movements, and the cerebellum encoding the motor 
control parameters for that action (Penhune and Steele, 2012). The role of the 
striatum in the learning process is in the “reward” response when an explicit 
goal is achieved (Penhune and Steele, 2012). Despite the term “functional” 
MRI, what this technique actually demonstrates is a signal that is thought to 
correlate with tissue metabolism: any inferences about the actual function of 
those structures in learning remain speculative. 
1.2.2. Cognitive dysfunction after stroke 
1.2.2.1. Cognitive impairment after stroke: a “disconnection” 
phenomenon   
As understanding of cognitive function has evolved, it has become apparent 
that injury to structures such as the basal ganglia, cerebellum, or white matter 
tracts may give rise to a picture of cognitive dysfunction that mimics a large 
cortical injury. Such phenomena have been termed “disconnection 
syndromes”, since they represent a failure of the network between brain 
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structures (Schmahmann and Pandya, 2008). Impairments in key cognitive 
domains such as memory, executive function, praxis, and visuospatial 
perception are common after stroke (Barker-Collo et al., 2010). They may 
occur as a result of a variety of underlying processes, with the common feature 
being disruption of distributed neural networks and thus failure of interactions 
between brain structures. Unfortunately, the wide array of pathological lesions 
that may lead to cognitive failure has led to a bewildering array of 
terminologies to describe these phenomena (O'Brien et al., 2003). Some imply 
the presence of specific histological findings: “multi-infarct dementia”, for 
example, presumes an additive burden of several cortical infarcts, whereas 
“subcortical dementia” and “subcortical ischaemic vascular dementia” suggest 
a burden of lacunar infarcts to the basal ganglia. The term “dementia”, 
common to all of the above, is based largely upon the characteristics of 
Alzheimer’s disease, and therefore presupposes the presence of memory 
impairment as a key diagnostic feature (O'Brien et al., 2003, Moorhouse and 
Rockwood, 2008). Other terms, such as “vascular cognitive impairment” seek 
to define a construct, whilst minimising assumptions about aetiology and 
pathophysiology (O'Brien et al., 2003).   
1.2.2.2. Classifying cognitive impairment after stroke 
Perhaps the most straightforward taxonomy is that proposed by O'Brien et al. 
(2003) and later elaborated by Moorhouse and Rockwood (2008) (Figure 
1.4.). The use of “Vascular Cognitive Impairment” (VCI) was initially proposed 
as an umbrella term for cerebrovascular pathology which results in a specific 
cognitive profile: preserved memory, with impairment in attentional and 
executive functioning (O'Brien et al., 2003). It has subsequently been 
suggested that vascular cognitive impairment which results in memory 
impairment (thereby meeting diagnostic criteria for “dementia”) be termed 
“VCI with dementia”. There is, of course, a substantial overlap between VCI 
and neurodegenerative pathology. 
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Figure 1.4. schematic representation of the overlap between syndromes of 
cognitive impairment.  
After Moorhouse and Rockwood (2008) 
1.2.2.3. Cognitive impairment as a result of a global burden of injury to 
neuronal networks  
If cognitive dysfunction is conceptualised as being a result of disruption to the 
network anatomy of the brain, then it is clear that this impairment may arise 
as a result of a variety of pathologies, and as a consequence of disruption to 
any of the structures or white matter tracts within the network. Some 
conditions, such as a stroke affecting a large cortical territory or the 
cerebellum, or a smaller “strategic” lesion to an area critical to cognitive 
function, may cause a sudden and dramatic deterioration, which may fulfil the 
criteria for dementia (Iadecola, 2013). However, a more generalised burden 
of chronic ischaemic injury to the cortico-basal and subcortical loop pathways 
may result in a subtle and insidious cognitive deterioration, which may even 
pre-date or occur in the absence of a large-vessel stroke (Iadecola (2013); 
Figure 1.5).  
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Figure 1.5. Mechanisms of injury to cortico-basal and subcortical loop circuits. 
Schematic illustration of the cortico-basal (green) and subcortical 
(purple) loop circuits. Different components of these pathways may be 
susceptible to injury by a variety of mechanisms (red). This may manifest 
as vascular cognitive impairment. 
In short, the overall picture of cognitive dysfunction after stroke most likely 
represents an interaction between a large-vessel lesion (infarct versus ICH) 
and a more global burden of “small vessel” injury (some of which may be pre-
existing). How this overall burden of structural (brain injury) and functional 
(cognitive) impairment might attenuate a patient’s ability to re-learn motor 
skills is of particular interest to rehabilitation practice.    
1.2.2.4. “Small vessel” injury: an underlying cause of cognitive 
impairment 
“Small vessel” injury is a concept that covers a variety of lesions seen on brain 
imaging, which may or may not have similar underlying pathological 
mechanisms. Here again, one encounters the problem of a lack of 
standardised terminology and definitions for these lesions (Wardlaw et al., 
2013b). Often several different terms are used to describe the same 
phenomenon. Some (such as “white matter hyperintensities”) describe 
radiological findings (the appearance of these lesions on T2-weighted MRI); 
others (such as “leukoencephalopathy”) refer to histopathological changes 
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(white matter necrosis of presumed ischaemic aetiology) (Wardlaw et al., 
2013b). From an imaging perspective, a single pathological process may 
mature to give very different radiological appearances on follow-up scans. For 
example, a small acute subcortical infarct may leave no visible lesion on a 
follow-up MRI scan, or it may appear as a cavitating lacunar lesion or white 
matter hyperintensity (Wardlaw et al., 2013b). In pathological terms, there are 
a wide range of possible mechanisms by which brain injury may occur; and 
yet, the repertoire of possible tissue responses to injury (inflammation, 
necrosis, scarring) are limited (Hachinski, 2007). It therefore cannot be 
assumed that lesions with similar histological appearances share a common 
mechanism. With these difficulties in mind, three common lesions implicated 
in vascular cognitive impairment will be discussed: white matter lesions, 
lacunar lesions, and microbleeds. For each an attempt will first be made 
attempt to instil some clarity around definitions, before the underlying 
pathophysiology of these lesions and their consequences for cognitive 
function are explored. 
1.2.2.5. Imaging correlates of small vessel disease: white matter 
lesions 
There are over 50 synonyms in use to describe white matter lesions: 
Binswanger’s disease, leukoariosis, leukoencephalopathy, white matter 
hyperintensity, white matter change, and white matter disease are amongst 
the most common (Wardlaw et al., 2013b). They appear on T2-weighted MRI 
as areas of hyperintensity in the deep or periventricular white matter, which 
may be patchy or confluent (Wardlaw et al., 2013b, Wardlaw et al., 2013a). 
On computerised tomography scanning (CT), they are hypodense, returning 
an attenuation lower than that of surrounding tissue (although not as low as 
cerebrospinal fluid (Wardlaw et al., 2013b). They are also seen in other 
conditions such as multiple sclerosis or leukodystrophies (Wardlaw et al., 
2013b). Wardlaw et al. (2013b) therefore proposed the radiological 
descriptors “white matter hyperintensities of presumed vascular origin” for the 
MRI appearance, with “white matter hypodensities of presumed vascular 
origin” endorsed for the equivalent CT finding. Since both magnetic resonance 
imaging (MRI) and CT findings will be discussed here, the more generic (but 
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less precise) term “white matter lesions” will be used, with reference to white 
matter “hyperintensitiy” or “hypodensity” only in the context of MRI and CT 
findings respectively. It will be assumed throughout that these lesions are “of 
presumed vascular origin”, unless otherwise stated. Following the 
recommendations of Wardlaw et al. (2013b), these terms will not be applied 
to lesions in the brain stem or deep grey matter. Radiologically, white matter 
lesions are known to be associated with a number of other findings including 
lacunes, atrophy, cerebral microbleeds, and prominent perivascular spaces 
(Wardlaw et al., 2013a). They are strongly associated with cardiovascular risk 
factors including hypertension, hyperlipidaemia, diabetes, and smoking 
(Wardlaw et al., 2013b, Iadecola, 2013) Histologically, a number of small 
vessels changes have been associated with these lesions including 
atherosclerosis, hyaline deposition in the vessel walls (lipohyalinosis), fibrosis 
and stiffening of small vessels (arteriosclerosis), and loss of integrity of the 
vascular basement membrane (fibrinoid necrosis) (Iadecola, 2013). How, or 
whether, these microvascular changes may give rise to white matter lesions 
remains opaque, but possible mechanisms include chronic hypoperfusion, 
and/ or dysfunction of the blood/ brain barrier with extravasation of fluid in to 
white matter tracts (Debette and Markus, 2010). Histological evidence of white 
matter injury includes axonal loss, vacuolation, and demyelination (Iadecola, 
2013). As they progress lesions tend to expand in to adjacent normal white 
matter, and may eventually become confluent (Iadecola, 2013). White matter 
lesions are common, with a prevalence of 11%-24% in over-65s, and 94% at 
age 82 (Debette and Markus, 2010). They may be asymptomatic, and were 
once thought to be a benign associate of normal ageing. However, it is now 
clear that they are associated with an increased risk of stroke, dementia, and 
death (Debette and Markus, 2010), a faster rate of decline in global cognitive 
performance, executive function, and information processing speed (Debette 
and Markus, 2010), gait disturbance (de Laat et al., 2011), and an increased 
risk of transition from independence to disability (Inzitari et al., 2009). 
1.2.2.6. Imaging correlates of small vessel disease: lacunar lesions 
“Lacunes” were first described in 1838 as cavitating lesions containing 
cerebrospinal fluid of around 3-20mm in diameter (Potter et al., 2010). They 
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are more common with age; one large MRI survey of participants aged over 
65 found one or more lacunes in around 25% of the sample (Longstreth et al., 
1998). On imaging, established lacunar lesions are isointense to 
cerebrospinal fluid (Roman et al., 2002). They are typically found in the deep 
white matter, basal ganglia, thalamus, and pons (Wardlaw, 2005). They are 
often assumed to be ischaemic in origin, although a small deep intracerebral 
haemorrhage can, when mature, give a radiological appearance that is 
indistinguishable from an ischaemic lacune (Wardlaw et al., 2013b). Although 
commonly used as such in the literature, the terms “lacune”, “lacunar stroke”, 
and “lacunar infarction” are not interchangeable. “Lacune” refers to a 
radiological or pathological finding of a cavitating lesion. Only a minority of 
“lacunar” small-vessel infarcts actually go on to cavitate and assume this 
appearance; the majority take on the appearance of white matter lesions 
(Potter et al., 2010). Simply counting the numbers of lacunes may therefore 
underestimate the true burden of ischaemic small vessel disease (Potter et 
al., 2010). “Lacunar stroke” describes a clinical stroke syndrome consistent 
with a small subcortical or brainstem lesion (Wardlaw, 2008, Bamford et al., 
1991). However, this clinical syndrome may not match radiological findings: in 
around 10-20% of patients with a clinically-defined “lacunar” syndrome a small 
cortical infarct is later identified on imaging as the culprit lesion (Mead et al., 
1999). Nor do all lacunes give rise to a “lacunar stroke” syndrome. As many 
as 89% are thought to be clinically silent, or are manifested by more subtle 
impairments in gait and cognition (Longstreth et al., 1998). “Lacunar infarct” 
implies a lacunar stroke syndrome for which an underlying ischaemic lacunar 
lesion is visible on imaging (Wardlaw, 2008). The radiological appearance of 
“lacunes” may be mimicked by expansion of the perivascular spaces around 
small perforating vessels (Wardlaw et al., 2013b). These are generally smaller 
than lacunes (around 3mm), run parallel to the course of vessels, and may be 
seen most prominently in the basal ganglia (Wardlaw et al., 2013b). 
Frustratingly, this phenomenon has also spawned its own rash of synonyms 
including “Virchow-Robin spaces”, “état crible” (for lesions located 
predominantly in the basal ganglia) or (confusingly) “Type 3 lacune” (Wardlaw 
et al., 2013b). Although both give the radiological appearance of fluid-filled 
cavities, the origins and significance of perivascular spaces cannot be 
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assumed to be the same as that of lacunes of presumed ischaemic or 
haemorrhagic origin. It is therefore necessary to distinguish carefully between 
the two. Wardlaw et al. (2013b) suggest the term “lacune of presumed 
vascular origin”, since this a) differentiates between vascular and non-
vascular causes of cavitation, and b) avoids making assumptions about 
whether the lesion is a consequence of ischaemia or haemorrhage where 
initial imaging is not available. For simplicity, the radiological term “lacune” will 
be used here, leaving implicit that this refers only to lesions “of presumed 
vascular origin” (ischaemic and haemorrhagic) unless otherwise stated. The 
clinical syndrome of “lacunar stroke” will be defined according to the Oxford 
Community Stroke Project classification (OCSP) of Bamford et al. (1991), 
whilst remaining mindful that this syndrome does not always correlate with 
imaging findings (Mead et al., 1999). 
Although the earliest descriptions of lacunes was of ischaemic necrosis on 
histology (Fisher, 1965), the presumption that small vessel occlusion is the 
underlying cause (Fisher, 1968) has been challenged. Common precipitants 
of ischaemic cortical stroke (carotid stenosis or cardiac emboli) are implicated 
in only around 10-15% of ischaemic lacunar strokes, and some studies 
purporting to demonstrate a link between lacunes and risk factors for 
embolisation actually included mild carotid stenosis (as little as 25%), or 
cardiac abnormalities not typically associated with emboli (such as left 
ventricular hypertrophy) (Wardlaw, 2005). In animal models, the majority of 
particles injected in to the carotid artery embolised to the cortical vasculature 
rather than the lenticulostriate arteries, suggesting that cardiac embolization 
is not the primary cause of lacunes in the majority of cases (Wardlaw, 2005). 
Nor may it be reasonable to assume that all lacunes share a common origin. 
There have been suggestions that larger lacunar infarcts are a consequence 
of atheromatous disease in more proximal arterioles, whereas lacunar lesions 
caused by lipohyalinosis and arteriolosclerosis of the microvasculature tend 
to coexist with white matter hyperintensities (Wardlaw et al., 2013a). The 
Leukoariosis and Disability (LADIS) study found that lacunes in the basal 
ganglia were associated with AF (suggesting an embolic cause), whereas 
those in the deep white matter were often accompanied by new or expanding 
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white matter lesions and were associated with a history of hypertension and 
stroke (Gouw et al., 2008). 
Reliable estimates for the incidence and prevalence of cognitive impairment 
after lacunar stroke are hard to come by. A recent systematic review (Makin 
et al., 2013) found that studies were generally small, with non-blinded 
assessment of cognitive function, and did not estimate the prevalence of 
cognitive dysfunction before the stroke (Makin et al., 2013). None used gold-
standard imaging techniques to confirm lacunar infarction. Long-term data are 
scant, with few studies including follow-up beyond one year (Makin et al., 
2013). Within these limitations, the prevalence of cognitive impairment and 
dementia after lacunar stroke was estimated at 29%: comparable with cortical 
stroke (24%) (Makin et al., 2013).  
The figure quoted in this meta-analysis were heavily influenced by one large 
study, which accounted for 38% of all patients included (Bejot et al., 2011). In 
this study, the odds ratio for cognitive impairment with lacunar versus non-
lacunar stroke was 3.48 (Bejot et al., 2011); far higher than for pooled 
estimates derived from all other studies analysed by Makin et al. (2013) (odds 
ratio 0.67 for cognitive impairment with lacunar versus non-lacunar stroke). 
One possible reason for the disparity is that Bejot et al. (2011) assessed 
cognitive function at one month post stroke. Their estimates may not reflect 
the true prevalence of cognitive impairment in the long term. Secondly, the 
odds  ratio for cognitive impairment after lacunar stroke changed significantly 
in the 24-year period in which the study was recruiting: from 10.1 in 1991-
1996, to 1.51 in 2003-2008 (Bejot et al., 2011). The reasons for this striking 
observation remain unclear: it is possible that changes in clinical practice over 
the course of the study period led to an improvement in dementia-free survival 
from stroke (Bejot et al., 2011). However, the possibility of a change in 
methodology over the course of that study cannot be discounted (Makin et al., 
2013).   
Although the limitations of the literature in this area must be acknowledged, it 
is nevertheless clear that cognitive impairment is common after lacunar 
stroke: perhaps surprisingly so, given the small size of the lesions concerned 
(Makin et al., 2013). This implies that the degree of cognitive dysfunction 
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manifested clinically is not dependent upon the size of the infarct, but rather 
its impact upon wider network functions, and perhaps an interaction with other 
markers of small-vessel disease, such as white matter lesions (Makin et al., 
2013).    
1.2.2.7. Imaging correlates of small vessel disease: microbleeds 
What are termed “cerebral microbleeds” are thought to represent small 
perivascular collections of haemosiderin-laden macrophages (Fazekas et al., 
1999) which form as a result of leakage of blood products from small vessels 
injured by hypertension (lipohyalinosis) or by amyloid deposition (amyloid 
angiopathy) (Werring et al., 2010). There are many synonyms (including 
“microhaemorrhage”), but “cerebral microbleed” is the most commonly used 
and has therefore been has been proposed as a consensus term (Wardlaw et 
al., 2013b). The descriptor is primarily radiological (Greenberg et al., 2009): 
on MRI sequences that are sensitive to magnetic effects (gradient-echo T2*), 
cerebral microbleeds are visible as small (5-10mm diameter), well-
demarcated, hypointense lesions (Werring et al., 2010). The pattern of lesions 
seen may reflect the underlying pathology: hypertensive vasculopathy 
generally causes microbleeds in the basal ganglia, thalamus, brainstem, and 
cerebellum, whereas amyloid angiopathy typically displays a lobar distribution 
(Greenberg et al., 2009). Cerebral microbleeds are associated with 
hypertension, and may co-exist with white matter lesions and lacunes 
(Greenberg et al., 2009).  They may also be associated with an increased risk 
of subsequent large-vessel ICH in patients following a first haemorrhage or 
infarct, although the evidence for this is based upon small samples 
(Greenberg et al., 2009). Their significance as a marker of future haemorrhage 
risk in those who have not already had an overt large-vessel stroke is unclear, 
and the balance of risks versus benefits in initiating antiplatelet therapy in 
patients with both cerebral microbleeds and risk factors for ischaemic stroke 
remains unknown (Greenberg et al., 2009). Several small studies have 
demonstrated an association between cerebral microbleeds and an increased 
risk of cognitive impairment, dependency, or death; but this may simply reflect 
the coexistence of these lesions with white matter lesions and lacunes 
(Greenberg et al., 2009).   
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1.2.2.8. “Small vessel disease”: a unifying theory?  
White matter lesions, lacunes, and cerebral microbleeds often coexist, and it 
is by no means clear that atherosclerotic processes analogous to those 
implicated in large-vessel stroke play a role in these processes (Wardlaw et 
al., 2013a). Associations between these lesions and “traditional” 
cardiovascular risk factors (such as hypertension, hyperlipidaemia, smoking, 
and diabetes) have not been firmly established (Vermeer et al., 2007). Indeed, 
antihypertensive treatment and lipid-lowering agents are ineffective in 
preventing the expansion of white matter lesions, and antiplatelet therapy is 
associated with an increased risk of symptomatic ICH and death after lacunar 
stroke (Wardlaw et al., 2013a). The hypothesis of endothelial dysfunction has 
recently been proposed as a common origin for these lesions (Wardlaw et al., 
2013a). This theory postulates that disruption of the vascular endothelium 
leads to localised leakage of tissue fluid in to the perivascular space and 
transepithelial migration of inflammatory cells, leading to localised tissue 
oedema and the characteristic microvascular changes seen in small vessel 
disease (fibrinoid necrosis, lipohyalinosis) (Wardlaw et al., 2013a). Over time 
this process could result in the pattern of demyelination and white matter 
necrosis seen in white matter lesions (Wardlaw et al., 2013a). The same 
process may also lead to thickening of arteriolar walls, resulting in luminal 
narrowing and thrombus formation (Wardlaw et al., 2013a). This could result 
in tissue ischaemia and “lacunar” infarction (Wardlaw et al., 2013a). How such 
endothelial dysfunction may arise remains speculative. The permeability of 
the blood-brain barrier is known to increase with normal aging, but how other 
stimuli might interact with this process to trigger a pathological cascade has 
yet to be delineated (Wardlaw et al., 2013a). Amyloid deposition in 
Alzheimer’s disease is known to enhance blood-brain barrier permeability: but 
permeability is higher in vascular cognitive impairment with dementia than in 
Alzheimer’s disease or age-matched healthy controls (Wardlaw et al., 2013a). 
1.2.2.9. The role of small vessel disease in cognitive impairment 
Clearly further work is needed to understand fully how the lesions that 
characterise so-called “small-vessel disease” arise, and how they may be 
prevented. What is clear, however, is that they are far from benign. Although 
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the role of microhaemorrhages in precipitating cognitive dysfunction is less 
clear, white matter lesions and lacunes are certainly known to be associated 
with cognitive decline in people who have not had a stroke. After stroke, they 
are associated with an increased risk of recurrent stroke, and of transition to 
dementia and dependency. The underlying mechanism for this is most likely 
network dysfunction. Pre-existing white matter lesions and lacunes may not 
cause an overt “stroke” syndrome but could, over time, cause injury and 
disruption to cortico-basal and subcortical loop circuits: in effect, a 
“disconnection syndrome”. To this pre-existing burden of brain injury may then 
be added the further insult of a cortical stroke. Even in the absence of 
significant pre-existing “small vessel” injury, a large-vessel stroke may cause 
injury to any one of a number of key “nodes” within these loop circuits: the 
cortex, white matter tracts, or basal ganglia. Crucially to our purposes, these 
loop circuits are thought to play a key role in motor learning processes. This 
may have important consequences in clinical practice, since impairment in 
learning ability may attenuate a patient’s ability to respond to rehabilitation 
and thereby act to limit recovery.  
1.2.3. Dopamine augmentation of rehabilitation in stroke: a 
theoretical background 
1.2.3.1. How might dopamine enhance rehabilitation interventions? 
Although there is considerable uncertainty about precisely how disparate 
brain structures interact to facilitate motor learning, it is clear that the basal 
ganglia play a key role in this process. Dopamine is a key modulator of basal 
ganglia function. It is thought to play a number of important roles in the control 
of movement and in learning processes, including the selection and 
termination of motor programmes for skilled movements (Nambu, 2008, 
Leblois et al., 2006), encoding the “value” of a reward (Wise, 2004), or 
“stamping in” associations between stimulus and response (Wise, 2004). 
More recently, it has been proposed that phasic dopamine release acts as an 
“alerting signal,” prompting the orientation of conscious attention and cognitive 
processing towards salient environmental cues and increasing general 
arousal and motivation (Bromberg-Martin et al., 2010). There has therefore 
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been considerable interest in the possibility of using dopamine agonists as an 
adjunct to standard rehabilitation interventions in stroke.  
Attention has focused in particular upon the use of Levodopa, an orally-
administered precursor of dopamine. This crosses the blood-brain barrier 
before being metabolised to dopamine centrally, resulting in a rise in brain 
dopamine levels (Berends et al., 2009). Co-careldopa is a combined 
preparation of levodopa 100mg with a peripheral DOPA-decarboxylase 
inhibitor, Carbidopa. Carbidopa reduces peripheral levodopa metabolism, 
thereby maximising the central bioavailability of levodopa (Nutt and Fellman, 
1984). Peak plasma levels of levodopa occur between 30minutes to 2hours 
after a single oral dose of co-careldopa, with a plasma half-life of 1 to 3 hours. 
Several trials have evaluated whether administering co-careldopa might 
enhance the efficacy of standard rehabilitation approaches such as 
physiotherapy and occupational therapy. A systematic review (Berends et al., 
2009) found only two trials of this drug in recovery of walking function after 
stroke (Sonde and Lokk, 2007, Scheidtmann et al., 2001).  Scheidtmann et al. 
(2001) reported an improvement in mean Rivermead Motor Assessment score 
of 6.4 points after a three-week course of levodopa, compared with an 
improvement of 4.1 points with placebo (p=0.004). Sonde and Lokk (2007) 
tested three drug regimens (levodopa, d-amphetamine, or levodopa and d-
amphetamine) delivered over ten rehabilitation sessions, and found no 
improvement in motor function or independence in activities of daily living for 
any of these treatments when compared with placebo. 
A number of smaller studies have also addressed the effect of dopaminergic 
agents on other aspects of recovery such as independence in activities of daily 
living and upper limb function (Lokk et al., 2011, Engelter et al., 2010, Rosser 
et al., 2008b, Restemeyer et al., 2007, Floel et al., 2005, Zorowitz et al., 2005, 
Acler et al., 2009a). Many were limited by small sample sizes (Restemeyer et 
al., 2007, Acler et al., 2009a) or comparatively short follow-up (Restemeyer et 
al., 2007), or administered only single doses of co-careldopa (Restemeyer et 
al., 2007, Floel et al., 2005). Some recruited patients months or years after 
stroke (Restemeyer et al., 2007, Acler et al., 2009a).  
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A wide range of outcome measures has been used to measure response to 
levodopa treatment, including: the Barthel Index (BI); NIHSS; the Functional 
Independence Measure (FIM); and walking speed. Unfortunately, the lack of 
a standardised approach to outcome measurement greatly complicates meta-
analysis in this area. Several trials have demonstrated benefit with dopamine 
on outcome measures including: the BI (Lokk et al., 2011); NIHSS (Lokk et 
al., 2011); FIM (Engelter et al., 2010); walking speed and manual dexterity 
(Acler et al., 2009a); procedural motor learning (Rosser et al., 2008b); and 
motor memory (Floel et al., 2005). However, others have found no 
improvement in length of hospital stay (Zorowitz et al., 2005), cognitive and 
motor function (Zorowitz et al., 2005), or upper limb function (Restemeyer et 
al., 2007). In summary, there is certainly a strong theoretical basis to suggest 
that taking co-careldopa in conjunction with therapy sessions could enhance 
the effects of rehabilitation and lead to an improvement in motor recovery: but 
high-quality evidence to support the implementation of this intervention in 
routine clinical practice has hitherto been lacking. 
1.2.3.2. Dopamine Augmented Rehabilitation in Stroke: the first large-
scale trial of levodopa use in stroke rehabilitation 
In 2009 the Efficacy and Mechanism Evaluation Programme of the National 
Institute for Health Research approved funding for a large double-blinded 
randomised controlled trial to assess the impact on recovery of walking ability 
of administering co-careldopa or placebo in conjunction with standard multi-
disciplinary rehabilitation following stroke. The protocol for this trial, (DARS: 
ISRCTN99643613), has been published elsewhere (Bhakta et al., 2014) and 
its methods will be described in detail in the Chapter 2. However, the trial did 
not show any significant benefit of administering co-careldopa on participants’ 
ability to walk 10m or more independently at up to a year after randomisation.  
1.2.3.3. Original aim of this Thesis: exploring factors that influence a 
patient’s response to Levodopa 
This Thesis was set in the context of the DARS trial, and utilises data derived 
from this study. The aims of this work have altered somewhat since the 
inception of the trial. At the time of trial set-up, it was believed that co-
careldopa would show an effect in enhancing motor recovery in the sample as 
43 
 
a whole. However, a fundamental assumption of interventional drug trials is 
that patients within the sample are homogeneous and that any benefit from 
treatment will be approximately the same for the whole group. This ignores 
the possibility that sub-populations within the sample may derive a greater- or 
less-than-average benefit from treatment (Dorresteijn et al., 2011). Standard 
trial analyses, which report an effect size for the whole sample, may thus fail 
to detect clinically-important variations in sub-groups of patients (Young et al., 
2005). Since levodopa is known to act upon the basal ganglia, it was felt to be 
possible that any response to levodopa might be heavily attenuated in patients 
who had experienced a stroke that included these structures; or conversely, 
that preservation of the basal ganglia might be a pre-requisite for responding 
to levodopa-linked rehabilitation. An understanding of how structural brain 
impairment (as seen on CT imaging) might influence a patient’s response to 
levodopa therefore could have been useful in informing future clinical 
guidelines about which patients might benefit from this treatment. 
The results of the DARS trial are currently in press. Unfortunately, co-
careldopa did not prove to be effective in enhancing motor recovery in the 
moderately-disabled sample of stroke survivors enrolled by DARS. 
Exploratory analyses showed no evidence of a differential effect of levodopa 
with stroke type (infarct versus haemorrhage), gender or age. Nor was there 
evidence of a beneficial effect of levodopa on secondary outcome measures, 
such as hand function or independence in activities of daily living. Hence, on 
the basis of the largest randomised controlled trial of levodopa-augmented 
stroke rehabilitation to date, this intervention cannot be recommended for 
routine clinical use.  
1.2.3.4. Why did Levodopa prove ineffective in enhancing stroke 
rehabilitation?  
Although these results are disappointing, the question of whether levodopa 
might enhance recovery of walking ability following stroke has at least been 
answered in a robust clinical trial that is likely to stand as the definitive study 
of this intervention. However, the mechanism by which levodopa might 
influence recovery was biologically plausible, and several smaller trials had 
suggested a positive effect on motor function and other outcomes. It is 
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therefore worth considering why levodopa did not deliver measureable clinical 
benefit when applied to a large sample of patients. As we have seen above, 
motor learning and other cognitive functions are crucially dependent upon 
interactions between disparate brain structures. Although the putative action 
of co-careldopa is as a modulator of basal ganglia functions, any effect is likely 
to be subsumed in vivo by the impact of more generalised brain injury both as 
a result of the stroke itself and as a consequence of a prior burden of 
microvascular disease. Motor learning ability may be heavily attenuated by 
both the global burden of brain injury, and by the impairment in cognitive 
function as a result of this. Furthermore, the efficacy of rehabilitation 
interventions may be reduced by other impairments in bodily functions that 
are ostensibly not directly related to the stroke itself, such as musculoskeletal 
pain, fatigue, and depression. 
1.2.4. Other impairments that might influence recovery from 
stroke 
1.2.4.1. Musculoskeletal pain 
Musculoskeletal pain is common in the general population (around 15% 
prevalence; Keenan et al. (2006)), but particularly so amongst stroke survivors 
(prevalence of up to 47%; Hettiarachchi et al. (2011)). The combined impact 
of these two pathologies is considerable, and greater than the individual 
impact of either condition occurring in isolation (Hettiarachchi et al., 2011). For 
example, having left hip pain without a co-existing stroke confers a ten-fold 
increase in the odds of reporting difficulty in standing and walking 
(Hettiarachchi et al., 2011), whereas an isolated right hemiparesis as a result 
of a stroke confers a five-fold increase in the odds of reporting problems with 
standing and walking (Hettiarachchi et al., 2011). When both impairments are 
present simultaneously, the odds for reporting problems in standing and 
walking is increased by almost fifty-fold (Hettiarachchi et al., 2011). This 
suggests that the combined effect of both impairments (right hemiparesis and 
contralateral hip pain) is far more disabling than either impairment alone. 
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1.2.4.2. Fatigue 
Fatigue is a debilitating consequence of stroke, but estimates of prevalence 
vary enormously (from 23% to 75%)  depending on the characteristics of the 
sample studied (Choi-Kwon and Kim, 2011). Definitions of “post stroke 
fatigue” (PSF) vary (Lynch et al., 2007, Staub and Bogousslavsky, 2001) and 
there is even debate about whether PSF represents a single construct or a 
common manifestation of a variety of underlying processes (Choi-Kwon and 
Kim, 2011, Wu et al., 2015). A recent systematic review found no evidence of 
an association between the onset of fatigue and the presence of white matter 
lesions and brain atrophy, and mixed evidence of an association between 
fatigue and stroke laterality and location (Kutlubaev et al., 2012). 
Nevertheless, fatigue may reduce a patient’s ability to participate in 
rehabilitation.  
1.2.4.3. Depression 
Depression occurs in up to a third of stroke survivors (Hackett et al., 2005, 
Kutlubaev and Hackett, 2014) but the interaction between mood and disability 
is complex. A small study conducted some years ago in an Irish sample found 
that 20% of patients met the criteria for major depression (Cassidy et al., 
2004). However, the presence of depression did not seem to influence final 
rehabilitation outcomes; the stronger predictor of rehabilitation outcome was 
the baseline Barthel Disability Score (Cassidy et al., 2004). Depression is 
associated with stroke severity and disability (Aben et al., 2002, Appelros and 
Viitanen, 2004, Brown et al., 2012, Desmond et al., 2003, Eriksson et al., 
2004, Kotila et al., 1998, Pohjasvaara et al., 1998, Townend et al., 2010, 
Verdelho et al., 2004, Kutlubaev and Hackett, 2014) but the directionality and 
causality of this relationship is unclear. It is possible that an extensive stroke 
leads to severe disability, with depression as a consequence of this; it is 
equally plausible that depression may attenuate a patient’s motivation to 
participate in rehabilitation, thereby increasing the risk of an adverse outcome 
(Kutlubaev and Hackett, 2014).  
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1.2.5. Might an assessment of brain structure contribute to 
predicting prognosis in rehabilitation? 
Although the initial intention of this Thesis (to explore the impact of structural 
brain impairment upon a patient’s ability to respond to co-careldopa-
augmented rehabilitation) was superseded by the negative results of the 
DARS trial, the data-set that DARS made available represents an important 
opportunity to explore how patients recover from stroke, and to begin to 
develop models that might contribute to more accurate prognostication. In 
particular, the availability of brain imaging for a large cohort of patients allows 
an exploratory analysis of how impairment in brain structure (as seen on CT) 
might interact with other impairment in bodily structures (musculoskeletal 
pain) and functions (cognition, fatigue, and mood) to produce limitation of 
motor recovery.  
1.2.5.1. The current role of brain imaging in rehabilitation assessment  
At present, a rehabilitation assessment usually begins with a detailed 
assessment of a person’s physical impairment, and seeks to understand how 
this interacts with contextual factors (both personal and environmental) to 
produce limitation of activities and restriction of participation (Gutenbrunner et 
al., 2006). However, the role of neuroimaging in predicting rehabilitation 
outcomes is unclear (Stinear and Ward, 2013). As such, although CT 
scanning remains useful in guiding the acute management of patients 
presenting with a clinical stroke syndrome, a detailed review of imaging does 
not at present form a routine part of prognostication in stroke rehabilitation 
(Stinear and Ward, 2013).  
1.2.5.2. The use of advanced imaging techniques in rehabilitation 
assessment  
It has been suggested that MRI scanning may allow impairment in brain 
structure (injury to the corticospinal tract) to be linked to impairment in bodily 
function (limb weakness), and thus to limitation of activity (walking) (Lee et al., 
2005, Tang et al., 2010). There is, however, there is no  consensus on the 
value of this approach in predicting walking ability (Dawes et al., 2008). More 
recently, an algorithm comprising a combination of clinical outcome 
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measures, neurophysiological assessment of corticospinal tract integrity, and 
MRI assessment of the posterior limb of the internal capsule has been used 
to predict recovery of upper limb function after stroke (Stinear et al., 2012). 
However, the value of such an approach in predicting walking ability has not 
been established. Functional MRI may be helpful in predicting recovery of 
certain functions such as language, (Saur et al., 2010) but it has not been 
widely applied in routine clinical practice (Stinear and Ward, 2013).  
1.2.5.3. Might CT imaging contribute to prediction of rehabilitation 
outcomes? 
The notion of combining an assessment of impairment in brain structure (on 
imaging) with impairment in brain function (using clinical assessment) to guide 
prognostication in rehabilitation is nevertheless appealing. However, if 
prognostic models are to be useful in clinical practice, then it is advantageous 
to utilise predictor variables that are easily collected. MRI scanning is more 
time consuming than CT. It is thus not currently the recommended imaging 
modality for acute stroke, due to the difficulties of managing safely patients 
who are unwell whilst images are being acquired, and the requirement for 
rapid imaging to inform time-sensitive treatment decisions such as 
thrombolysis. More specialised MRI modalities such as fMRI may have the 
potential to provide a more detailed assessment of brain structure, but are not 
yet in routine clinical use. CT scanning, although not without its limitations, is 
thus the investigation of choice for acute stroke and is  routinely performed in 
all patients presenting with symptoms suggestive of stroke. Thus, if imaging 
parameters are to be included in a prognostic model, then variables derived 
from CT imaging are more likely to be routinely available than those that rely 
upon MRI or fMRI. However, the use of CT imaging in prognostic modelling 
depends upon a standardised and clinically-meaningful method of coding 
scan findings. Several such templates exist, for both ischaemic stroke and 
ICH, and will be discussed below.   
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Part 1.3 Standardised image analysis instruments 
1.3.1. Mechanisms of brain injury in stroke 
The use of brain imaging as a predictor of rehabilitation outcomes is not at 
present widespread. The association between imaging markers of brain injury 
and motor recovery will be one of the key considerations of this Thesis. 
However, in order to understand radiological descriptors of tissue injury and 
how imaging findings evolve over time, it is helpful to first review the cellular 
mechanisms that underpin these processes.   
1.3.2. Mechanisms of brain injury in ischaemic stroke 
1.3.2.1. Initial cascades of brain injury following acute ischaemia 
In ischaemic stroke the initial cause of tissue injury is hypoxia. This unleashes 
several cascades of events that lead to neuronal injury and cell death. Some 
of these pathways cause immediate injury, others result in a delayed insult 
over subsequent hours and days (Albert-Weisenberger et al., 2013). Acute 
ischaemia initially results in an inability to maintain transmembrane ion 
gradients, and water influx causing cell swelling (“cytotoxic oedema”; Meuth 
et al. (2009)). More prolonged ischemia results in the production of free 
radicals and changes in intracellular pH (Albert-Weisenberger et al., 2013). 
Oxidative stress stimulates the release of glutamate, causing the activation of 
lytic enzymes (Iadecola and Anrather, 2011). Tissue perfusion may be further 
compromised by microvascular thrombosis as a result of dysfunction of the 
vascular endothelium (Stoll et al., 2008). In the most severe cases disruption 
of the blood/ brain barrier may lead to vasogenic oedema, with a life-
threatening rise in intracranial pressure (Ayata and Ropper, 2002). In the post-
acute phase, a variety of immune-cell-based mechanisms also contribute to 
tissue injury (Albert-Weisenberger et al., 2013, Iadecola and Anrather, 2011). 
1.3.2.2. Evolution of CT findings after acute ischaemic stroke 
Cellular injury following stroke is a dynamic process that evolves over time. 
The same is true of the imaging findings that result from brain ischaemia. In 
the early stages of an infarct, swelling as a result of cytotoxic oedema may be 
seen on plain CT as effacement of the sulci overlying the infarct (Wardlaw and 
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Mielke, 2005). The increased water content of ischaemic brain tissue causes 
reduced attenuation of the x-ray beam, and therefore an apparent reduction 
in density of ischaemic tissue relative to surrounding brain. In its earliest 
stages this may be visible as loss of the normal differentiation at interfaces 
between grey and white matter (the basal ganglia, frontoparietal cortex, and 
insular ribbon) (Grotta et al., 1999, Wardlaw and Mielke, 2005), or later as an 
area of “hypodensity”. The presence of an acute clot within a vessel may 
cause it to assume a hyperattenuated appearance (Wardlaw and Mielke, 
2005), which, if visible, may suggest an infarct involving that vascular territory 
even if other signs of parenchymal ischaemia are not yet obvious. As an infarct 
matures, more marked hypodensity develops, with both the cortex and white 
matter of the infarcted zone appearing darker than normal on CT (Grotta et 
al., 1999). Early signs of ischaemia are often subtle; a systematic review found 
inter-observer agreement for these signs to be poor to moderate (Wardlaw 
and Mielke, 2005). However, these findings were based on evidence that in 
some cases dates back to the early 1990s (Wardlaw and Mielke, 2005). The 
technology for both acquiring and viewing imaging has changed considerably 
since then. For example, only one study reviewed images in digital format on 
computer workstations (as is current practice); the remainder using lightboxes 
to view images printed on to films (Wardlaw and Mielke, 2005). Whether 
subsequent advances in technology have improved detection rates for early 
ischaemic changes remains unknown (Wardlaw and Mielke, 2005). 
Interestingly, blinding observers to patients’ clinical symptoms did not affect 
detection rates for early ischaemic change (Wardlaw and Mielke, 2005). 
1.3.2.3. Brain imaging findings and prognosis after stroke 
Although scanning provides at best a proxy assessment of clinical impairment 
after stroke (Kobayashi et al., 2009), the presence of any visible infarct on a 
baseline CT scan is associated with an increased risk of dependency 
(Wardlaw et al., 1998). It is also positively correlated with adverse functional 
outcome on the BI, Glasgow Outcome Scale (GOS), and NIHSS (Saver JL et 
al., 1999), although other studies have found that models incorporating 
imaging variables are not superior to those incorporating clinical variables 
alone (Reid et al., 2010). The initial volume of an infarct or haemorrhage 
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significantly predicts outcome measured by the mRS at 90 days, adding 15% 
to the explicable variance compared with a model comprising age and NIHSS 
score alone (Vogt et al., 2012).  
1.3.3. Mechanisms of brain injury in ICH 
1.3.3.1. Causes of ICH 
ICH is typically the result of spontaneous rupture of arterioles that have 
sustained long-term injury to the intima and sub-endothelium due to 
hypertension, atherosclerosis, or beta amyloid deposition (Qureshi et al., 
2009). More rarely, a secondary cause will be found such as a vascular 
malformation, coagulopathy, or an underlying neoplasm (Macellari et al., 
2014). The sites most commonly affected are the cerebral hemispheres, basal 
ganglia, thalamus, pons, and cerebellum (Qureshi et al., 2009). Up to 60% of 
those experiencing an ICH will be dead within a year, with half of these 
fatalities occurring within the first seven days (Sacco et al., 2009).  
1.3.3.2. Mechanisms of brain injury in ICH 
Tissue injury and cell death following intracerebral haemorrhage occur via a 
variety of mechanisms, which will be reviewed in detail below. The initial injury 
is usually a direct mechanical disruption of tissue as a result of the expanding 
haematoma (Xue and Yong, 2008). Subsequently the release of blood 
products, inflammatory cells, and proteases into the brain parenchyma causes 
a widespread inflammatory response (Xue and Yong, 2008). Rupture of a 
haematoma into the ventricular system with subsequent formation of 
intraventricular thrombus may also obstruct the normal circulation of 
cerebrospinal fluid, causing secondary brain injury due to acute obstructive 
hydrocephalus (Balami and Buchan, 2012). 
1.3.3.3. Causes of early deterioration in ICH: haematoma expansion 
Deterioration in neurological status is common within the first 48hours 
following ICH (Mayer et al., 1994). The most common cause is early 
expansion of the haematoma. Radiologically, there is no consensus on what 
constitutes h\aematoma “expansion”: various definitions have been proposed 
including absolute increase in volume or percentage change in haematoma 
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volume relative to initial lesion size (Dowlatshahi et al., 2011). Various cut-offs 
have been proposed, including absolute volume change by >3ml, >6ml, or 
>12.5ml (Dowlatshahi et al., 2011), and relative increase by >33% or >40% 
(Dowlatshahi et al., 2011). Although haematoma expansion is associated with 
adverse functional outcome (defined using the mRS), the sensitivity and 
specificity of this predictor for unfavourable outcome change depending upon 
how “expansion” is defined (Dowlatshahi et al., 2011, Davis et al., 2006). 
Furthermore, detecting haematoma expansion relies upon serial imaging at 
two or more time-points. This necessitates additional radiation exposure for 
the patient, and is thus not routine practice unless there is strong clinical 
evidence to suggest expansion. Since serial imaging is not universally 
performed in stroke care, the models presented here will be constructed using 
only findings from the first available CT scan. For this reason, haematoma 
expansion will not be included as a possible predictor variable.  
The initial volume of a haematoma, however, may be obtained from first 
imaging and appears to be important in predicting the risk of early expansion. 
Data from several trials in the Virtual International Stroke Trials Archive 
(VISTA: Ali et al. (2007)) have shown that a smaller initial haematoma volume 
is not only independently associated with lower mortality and favourable 
functional outcomes on the mRS at 90 days, but also with a decreased risk of 
subsequent haematoma expansion (Dowlatshahi et al., 2010). No 
haematomas with an initial size of <3ml went on to expand by >6ml, whereas 
7% of haematomas of 3-10ml, and 30.4% of those >10ml did so (Dowlatshahi 
et al., 2010). For an expansion of >12.5ml, the percentages of haematomas 
expanding were 0% (initial volume <3ml), 1.4% (initial volume 3-10ml), and 
16.9% (initial volume >10ml). For expansion of >33% above baseline, 17.6% 
of haematomas <3ml expanded, versus 22.4% of those 3-10ml and 27.6% of 
those >10ml (Dowlatshahi et al., 2010). 
1.3.3.4. Causes of early deterioration in ICH: rupture of the haematoma 
in to the ventricular system 
Aside from direct pressure effects of the initial lesion, a further burden of brain 
injury may be imposed by rupture of the haematoma into the ventricular 
system. This results initially in a widespread ventriculitis. Subsequently, clot 
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formation within the ventricular system may cause impedance of the normal 
circulation of cerebrospinal fluid, leading to an obstructive hydrocephalus in 
up to 50% of patients (Balami and Buchan, 2012). This may contribute further 
to rising intracranial pressure, causing secondary brain injury (Balami and 
Buchan, 2012). The mortality attendant with intraventricular extension is 
greater than that of intracerebral haemorrhage alone, and is estimated at 50-
75% (Balami and Buchan, 2012). Thalamic and caudate haematomas have 
the highest incidence of Intraventricular rupture due to their anatomical 
proximity to the ventricular system (Hallevi et al., 2008). Although larger 
haematoma volumes are generally correlated with the risk of intraventricular 
rupture (Steiner et al., 2006), the actual volume of blood required to precipitate 
this is lower for thalamic and pontine haematomas versus lobar lesions 
(Hallevi et al., 2008).  
The volume of blood in the ventricles is of prognostic importance, with 20ml 
or more being associated with poor outcome (Young et al., 1990). A combined 
volume of parenchymal and intraventricular blood of >40ml also predicts poor 
outcome on the mRS, with combined volumes of >60ml being predictive of 
mortality (Hallevi et al., 2009). With a combined haemorrhage volume above 
50ml, poor outcome (death or dependency) is universal (Hallevi et al., 2009). 
The presence of any intraventricular extension is also indicative of a poor 
prognosis, irrespective of volume. Hallevi et al. (2008) found that patients with 
intraventricular haemorrhage were twice as likely to be dead or dependent 
(mRS 4-6), and three times more likely to die than those with an isolated 
parenchymal haemorrhage. In the one large study of recombinant clotting 
Factor VII for intracerebral haemorrhage, only 20% of patients with 
intraventricular haemorrhage achieved a good outcome (mRS of 1-3), versus 
43% of those with unruptured parenchymal haematomas (Steiner et al., 2006). 
The presence of intraventricular rupture at any time-point independently 
predicted death or dependency (mRS of 4-6) at 90 days (Steiner et al., 2006). 
The Surgical Trial in Intracerebral Haemorrhage (STICH) likewise 
demonstrated that 31.4% of those without intraventricular extension achieved 
a good outcome (defined using the GOS), versus 15.1% of those with 
haematomas that ruptured (Bhattathiri et al., 2006). 
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1.3.3.5. Evolution of CT findings after acute ICH 
The appearance of a haematoma on CT changes as it matures, and may 
provide a rough estimate of its age (Macellari et al., 2014). An acute 
haematoma returns a homogenous, hyperdense appearance (Macellari et al., 
2014). Over the first 48 hours fluid levels may become apparent within the 
haematoma, reflecting different rates of coagulation or new bleeding within 
the haematoma (Macellari et al., 2014). The haematoma itself is typically 
surrounded by oedematous tissue (Balami and Buchan, 2012). Initially this is 
vasogenic oedema: a consequence of the leakage of osmotically active 
proteins from injured vessels in to the brain parenchyma (Balami and Buchan, 
2012). There is often an initial rapid expansion of oedema volume within the 
first 72 hours after haemorrhage (Arima et al., 2009). This may be seen on CT 
as a rim of hypodensity surrounding the haematoma itself (Macellari et al., 
2014).  
Subsequently, the presence of highly irritant blood products within the 
extravascular space stimulates activation of the inflammatory cascade, 
leading to a second phase of oedema accumulation which may persist over 
the first few days and weeks after ictus (Balami and Buchan, 2012). Over the 
next three weeks the appearance of the haematoma on CT imaging slowly 
becomes less intense, and when intravenous contrast medium is 
administered the periphery of the lesion may enhance to give a ring-like 
appearance mimicking an abscess (Macellari et al., 2014). By around nine 
weeks the lesion assumes its final hypodense appearance on CT (Macellari 
et al., 2014). Whilst plain CT is used primarily for confirming the diagnosis of 
ICH, contrast-enhanced CT (CE-CT) may be helpful in judging the risk of 
further haematoma expansion (Macellari et al., 2014). Leakage of contrast 
medium from injured vessels in to the haematoma cavity (the “spot sign”) has 
been shown to predict haematoma expansion and clinical deterioration 
(Macellari et al., 2014). CE-CT may also be used to detect underlying vascular 
abnormalities (Macellari et al., 2014). However, CE-CT carries a greater 
radiation exposure than plain CT, and in some patients a risk of precipitating 
renal failure or allergic reaction to the contrast medium (Macellari et al., 2014). 
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In practice, the use of this modality in evaluating acute ICH is therefore limited 
(Macellari et al., 2014). 
1.3.3.6. Models to predict prognosis after acute ICH 
Several models have been developed in order to predict which patients might 
be at risk of adverse outcomes following ICH. These are referenced and 
summarised in Appendix A. Many include radiological, as well as clinical, 
predictors. The aims of such models range from informing initial management 
decisions (such as who might benefit from surgery or intensive care) to 
providing more accurate prognostic information to patients and their families, 
or stratifying patients for entry in to research trials. For this reason, all models 
incorporated predictors that could be collected shortly after admission: 
typically a combination of radiological and clinical variables. Early mortality 
remains a key outcome with predictors including age, disordered 
consciousness on admission, admission GCS, haematoma diameter, volume 
of haematoma, the presence or absence of intraventricular extension, the 
presence of hydrocephalus, haemorrhage location (supratentorial versus 
infratentorial), history of hypertension, pulse pressure, subarachnoid 
extension, NIHSS score, blood glucose level, displacement of midline 
structures, mean arterial pressure, vomiting on admission, and the presence 
of signs of ischaemia on CT. Many of these variables (age, impairment of 
consciousness, baseline GCS, volume of haematoma, intraventricular 
extension, presence of hydrocephalus, supratentorial versus infratentorial 
location, midline shift, pulse pressure, admission temperature, and NIHSS 
score) are also predictors of functional outcomes measured using the mRS, 
GOS, or BI. Models therefore tend to include combinations of the same 
predictors, but with differing categorisation of predictor variables, cut-off 
scores, or score weightings used to provide additional sensitivity or specificity 
for mortality or for functional prognosis as required. 
1.3.4. The need for a standardised system to code scan findings 
As has been shown above, CT findings may offer important prognostic 
information; at least in terms of predicting the risk of death or dependency in 
activities of daily living (Wardlaw et al., 1998, Saver JL et al., 1999, Vogt et 
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al., 2012, Cheung and Zou, 2003, Cho et al., 2008, Lisk et al., 1994, Ruiz-
Sandoval et al., 2007, Tuhrim et al., 1991). However, the value of early CT 
scanning as a predictor of walking ability is less certain. If the question of 
whether or not baseline imaging is a useful predictor of rehabilitation outcome 
is to be addressed, then a standardised system for analysing scans and 
coding findings is required. The use of standardised templates to aid scan 
reporting is thought to improve the accuracy of scan reporting by non-
radiologists, since having a systematic approach to reviewing images helps to 
ensure that subtle signs are not missed (Wardlaw et al., 2007, Wardlaw et al., 
2010), 
1.3.5. Standardised systems for coding ischaemic stroke 
1.3.5.1. Why were standardised coding systems for CT findings in 
acute ischaemic stroke first developed? 
Several standardised templates for reporting scan findings in ischaemic stroke 
exist: but they were not developed with prediction of functional prognosis in 
mind. Their development can be traced back to early trials of thrombolysis, 
which showed that patients with more extensive infarcts carry a greater risk of 
subsequent haemorrhagic transformation (Kaste et al., 1995, Anonymous, 
1995, Anonymous, 1996, Hacke et al., 1995). The ability to determine the 
extent of an infarct on early imaging was therefore felt to be crucial to the safe 
implementation of this intervention. This prompted the development of 
standardised methods for quantifying the extent of ischaemic change on CT 
scans. Such systems required good inter-observer agreement: not only 
amongst neuro-radiologists, but also amongst the stroke physicians, 
neurologists, and acute physicians who it was felt would most likely be 
involved in making a decision to proceed with thrombolysis (Grotta et al., 
1999). 
1.3.5.2. The “⅓MCA rule” 
The earliest and simplest system to be developed was the so-called “⅓MCA 
rule” (Kaste et al., 1995). This divided the volume of the middle cerebral artery 
(MCA) territory into 3, with ischaemic change in >⅓ thought to pose a higher 
risk for thrombolysis (Kaste et al., 1995, Hacke et al., 1998). Unfortunately this 
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system yields only moderate inter-observer agreement (Grotta et al., 1999). 
When used to determine eligibility for a hypothetical thrombolysis trial, even 
experienced observers correctly classified only 45% of patients as eligible or 
ineligible, although prior training did improves the rate of correct classification 
(von Kummer, 1998). This system does however have reasonable test-retest 
reliability, with 80% of scans being coded identically on first and second 
reading (Wardlaw et al., 1999). The utility of the “⅓MCA rule” in predicting 
recovery of walking has not been established. 
1.3.5.3. The Alberta Stroke Program Early CT Score (ASPECTS) 
The difficulty in estimating the extent of ischaemic change using the ⅓MCA 
rule prompted the development of more systematic methods for quantifying 
MCA ischaemia, in the hope of improving inter-observer agreement (Barber 
et al., 2000). The Alberta Stroke Program Early CT Score (ASPECTS; Barber 
et al. (2000)) defines ten regions within the MCA territory: six cortical 
(numbered M1-M6), and four subcortical (caudate, lentiform nucleus, insular 
cortex, and internal capsule). From an initial score of ten points, one point is 
deducted for each region in which signs of acute ischaemia (swelling, 
hypoattenuation, or loss of grey/ white matter definition) are seen (Barber et 
al., 2000). A score of 10 therefore denotes no visible ischaemic change, whilst 
a score of zero indicates ischaemia involving the entire MCA territory (Barber 
et al., 2000).   
1.3.5.4. ASPECTS as a predictor of prognosis  
In contrast to the “⅓MCA rule”, the ASPECTS was intended from the outset 
to predict functional outcome: albeit dichotomised as “independent” versus 
“dead or dependent” (Barber et al., 2000). It was anticipated that it would be 
helpful not only as a decision aid for thrombolysis but also in the selection of 
patients for trials of future neuroprotective drugs (Barber et al., 2000). 
Dichotomising baseline ASPECTS (scored on the CT scan performed at 
presentation) in to ≤7 or >7 discriminated independence (mRS 0-2) from 
dependence and death (mRS 3-6) at 3months (Barber et al., 2000). 
Dichotomised ASPECTS was also predictive of symptomatic haemorrhage 
after thrombolysis (p=0.012; Barber et al. (2000)). With knowledge of the 
affected side, the inter-observer agreement for dichotomised ASPECTS 
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ranged from k=0.71 for radiology trainees to k=0.86 for stroke neurologists 
and k=0.89 for neuro-radiologists (Barber et al., 2000). This compared 
favourably with the ⅓MCA rule (k-0.64 for radiology trainees, 0.61 for stroke 
neurologists, and 0.52 for experienced neuro-radiologists). Without 
knowledge of the affected side agreement was more modest (k=0.39 for 
radiology trainees,0.69 for stroke neurologists, and 0.47 for neuro-
radiologists), but agreement remained higher than that achieved using the 
⅓MCA rule (k=0.14 for trainees, 0.49 for neurologists, and 0.37 for 
neuroradiologists; Barber et al. (2000)). The sensitivity of dichotomised 
ASPECTS for good versus poor functional outcome was 0.78, with a 
specificity of 0.96 (Barber et al., 2000). Comparable figures for the ⅓MCA rule 
are sensitivity 0.73, specificity 0.91.  
As a predictor of good/poor functional outcome, the ASPECTS score thus 
compares favourably with baseline clinical findings using the NIHSS. When 
dichotomised as ≤15 or >15, the NIHSS has sensitivity 0.69, and specificity 
0.76 for good versus poor outcome (Barber et al., 2000). Since its inception, 
ASPECTS has been widely used and evaluated. When comparing ASPECTS 
scored in “real time” clinical practice (i.e. at the point of treatment) by stroke 
physicians with the score subsequently allocated by a radiologist on later 
review, there was substantial agreement (weighted k=0.69), although the 
stroke physicians tended to under-estimate the extent of ischaemic change 
when ASPECTS was >7, and over-estimate the extent of changes by nearly 
two points for the worst-affected scans (ASPECTS<3) (Coutts et al., 2004). 
Although useful in predicting “good/ poor” functional outcome, the ASPECTS 
remains a comparatively crude assessment of the extent of an infarct. For 
example, an ASPECTS of 8 indicates ischaemia in two of the ten areas of 
interest, but does not specify which two (Wardlaw et al., 2010). Also, 
ASPECTS only codes infarction in the MCA territory. It offers no information 
on other vascular territories, and nor does it provide accurate coding of 
features such as oedema, mass effect, lacunar lesions, white matter lesions, 
and haemorrhagic transformation of infarcts. It does not classify old infarcts 
and non-stroke lesions. 
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1.3.5.5. The Acute Ischaemic Stroke Classification Template (AISCT) 
The Acute Ischaemic Stroke Classification Template (AISCT), was developed 
by Professor J.M. Wardlaw et al, of the Brain Research Imaging Centre, 
Neuroimaging Sciences, Edinburgh (www.bric.ed.ac.uk; Wardlaw and Sellar 
(1994)). It comprises a series of templates for coding the location and extent 
of ischaemic change and tissue swelling, which were constructed following a 
review of over 100 scans (Appendix B; Wardlaw and Sellar (1994)). The 
AISCT addresses many of the deficiencies of the “⅓MCA rule” and ASPECTS, 
and was thus used in DARS with the agreement of Professor Wardlaw.  
1.3.5.6. Inter-observer agreement of the AISCT 
Amongst experienced neuroradiologists, the AISCT has good inter-observer 
agreement for infarct size and type (K=0.78), excellent agreement for infarct 
swelling (K=0.80), and moderate agreement for haemorrhagic transformation 
of the infarct (Wardlaw and Sellar, 1994). Amongst radiology trainees, it has 
moderate to good agreement for infarct size and site, fair to moderate 
agreement for infarct swelling, and poor to fair agreement for haemorrhagic 
transformation (Wardlaw and Sellar, 1994). The inter-observer agreement of 
AISCT system has also been evaluated in a large sample of non-radiologists 
from a variety of specialties and with prior experience of CT interpretation 
ranging from <5 years to >10 years (Wardlaw et al., 2007, Wardlaw et al., 
2010). The inter-observer agreement of the AISCT is comparable to that of 
the ⅓MCA rule, ASPECTS (area under receiver operator characteristics curve 
0.602-0.604 for all scales; Wardlaw et al. (2010)). When the performance of 
neuroradiologists was compared to that of non-radiologists, the expert 
observers tended to spot more subtle signs of ischaemia compared with non-
experts (Wardlaw et al., 2007), and took longer to read each scan (Wardlaw 
et al., 2010). More severe ischaemia (hypodensity and swelling) was more 
reliably detected than subtle signs, and a longer time from presentation to 
scan also improved detection rates for ischaemic change (Wardlaw et al., 
2010). Detection of acute ischaemia was not influenced by scan quality, or by 
the presence of an old ischaemic lesion (Wardlaw et al., 2010). The AISCT 
has been used in the Third International Stroke Trial, IST-3 (Sandercock et 
al., 2012, The IST collaborative group, 2015), and was also adapted for a 
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subsidiary study to determine if CT or MRI angiography might be used to guide 
administration of tissue plasminogen activator at up to six hours after stroke 
(Wardlaw et al., 2014a). The relationship between infarct classification using 
this system and prognosis for return to walking has not yet been established. 
1.3.5.7. How well does the AISCT correlate with clinical impairment? 
In DARS, the diagnosis of “stroke” was clinically defined (Aho et al., 1980, 
Bhakta et al., 2014). Patients were not required to have a compatible stroke 
lesion visible on imaging in order to be eligible to participate. However, the 
AISCT classification of ischaemic lesions has shown a good correlation with 
the clinical classification of ischaemic stroke described by Bamford et al. 
(1991). Radiological lesions that are compatible with a total anterior circulation 
stroke syndrome (TACS) include infarcts involving: the whole of the cortical 
MCA territory (Kobayashi et al., 2009); the whole of the cortical MCA territory 
plus the lateral basal ganglia (Kobayashi et al., 2009); the whole MCA territory 
(Kobayashi et al., 2009); or more than 50% of the MCA territory plus the 
anterior cerebral artery (ACA) or posterior cerebral artery (PCA) territory 
(Mead et al., 2000). Infarcts compatible with a partial anterior circulation stroke 
syndrome (PACS) include: small cortical infarcts; infarcts of the ACA territory; 
or a border-zone infarct between the MCA and ACA or MCA and PCA 
territories (Mead et al., 2000). Lesions compatible with either a TACS or a 
PACS syndrome include: medium-sized cortical infarcts of about half the MCA 
territory; or large (>1.5cm) striatocapsular infarcts (Mead et al., 2000). A 
posterior circulation stroke syndrome (POCS) is compatible with a cortical 
infarct in the posterior cerebral artery (PCA) territory, or a lesion in the brain 
stem or cerebellum, including small infarcts to the pons (Mead et al., 2000). A 
lacunar stroke syndrome (LACS) is compatible with any subcortical lacunar 
infarct, including in the centrum semiovale (Mead et al., 2000).  
With this in mind, it is possible to determine the proportion of patients in a 
sample who manifest imaging findings that are compatible with their clinical 
stroke syndrome. Mead et al. (2000) reported a series of 1012 patients with 
ischaemic stroke, of whom 655 had a recent infarct visible on CT or MRI. Of 
those with a visible recent infarct, 75% had a lesion compatible with their 
clinical syndrome (Mead et al., 2000). Breaking down by syndrome, 79% of 
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patients with a TACS syndrome had a compatible lesion, as did 71% of 
patients with a PACS syndrome, 83% of those with a POCS, and 73% of those 
with a LACS (Mead et al., 2000). Figures for the whole sample can be 
estimated by assuming a “best case scenario (in which all patients with no 
visible acute infarct at baseline later develop a lesion compatible with their 
clinical syndrome), and a “worst case” scenario (under which no patients 
without a visible infarct initially later develop a lesion compatible with their 
clinical syndrome). Assuming the “best case” scenario the total percentage of 
patients who would have a compatible lesion would be 84%: 81% for TACS; 
81% for PACS; 90% for POCS; and 85% for LACS (Mead et al., 2000). 
Assuming the “worst case” scenario, the total percentage with compatible 
scan findings would be 49% (73% for TACS; 48% for PACS; 50% for POCS; 
and 40% for LACS; Mead et al. (2000)). The positive predictive values of each 
clinical syndrome for a compatible CT lesion were: TACS 79% (95% CI 68%-
87%); PACS 71% (66%-75%); POCS 83% (75%-89%); and LACS 73% (63%-
80%) (Mead et al., 2000).  
Kobayashi et al. (2009) reported findings from the first 510 patients presenting 
to the IST-3 trial. Of those with abnormal scans (329/510), figures for those 
presenting with a compatible clinical syndrome and radiological lesion were: 
79% for TACS; 57% for PACS; 33% for POCS; and 40% for LACS. Assuming 
a “best case” scenario in the whole sample gives: 100% TACS; 80% PACS; 
81% POCS; and 62% LACS (Kobayashi et al., 2009). Assuming a “worst 
case” scenario in the whole sample, the estimates are: 79% TACS; 37% 
PACS; 14% POCS; and 2% LACS (Kobayashi et al., 2009). This indicates 
that, if an infarct is not seen on imaging, the clinical syndrome as defined by 
the Oxford Community Stroke Project classification may provide a reasonably 
reliable surrogate estimate of its location and size (Mead et al., 2000): at least 
for TACS and PACS syndromes (Kobayashi et al., 2009). Findings for POCS 
and LACS were less consistent. This may in part reflect the lower sensitivity 
of acute CT imaging for lacunar infarcts (Kobayashi et al., 2009). It may also 
reflect the mis-assignment of patients to the LACS category by the computer 
algorithm used by IST-3: in the sample reported by Kobayashi et al, around 
20% of those judged to have a “LACS” syndrome in fact had a small cortical 
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or striato-capsular infarct that would be more consistent with a PACS 
syndrome (Kobayashi et al., 2009). 
1.3.6. Standardised systems for coding ICH 
1.3.6.1. What imaging variables are of prognostic importance after ICH? 
Several imaging variables are associated with poor functional outcome from 
intracerebral haemorrhage. These include: volume of intracerebral 
haemorrhage (Cho et al., 2008, Godoy et al., 2006, Ruiz-Sandoval et al., 
2007, Tuhrim et al., 1991, Lisk et al., 1994, Mase et al., 1995, Schwarz et al., 
2000, Shaya et al., 2005); intraventricular extension (Godoy et al., 2006, Ruiz-
Sandoval et al., 2007, Tuhrim et al., 1991, Portenoy et al., 1987, Mase et al., 
1995, Schwarz et al., 2000, Hallevy et al., 2002, Bhattathiri et al., 2006); 
presence of hydrocephalus (Shaya et al., 2005); supra-tentorial versus infra-
tentorial location (Ruiz-Sandoval et al., 2007); and midline shift (Hallevy et al., 
2002). As discussed previously the utility of these variables in predicting other 
outcomes such as recovery of walking ability remains unknown. The 
classification systems for ischaemic stroke that were described above either 
do not include detailed coding of ICH (Barber et al., 2000, Kaste et al., 1995), 
or code ICH primarily in the context of haemorrhagic transformation of an 
underlying infarct (Wardlaw and Sellar, 1994). Additional coding for specific 
ICH variables that may be of prognostic importance is therefore required. A 
variety of classification systems have been developed, for purposes as 
diverse as enrolling patients in to clinical trials of surgical haematoma 
evacuation (Bhattathiri et al., 2003, Mendelow et al., 2005), judging the effects 
of interventions such as blood pressure reduction (Delcourt et al., 2012, 
Delcourt et al., 2010) or recombinant factor VII for intracerebral haemorrhage 
(Mayer et al., 2005a, Mayer et al., 2005b), or the recording and reporting of 
intracerebral haemorrhage as an adverse event during trials of thrombolysis 
for acute myocardial infarction (Gebel et al., 1998).  
1.3.6.2. Assessment of haematoma volume 
All of the standardised systems for coding ICH that were outlined above 
incorporate an assessment of haematoma volume (Bhattathiri et al., 2003, 
Mendelow et al., 2005, Delcourt et al., 2012, Delcourt et al., 2010, Mayer et 
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al., 2005a, Mayer et al., 2005b, Gebel et al., 1998), but methods for deriving 
this vary. Computer-assisted planimetry uses computer software to estimate 
the surface area of each axial slice, which is then multiplied by slice thickness 
and summed to provide an estimate of volume (Gebel et al., 1998, Delcourt 
et al., 2012, Delcourt et al., 2010, Mayer et al., 2005b, Mayer et al., 2005a, 
Kosior et al., 2011). These software packages are rarely available in routine 
clinical practice (Divani et al., 2011). A more straightforward, albeit less 
accurate, method for estimating the volume of a haematoma utilises the 
formula: 
Volume = A × B × C 
                2 
in which A is the greatest dimension of the haemorrhage on axial imaging; B 
is the greatest diameter at 90° to A; and C is the approximate number of axial 
imaging slices on which the haematoma is visible, multiplied by slice thickness 
(Kwak et al., 1983, Kothari et al., 1996). This “ABC/2 method” has been widely 
used (Bhattathiri et al., 2003, Mendelow et al., 2005, Mendelow et al., 2011, 
Hemphill et al., 2001, Ruiz-Sandoval et al., 2007, Vogt et al., 2012, Sloan et 
al., 1995, Claassen et al., 2001, Leira et al., 2004, Lisk et al., 1994), but it 
assumes that the 3-dimensional shape of a haematoma approximates to an 
ellipsoid (Divani et al., 2011). It therefore provides a less accurate estimation 
of the volume of irregularly-shaped haematomas than computer-assisted 
planimetry (Kothari et al., 1996, Divani et al., 2011), with reports of an error of 
up to 8% in such lesions (Divani et al., 2011). The measurement error for the 
“C” term has also been shown to increase with each millimetre of axial slice 
thickness (Divani et al., 2011). These sources of error may be problematic in 
studies that rely upon detecting change in haematoma volume over two or 
more imaging series acquired at different time points (Divani et al., 2011): but 
in this Thesis only the initial haematoma volume will be considered. 
Furthermore, the ABC/2 method can be used with little training and without 
the need for computerised post-acquisition image processing. For these 
reasons, this was the method chosen for estimating haematoma volume in 
DARS. 
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1.3.6.3. Systems for coding other ICH characteristics 
Numerous systems have been proposed to classify other lesion 
characteristics such as haematoma location, and the presence of 
intraventricular extension, hydrocephalus, or mass effect (Bhattathiri et al., 
2003, Gebel et al., 1998, Lisk et al., 1994).  
Gebel et al. (1998) classified haemorrhage location as parenchymal, 
subdural, intraventricular, or subarachnoid. The site was coded as frontal, 
parietal, occipital, thalamus, basal ganglia/ internal capsule, cerebellar, and 
brainstem (Gebel et al., 1998). They noted haematoma characteristics such 
as the presence of a blood/ fluid level, and the haematoma appearance 
(confluent, mottled, or hypodense) (Gebel et al., 1998). Signs of mass effect 
were noted including: ventricular effacement; horizontal or vertical shift of the 
pineal gland; effacement of the cisterns; and subfalcine or transtentorial 
herniation of brain structures (Gebel et al., 1998). Hydrocephalus and 
intraventricular extension were classified as mild, moderate, or severe, with 
descriptors of each provided (Gebel et al., 1998). The presence of any other 
brain lesion (cortical or lacunar infarct, atrophy, periventricular leucomalacia, 
underlying mass lesion) were noted (Gebel et al., 1998). The volume of the 
largest haematoma was calculated using computer-assisted planimetry: and 
thus relied upon software that would not be available for use in routine clinical 
practice (Gebel et al., 1998).  
Lisk et al (Lisk et al., 1994) classified the site of the haemorrhage as 
putaminal, thalamic, or lobar; ventricular enlargement, ventricular extension, 
and mass effect were graded as “none”, “slight”, “moderate”, or “severe”; 
subarachnoid blood was coded as present or absent; the volume of 
haemorrhage was calculated using the ABC/2 method; and the largest 
diameter of the haemorrhage was noted (Lisk et al., 1994).  
Although comprehensive, the methods of Gebel et al. (1998) and Lisk et al. 
(1994) have not been validated for inter-observer agreement. The system 
proposed by Bhattathiri et al. (2003), however, has  a published assessment 
of inter-observer agreement. This system calculates volume (using the ABC/2 
method), records the subjective presence or absence of hydrocephalus, a 
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measurement of midline shift, depth of the haematoma from the cortical 
surface, and haematoma location (classified as frontal, temporal, parietal, 
occipital, basal ganglia, internal capsule, and thalamus) . When inter-observer 
agreement for this system was evaluated (in two consultant neurosurgeons, 
two neurosurgical trainees, one consultant neuroradiologist, and one 
radiology trainee), there was good agreement for side of haemorrhage 
(k=0.87), lobar (versus deep) origin (k=0.78), involvement of the basal ganglia 
and thalamus (k=0.85), and the presence of intraventricular extension 
(k=0.82). However, agreement was moderate (k=0.44) for the presence of 
hydrocephalus (Bhattathiri et al., 2003). The system developed by Bhattathiri 
et al. (2003) will therefore form the basis of the haemorrhage classification 
system used for DARS, albeit with one minor addition not included in the 
original: the presence or absence of intraventricular extension as a 
dichotomous variable. 
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Part 1.4 Developing a prognostic model to predict recovery 
of mobility after stroke 
1.4.1. The need to predict specific rehabilitation outcomes 
1.4.1.1. What is a “prognostic model”? 
A prognostic model is a means of combining a series of predictor variables in 
order to generate an estimate of the risk of a specified outcome for an 
individual patient (Steyerberg et al., 2013). As detailed above, there has been 
substantial research interest in predicting outcome after both ischaemic stroke  
and ICH. However, many existing models focus upon predicting the risk of 
death (Broderick et al., 1993, Hemphill et al., 2001, Cheung and Zou, 2003, 
Godoy et al., 2006, Tuhrim et al., 1991, Lisk et al., 1994, Cho et al., 2008, 
Ruiz-Sandoval et al., 2007, Bhattathiri et al., 2006), the risk of adverse events 
such as post-thrombolysis haemorrhage (Kaste et al., 1995, Hacke et al., 
1998), or crude “dependent/ independent” functional outcomes such as the 
mRS (Cheung and Zou, 2003, Lisk et al., 1994, Hallevy et al., 2002, Portenoy 
et al., 1987, Schwarz et al., 2000).  
1.4.1.2. How useful are existing prognostic models in rehabilitation 
practice? 
Whilst such models might be of value in guiding treatment decisions in the 
acute stages of care, their value in the rehabilitation phase is limited. In 
rehabilitation practice, patients and their families are usually concerned about 
the recovery of specific activities (Craig et al., 2011). Although measures such 
as the NIHSS have some relationship to broad functional outcome, they are 
of limited value in predicting whether an individual patient might be able to 
achieve goals such as walking, using a computer, or holding a conversation 
(Stinear and Ward, 2013). 
1.4.1.3. The potential uses of models to predict specific rehabilitation 
outcomes  
The ability to offer a more detailed rehabilitation prognosis than “death or 
dependency” would be enormously useful for rehabilitation professionals and 
patients and their families. In particular, the ability to walk independently is a 
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crucial determinant of whether or not a patient is likely to be able to return to 
independent living or require institutional care (Craig et al., 2011). Being able 
to predict reliably who might walk again would therefore allow the rehabilitation 
team to deliver a more accurate prognosis when speaking to patients and their 
families (Craig et al., 2011). This would in turn allow both patients and the 
team to set achievable rehabilitation goals, and may also facilitate early 
planning for discharge thereby minimising the length of a patient’s hospital 
stay (Kwakkel and Kollen, 2013). Accurate prognostication may also allow 
rehabilitation interventions to be selected and tailored towards the needs of 
individual patients. For example, those who have the highest probability of 
regaining independent walking may be more likely to benefit from restorative 
approaches, whereas for those with a low probability of walking again the 
focus of rehabilitation would be to teach the use of adaptive and compensatory 
strategies. Perhaps most interestingly, prognostic models may allow 
emergent rehabilitation interventions such as robotics to be targeted towards 
those who stand the greatest chance of responding to these treatments 
(Kwakkel and Kollen, 2013). However, the derivation and introduction in to 
clinical practice of a prognostic model poses several challenges. 
1.4.2. The challenges of developing prognostic models 
1.4.2.1. Clinical versus statistical validity 
Of course, fully realising the potential benefits of prognostic modelling will 
depend upon constructing valid models to predict outcomes that are important 
in rehabilitation practice. It is therefore important to consider what is meant 
when one refers to the “validity” of a model. In modelling, “validity” may be 
viewed as both a clinical and a statistical concept. The clinical validity of a 
model refers to its ability to predict satisfactorily an outcome that is of clinical 
importance (Altman and Royston, 2000). This is determined in part by the 
choice of predictor variables that are fitted to the model. If variables that are 
intrinsically weak predictors are used, then its predictive ability in practice will 
be limited. The concept of statistical validity refers to the goodness-of-fit of a 
model to both the data-set in which it was derived, and to the population of 
patients to which it is ultimately applied. The two concepts are not 
synonymous. For example, it is possible to derive a model that is an excellent 
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fit to data, but which predicts an outcome that is of no clinical interest 
whatsoever (Vickers and Cronin, 2010). Such a model might be said to have 
good statistical validity, but limited clinical validity. Conversely, the 
Framingham model to predict mortality from cardiovascular disease has high 
clinical validity and is widely used in practice, despite having only modest 
discriminatory power in some sub-populations (Moons et al., 2009a). Some of 
the difficulties associated with the development and introduction in to clinical 
use of prognostic models are well-illustrated by considering the myriad of 
models developed to predict outcomes in ICH that were discussed above.  
1.4.2.2. What is meant by the “clinical validity” of a model? 
If the clinical validity of a model depends upon its ability to predict an outcome 
reliably, then the choice of predictor variables included is a crucial and often 
difficult judgement when constructing a model. Often this decision is based 
upon what has already been demonstrated to be of prognostic importance, 
with variables being entered in to or excluded from the model in order of the 
strength of their individual association with the outcome of interest (Altman 
and Royston, 2000). Statistical software packages may allow this process to 
be semi-automated, with little or no intellectual input in to selection of predictor 
variables (Altman and Royston, 2000). Unfortunately it does not always follow 
that predictors selected by a computer algorithm are the most clinically valid, 
or that they will yield the strongest prediction (Altman and Royston, 2000). 
Furthermore, choosing candidate predictors based upon a review of previous 
literature may present a problem if the outcome of interest has not been 
explored previously. For example, although several models predict survival 
with disability following ICH (Cheung and Zou, 2003, Lisk et al., 1994, Hallevy 
et al., 2002, Portenoy et al., 1987, Schwarz et al., 2000, Ruiz-Sandoval et al., 
2007, Godoy et al., 2006, Cho et al., 2008, Shaya et al., 2005, Tuhrim et al., 
1991, Bhattathiri et al., 2006), the outcome measures they adopted (Jennett 
and Bond, 1975, Bonita and Beaglehole, 1988) are fairly crude categorical 
scales that classify disability as mild, moderate, or severe. It is possible that 
variables that are predictive of dichotomised “death or dependency” outcomes 
will have little or no validity in predicting specific rehabilitation outcomes such 
as recovery of walking ability.  
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1.4.2.3. What is meant by the “statistical validity” of a model?  
The construction of a statistical model is simply the first step in the process of 
development and introduction into clinical use. Many of the models developed 
to predict prognosis in ICH appeared to perform reasonably well in predicting 
outcomes in the samples in which they were derived (Ariesen et al., 2005). 
However, their adoption into routine clinical practice has been limited (Ariesen 
et al., 2005). It is  worth considering why this might be so. Firstly, fitting a 
model to a single sample without subsequent validation risks over-estimating 
the predictive value of variables included: so-called “over-fitting” (Altman and 
Royston, 2000). Models that are over-fitted tend to be unduly complex and 
may contain predictors that, whilst statistically significant in the derivation 
cohort, add little or no predictive value when applied to other samples (Altman 
and Royston, 2000). This may explain why an evaluation of three prognostic 
models for intracerebral haemorrhage (Hemphill et al., 2001, Ruiz-Sandoval 
et al., 2007, Cho et al., 2008) found that the predictive power of the GCS alone 
was similar to that of all three more complex models (Parry-Jones et al., 2013). 
Furthermore, the properties of an over-fitted model may change when it is 
applied to a sample of patients with different characteristics to the derivation 
cohort. This instability may engender mistrust amongst clinicians (Ariesen et 
al., 2005). For example, models to predict outcome in intracerebral 
haemorrhage tend to be most reliable in identifying patients with the highest 
probabilities of death or poor outcomes (Ariesen et al., 2005). In clinical 
practice however, the majority of patients have a somewhat lower risk of death 
or disability (Ariesen et al., 2005). The accuracy of models in discriminating 
moderate from high risk of death or poor outcome is questionable, and  raises 
concerns that patients may be inappropriately assigned to the “poor 
prognosis” group and thus denied aggressive care (Ariesen et al., 2005). 
Statistical models cannot therefore be assumed to be generalisable beyond 
the data-set in which they were originally derived (Altman and Royston, 2000). 
For this reason, fmal validation is required for all models prior to adoption in 
to clinical practice (Altman and Royston, 2000). Moons et al. (2015) have 
proposed a hierarchy of validation, ranging from development only (in which 
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a model is derived but not validated) to the evaluation of a published model 
using an independent data-set. 
1.4.2.4. Other considerations when developing a prognostic model 
Aside from the requirement for both statistical and face validity, the ease with 
which a model may be used in practice is an important determinant of how 
widely it is ultimately adopted. The use of predictors that are time-consuming 
to collect or that are not collected as part of routine practice may severely limit 
a model’s clinical utility. A second consideration is how the model is used to 
generate a summary risk score. Using a single predictor variable (a univariate 
model) is most straightforward, but in practice univariate models rarely provide 
sufficient predictive ability (Moons et al., 2015). Combining several predictors 
in a multivariate model may improve the accuracy of predictions, but the 
complex scoring systems required to assimilate data from several variables 
into a summary statistic may be difficult to apply and interpret in practice 
(Moons et al., 2015). This was certainly the case for several early prognostic 
models for intracerebral haemorrhage, which derived their output scores using 
complex algebraic equations (Ariesen et al., 2005).  
1.4.3. Aims of this Thesis 
The development and introduction into clinical practice of a prognostic model 
is thus no easy matter. However the rich DARS data-set presents an 
opportunity for an exploratory analysis of variables that influence recovery of 
walking ability after stroke, whilst remaining mindful of the above 
considerations. This Thesis  aims to develop a series of models to predict who 
might recover the ability to walk 10m or more after stroke. It will utilise a 
combination of clinical predictor variables and markers of impairment in brain 
structure derived from CT to predict the dichotomous outcome “able to walk 
independently for 10m or more, with aid if necessary but no standby help” at 
two time points: eight weeks and six months after randomisation in to the 
DARS trial.  
This work will focus upon the initial development of the models, but not their 
validation. Nor will their utility in a clinical setting be assessed. It must be 
stressed that these models are derived “post-hoc” from an existing data-set. 
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The limitations of this approach are well recognised, and  will be discussed in 
detail in the concluding chapter. The intention of this work is to generate 
hypotheses that might be explored subsequently in a prospective cohort. 
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Chapter 2. Methods 
Part 2.1 Methods for the DARS trial  
2.1.1. What was the DARS trial? 
2.1.1.1. Primary objective of the DARS trial 
DARS was a multi-centre double-blinded randomised controlled trial of co-
careldopa or placebo in conjunction with standard NHS physiotherapy and 
occupational therapy in patients presenting with a new clinical diagnosis of 
stroke (Bhakta et al., 2014). The primary objective of the trial was to compare 
the proportion of patients in the active treatment and placebo arms who were 
walking independently by eight weeks after randomisation (Bhakta et al., 
2014).  
2.1.1.2. Primary outcome measure 
The primary outcome measure was the self-reported ability of patients to walk 
ten metres or more (with an aid if necessary) at eight weeks after 
randomisation (Bhakta et al., 2014). This was defined using the Rivermead 
Mobility Index (RMI; Collen et al. (1991)): specifically a RMI score or seven or 
greater, or answer “yes” to question seven. Since co-careldopa proved 
ineffective in enhancing recovery from stroke, the DARS data-set has been 
treated as a large observational cohort for the purposes of this Thesis. The 
process of randomisation and the medication regimen administered are thus 
of little relevance to this work: they will be outlined here in sufficient detail to 
provide context, but the full protocol for DARS has been published elsewhere 
(Bhakta et al., 2014). 
2.1.2. Trial setup 
2.1.2.1. Sponsorship and sources of funding 
The DARS trial was funded by the National Institute for Health Research 
(Grant reference number 08/43/61; Bhakta et al. (2014)). It was sponsored by 
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the University of Leeds, and coordinated from the University of Leeds Clinical 
Trials Research Unit (CTRU; Bhakta et al. (2014)).  
2.1.2.2. Trial management and oversight 
The management of the trial was the responsibility of the Trial Management 
Group, with support from the Trial Steering Committee (TSC). An independent 
Data Monitoring and Ethics Committee (DMEC) was convened to provide 
oversight as the trial progressed (Bhakta et al., 2014). The DMEC had full 
access to unblinded trial data, including all end-points and reports of adverse 
events and serious adverse events. They had the authority to terminate the 
trial at any point in the light of concerns about safety, or in the event of new 
evidence emerging that called in to question the clinical equipoise of the trial. 
The design and conduct of the trial, data analysis, and authorship of any 
papers that arise from this work are at the sole discretion of the TSC, without 
influence from the Sponsor or funding body. 
2.1.2.3. Trial registration 
DARS was registered with the International Standard Randomised Controlled 
Trial Number (ISRCTN) database (Faure and Hrynaszkiewicz (2011); 
www.isrctn.com, registration number ISRCTN99643613) and the European 
Union Drug Regulating Authorities Clinical Trial Register 
(https://eudract.ema.europa.eu/: registration number 2009-017925-20) 
(Bhakta et al., 2014).  
2.1.2.4. Legal framework and ethical approval 
The Trial was approved by the Medicines and Healthcare Products Regulatory 
Agency, and was conducted in accordance with: applicable legislation 
including the European Union Clinical Trials Directive 2001/20/EC (The 
European Parliament and Council, 2001) and the UK Medicines for Human 
Use (Clinical Trials) Amendment Regulations, 2006 (The Stationery Office, 
2006); the principles of Good Clinical Practice in research as laid down in the 
Declaration of Helsinki (The World Medical Association, 2013); and the NHS 
Research Governance Framework for Health and Social Care, 2005 
(Department of Health, 2005). All data received, including digital copies of 
scans, were collected,  handled, and stored securely in accordance with the 
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requirements of the Data Protection Act, 1998 (The Stationary Office, 1998). 
Ethical approval was granted by the UK National Research Ethics Service 
(reference 10/H1005/6; Bhakta et al. (2014)). Initial ethical approval was 
followed by approval of an amendment to the protocol and patient information 
sheet, to make explicit the intention of the trial team to collect copies of any 
available neuroimaging for the index admission.  
2.1.2.5. Recruiting centres 
Participants were recruited from NHS stroke services across all four nations 
of the United Kingdom. Coordination of site setup, recruitment, and 
randomisation was managed by The University of Leeds CTRU. The trial 
opened to recruitment in May 2011; the final participant was recruited in March 
2014. The large number of centres that were recruiting to DARS necessitated 
the establishment of a network of local Principal Investigators (PIs), each of 
whom was responsible for the conduct of the trial at their site. PIs were 
consultant physicians, usually in stroke medicine, neurology, or rehabilitation 
medicine. Their duties included the recruitment and consenting of participants, 
overseeing the clinical care of patients enrolled in the trial, and the reporting 
and medical management of adverse events. Screening, consent, 
randomisation, and follow-up of participants were performed by researchers 
employed by the Comprehensive Local Research Network (CLRN). However, 
the DARS trial also necessitated considerable involvement from NHS staff 
such as ward nurses and therapists: many of whom had had no previous 
involvement in research. For this reason, a series of face-to-face site initiation 
visits were arranged, with training in trial procedures provided for key 
personnel. The training package was developed and delivered by Dr John 
Pearn (JP: Clinical Research Fellow to the DARS trial) and Ms Lorna Barnard 
(CTRU Trial Monitor). Ongoing support and advice to sites was also provided 
throughout the recruitment period by CTRU. 
2.1.3. Participants 
2.1.3.1. Sample size and power calculation 
An initial target of 572 participants was set, providing a 90% power to detect 
a 50% difference in the proportion of patients walking independently in the 
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intervention and control arms at eight weeks, using a 5% significance level. 
This sample size also provided an 80% power to detect a small to moderate 
effect size (0.3) in key secondary outcomes (Bhakta et al., 2014). However, a 
slightly higher than expected rate of loss to follow-up at the eight-week time 
point necessitated continuation of recruitment to a larger sample size of 592 
participants in order to retain power for the primary outcome at the specified 
level (The DARS Collaborators: data not yet published).  
2.1.3.2. Inclusion criteria 
Patients were eligible to participate if they: had sustained a new or recurrent 
clinically diagnosed ischaemic stroke or ICH (excluding subarachnoid 
haemorrhage) within 5 to 42 days prior to randomisation; were unable to walk 
ten metres or more indoors independently (with an aid if necessary, but no 
physical assistance); had a therapist-completed RMI score of <7; were 
expected to require rehabilitation treatment; were aged 18 years or above; 
were able to give informed consent; were able to access continuity of 
rehabilitation treatment following discharge from hospital (defined as being 
able to access community-based rehabilitation services within five days of 
hospital discharge); were expected to be able to comply with the treatment 
schedule (for example, were able to swallow whole tablets); and were 
expected to be in hospital for at least the first two doses of trial medication 
(Bhakta et al., 2014).  
2.1.3.3. Exclusion criteria 
Patients were deemed ineligible if they: were not expected to survive for two 
months following stroke; had a diagnosis of Parkinson’s disease, severe 
medical or surgical illness, or severe psychosis; had a known hypersensitivity 
or contraindication to co-careldopa treatment; had symptomatic orthostatic 
hypotension; needed physical assistance of at least one person to walk prior 
to their index stroke due to pre-existing co-morbidities (for example, heart 
failure, or osteoarthritis); were pregnant, lactating, or a women of child-bearing 
potential (unless they were willing to use medically approved contraception 
whilst receiving treatment and for one month after the cessation of treatment); 
could not walk 10 metres or more indoors prior to their stroke (Bhakta et al., 
2014). 
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2.1.3.4. Patient consent 
Written informed consent was obtained from all participants by local stroke 
physicians, all of whom had received training in trial procedures and in Good 
Clinical Practice in Research (Bhakta et al., 2014). Provisions were made to 
allow witnessed consent to be obtained in patients who had capacity to 
consent but were unable to sign the consent form (for example, due to 
weakness of the dominant hand).  
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Part 2.2 Treatment and follow-up 
All DARS participants were randomised to receive up to eight weeks of co-
careldopa or placebo, in conjunction with usual NHS physiotherapy and 
occupational therapy sessions (Bhakta et al., 2014). There were four points at 
which data were collected: at entry in to the trial; at eight weeks after 
randomisation; at six months after randomisation; and at twelve months after 
randomisation. The process of data collection and the treatment regimen will 
be described below.  
2.2.1. Timing of assessments 
2.2.1.1. Protocol-specified timing of assessments 
The timing of assessments was specified in the DARS protocol (Bhakta et al., 
2014), and is summarised in Figure 2.1. A baseline assessment was 
performed on the day of randomisation. Follow-up assessments were then 
conducted at “eight weeks” and “six months” after randomisation. However, 
since patients were eligible for enrolment in to the trial between 5 and 42 days 
after stroke, the actual timing of assessments in relation to the date of the 
stroke was heterogeneous. For example, when allowance was made for the 
recruiting window, the “eight week” assessment could be conducted within a 
range of 61-96 days. In addition, a grace period of ±5 days was permitted 
within which visits could be arranged. Hence, the window within which “eight 
week” assessments could be conducted was 56-101 days after stroke. 
Similarly, the window for performing “six month” visits (accounting for the 
recruitment period and a “grace period” of ±7 days) was 178-229 days after 
stroke.  
2.2.1.2. Definition of data collection points used in this Thesis 
This Thesis will refer to the timing of assessments as follows: “baseline” 
assessment as “T0”; “eight week” assessment as “T1”; and “six month” 
assessment as “T2”. The protocol also specified a final follow-up visit at up to 
one year after randomisation (Bhakta et al., 2014). These data are not 
available at the time of writing, so the latest end-point which will be considered 
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here is T2. For consistency, the “twelve month” follow-up will where necessary 
be referred to as “T3” (Figure 2.1.). 
 
Figure 2.1. Summary of timeline for screening, recruitment, treatment, and 
follow-up of DARS participants. 
2.2.2. Summary of outcome measures used in the DARS trial 
2.2.2.1. Overview of data collection 
The outcome measures used in DARS, and the timing of their collection, are 
summarised Appendix C. The primary outcome measure was the RMI (Collen 
et al. (1991); see Appendix D) This was collected at T0, T1, T2, and T3. Data 
Day 0: patient presents with new stroke symptoms 
Day 0-5: screening 
Day 5-42: recruitment 
T0 assessment on day of randomisation  
Up to six weeks of rehabilitation in conjunction with co-
careldopa 100/25mg OR matching placebo  
Day 61-96: T1 assessment (eight weeks after randomisation) 
Day 178-229: T
2
 assessment (six months after randomisation) 
Day 363-414: T
3
 assessment (one year after randomisation) 
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were also collected on possible modifiers of levodopa effect, including 
psychological morbidity (the 12-item version of the General Health 
Questionnaire: GHQ-12) (Goldberg and Blackwell, 1970, Goldberg and Hillier, 
1979); musculoskeletal pain (the Musculoskeletal Signs, Symptoms, and Pain 
Manikin: MSK-SSP, Keenan et al. (2006)); fatigue (the Fatigue Assessment 
Scale: FAS, Michielsen et al. (2003)); and cognitive impairment (the Montreal 
Cognitive Assessment: MoCA, Nasreddine et al. (2005)). Each will be 
described below. A range of secondary outcome measures were also 
collected, encompassing other aspects of physical function (the Abilhand 
scale; Penta et al. (1998)), independence in activities of daily living (a postal 
version of the BI (pBI) (Gompertz et al., 1994, Mahoney and Barthel, 1965); 
and the Nottingham Extended Activities of Daily Living scale (NEADL; Nouri 
and Lincoln (1987)); health-related quality of life (the EuroQol EQ-5D; Rabin 
and de Charro (2001)); and global disability (the mRS; Bonita and Beaglehole 
(1988)). These secondary outcome measures did not form part of the analysis 
presented here, and thus will not be described in detail. 
2.2.2.2. Clinician-reported and self-reported Rivermead mobility Index 
The RMI score at T0 was crucial both for confirming eligibility and for the 
stratification of participants during randomisation. For this reason, a clinician-
completed RMI was obtained at T0. This was filled in by the patient’s therapist, 
based upon their knowledge of the patient’s capabilities. The RMI was also 
the primary outcome measure at T1, T2, and T3. However, it was deemed 
impractical to collect therapist-completed RMI scores at these times, since a 
proportion of patients (particularly at T2, and T3) would have been discharged 
from therapy by the time of follow-up. A patient self-reported RMI was 
therefore collected at T1, T2, and T3 as an outcome measure, and also at T0 
to facilitate comparison with the self-reported RMI. Clinician-reported and self-
reported versions of the RMI were identical in all respects, with no difference 
in the wording of items or in their scoring. Nevertheless, the abbreviations C-
RMI (for the clinician-scored RMI administered only at T0) and SR-RMI (self-
reported RMI collected at T0, T1, T2, and T3) will be used in order to make 
explicit how they were completed. The abbreviation “RMI” will also be used, 
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when referring to the Rivermead Mobility Index in a context in which it is not 
necessary to specify the manner of its completion. 
2.2.3. Assessment at T0 and treatment regimen 
2.2.3.1. Assessment at T0 
The assessment at T0 was conducted after consent had been obtained, but 
prior to randomisation. It included the administration of a basket of 
standardised outcome measures and basic demographic and clinical 
information. The demographic information collected included: initials; date of 
birth; and number of years of formal education. Clinical history included: the 
date and type (ischaemic or haemorrhagic) of stroke; the date and type (CT 
or MRI) of any available neuroimaging; whether the patient had received 
intravenous thrombolysis; and details of the patient’s past medical history. 
Those with ischaemic stroke were prospectively categorised by treating 
clinicians according to the Oxford Community Stroke Project classification 
(Bamford et al., 1991). This categorises the patient’s clinical stroke syndrome 
on the basis of their presenting features as TACS, PACS, POCS, or LACS 
syndromes (Bamford et al., 1991).  
In addition to baseline demographic and clinical information, each patient was 
asked to complete a range of self-reported outcome measures including: the 
SR-RMI; the pBI; the NEADL; the Abilhand, the EQ-5D; the GHQ-12; and the 
MSK-SSP (Bhakta et al., 2014). The NEADL, Abilhand, and MSK-SSP were 
answered with respect to the patient’s pre-stroke status: all other self-reported 
outcome measures were answered in relation to the patient’s current abilities 
(Bhakta et al., 2014). All of these questionnaires could either be self-
completed by the patient or directly administered by the researchers if the 
patient was physically incapable of marking responses. The MoCA was 
supplied separately, and was administered by the DARS researchers during 
a face-to-face visit (Bhakta et al., 2014).  
2.2.3.2. Randomisation and blinding 
Following the T0 assessment, patients were randomised on a 1:1 basis to 
receive either co-careldopa 125mg (levodopa 100mg, and a peripheral DOPA 
decarboxylase inhibitor, carbidopa 25mg) or matching placebo. To ensure that 
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treatment groups were well balanced patients were stratified (Bhakta et al., 
2014) by: recruiting centre; type of stroke (infarct versus haemorrhage); and 
C-RMI score (0-3, 4-6).  
2.2.3.3. Medication regimen 
The medication regimen for DARS has been described elsewhere (Bhakta et 
al., 2014). In brief, one oral tablet of either co-careldopa 125mg or matching 
placebo was taken 45-60minutes before the start of physiotherapy or 
occupational therapy sessions. The medication was administered only prior to 
therapy sessions in which the focus was on motor activity (Bhakta et al., 
2014). The timing of dosing reflected the absorption kinetics of levodopa 
(which reaches peak plasma levels at 30-120minutes after a dose), as well as 
evidence from previous trials of co-careldopa in stroke (Rosser et al., 2008a, 
Scheidtmann et al., 2001). Although the protocol stipulated that trial 
medication should be administered within this optimum time window, it was 
appreciated from the outset that circumstances may not always permit this. A 
pragmatic approach was therefore adopted, under which it was deemed 
permissible to administer the drug between at any time prior to the start of a 
therapy session if necessary (Bhakta et al., 2014). If a patient had two therapy 
sessions within three hours of a first dose, then an additional dose of the drug 
was not given prior to the second session (Bhakta et al., 2014). A maximum 
of two doses were administered in any 24-hour period (Bhakta et al., 2014). 
Sufficient medication was supplied to each patient for a maximum course of 
six weeks of treatment: a duration which reflects that used in previous trials of 
co-careldopa-augmented stroke rehabilitation (Acler et al., 2009a). If a clinical 
decision was taken by the treating team that further rehabilitation intervention 
was no longer required before the conclusion of the six week drug treatment 
period, then the drug was discontinued at the point of discharge from 
rehabilitation services. When patients were discharged to the care of a 
community stroke team, the treating therapist was asked to provide a 
medication prompt by telephone up to an hour before their planned session. 
Adverse events were classified in accordance with definitions laid down by the 
European Union Directive 2001/20/EC (The European Parliament and 
Council, 2001). Responsibility for detecting, managing, and reporting these 
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events rested with local PIs. Adherence to the medication regimen was 
estimated by performing a count of the number of tablets remaining in the 
medication kit at the end of the treatment period, and reconciling this count 
with records of the number of drug-linked therapy sessions the patient had 
received. This was perhaps an imperfect measure of pharmacoadherence, 
since it relied upon a retrospective review of records which were in some 
cases incomplete. Pill counts are also time consuming, and may over-estimate 
adherence since they assume that all tablets that are not present have actually 
been taken (Chisholm-Burns and Spivey, 2008). However, these methods 
were felt on balance to provide a more reliable estimate than direct 
questioning of the patients. 
2.2.3.4. Content of therapy sessions 
The content of drug-linked therapy sessions was entirely at the discretion of 
the treating teams according to their assessment of the patients’ needs and 
their routine clinical practice (Bhakta et al., 2014). Therapists were blinded to 
treatment allocation, and instructions given to ward nurses and therapy staff 
concerning drug administration were the same for both treatment arms 
(Bhakta et al., 2014). After each drug-linked session, therapists were asked 
to complete a short case report form. This detailed the time at which the drug 
was taken (or the reason for omission of the drug), and an approximate 
breakdown of the amount of time devoted to upper limb motor therapy, lower 
limb motor activity, and non-motor work. The purpose of this was to allow the 
amount of therapy intervention delivered to be ascertained, and to verify parity 
between intervention and control arms. 
2.2.4. Follow-up of participants 
2.2.4.1. Follow-up assessment at T1 
Follow-up assessments were conducted by a network of CLRN researchers 
at T1, T2, and T3. Visits at T1 were sometimes conducted whilst the participant 
was still an inpatient. Visits at T2 and T3 were usually conducted in the patient’s 
usual place of residence, but allowance was made for participants to be 
recalled to research clinics where this was local practice. Telephone follow-up 
was permitted only under exceptional circumstances. A booklet of 
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questionnaires for the T1 follow-up was supplied to the patient at the point of 
randomisation, as part of a patient information pack which also contained a 
patient information booklet, DVD, and CRFs for therapists to complete in their 
sessions. The self-reported outcome measures contained in this booklet 
included: the SR-RMI; the pBI; the NEADL; the ABILHAND; the EQ-5D; the 
GHQ-12; the MSK-SSP; and the FAS (Bhakta et al., 2014). All were recorded 
in relation to the patient’s current status. The patient was contacted by the 
researcher prior to the visit, and asked to complete them in advance. If this 
was not possible, they were administered directly by the researcher during 
their visit. The Modified Rankin Scale (mRS) (Bonita and Beaglehole, 1988) 
and the MoCA (Nasreddine et al., 2005) were administered directly (Bhakta 
et al., 2014). Patients were also asked about any adverse events associated 
with treatment.  
2.2.4.2. Follow-up assessment at T2 and T3 
The visits at T2, and T3 were similar in nature. A booklet of patient self-
completed questionnaires was posted out to the patient in advance. As for the 
follow-up visit at T1, these comprised: the SR-RMI; the pBI; the NEADL; the 
ABILHAND; the EQ-5D; the GHQ-12; the MSK-SSP; and the FAS (Bhakta et 
al., 2014). Once again questions were answered with respect to the patient’s 
current status. The patient was asked to complete them within the week before 
the researcher’s visit, but direct administration by the researcher was 
permitted if necessary. The mRS (Bonita and Beaglehole, 1988) and the 
MoCA (Nasreddine et al., 2005) were administered directly by the researcher 
(Bhakta et al., 2014). Patients were also asked if they had experienced any 
new and significant medical or surgical illnesses since the last follow-up visit. 
At the T3 visit an exit poll was also conducted, asking the patient if they thought 
they had been in the active or placebo arm of the trial: the purpose of this was 
to assess the security of blinding procedures. 
The DARS data-set thus comprises an extensive set of outcome measures, 
taken at four time-points. The purpose of the models derived here is to 
establish whether impairment-level variables (depression, fatigue, 
musculoskeletal pain, and cognitive dysfunction) may serve as useful 
predictors of walking ability at T1 and T2. However, in order to understand how 
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these variables were used in analysis, it is important to consider the properties 
of the scales used to measures them. 
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Part 2.3 Outcome measurement in the DARS trial  
2.3.1. The principles of measurement 
2.3.1.1. What is “measurement”? 
It is common to make measurements in medicine. For example, when 
predicting the future risk of stroke in a person with AF, we might wish to 
measure certain biometric parameters such as their SBP, or serum glucose 
levels (Wang et al., 2003). These are all easily observable and can be 
quantified directly by measuring devices, for example a sphygmomanometer, 
or laboratory tests (Hobart and Cano, 2009). The units in which they are 
described have precisely the same interval between each gradation. One can 
therefore be confident that, within the limits of measurement error, a blood 
glucose level of 10mmol/L is twice as great as a level of 5mmol/L. When 
intervening to control risk factors for stroke, one might also define success in 
terms of change in these parameters over time: for example, in reducing a 
patient’s SBP from 180mmHg to 130mmHg (a fall with a magnitude of 
50mmHg). Clinical trials commonly report mean reductions in SBP for different 
treatments (Rashid et al., 2003). A key property of such measurements is that 
the interval between each unit change is a fixed, and known, value. Such 
measurements are thus termed “interval-level”, and can be subjected quite 
legitimately to mathematical operations such as calculation of mean values or 
the change in value between from one measurement to another. 
2.3.1.2. Measuring rehabilitation outcomes 
Unfortunately measuring rehabilitation outcomes is not as straightforward as 
measuring physiological variables, since the property that is under 
consideration is frequently some aspect of a person (or their physical 
performance) that cannot be observed or measured directly: for example 
“mobility,” “fatigue,” “depression,” or “independence” (Hobart and Cano, 
2009). These are termed latent (hidden) traits. Although they are not directly 
measurable, it is often possible to draw inferences about the degree to which 
they are present in an individual or a group (Hobart and Cano, 2009). To do 
this one must first define the property (or “construct”) to be measured, then 
devise a range of questions (“items”) that map out its possible range on a 
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continuum or “lesser” to “greater” (Hobart and Cano, 2009). This is what 
outcome measures such as the RMI, GHQ-12, or FAS seek to do for the 
constructs of “mobility”, “depression”, and “fatigue” respectively. The 
properties of the RMI, GHQ-12, mRS, MSK-SSP, FAS, MoCA will be 
examined below. 
2.3.2. Outcome measures used in the DARS trial 
2.3.2.1. Primary outcome measure: the Rivermead Mobility Index 
The RMI (Collen et al. (1991); Appendix C) was the primary outcome measure 
selected for DARS. It is a fifteen-item scale, with each item having two 
possible responses: “yes” (able to do the task) or “no” (unable to do the task) 
(Collen et al., 1991, Hobart and Cano, 2009). Items are presented in order of 
increasing difficulty, with the first item being turning over from the back to the 
side in bed, and the final item running ten meters in four seconds without 
limping (Collen et al., 1991). Fourteen items rely upon the patient’s self-report; 
one (question 5) requires the interviewer to observe the patient standing 
unsupported for ten seconds. In the DARS trial question 5 was operationalised 
by simply relying upon the patient’s self-report of whether they could achieve 
this. Each “yes” response scores one point, which are then summed to give a 
total score out of 15. 
2.3.2.2. The Modified Rankin Scale (mRS) 
The Rankin Scale is an ordinal hierarchical scale that ranks different levels of 
disability (Rankin, 1957). The original measure was developed in 1957, and 
mapped a continuum from Grade I (“No significant disability: able to carry out 
all usual duties”) to Grade V (“Severe disability: bedridden, incontinent and 
requiring constant nursing care and attention”; Rankin (1957)). This original 
metric has since been modified several times. A Grade 0 (“no symptoms at 
all”) was proposed in 1988 (van Swieten et al., 1988). A Grade VI (denoting 
death) is also sometimes applied (O'Connor et al., 2011, Uyttenboogaart et 
al., 2005), although it is unclear when this modification was made or by whom. 
Here we will use the terms “Rankin Scale” (RS) to denote the original five-
level version described by Rankin (1957), and “Modified Rankin Scale” (mRS) 
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to denote all subsequent variations (Farrell et al., 1991, van Swieten et al., 
1988). 
Although a commonly used outcome measure in stroke research (Banks and 
Marotta, 2007, Quinn et al., 2009b), the original descriptions of the RS and 
mRS did not clearly define parameters for each grade (O'Connor et al., 2011). 
This led to significant inter-observer variability in how the RS/mRS are scored 
(Quinn et al., 2009a, O'Connor et al., 2011, Huppert et al., 1988, Quinn et al., 
2009c), with the obvious potential to confound results (O'Connor et al., 2011). 
Several attempts have been made to improve the inter-observer agreement 
of the mRS: by offering formalised training courses with accreditation on 
completion (Quinn et al., 2007); the use of semi-structured interviews with pre-
specified questions (Wilson et al., 2002, Wilson et al., 2005); and the 
development of a simplified scoring algorithm (Bruno et al., 2010). The 
success of these interventions has been mixed. Even after formal training 
there is considerable inter-observer variability in mRS scores, and also 
between observers from different countries (O'Connor et al., 2011). A 
structured interview has been shown to improve the agreement between 
observers (k=0.25 and weighted k=0.71 for mRS administered conventionally, 
versus k=0.85 and weighted k=0.94 for structured interview; Wilson et al. 
(2005)), but is time-consuming to administer taking around 15 minutes (Wilson 
et al., 2002). Use of a short algorithm to assign mRS scores shows 
comparable reliability to the longer structured interviews, but can be 
completed in less than two minutes (Figure 2.2.; Bruno et al. (2010)). It was 
this version that was adopted for use in DARS (Bruno et al., 2010). It is 
interesting to note that studies validating the use of structured interviews or 
algorithms to administer the mRS all used small numbers of observers, all of 
whom had received prior training In the use of the mRS either delivered “in 
house” as part of the validation study itself (Wilson et al., 2005) or using 
existing training packages developed by others (Bruno et al., 2010). It is 
therefore difficult to unpick the extent to which the observed improvements in 
inter-observer agreement are attributable to the changes made to the way in 
which the mRS is administered, or simply to training of the interviewers. 
Whether similar improvements would be seen if these versions of the mRS 
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were administered in clinical practice without prior training is not known. 
  
Figure 2.2. Simplified algorithm for assigning mRS score.  
Developed by Bruno et al, 2010 
A number of cut-off scores for defining “favourable” outcomes on the mRS are 
reported: ≤1, ≤2 or ≤3 (Sulter et al., 1999, Steiner et al., 2006). The choice of 
which to use may influence the results of a trial. For example, post-hoc 
analysis of a major stroke thrombolysis trial  yielded no significant effect for 
thrombolysis using a cut-off score of ≤1, but a statistically-significant benefit 
when a cut-off of ≤2 was used (Sulter et al., 1999). In trials of interventions to 
prevent an adverse outcome, a score of 6 (“death”) is sometimes appended 
to the standard 0-5 metric of the mRS, and outcomes dichotomised as 
“independent” or “death or dependency”. Several trials in intracerebral 
haemorrhage have taken this approach, utilising scores of 0-3 to denote a 
favourable outcome and 4-6 for death or dependency (Steiner et al., 2006, 
Hallevi et al., 2009). Although adding a “death” term to the metric may appear 
to be a convenient way to capture the full range of adverse outcomes, it is 
illogical to regard “death” as lying on the same continuum as “disability”. This 
illustrates well the perils of arbitrarily altering outcome measures without 
regard for the underlying construct that the scale is supposed to measure. The 
mRS will be used here only to describe the distribution of disability in the 
Are you able to do everything that you 
were doing right before your stroke, 
even if slower and not as much? 
YES 
Could you live alone without any help from another 
person? This means being able to bathe, use the toilet, 
shop, prepare or get meals, and manage finances. 
Are you able to walk without 
help from another person? 
NO 
Are you completely back 
to the way you were right 
before your stroke? 
SCORE 0 SCORE 1 SCORE 2 SCORE 3 
Are you bedridden or needing 
constant supervision? 
SCORE 4 SCORE 5 
NO 
NO YES 
YES 
YES NO 
YES NO 
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sample at T0. It will not be entered as a covariate in analyses, and change in 
mRS scores will not be reported. 
2.3.2.3. The GHQ-12 
The General Health Questionnaire (GHQ) was originally developed as a 
global measure of psychological morbidity for use in general practice 
(Goldberg and Blackwell, 1970, Goldberg and Hillier, 1979). Several variants 
are available including 12-, 28-, 30, and 60-item versions. The twelve-item 
version (GHQ-12) was used in DARS. It comprises twelve items: six 
describing positive psychological states (such as “I feel as though I play a 
useful part in things”), and six describing negative states (for example, “I have 
lost sleep over worry”; Hankins (2008a)). The original numerical rating scale 
scoring system asked patients to rank their experience of these states on a 
four-point scale: “no more than usual”; “not at all”; “rather more than usual”; 
and “much more so than usual” (Hankins, 2008b). Each item thus scores 
between 0 and 3 points, for a total possible score of 36 (Kelly et al., 2008). 
This was the scoring system adopted in DARS. However, this structure has 
been criticised for its ambiguity. In particular the response “no more than 
usual”, when applied to a negative psychological state, may actually be 
interpreted as denoting the presence of this state (Hankins, 2008b). For this 
reason, updated scoring systems have been devised. The first collapses 
dichotomises responses as “present” or ”absent” (Hankins, 2008b), resulting 
in a range of scores from 0-12. The second, the “chronic GHQ,” retains the 
usual 0-3-point scoring system for the “positive” items, but adjusts scoring for 
the “negative” items such that only the response “not at all” is regarded as 
healthy (Huppert et al., 1988).  
2.3.2.4. The musculoskeletal signs, symptoms and pain manikin (MSK-
SSP) 
Patients’ self-reported experience of musculoskeletal pain was evaluated in 
DARS using the MSK-SSP (Keenan et al., 2006). This was developed as a 
means to facilitate the self-reporting of joint symptoms. Patients are asked to 
tick boxes on the manikin that correspond to the major joints, to indicate the 
location of musculoskeletal signs such as joint swelling, or symptoms such as 
pain or stiffness (Figure 2.3.; Keenan et al. (2006)). 
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Figure 2.3. The musculoskeletal signs, symptoms, and pain manikin (MSK-
SSP) 
2.3.2.5. The Fatigue Assessment Scale 
A measure of fatigue was included in DARS as a possible effect modifier, 
although the interaction between post-stroke fatigue (PSF), functional 
outcome, and other possible effect modifiers is not straightforward. Although 
there is an association between PSF and dependency in instrumental 
activities of daily living and poor quality of life, these relationships do not 
persist once the presence of depression is controlled for (Mead et al., 2007, 
Wu et al., 2015). There is no apparent association between PSF and cognitive 
impairment on the Mini Mental-State Examination (MMSE): but the limitations 
of the MMSE are well known, and there is a suggestion that PSF may be 
associated with deficits in attention to which the MMSE is relatively insensitive 
(Wu et al., 2015). Both the absence of a unified definition for PSF, and doubts 
over whether “PSF” is truly a single construct are problematic when attempting 
to measure this. Additionally, many of the scales available have been 
developed for other conditions. A review by Mead et al. (2007) found fifty-five 
fatigue scales, none of which had been originally developed in stroke 
populations. Of these, only five (the vitality subscale of the 36-item Short Form 
Knee 
Knee 
Ankle Ankle 
Foot/ toes 
Neck 
Elbow 
Shoulder Shoulder 
Elbow 
Wrist 
Wrist 
Fingers Fingers 
Foot/ toes 
Thumb Thumb 
Hip Hip 
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Health Survey, Version 2; the fatigue subscale of the Profile of Mood States; 
the Fatigue Assessment Scale; the Multidimensional Fatigue Symptom 
Inventory; and the Brief Fatigue Inventory) had acceptable face validity: other 
scales included items that could be confounded by the neurological sequelae 
of stroke (Mead et al., 2007). The Brief Fatigue Inventory was found to contain 
items that could not be completed easily by patients (Mead et al., 2007). Of 
the remainder, there were no significant mean differences in scores assigned 
by different observers: but the Fatigue Assessment Scale (FAS: (Michielsen 
et al., 2003, Michielsen et al., 2004)) was found to have the narrowest limits 
of agreement and a high inter-class correlation coefficient of 0.77 (Mead et 
al., 2007). Unlike the other three scales, which ask about fatigue simply by 
using a common question stem suffixed by different  descriptors (“in the past 
week I feel run down; worn out; fatigued; sluggish”), the FAS enquires about 
several different aspects of fatigue such as mental and physical exhaustion 
and problems concentrating (Mead et al., 2007). Although it has a lower 
internal consistency than the other scales, it may actually be more useful in 
clinical practice (Mead et al., 2007). The FAS has ten items, five for physical 
fatigue and five for mental fatigue. Each is scored as: never (1); sometimes 
(2); regularly (3); often (4); and always (5). The maximum score is therefore 
50. However, assigning a case definition of fatigue based the FAS is difficult, 
since it depends upon using an arbitrarily-defined cut-off score to distinguish 
between normal “physiological” fatigue and the more debilitating 
“pathological” fatigue that may occur in neurological conditions (Duncan et al., 
2014). A change in FAS score of 4 points or more has been used to define a 
clinically-relevant change in fatigue status (Duncan et al., 2014). However, 
this definition is based upon studies in patients with sarcoidosis (de Kleijn et 
al., 2011): the validity and clinical relevance of this approach in stroke patients 
has not been established.  
2.3.2.6. The Montreal Cognitive Assessment (MoCA) 
When choosing a scale to evaluate cognitive function in DARS participants 
there were several considerations. The scale had to be quick to administer, 
and usable with only brief training. It also had to cover cognitive domains that 
are commonly affected by stroke. As noted above, traditional diagnostic 
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criteria for “dementia” (The World Health Organisation, 2010, The American 
Psychiatric Association, 2012) are based upon impairment in memory 
(O'Brien et al., 2003, Moorhouse and Rockwood, 2008): and yet stroke 
survivors often display more subtle impairments including in executive 
function, praxis, and visuospatial abilities (Barker-Collo et al., 2010). The 
MMSE (Folstein et al., 1975) is amongst the most widely used and cited brief 
cognitive assessments in dementia screening (Ismail et al., 2010), but has 
been heavily criticised for its lack of sensitivity to impairment in executive 
function, visual perception/construction, and abstract reasoning (Nys et al., 
2005). Its performance is also dependent on the educational and cultural 
background of the patients to which it is administered: there is a substantial 
“ceiling effect” in people of high pre-morbid intelligence with the attendant 
possibility of false negatives (Pendlebury et al., 2010), whereas older patients, 
non-English speakers, and those with sensory impairment or a low prior 
educational attainment may be misidentified as impaired due to difficulty 
completing some of the items (Ismail et al., 2010).   
The MoCA (full original version, in English) was chosen for evaluation of 
cognitive function in DARS participants. It was developed by Nasreddine et al. 
(2005) as a screening tool for minor cognitive impairment, and is freely 
available for non-commercial purposes at www.mocatest.org (©Dr Ziad 
Nasreddine, MD: used in DARS with permission). Although originally 
developed for dementia screening, the MoCA has been evaluated for use in 
stroke populations, and has been shown to detect cognitive dysfunction in 
patients who were not identified as impaired on the MMSE (Dong et al., 2010, 
Pendlebury et al., 2010). The assessment takes approximately ten minutes to 
administer (Nasreddine et al., 2005), and covers several domains including: 
executive function; phonemic fluency; abstract reasoning; visuospatial 
functioning; object naming; attention; concentration; working memory; and 
orientation (Nasreddine et al., 2005).  
The maximum total score is 30, with a correction of one point added for 
anybody who has had 12 years or fewer of formal education (Nasreddine et 
al., 2005). The validity of calculating summary scores in this way has not been 
established in stroke patients, although Rasch analysis has demonstrated that 
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the MoCA is capable of providing interval-level measurement in elderly 
patients attending a memory clinic (Koski et al., 2009). Summed scores are 
then typically treated as dichotomous variables, with a cut-off point defined 
below which patients are deemed to have cognitive impairment. The cut-off 
chosen is typically a score of ≤26: but this was derived from a mixed group of 
patients attending a memory clinic, so may not be appropriate for those with 
cerebrovascular disease (Pendlebury et al., 2012). Using the accepted cut-off 
score of ≤26, the MoCA has a sensitivity of 0.97 for minor cognitive impairment 
after stroke, but a specificity of only 0.19 (Godefroy et al., 2011). By 
comparison the MMSE has a lower sensitivity (0.86) but higher specificity 
(0.61) using a  cut-off score of ≤27 (Godefroy et al., 2011). The cut-off scores 
for both measures may be adjusted to confer a different balance of sensitivity 
and specificity: for example, using a cut-off score of ≤20 the MoCA has a 
sensitivity of 0.72 and a specificity of 0.90; using a cut-off score of ≤24, the 
MMSE has a sensitivity of 0.70, and a specificity of 0.94  (Godefroy et al., 
2011).  
The MoCA has been used in the a trial of very early mobilisation after stroke 
(A Very Early Rehabilitation Trial; AVERT) (Bernhardt et al., 2015): interim 
MoCA data from the first 294 patients randomised were reported in 2011 
(Cumming et al., 2011). The distribution of scores in this sample were skewed 
towards the higher end of the range, with a mean of 21.1 (standard deviation 
7.5) and a median of 23 (inter-quartile range 17-27) (Cumming et al., 2011). 
Nevertheless, the majority of this sample (65%) scored below the defined cut-
off score for cognitive impairment (<26) (Cumming et al., 2011). This is in line 
with previous estimates of the prevalence of cognitive impairment after stroke, 
but may also suggest that the accepted cut-off score of <26 is too high for this 
sample (Cumming et al., 2011). The poorest performance was seen on tests 
of executive function (trail making: 50% answered correctly), visuospatial 
function (cube copying: 50% correct responses), and phonemic fluency (just 
over 40% generated eleven or more words), and delayed recall of five objects 
(30% recalled no words, 10% recalled one) (Cumming et al., 2011). 
Orientation questions were generally answered correctly, with 60% of patients 
correct on all six (Cumming et al., 2011).  
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2.3.3. Interpreting the output of rehabilitation outcome measures 
The “output” of rehabilitation outcome measures is often quoted as a 
numerical value. In the case of dichotomous (“yes/ no”) responses such as 
the RMI (Collen et al., 1991), this is typically a simple sum of all questions 
endorsed as “yes” by the patient. Scales that utilise polytomous responses 
(for example the GHQ-12) typically derive a score by weighting responses in 
some way (Goldberg and Blackwell, 1970, Goldberg and Hillier, 1979). The 
MoCA derives a summary score by adding together sub-scores that cover 
several domains of cognitive function (Nasreddine et al., 2005). The summary 
scores thus derived are assumed to correlate with a patient’s true clinical 
impairment.  
2.3.3.1. Interpreting “summary scores” derived from rehabilitation 
outcome measures 
The legitimacy of deriving such “summary scores” must be questioned. The 
RMI, for example, defines a range of items ranging from turning over in bed 
(assumed to be the easiest item on the scale) to running 10m in 4 seconds 
(assumed to be the hardest item). These mark extremes of the metric, and 
represent a progression from “lesser” to “greater” mobility. Each item in 
between marks a greater degree of mobility. The probability that an individual 
will answer “yes” to a given item is assumed to depend upon the level to which 
the latent trait under consideration (in this case mobility) exists in them (da 
Rocha et al., 2013). The items on the scale therefore provide “locations” along 
the continuum, against which an individual’s performance can be measured 
(Hobart and Cano, 2009). However, the location of items along the continuum 
cannot be assumed to be spaced at equal intervals (Hobart and Cano, 2009). 
In other words, the actual magnitude of any clinical change observed for each 
one-point change in score may vary considerably depending upon where on 
the continuum that change occurs. For example, consider two patients whose 
scores on the RMI change by two points. It is illogical to assume that the 
functional implications of a change from a score of 5 (standing unsupported 
for ten seconds) to a score of 7 (ability to walk ten meters or more unaided) 
are the same as a two point gain from an initial score of 1 (able to turn over in 
bed) to 3 (can sit on the edge of the bed for ten seconds). It is equally illogical 
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to state that a patient with a summary score of 10 on the RMI is “twice as 
mobile” as a patient with a RMI score of 5.  
2.3.3.2. Implications for regression modelling 
These scales are thus ordinal measures, and cannot be assumed to provide 
interval-level measurement. Scores derived from such scales should not be 
used in mathematical operations: for example, the calculation of mean scores 
or change in score between two time points. This poses a dilemma when 
utilising such scales as outcome variables in a regression analysis. The 
principles of regression modelling will be described in detail in Part 4: but at 
present it may be noted that two broad categories of model may be fitted. 
Linear regression modelling makes efficient use of available data, but relies 
upon the use of a continuous, as opposed to an ordinal, outcome measure. 
By contrast, logistic regression modelling allows the prediction of a categorical 
outcome (either binary or multinomial). Unlike linear regression models, 
categorical predictors may be fitted to logistic regression models. Such 
categorical variables may be derived from ordinal scales, by pre-specifying 
“cut points” and assigning each participant to one of two or more groups (da 
Rocha et al., 2013). Treating predictor variables in this way dispenses with the 
need to prove that an ordinal scale can provide interval-level measurement. 
However, logistic regression models make a less efficient use of the available 
data than a linear regression models. Furthermore, if the treatment of ordinal 
scales as categorical variables is to yield meaningful results then the cut-off 
point(s) must be selected on logical and clinically-relevant grounds. For the 
RMI, dichotomising scores at <7 or ≥7 has a sound theoretical basis, since 
the ability to walk short distances indoors after a stroke may allow a patient to 
be sufficiently independent to be discharged home as opposed to a care 
facility. However, the reasons for choosing a particular cut-off score is, for 
some scales, not clear. For example, a Barthel Index score of >95/100 is 
commonly cited as signifying almost complete independence in activities of 
daily living (Quinn et al., 2011), and was thus used in two major thrombolysis 
trials (Anonymous, 1995, Hacke et al., 1998). However, the rationale for using 
such a high cut-off score is questionable, particularly since a lower score 
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would still have signified a reasonable degree of independence (Sulter et al., 
1999). 
The methods by which models were constructed in this Thesis will be 
described below. However, the aim of this work was to establish whether a 
combination of clinical and radiological variables might be helpful in predicting 
mobility after stroke. Therefore, before discussing how the models were 
constructed, consideration must first be given to the process for analysing CT 
scans. 
96 
 
Part 2.4 Analysis of neuroimaging 
2.4.1. Analysis of imaging in the DARS trial 
2.4.1.1. The need for centralised review of imaging 
Plans for the analysis of scans evolved in the early stages of trial setup, when 
an initial proposal to review imaging at local recruiting centres was found to 
be impractical. A decision was therefore made to undertake centralised review 
of scans, but doing so required a substantial amendment to the protocol. This 
was approved after the trial had opened to recruitment. Imaging could 
therefore not be obtained for some patients who had been recruited using the 
initial version of the protocol, since their explicit consent for centralised 
collation of imaging had not been obtained. For those recruited onto the 
revised protocol, all available neuroimaging performed in the course of the 
index admission was despatched to CTRU. All scans had been acquired in 
the course of the patient’s routine care for the index stroke event. The DARS 
protocol did not stipulate a requirement for additional imaging beyond that 
which was clinically indicated. Nor was the time of imaging in relation to the 
index stroke specified.  
2.4.1.2. Obtaining scans from recruiting sites 
Images were copied to Compact Disc (CD) or Universal Serial Bus (USB) 
memory stick in Digital Imaging and Communication in Medicine (DICOM) 
format (National Electrical Manufacturers Association, 2011) for despatch to 
CTRU. Since both CDs and USB memory sticks were accepted, they will be 
referred to using the generic term “data storage media”. Electronic transfer of 
files by a secure data link was considered, but was deemed impractical in the 
time available due to the requirement to obtain individual permission and set-
up from every participating recruitment centre. Every effort was made to 
redact scans of patient-identifiable information (name, NHS number, and 
treating clinician) prior to despatch. The responsibility for this rested with 
recruiting centres, and was conducted according to their local protocols. 
Where complete redaction was not possible, it was agreed with the ethics 
committee that encryption would be used to protect trial data in transit. 
Passwords for encrypted media were forwarded to the data management 
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team at CTRU by email, separately from the images themselves. The 
possibility that scans would be incompletely anonymised was explained to 
participants in the patient information sheet and as part of the consent 
process. Once anonymised, scans and data storage media were identified 
only by the participant’s unique trial identification number, initials, and date of 
birth. It was the responsibility of the recruiting centres to ensure that the 
correct scans for the correct patient were sent: once anonymised, CTRU had 
no direct means of verifying that the images sent were for a particular 
participant. Data storage media were despatched to CTRU by recorded 
delivery. Receipt was logged by CTRU, who also confirmed passwords for 
encrypted media with the recruiting centre.  
2.4.1.3. Training JP in CT brain scan interpretation 
All scans were co-reported by the Clinical Research Fellow (JP) and one of 
two experienced consultant neuroradiologists (Dr Jeremy Macmullen-Price, 
JMP; and Dr Tufail Patankar, TP) using a standardised Case Report Form 
(CRF) (The Royal College of Radiologists, 2011). Having had no prior 
experience in interpreting neuroimaging, a specific training programme was 
devised to allow JP to undertake this role. The initial training consisted of 
attendance at two organised teaching courses in scan interpretation, The 
Acute Stroke Training and Assessment in Computerised Axial Tomography 
course (Emsley et al., 2013) was a two-day theoretical and practical seminar 
in axial CT interpretation designed to meet the needs of stroke physicians who 
administer intravenous thrombolysis. The course focused primarily on axial 
CT imaging, since this is the modality of choice for the evaluation of acute 
stroke (Emsley et al., 2013). Learning objectives included: recognition of early 
ischaemic change on CT; recognition of primary intracerebral haemorrhage, 
subarachnoid haemorrhage, and infarction with haemorrhagic transformation; 
how to determine the extent of an infarct using the ASPECTS score; and an 
understanding of advanced imaging techniques (CT perfusion) and imaging 
appearances of conditions that may mimic stroke (Emsley et al., 2013). The 
course is accredited by the Royal College of Physicians with ten Continuing 
Professional Development credits awarded for completion. In addition JP 
attended the Leeds Third Surgical Neuroradiology course. This was a two-day 
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course designed to meet the needs of surgical trainees, and covered the 
principles of neuroimaging techniques and sequences. 
2.4.1.4. Procedures for centralised review of scans 
Review of the scans was conducted in Leeds Teaching Hospitals NHS Trust 
(LTHT). Scans were reviewed in small batches, corresponding to the order in 
which they were received by CTRU, not the order of enrolment of participants 
in to the trial. An accountability log was established to monitor their despatch 
from CTRU, receipt by JP, and return to CTRU. Whilst at LTHT data storage 
media were kept in locked filing cabinets in a secure office, in accordance with 
the principles of the Data Protection Act (The Stationary Office, 1998). It was 
not possible to upload scan to LTHT’s Picture Archiving and Communication 
System (Meyer-Ebrecht, 1994, Ratib et al., 1994), since the limited storage 
capacity of these servers was required to meet clinical demands. Scans were 
therefore reviewed directly from the storage media using open-access DICOM 
viewer software. The time to read each scan was not recorded; observers 
were free to take as long as they deemed necessary to review the images. 
Scans were read blinded to clinical information (including the Oxford 
Community Stroke Project classification, the laterality of symptoms, and 
reports issued by local radiologists) and to treatment allocation. Although this 
does not reflect the way in which scans would be interpreted in clinical 
practice, it has been shown that interpreting images with knowledge of the 
patient’s symptoms does not improve detection rates for early ischaemic 
change (Wardlaw and Mielke, 2005). The published validations of the AISCT 
have so far utilised blinded interpretation (Wardlaw et al., 2007, Wardlaw et 
al., 2010). Although observers in validation studies of the AISCT did not 
appear to “over-call” signs of ischaemic change (Wardlaw et al., 2007), it is 
not clear whether rates of over-calling would be higher if clinical information 
were provided.  
2.4.1.5. Management of unexpected radiological findings 
It was anticipated that, in accordance with standard practice, all scans would 
have been subjected to routine reporting by local radiologists in order to guide 
the clinical management of the patient. It was therefore thought unlikely that 
review of scans by the DARS team would yield findings of which local 
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clinicians were not already aware. Since the reporting of scans for DARS 
could be delayed by as much as three years from the point of a patient’s 
enrolment in to the trial, the imaging review provided for the trial could not be 
relied upon to deliver clinically-significant information in a timely manner. It 
was also important that the trial team did not seek to influence or guide the 
clinical management of participants in any way. Feedback on reports was 
therefore not provided routinely to recruiting centres. However, under limited 
circumstances, the research team had an ethical obligation to make the 
treating team aware of certain findings that were unexpected and of clinical 
significance. A list of findings that would be fed back to the recruiting centres 
was not specified a priori: it was left to the discretion of the consultant 
neuroradiologist (JM-P or TP) to decide if notification was necessary. It was 
agreed that information would be communicated to the local PI, with whom 
responsibility for the clinical management and safety of participants at each 
centre rested. It was then the responsibility of the PI to ensure that the findings 
were acted upon appropriately. In practice, this procedure was invoked only 
twice in the course of the trial: the first for a suspected base of skull 
meningioma, and the second for a possible aneurysm at the tip of the middle 
cerebral artery.  
2.4.2. Coding scan findings 
2.4.2.1. The CT Imaging Interpretation Case Report Form (CRF) 
A flow diagram summarising the process of image review is provided in 
Appendix E. For reporting of ischaemic stroke the AISCT, developed by 
Wardlaw and Sellar (1994), was utilised. For ICH some additional elements 
not included in the AISCT were incorporated, due to their prognostic 
importance. These were configured as an image analysis CRF (Appendix F). 
One CRF was used for each sequence acquired.  
2.4.2.2. Initial coding: image quality and presence of any visible 
abnormality  
Review of each scan began by recording the patient identification number and 
date of birth, date and time of image acquisition, the modality used (plain CT 
or CT angiography), and then a subjective judgement of image quality (good, 
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moderate, or poor) (Wardlaw et al., 2010). The first judgement was whether 
there were any abnormal findings (both stroke and others). The presence and 
side of any acute ischaemic lesion was then documented. If more than one 
ischaemic lesion was present, clinical judgement was used to decide which 
was the more recent or (in the case of two infarcts of a similar age) the more 
clinically significant.  
2.4.2.3. Coding of acute ischaemic change 
The main lesion was coded in detail as below, and secondary lesions were 
classified as a “second (minor) acute ischaemic lesion” under question 12. 
Features of early ischaemia were classified as: loss of definition between the 
cortical grey matter and underlying white matter; loss of the outline of the basal 
ganglia; and frank hypodensity (Wardlaw et al., 2007, Wardlaw et al., 2010, 
Wardlaw et al., 2014a). Acute swelling was classified using the AISCT 
framework and reference diagrams (Wardlaw et al. (2010); Appendix B). MCA 
lesions were also classified as involving less than or more than a third of this 
territory (Kaste et al., 1995, Wardlaw et al., 2010). Using the reference 
diagrams developed for the AISCT, MCA lesions were then further classified 
as: small cortical; basal ganglia striatocapsular; lateral to ventricle 
striatocapsular; anterior cortical MCA territory; posterior cortical MCA territory; 
whole of cortical MCA territory; whole of cortical MCA territory with lateral part 
of basal ganglia; and whole MCA territory (Wardlaw et al., 2010). Lesions in 
the ACA and PCA territories were each defined as involving less than 50% of 
that territory, more than 50%, or complete (Wardlaw et al., 2010). Lacunar 
lesions were classified as involving: the internal capsule or lentiform; the 
internal border zone; the centrum semiovale; or the thalamus (Wardlaw et al., 
2010). Infarcts involving the anterior and posterior border zones were noted 
(Wardlaw et al., 2010). Cerebellar lesions were classified as lacunar infarcts, 
or as involving <50% or >50% of the hemisphere (Wardlaw et al., 2010). 
Similarly, brain stem lesions were classified as lacunar or as involving less 
<50% or >50% of the brain stem (Wardlaw et al., 2010). The ASPECTS score 
(Barber et al., 2000) was recorded for all lesions involving the MCA territory 
(Wardlaw et al., 2010). The presence of arterial hyperattenuation (suggestive 
of acute thrombus) (Gacs et al., 1983) in the MCA main stem, the insular 
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branch of the MCA, the internal carotid artery, the ACA, the PCA, the basilar 
artery, and the vertebral arteries was recorded (Wardlaw et al., 2010).  
2.4.2.4. Coding of ICH 
The location of confluent haematomas was classified as: frontal, temporal, 
parietal, occipital, basal ganglia/ thalamus, internal capsule, brain stem, 
cerebellum (Bhattathiri et al., 2006). The extent of midline shift (in millimetres), 
and the presence or absence of intraventricular extension and hydrocephalus 
were recorded. Haematoma volume was calculated using the formula 
Volume=A×B×C/2) (Kwak et al., 1983, Kothari et al., 1996). Haemorrhage was 
classified as: petechial haemorrhage; significant haemorrhagic transformation 
of an underlying infarct; parenchymal haematoma with no infarct visible; 
parenchymal haematoma clearly remote from infarct; subdural haematoma; 
subarachnoid haemorrhage; and extradural haemorrhage (Wardlaw et al., 
2014a). For confluent haematomas, the maximum diameter of the lesion was 
recorded (<3cm, 3-5cm, 5-8cm, and >8cm) (Wardlaw et al., 2014a). If blood 
was present in more than one location (for example a primary parenchymal 
haematoma with rupture in to the sub-arachnoid space) then the presence of 
both was recorded, and clinical judgement utilised in determining which was 
the most clinically important lesion (Wardlaw et al., 2014a). The presence or 
absence of changes in the anterior and posterior white matter was noted using 
the van Swieten scale as grade of 0 (no white matter change), 1 (change 
restricted to the periventricular region) or 2 (change extending from the lateral 
ventricle to the cortex) (van Swieten et al., 1990).  
2.4.2.5. Coding of other findings 
The presence of a second recent infarct was documented (Wardlaw et al., 
2014a). Old vascular lesions were classified as: old cortical infarct(s); old 
striatocapsular infarct(s); old borderzone infarct(s); old lacunar infarct(s); old 
brainstem/cerebellar infarct(s); and probable old haemorrhage (Wardlaw et 
al., 2014a). Finally non-stroke lesions were classified as: cerebral tumour; 
encephalitis; cerebral abscess; and demyelination (Wardlaw et al., 2014a). 
Brain atrophy was not scored quantitatively, merely recorded as present or 
absent. 
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Part 2.5 Statistical analysis procedures 
2.5.1. An overview of regression modelling 
2.5.1.1. What is regression modelling? 
As discussed previously, the purpose of a prognostic model is to combine 
several predictor variables in order to generate an estimate of the risk of a 
particular outcome for an individual patient (Steyerberg et al., 2013). These 
predictions may be useful in informing patients and their families about the 
likely outcome of their illness, in guiding the treatment of individual patients, 
and in selecting patients for participation in research trials (Moons et al., 
2009b). Two broad types of regression models exist: linear regression, or 
logistic regression (Stoltzfus, 2011). The choice of which to use will depend 
upon the outcome variable chosen (in particular, whether it is continuous, 
binary, or categorical) (Stoltzfus, 2011). In order to understand the rationale 
for choosing  type of model to use, and how its output might be interpreted, it 
is helpful to summarise briefly the mathematics of regression models. 
2.5.1.2. Modelling using continuous predictor and outcome variables: 
linear regression 
Of the two classes of model, linear regression is perhaps the most readily 
understood, and will thus be discussed here as a prelude to an explanation of 
logistic regression. A linear regression model makes two assumptions: firstly, 
that the outcome is a continuous (as opposed to a categorical) variable; 
secondly, that the relationships between the outcome and predictor variables 
can be expressed graphically as a straight line (Stoltzfus, 2011). Plotting the 
relationship between a continuous outcome and a single predictor variable 
might thus yield a graph similar to Figure 2.4. 
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Figure 2.4. Linear relationship between a continuous predictor variable, x, and 
a continuous outcome variable, Y. 
The relationship can be expressed by the equation Y=mx+c: in which m 
is the gradient of the line, and c is its Y-intercept. 
The value of the outcome, Y, for any given value of the predictor, x, can be 
expressed by the equation: 
Y=mx+c 
In this case, c is the point at which the line intercepts the y-axis, and m is the 
gradient of the line (Field, 2013). In linear regression, the analogous term for 
the Y-axis intercept c is β0, also known as the constant for the equation (Field, 
2013). This is, in effect, the predicted value of Y before any predictor variables 
are fitted (Stoltzfus, 2011). Where a single predictor, variable i, is fitted, the 
gradient of the resulting line may be termed βi: also known as the coefficient 
for the variable i (Field, 2013). The values that variable i may assume are 
termed Xi. Hence, a univariate regression equation using the variable i to 
predict an outcome variable, Ŷ, may be expressed as (Field, 2013): 
Outcome 
variable, Y 
Predictor 
variable, x 
C 
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Ŷ= β0+ βiXi 
If several predictor variables are fitted to a model, then the resulting linear 
regression equation may be expressed as (Stoltzfus, 2011): 
Ŷ= β0+ β1X1+ β2X2+… βiXi 
In which β0 is once again the constant (representing the y-axis intercept for a 
regression line with no predictor variables fitted) and xi is the value (x) of the 
ith predictor variable weighted by its coefficient βi (Stoltzfus, 2011).  
Interpreting the output of simple linear regression is comparatively 
straightforward. In essence, the equation returns a predicted value, Ŷ, of the 
outcome variable, given specified values of each predictor variable Xi 
(Stoltzfus, 2011). It is possible to assess the contribution that each predictor, 
i, makes to the model in two ways: firstly, by determining the change in the 
outcome Ŷ for a one-unit change in the value of each variable i (assuming that 
values of all other predictor variables are held constant); secondly by 
examining the coefficient, β, for each variable (the greater the value of βi, the 
greater the contribution made by the variable i to predicting Ŷ) (Stoltzfus, 
2011). 
2.5.1.3. Modelling using categorical predictor or outcome variables: 
logistic regression 
When a binary outcome variable is used, it is obviously impossible to compute 
an absolute value of Ŷ (Stoltzfus, 2011). Instead, the prediction made by the 
model is of the probability (P) of belonging to a specified category (i) of an 
outcome event Ŷ (Stoltzfus, 2011). To facilitate this, the standard linear 
regression equation quoted above must be expressed on a logarithmic scale 
as eβ0+ β1X1+ β2X2+… βiXi. The probability (P) of belonging to category i of a binary 
outcome Ŷ may thus be expressed as (Stoltzfus, 2011): 
P(Ŷi )=eβ0+ β1X1+ β2X2+… βiXi/1+ eβ0+ β1X1+ β2X2+… βiXi 
In which e is the base of the natural logarithm; β0 is a constant (the y-axis 
intercept for a regression line with no predictor variables fitted); and Xi is the 
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value of the ith predictor variable (X) weighted by its coefficient βi (Stoltzfus, 
2011).  
Note that a binary outcome must have a probability that lies between 0 (the 
outcome never occurs) and 1 (the outcome always occurs). Since the 
continuous predictor variables in the above equation may take any value, 
there is a possibility that the equation may yield values of P(Ŷi ) that are <0 or 
>1 (Stoltzfus, 2011). This problem may be circumvented by expressing the 
output of a regression model as an odds ratio: the odds for membership of 
one outcome group (Ŷ) divided by the odds of belonging to the other outcome 
category (1-Ŷ) (Stoltzfus, 2011). This allows a variant of the standard linear 
regression equation to be used (Stoltzfus, 2011).  
Ln(Ŷ/(1-Ŷ)= β0+ β1X1+ β2X2+… βiXi 
This output is expressed on a logarithmic scale, and is therefore a little more 
complex to interpret than standard linear regression (Stoltzfus, 2011). The 
term Ln(Ŷ/(1-Ŷ) is essentially the natural log (the “logit”) of an odds ratio for 
membership of one group versus the other. The influence of each continuous 
predictor variable, i, on the model is thus expressed as the change in Ln(odds) 
of belonging to the specified category of outcome Ŷ for each one-unit change 
in the predictor variable (assuming that values of all other predictor variables 
are held constant) (Stoltzfus, 2011). This may be converted to a simple odds 
ratio by raising the base of the natural logarithm, e, to the power of the 
coefficient β of variable i (Stoltzfus, 2011): 
OR=eβi 
A positive value for the OR suggests that the odds of outcome Ŷ increase as 
the value of variable i increases; conversely, a negative OR implies a negative 
relationship between the odds of outcome Ŷ and variable i (Field, 2013). The 
statistical significance of the OR for each variable may be determined by 
examining 95% confidence intervals and p-values (Field, 2013). The odds of 
the outcome Ŷ following a one-unit change in a continuous variable i may be 
computed by multiplying the “baseline” odds of Ŷ by eβi (Stoltzfus, 2011). 
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Unlike in linear regression, which relies upon a linear relationship between 
continuous predictor and outcome variables, dichotomous or categorical 
predictors may be entered in to a logistic regression model. Where such 
variables are included, the impact of the variable is still expressed in terms of 
an odds ratio for a specified category of outcome Ŷ: but the interpretation of 
that odds ratio is complex. For a dichotomous predictor with two possible 
states (“A” and “B”), one state (for example, A) is nominated as the “basal” 
state, and the value of eβi quoted for state B is the change in odds ratio that 
results when a participant moves from state A to state B. Similarly, for a 
categorical predictor (which includes, for example, states A, B, C, and D) a 
“basal” state is defined to which the odds ratios for all other states are then 
referenced. For example, if the “basal” group is state A, then the values of eβi 
quoted for states B, C, and D will reflect the change in the odds ratio for the 
outcome Ŷ for participants in those states, relative to state A. 
2.5.1.4. Assumptions of logistic regression modelling 
Logistic regression makes no assumptions about the normality of the 
distribution of predictor variables (Bewick et al., 2005). There are, however, 
several key assumptions which must be tested to ensure the validity of any 
models derived from logistic regression. The first assumption is that sample 
group outcomes are uncorrelated, and that there are no duplicated measures 
amongst the sample (Stoltzfus, 2011). In the case of the DARS sample, this 
assumption was met since each individual case within the data-set is 
independent. The second assumption is that there exists a linear relationship 
between any continuous predictor variables and their natural-log transform 
(the “linearity of the logit”) (Stoltzfus, 2011). Thirdly, a high degree of 
correlation between two or more predictor variables (“collinearity”) is 
undesirable, since this may lead to large standard errors for values of βi, 
(Stoltzfus, 2011). Finally, the model must be examined both for adequate fit in 
general, and also to ensure that there are no outlying cases which are 
disproportionately influencing the coefficients (Stoltzfus, 2011). The 
procedure for testing these assumptions will be discussed in detail later. 
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2.5.2. Modelling walking ability at T1 and T2 in the DARS data-set 
2.5.2.1. Summary of the models 
Since Levodopa is not effective in promoting recovery of walking ability after 
a stroke, treatment allocation was disregarded for the purposes of this 
analysis. The DARS cohort was treated as a large observational data-set. 
Using binary logistic regression, a series of six models was developed (Table 
2.1) to predict ability to walk 10m or more independently at T1 and at T2. A full 
definition of this outcome variable is given below in Section 2.5.2.2. 
Table 2.1. Summary of models presented for the “primary infarction, with scan 
available” (IWS), “primary intracerebral haemorrhage, with scan 
available” (HWS) and “whole DARS sample” groups. 
Model Analysis population Outcome 
measured at 
Candidate predictors 
1 Primary infarction, with 
scan available (IWS) 
T1 Demographic variables; Clinical 
impairment at T0; Imaging findings 
2 Primary infarction, with 
scan available (IWS) 
T2 Demographic variables; Clinical 
impairment at T0; Clinical 
impairment at T1; Imaging findings 
3 Primary intracerebral 
haemorrhage, with scan 
available (HWS) 
T1 
 
Demographic variables; clinical 
impairment at T0; Imaging findings 
4 Primary intracerebral 
haemorrhage, with scan 
available (HWS) 
T2 Demographic variables; clinical 
impairment at T0; clinical 
impairment at T1; imaging findings 
5 Whole DARS sample T1 Demographic variables; clinical 
impairment at T0 
6 Whole DARS sample T2 Demographic variables; clinical 
impairment at T0; clinical 
impairment at T1 
Analysis was performed using IBM Statistical Package for the Social Sciences 
(SPSS Statistics), Version 23. Since imaging was not available for a 
proportion of cases, it was necessary to define two analysis sub-groups. The 
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analysis for models 1 and 2 considered a sub-group of DARS participants 
(n=438) who presented with a primary cerebral infarction (as defined by the 
recruiting centre) and for whom a first CT scan was available for analysis. This 
group will be referred to as the “infarct with scan” (IWS) group. The analysis 
for models 3 and 4 considered a sub-group of DARS participants (n=75) who 
presented with a primary intracerebral haemorrhage (as defined by the 
recruiting centre) and for whom a first CT scan was available for analysis. This 
group will be referred to as the “haemorrhage with scan” (HWS) group. Models 
5 and 6 considered predictors of walking ability in the DARS sample as a 
whole (n=593). Since imaging was not available for every patient, only 
demographic and clinical predictors were considered for inclusion in these 
models. 
2.5.2.2. Definition of primary outcome measure: dichotomised RMI 
SR-RMI (Collen et al., 1991) scores were used as the primary outcome 
measure at T1 and T2. When used as an outcome measure, the RMI was 
dichotomised as “able to walk 10m or more independently (yes/no)”. This was 
defined as a score of 7 or more, and item 7 answered “yes”, per the following 
algorithm (Figure 2.5): 
 
Figure 2.5. Algorithm for dichotomising RMI scores. 
Total RMI score 
7 or more? 
Question 7 
answered “yes”? 
Classify as 
unable to walk 
Classify as 
unable to walk 
Classify as able 
to walk 
Yes 
Yes 
No 
No 
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2.5.3. Treatment of predictor variables 
For simplicity, the treatment of predictor variables will be discussed in terms 
of: demographic variables at T0; clinical impairment at T0 and at T1; imaging 
predictor variables in ischaemic stroke; and imaging predictor variables in 
ICH. 
2.5.3.1. Demographic variables 
Age was entered in to the models as a continuous variable. Gender was 
dichotomised as male/female, and administration of thrombolysis (in the case 
of infarcts) as yes/no. The OCSP clinical stroke syndrome (Bamford et al., 
1991) was used for infarcts only, and was entered as a categorical variable. 
2.5.3.2. Clinical impairment at T0 and T1   
The GHQ-12, FAS, and MoCA were analysed as continuous variables. When 
entering variables taken at T0 into models to predict outcomes at T1 and T2, 
the C-RMI was used as a predictor in preference to the SR-RMI. When 
variables at T1 were used as predictors of outcome at T2, only the SR-RMI 
was available. When used as predictors (as opposed to as the outcome 
measure), both C-RMI and SR-RMI were treated as continuous variables. As 
discussed above the assumption that the RMI, GHQ-12, FAS, and MoCA 
provide interval-level measurement (and can thus be treated as continuous as 
opposed to ordinal scales) is not necessarily legitimate. However, ordinal 
scales are frequently analysed as interval-level measures: even in high 
impact-factor stroke and rehabilitation journals (Khan et al., Kozlowski et al., 
Lu et al., Takahashi et al.). At present, the limitations of treating these scales 
in this way will merely be acknowledged here. Consideration will be given in 
the concluding chapter to the principles of psychometrics, including a 
discussion of methods by which interval-level measurement may be derived 
from ordinal scales. 
The MSK-SSP manikin (Hettiarachchi et al., 2011) was treated as a series of 
dichotomous variables. “Any MSK pain” was defined as pain in one or more 
body locus, irrespective of location. Upper-limb pain was defined as pain in 
one or more upper-limb locus (the shoulder, elbow, wrist, or hand). Lower-
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limb pain was defined as pain in one or more lower-limb locus, including hips, 
knees, ankles, or feet. Recognising the possible confounding effect of central 
(neuropathic) post-stroke pain, Hettiarachchi et al. (2011) defined this as pain 
reported in all loci on the side ipsilateral to the clinical stroke syndrome. In 
DARS, the laterality of stroke symptoms was not recorded, so this distinction 
could not be reliably made. All reported pain was therefore assumed to be of 
musculoskeletal origin, whilst acknowledging the limitations of this 
assumption. 
2.5.3.3. Imaging variables in ischaemic stroke 
For the present analyses, only the first available plain CT scan performed after 
stroke was analysed. Wardlaw et al (The IST collaborative group, 2015) used 
the AISCT template to classify infarcts as small, medium, large, or very large. 
The same classification was followed in the present analysis. However, only 
two patients fulfilled the criteria for a “very large” infarct. The categories of 
“large” and “very large” were therefore combined under the heading of “large 
infarct”. A separate category of “no visible infarct” (not originally included by 
Wardlaw et al)  was also added. The definition of these categories is 
summarised in Table 2.2.  
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Table 2.2. Classification of infarct size  
Based on the AISCT template of Wardlaw et al. (The IST collaborative 
group, 2015). The category “no visible infarct” has also been added. 
Classification Scan findings 
No visible infarct No visible acute ischaemic change 
Small infarct Lacunar infarct; small cortical infarct; small cerebellar 
infarct; infarct involving less than half of brainstem, 
ACA territory, or PCA territory 
Medium infarct Striatocapsular infarct; infarct involving anterior or 
posterior half of peripheral MCA territory; infarct 
involving more than half of ACA or PCA territory;  
Large infarct Infarct involving: whole of peripheral MCA territory; 
whole of MCA territory; all of the MCA and ACA 
territory; all of MCA, ACA, and PCA territories. 
Since the basal ganglia and other subcortical structures are thought to play a 
crucial role in motor learning (Penhune and Steele, 2012, Hikosaka et al., 
2002, Doyon et al., 2009), a separate variable was also created which 
classified ischaemic stroke as: no visible infarct; “cortical” (infarct involving the 
cortex only); “subcortical” (infarct involving only the basal ganglia, cerebellum, 
or brain stem); or “both” (infarct affecting both cortical and subcortical 
structures). 
Dichotomised variables were also created for the presence or absence of: any 
visible abnormality (infarct or other abnormality); a visible acute infarct; a 
visible acute infarct in the MCA territory; a visible acute infarct in the ACA 
territory; a visible acute infarct in the PCA territory; a visible acute lacunar 
infarct; a visible acute borderzone infarct; a visible acute cerebellar infarct; a 
visible acute brainstem infarct; a visible old vascular lesion (infarct or 
haemorrhage); any white matter lesions; and any atrophy.  
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2.5.3.4. Imaging variables in intracerebral haemorrhage 
Haematoma volume (in mm3) and midline shift (in mm) were entered as 
continuous variables. Haematoma location was entered as a categorical 
variable (frontal, temporal, parietal, occipital, basal ganglia, internal capsule, 
brain stem, cerebellum). The presence or absence of intraventricular 
extension or hydrocephalus were treated as dichotomous variables. The 
presence or absence of a visible old vascular lesion (infarct or haemorrhage), 
any white matter lesions, and any atrophy were also entered as dichotomous 
variables. 
2.5.3.5. Management of missing data 
Data could be “missing” to varying extents, and for several reasons. Complete 
loss of data occurred when a patient died or withdrew from the trial, or when 
the research team were unable to contact patients to arrange follow-up. Those 
who remained in follow-up may have found it difficult to complete the 
questionnaires due to dominant hand weakness, visuospatial neglect, 
cognitive dysfunction, or fatigue. Short of complete loss of an entire data-set, 
the spectrum of missing data therefore ranged from all questionnaires 
attempted but with some missing items, to non-completion of whole outcome 
measures.  
Up to three missing items on the SR-RMI were imputed, as follows. If items 
above and below the missing item were the same, then the missing item was 
assigned the same value as those items. If the first completed item after the 
missing item had a different value to the items below the missing item, then 
the missing item was assigned the value of the higher item. Dichotomising the 
RMI therefore depended upon having no more than three variables missing, 
and a valid response to question seven. The RMI was therefore classified as 
“missing” if a completed questionnaire was not received, or if a partially-
completed questionnaire was received with more than 3 missing items or 
question 7 unanswered. If the T1 SR-RMI was missing, then the patient was 
classified as “unable to walk” for the purposes intention-to-treat analysis. If the 
T2 SR-RMI was missing, but a completed T1 SR-RMI was available, then the 
assumption was made that no change in function had occurred in the interim 
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and the patient was classified on the basis of their response to the T1 SR-RMI. 
If at T2 both T1 and T2 SR-RMIs were missing, then the patient was classified 
as “unable to walk”. 
2.5.4. Constructing the models: general considerations 
2.5.4.1. Number of predictor variables fitted 
When undertaking logistic regression modelling, it is important to understand 
how many variables it is reasonable to include in the model. Including a large 
number of variables results in a model that is over-fitted, and not generalisable 
beyond the data-set in which it was derived (Stoltzfus, 2011). Including 
variables for which there is an insufficient number of “observed” events may 
result in inflated values of βi, with large standard errors (Stoltzfus, 2011). The 
challenge of model fitting is therefore to construct a parsimonious model, 
which provides a reasonable explanation of observed data whilst avoiding 
over-fitting (Stoltzfus, 2011). As a guide, binary outcomes require a minimum 
of ten outcome events (outcome occurred/did not occur) for each predictor 
variable included in the model (Stoltzfus, 2011). For example, a model to 
predict survival derived from a study in which 50 patients lived and 30 died 
should include at most 3 predictor variables (Stoltzfus, 2011). 
2.5.4.2. Entry of predictor variables in to the model 
Perhaps the most fundamental decision when fitting a regression model is: 
how should the variables be entered, and in what order? Three main methods 
have been proposed for fitting predictor variables (Stoltzfus, 2011). If there is 
no theoretical basis to support the inclusion of any particular variables, then 
all may be assumed to have equal importance and are entered in to the model 
simultaneously. This is the so-called “direct” approach (Stoltzfus, 2011). If 
previous work has suggested that particular predictors are likely to be 
important, then these may be entered first and additional variables entered 
sequentially thereafter. After each variable is entered, the model is re-
evaluated to see if the new variable has improved its performance (Stoltzfus, 
2011). The final method, stepwise regression, uses pre-defined statistical 
parameters to determine both the order in which variables are entered in to 
the model and also whether each variable is subsequently retained or 
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removed (Stoltzfus, 2011). Two variants of stepwise regression are 
recognised: the forward approach, in which variables are entered one at a 
time; and the backwards approach, in which all variables are first forced in to 
the model simultaneously, with subsequent stepwise removal of non-
significant variables until only those that make a significant contribution to the 
model remain (Stoltzfus, 2011). SPSS allows stepwise regression to be 
automated, with variables included or excluded by the software algorithm on 
the basis of their statistical significance. However, this approach removes any 
clinical judgement about what variables are included in the final model 
(Stoltzfus, 2011). Variables that are of clinical importance but which make a 
marginal or non-significant contribution to the model may be excluded; or 
variables that are strongly statistically significant but have little clinically-
plausible relationship to the outcome variable may be included. This may 
result in a model that is over-fitted to the sample in which it was derived 
(Stoltzfus, 2011). Although some have criticised stepwise approaches to 
model building on this basis (Field, 2013), others have argued that it is not the 
stepwise approach per se that is problematic but rather its thoughtless 
application (Stoltzfus, 2011).  
2.5.4.3. Collinearity between predictor variables 
Relationships between two or more variables may also profoundly affect the 
validity of the final model. Two or more predictor variables that are highly 
correlated are said to be “collinear”. Including collinear variables in a model 
may bias the coefficients for the variables concerned, or cause them to display 
a “direction” of effect paradoxical to that which might be expected (O'Brien, 
2007). The possibility of collinearity between pairs of predictor variables was 
therefore explored prior to any formal modelling. A correlation matrix of 
Spearman’s Rho (r) values was constructed, together with associated 
significance levels. Spearman’s r is a non-parametric test of the correlation 
between two variables, and as such does not make an assumption of 
normality in the variable pairs it tests (Field, 2013). Interpretations of 
correlation coefficients vary, but as a guideline values of r of 0.10-0.29 indicate 
a small correlation, 0.30-0.49 a moderate correlation, and 0.50-1.00 a 
substantial correlation (Pallant, 2010). A second means of checking for the 
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presence of collinearity between predictor variables is to calculate tolerance 
values and Variance Inflation Factors (VIF) for each predictor variable entered 
(Field, 2013). Tolerance may be defined as “the proportion of variance of the 
ith independent variable that is not related to the other independent variables 
in the model” (O'Brien, 2007). The VIF is the reciprocal of the tolerance value 
(O'Brien, 2007). It has been suggested that tolerance values of <0.1 and VIF 
values of >10 indicate possible collinearity (Field, 2013), although some 
question the wisdom of rigorously applying such arbitrary “rules of thumb” 
(O'Brien, 2007). 
Establishing that two variables show collinearity is, perhaps, only the first step: 
what is more crucial is how this is managed or mitigated. Although it might be 
tempting to remove one of the pair, there may be equally valid theoretical and 
statistical grounds to support the inclusion of either (Field, 2013). It is 
sometimes possible to include a pair of collinear variables in a model, provided 
that the estimates of βi are plausible with reasonable standard errors and 
narrow confidence intervals (O'Brien, 2007). Finally, addressing collinearity 
does not obviate the need to examine other factors that may influence model 
stability, such as sample size (O'Brien, 2007). 
2.5.5. Procedure for constructing the models 
2.5.5.1. Fitting of predictor variables 
For each of the six models, binary logistic regression was used to construct a 
series of univariate models exploring associations between patients’ clinical 
characteristics and imaging variables (where available, in the case of models 
1-4), and dichotomised ability to walk 10m or more independently at T1 or T2. 
Multivariate models were then built using a forward stepwise approach, with 
manual as opposed to automated selection of variables. In the case of models 
predicting T1 outcome, only demographic variables, imaging variables (where 
available), and T0 predictors were used. Variables were entered in order of 
their statistical significance, with the most strongly significant univariate 
predictor entered first.  
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2.5.5.2. Assessing the contribution of each variable 
After each step, the contribution of each new variable to the model was 
assessed, as was the contribution of each of the other variables already 
included. The significance of individual coefficients was calculated using the 
Wald χ2 statistic (Bewick et al., 2005), in which:  
Wald χ2 = (βi /Standard error of βi) 
The Wald statistic was then compared to the χ2 distribution using one degree 
of freedom, and significance values ascertained (Bewick et al., 2005). A 
threshold significance of p<0.05 was taken to provide evidence that the 
variable made a statistically-significant contribution to the model. The 
magnitude of standard errors for βi were also considered, as were the 95% 
confidence intervals for the odds ratio of each predictor variable.  
2.5.5.3. Estimating the percentage of variance explained by the model 
The overall performance of each iteration of the model was also assessed, by 
determining the percentage of participants correctly classified by the model 
and by using Cox&Snell R2 and Nagelkerke R2 to provide estimates of the 
amount of previously unexplained variance in outcome accounted for by the 
model (Field, 2013). Variables with non-significant coefficients or which did 
not improve the classification frequency or percentage of explained variance 
were deleted, unless there was compelling clinical grounds to justify their 
inclusion. 
2.5.5.4. Managing collinearity between predictor variables 
Where collinearity was known to exist between two variables, a decision was 
taken regarding which to omit. In taking this decision, two models were fitted, 
each identical in all other predictors but containing only one of the collinear 
variables. The properties of each model were examined, including the 
percentage of cases correctly classified and Cox&Snell R2 and Nagelkerke R2 
(as estimates of the variance in outcome explained by each model). 
Consideration was also given to the magnitude of the coefficients, their 
standard errors, and significance levels for each of the collinear variables 
(when fitted to separate models). However, model properties alone were not 
117 
 
the sole factor in determining which of the variables to fit to the final model. 
For example, stroke services are typically configured to provide the most 
intensive rehabilitation input in the first few weeks or months after an event. 
The ability to predict outcomes using variables that would be available at the 
time of a patient’s entry in to a rehabilitation programme might therefore be 
more clinically useful than a model which utilises predictors recorded some 
weeks later: even if the latter model has a higher classification rate and 
explains a greater proportion of the variance in outcome. This was an 
important consideration where collinearity existed between serial 
measurements of the same variable. 
2.5.5.5. Managing missing data in categorical variables 
When entering continuous variables, cases with missing data were included 
in the model. However, when dichotomised variables were entered cases with 
missing data were excluded. Recruiting centre was not included as a fixed 
effect in any of the models, since several centres recruited fewer than five 
participants. A significance level of 95% (p=0.05) was used as the threshold 
at which a variable was considered for entry in to a multivariate model.  
Once a candidate model had been constructed, the overall performance of the 
model was assessed using the classification rate, estimates of explained 
variance (Cox&Snell R2 and Nagelkerke R2). Each model was then evaluated 
to ensure that the assumptions of linear regression (Stoltzfus, 2011) had been 
met, before a final version was settled upon. 
2.5.6. Evaluating the models: assumption testing 
2.5.6.1. The Box-Tidwell test for linearity of the logit 
The assumption of linearity of the logit was assessed using the Box-Tidwell 
test (Field, 2013). This test depends upon forcing all continuous predictors 
into a binary logistic model together with their natural-log interaction term 
(predictor*Ln[Predictor]). Failure of the natural-log interaction terms to make 
a statistically significant contribution (at p<0.05) to this model is taken as 
evidence that the assumption of linearity had been met (Field, 2013). 
However, for continuous predictor variables in the DARS dataset (C-RMI, SR-
RMI, MoCA, GHQ-12, and FAS), it was possible for participants to achieve a 
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value/score of 0. Since the natural log of 0 cannot be computed, a visual 
inspection of raw scores for each continuous predictor variable was 
performed. Where necessary, a single point was added to the scores of all 
participants, in order to eliminate values of 0 prior to natural-log transformation 
of the scores. When the Box-Tidwell test was performed, the interaction terms 
used for continuous predictor variables were therefore 
(predictor+1*Ln[predictor+1]). Since all participants were aged ≥18 at the time 
of randomisation, the variable “age” was natural-log transformed without prior 
adjustment. 
2.5.6.2. Howsmer and Lemeshow goodness-of-fit test 
Model fit was assessed using the Hosmer and Lemeshow chi-squared 
goodness of fit test. This test groups observations in to deciles based on the 
predicted probability of the outcome occurring (Bewick et al., 2005). The χ2 
statistic is calculated as follows: 
χ2= ∑(observed – expected)2/expected 
Significance values for χ2 are calculated using eight degrees of freedom 
(Bewick et al., 2005). The null hypothesis for this test is that the model under 
consideration is an adequate fit to the observed data; a p-value of >0.05 was 
therefore taken as evidence of adequate model fit (Bewick et al., 2005).  
2.5.6.3. Testing for the presence of influential cases 
As well as the overall fit of the model to the data, it is important to determine 
if a handful of outlying cases are exerting a disproportionate influence on the 
model. Residual values are a measure of the distance between the “observed” 
location of a case and its “predicted” location on the regression line (Stoltzfus, 
2011). For ease of interpretation they are usually quoted as “standardised” 
values, with values >±2.58 indicating cause for concern (Field, 2013). Case-
wise listings of standardised residuals were derived for all six models, and 
examined for the presence of outlying cases. Where such cases were 
detected, an examination was made of the source data and where possible a 
reason for localised poor fit was determined.  
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Where outlying cases are detected, it is also important to understand how 
much influence they exert over the final model. A small number of outliers may 
influence the gradient of regression lines, and thereby bias estimates of 
coefficients. Several methods exist to detect so-called “influential cases”. 
Cook’s distance (Cook, 1979) is an estimate of the overall influence of a case 
on the model. It is calculated for each case in the data-set; cases with values 
>1 are usually deemed to warrant further examination (Field, 2013). The 
leverage value is an indication of the influence that each observed value of 
the outcome variable exerts over the predicted values of that variable (Field, 
2013). The expected leverage value is calculated as: 
Leverage = k+1/N 
where k is the number of predictors and N is the sample size (Field, 2013). In 
the absence of any influential cases, all values would be close to this value. 
Cases with multiples of 2 or 3 times the “expected” value have been 
suggested as meriting evaluation (Field, 2013). The final method for detecting 
influential cases is to examine the difference between coefficients when one 
case is excluded from analysis, versus when all cases are included (Field, 
2013). These values, known as DFBeta, are calculated for both the constant 
and for each predictor variable for each case. Values of >1 are interpreted as 
giving cause for concern (Field, 2013). 
The dilemma is not in detecting outliers or influential cases, but in deciding 
how they should be managed. When deciding whether to include or exclude 
such cases, it is important to take in to account the magnitude of the observed 
change in model parameters as a result of including these cases. This is 
achieved by fitting a series of models: the first with all cases included, and 
subsequent iterations with each of the influential cases omitted in turn 
(Stoltzfus, 2011). If the effect of including a particular case on the overall 
model parameters is modest, then it is reasonable to retain that case in the 
analysis (Stoltzfus, 2011). Cases with a more dramatic influence may be 
omitted, but reasons for doing so must be fully justified.   
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2.5.7. Summarising the models 
For each model, classification tables (Table 2.3.) were derived, and the 
sensitivity, specificity, and positive and negative predictive values of each 
model were ascertained: 
Table 2.3 Example classification table, illustrating calculation of sensitivity, 
specificity, and positive and negative predictive values. 
  Predicted  
  Not walking Walking % correct 
Observed Not walking A B Y 
Walking C D X 
The sensitivity of a model refers to the percentage of participants with the 
target outcome (in this case, walking) who have been correctly classified by 
the model (Pallant, 2010): value X in the table above. Specificity, or the 
percentage of patients without the target outcome who are correctly identified, 
corresponds to value Y in the table above (Pallant, 2010). The positive 
predictive value is the percentage of patients that the model predicts will have 
the outcome of interest who do indeed have that outcome (Pallant, 2010). It 
is calculated as: 
Positive predictive value = D/B+D 
Conversely, the negative predictive value in the percentage of patients that 
the model predicts will not have the outcome of interest, who actually do not 
go on to display that outcome (Pallant, 2010). It is calculated as: 
Negative predictive value = A/A+C 
2.5.8. Testing assumptions made for missing outcome data 
Where no SR-RMI score was returned at T1 or T2, assumptions were made 
for missing data as outlined above. The impact of these assumptions on model 
parameters was explored by re-fitting each model with alternative 
assumptions made (Table 2.4.). 
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Table 2.4. Summary of alternative assumptions for missing data that were 
tested. 
Condition Assumption Applied to 
1 Those who did not return a SR-RMI 
are excluded from analysis 
Models 1-6 
2 Those who did not return a SR-RMI 
are able to walk independently. 
Models 1-6 
3. Those who did not return a SR-RMI 
are unable to walk independently. 
Models 2, 4, and 6 
Assumption 3 was, in effect, the default assumption made for missing data in 
models derived for T1 outcome (models 1, 3, and 5). This assumption was 
therefore only tested for models predicting outcome at T2 (models 2, 4, and 
6). Coefficients, odds ratios, and 95% confidence intervals were calculated for 
each predictor variable. The percentage of patients correctly classified by the 
model under each condition was calculated as above. Cox&Snell R2 and 
Nagelkerke R2 values were determined, as a measure of the percentage of 
variance explained by each model. Sensitivity, specificity, and positive and 
negative predictive values were calculated as above. 
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Chapter 3. Results 
Part 3.1 Summary of recruitment 
3.1.1. Summary of recruitment, and sample characteristics 
3.1.1.1. Total numbers of participants recruited 
The DARS trial opened in July 2011, and recruitment continued until March 
2014. During the recruitment phase, a total of 19,509 patients were screened, 
of whom 1,547 were eligible. Of these, 599 consented to participate, and 593 
were randomised: 308 to co-careldopa, and 285 to placebo. The mean interval 
between stroke onset and randomisation to the trial was 17 days (range 3-59 
days, SD 10.06). Recruitment to the trial is summarised in Figure 3.1. 
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Figure 3.1. Summary of patients screened, eligible, recruited, randomised, 
and followed up in the DARS trial. 
Cumulative loss to follow-up across both arms of the trial was higher than 
anticipated: 61 patients (10.3%) at T1, and 101 patients (17.0%) at T2. This 
may have resulted in decreased power to detect a difference between the 
intervention and control arms had the original sample size of 572 patients 
been retained. In view of this, an increase in the sample size to 593 
participants was authorised.  
Screened: 19,509 
Eligible: 1,547 
Consented: 599 
Randomised: 593 
Ineligible: 17,962 
 Previously immobile: 8,445 
 Unable to consent: 2,404 
 No continuity of rehabilitation: 1,426 
 Other: 5,687 
Not consented: 948 
 Refused: 495 
 Discharged before consented: 216 
 Died: 187 
 Other: 50 
Follow-up at T1: 532 Cumulative loss to follow-up: 61 
 Withdrawn: 35 
 Died: 7 
 Data lost at site: 4 
 Too unwell: 3 
 Unable to contact patient: 2 
 Moved out of area: 2 
 Refused to complete assessment: 2 
 Unknown: 2 
 Data lost in post: 1 
 Other: 3 
Follow-up at T2: 492 Cumulative loss to follow-up: 101 
 Withdrawn: 45 
 Died: 20 
 Unable to contact patient: 15 
 Moved out of area: 8 
 Too unwell: 5 
 Refused to complete assessment: 2 
 Unknown: 2 
 Refused follow-up visit: 1 
 Data lost at site 1 
 Other: 2 
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3.1.1.2. Availability of SR-RMI scores at T1 and T2 
In addition to patients for whom no data were returned, in some cases 
partially-completed SR-RMI scores were returned for which missing values 
could not be imputed. When these patients are taken in to account, the 
numbers of patients for whom SR-RMI scores were not available at T1 and T2 
are slightly higher than those suggested in Figure 3.1: 69 patients at T1, and 
106 patients at T2. When the characteristics of those who returned a SR-RMI 
score at T1 were compared with those who did not, there was no evidence of 
a statistically significant difference in the age, the balance of males versus 
females, or the spectrum of clinical stroke syndromes (classified using the 
OCSP) between the two groups. There were no statistically significant 
differences in C-RMI, mRS, MoCA, and GHQ-12 scores at T0, nor in the 
presence of musculoskeletal pain at T0 between those who remained in follow-
up at T1 versus those lost to follow-up. Likewise, there was no statistical 
evidence of a difference in demographics or clinical impairment at T0 between 
those who for whom SR-RMI scores were available at T2 versus those who 
did not return a SR-RMI score at this time. 
When impairment at T1 was compared for patients who did and did not return 
SR-RMI scores at T2, some important differences were found. Those who 
remained in follow-up at T2 had slightly higher MoCA scores at T1 than those 
who were lost to follow-up (22.83 for versus 21.06; p=0.037), indicating 
marginally better cognitive performance in this group. The group who 
remained in follow-up at T2 also had lower mean GHQ-12 scores (16.32 
versus 19.42; p=0.002), and lower mean FAS scores (24.49 versus 29.24; 
p<0.0005). This indicates that, in comparison to those who remained in follow-
up, those patients who were lost to follow up at T2 had slightly greater levels 
of cognitive impairment, depression, and fatigue at the last time-point for 
which data were available for them. There was no evidence of a statistically 
significant difference between the group who remained in follow-up at T2 and 
those lost to follow up in SR-RMI scores, mRS, or the prevalence of 
musculoskeletal pain at T1.   
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3.1.1.3. Availability of brain imaging 
The number of patients for whom imaging was available for analysis is 
summarised in Figure 3.2. 
 
Figure 3.2. Summary of the availability of brain imaging for DARS participants 
No imaging could be obtained for 57 of 593 (9.3%) participants. Of note, 24 
patients were consented to the initial version of the protocol (which did not 
explicitly grant permission for despatch of scans to CTRU), and could not 
subsequently be contacted to obtain consent for review of their scans. Of the 
533 patients for whom images were received and reviewed, 20 patients had 
only MRI images available. These patients were excluded from analysis. A 
total of 513 patients thus had a first CT scan available for analysis.  
Comparing the demographic characteristics of those for whom imaging was 
available versus those for whom it was not revealed no evidence of a 
statistically significant difference between the groups in age, gender balance, 
proportion of infarcts versus haemorrhages, or OCSP clinical stroke 
Randomised: 593 
Images received: 536 
 Randomised before protocol change: 24 
 Scans performed at another Trust: 17 
 Unable to obtain scans from site: 7 
 Site unable to download images: 6 
 Imaging not received by CTRU: 2 
 Patient withdrew consent: 1 
Images not received: 57 
Images reviewed: 533 
Images not reviewed: 3 
 Incorrect images sent: 2 
 Site did not respond to request 
for additional information: 1  
Images included 
in analysis: 513 Images not included in analysis: 20 
 Only MRI received, no CT: 20 
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syndrome. Comparison of clinical impairment at T0, T1, and T2 revealed that 
those for whom scans was obtained had slightly lower mean SR-RMI scores 
than those for whom imaging was not available at T1 (mean score 6.71 versus 
8.06; p=0.012) and T2 (6.00 versus 9.43; p=0.016), but there was no 
statistically significant difference in the proportion of either group who were 
walking independently at each of these time-points. Nor was there any 
significant difference in cognitive function, depression, fatigue, or the 
prevalence of musculoskeletal pain at T0, T1, or T2. 
3.1.1.4. Clinical impairment of DARS participants at T0 
The demographics of the DARS sample and the clinical impairment of 
participants at T0 are summarised below in Table 3.1.  
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Table 3.1. Demographic characteristics and clinical impairment in the DARS 
sample at T0. 
Mean age (range, SD) 68 (20-98, SD 13.23) 
Gender  
 Female/ Male (%) 229/ 364 (38.6%/ 61.4%) 
Type of stroke  
 Infarct/ ICH (%) 508/ 85 (85.7%/ 14.3%) 
Clinical stroke syndrome (OCSP)*  
 N (Missing, %)) 508 (1, 0.2%) 
 TACS 161 (27.2%) 
 PACS 178 (30.0%) 
 LACS 116 (19.6) 
 POCS 52 (8.8%) 
Mobility (C-RMI)  
 Mean (range, SD) 2.25 (0-6, 1.791) 
Disability (mRS)  
 0 4 (0.7%) 
 1 25 (4.2%) 
 2 53 (8.9%) 
 3 214 (36.1%) 
 4 172 (29.0%) 
 5 68 (11.5%) 
 Missing 57 (9.6%) 
Cognition (MoCA)  
 N (Missing, %) 580 (13, 2.2%) 
 Mean (range, SD) 20.23 (0-30, 6.308) 
Depression (GHQ-12)  
 N (Missing, %) 570 (23, 3.5%) 
 Mean (range, SD) 19.36 (3-36, 6.848) 
Musculoskeletal pain  
 Missing 10 (1.7%) 
 Any musculoskeletal 
pain1 
236 (39.8%) 
 Upper limb pain2 114 (19.2%) 
 Lower limb pain3 154 (26.0%) 
* Ischaemic stroke only. 1Any musculoskeletal pain (upper limb, lower limb, 
spine). 2 Any upper limb pain (shoulders, elbow, wrist, small joints of hand). 3 Any 
lower limb pain (hips, knees, ankles, feet)  
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3.1.2. The modelling process 
3.1.2.1. Caveats for the models presented here 
As described in Chapter 2, a series of six models were constructed to predict 
dichotomised walking ability in the IWS group, the HWS group, and the whole 
DARS sample at T1 and T2. Before describing the construction of these 
models, some important caveats must be acknowledged. Firstly, the findings 
presented below represent a post-hoc analysis on an existing data-set. As 
such, only predictor variables that were collected as part of the DARS trial will 
be included in these models. Secondly, the numbers of participants available 
for analysis (particularly in the HWS group) are small. Thirdly, no attempt will 
be made here to undertake formal validation of the models derived. All of the 
above limitations will be explored in detail in Chapter 4. 
3.1.2.2. Testing for collinearity between predictor variables 
Prior to model construction, the presence of collinearity between pairs of 
continuous predictor variables was assessed using Spearman’s r (Field, 
2013). A Spearman r of 1 indicate perfect correlation between two variables, 
whereas a Spearman r of 0 indicates that no correlation exists (Field, 2013). 
When interpreting Spearman’s r, values of 0-0.39 are generally considered to 
be evidence of a weak association. For example, the correlation between age 
and FAS score at T1 has a Spearman r of 0.009). Plotting the two variables 
on a scatter plot and fitting a line of best fit to this plot allows the absence of 
any relationship between the two to be visualised clearly (Figure 3.3.): 
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Figure 3.3. Example of a weak correlation between two predictor variables. 
Age, and FAS score at T1.  
Values of Spearman r of 0.4-0.59 are generally taken to imply an association 
of moderate strength. An example of such a relationship is that between SR-
RMI at T1 and MoCA at T1 (r=0.379). Once again, this relationship may be 
visualised using a scatter plot (Figure 3.4.): 
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Figure 3.4. Example of a moderate correlation between two predictor 
variables. 
SR-RMI and MoCA at T1.  
Strong associations are generally held to exist for values of r between 0.6-1.0. 
An example of such a relationship is that between MoCA scores at T0 and T1 
(r=0.750). as demonstrated in Figure 3.5.:   
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Figure 3.5. Example of a strong correlation between two predictor variables. 
MoCA score at T0 and MoCA score at T1. 
The sign of Spearman’s r provides some indication of the nature of the 
relationship between the variables: a positive sign implies a positive 
correlation: i.e. that as the value of one variable increases, so the value of the 
second variable increases. Conversely, a negative sign implies an inverse 
relationship: i.e, that as one variable increases, the second decreases. An 
example of this is the relationship between age and MoCA score at T1 (r=-
0.351), which is summarised in Figure 3.6.:  
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Figure 3.6. Example of a negative correlation between two predictor variables 
Age and MoCA score at T1. 
Although the Spearman’s r provides an estimate of the strength of an 
association between two variables, it does not prove a causal link between 
them. Furthermore, the p-values cited for each value merely provide an 
estimate of the probability that the Spearman r value quoted has been 
obtained by chance: they provide no information about the strength of 
association between the two variables (Field, 2013). The Spearman’s 
coefficient for each pair of predictor variables used in DARS, together with 
with their associated significance levels, are summarised in Table 3.2 
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Table 3.2. Correlation matrix for predictor variables 
  Variables recorded at T0 Variables recorded at T1 
Age C-RMI GHQ-12 MoCA SR-RMI GHQ-12 MoCA FAS 
 
A
g
e
 
r 1.000 -0.186 -0.052 -0.274 -0.265 0.023 -0.351 -0.009 
Sig . * 0.213 * * 0.597 * 0.831 
N 593 593 570 580 524 523 526 523 
V
a
ri
a
b
le
s
 r
e
c
o
rd
e
d
 a
t 
T
0
 
C
-R
M
I 
r  1.000 -0.187 0.229 0.554 -0.080 0.193 -0.002 
Sig  . * * * 0.066 * 0.958 
N  593 570 580 524 523 526 523 
G
H
Q
-1
2
 
r   1.000 -0.104 -0.098 0.343 -0.138 0.251 
Sig   . 0.014 0.027 * 0.002 * 
N   570 562 505 503 508 504 
M
o
C
A
 
r    1.000 0.268 -0.064 0.750 -0.076 
Sig    . * 0.146 * 0.087 
N    580 515 514 520 515 
V
ar
ia
b
le
s 
re
co
rd
ed
 a
t 
T 1
 
S
R
-R
M
I 
r     1.000 -0.293 0.379 -0.202 
Sig     . * * * 
N     524 516 509 517 
G
H
Q
-1
2
  r      1.000 -0.165 0.613 
Sig      . * * 
N      523 509 518 
M
o
C
A
 
r       1.000 -0.143 
Sig       . 0.001 
N       526 510 
F
A
S
 
r        1.000 
Sig        . 
N        523 
* Value of r is significant at a level of p<0.0005 
The correlation matrix presented above shows strong collinearity for several 
pairs of predictors, including: C-RMI at T0 and SR-RMI at T1 (r=0.554); MoCA 
scores at T0 and T1 (r=0.750); and GHQ-12 and FAS at T1 (r=0.613). Moderate 
correlations exist between: age and MoCA at T1 (r=-0.351); GHQ-12 at T0 and 
T1 (r=0.343); and SR-RMI and MoCA at T1 (r=0.379). All of these relationships 
were also strongly statistically significant (p<0.0005). The variable pairs which 
display strong collinearity will not be fitted to the same model concurrently; the 
management of more modest degrees of collinearity is discussed in Chapter 
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2. The fitting of the models themselves will next be discussed, beginning with 
models 1 and 2 (derived in the IWS group). 
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Part 3.2 Modelling walking ability in IWS group 
3.2.1. Characteristics of the IWS group 
3.2.1.1. Comparison of IWS group with the whole DARS sample 
Models 1 and 2 were derived in the IWS group: a sub-sample (n=438) of the 
whole DARS data-set (n=593). Prior to commencing model fitting, the 
characteristics of the IWS group were compared to those of the whole DARS 
sample. There was no evidence of a statistically-significant difference in the 
age profile or gender balance between the two groups. Nor was there 
evidence of a significant difference in any of the major clinical measures 
(dichotomous or mean RMI, mRS, MoCA, GHQ-12, FAS, and the prevalence 
of musculoskeletal pain) at T0, T1, and T2. 
3.2.1.2. Determining how many variables might be fitted  
The proportion of patients in the IWS group who were able to walk 
independently at T1 and T2 is crucial for estimating the number of variables 
that might be fitted to the model. At T1, 176 patients (40.2% of the IWS group) 
were able to walk independently for 10m or more; 262 (59.8%) were unable 
to do so. If a ratio of ten patients per observed outcome is applied to the 
smaller of the two outcome groups, then a maximum of 176/10=17 variables 
may be fitted to model 1. Allowing for a more stringent ratio of 20 patients per 
variable would allow up to eight variables to be fitted (Stoltzfus, 2011). 
Similarly, 221 patients (50.5%) were able to walk independently at T2, and 217 
(49.5%) were unable to do so. This implies that it is reasonable to fit between 
10 to 20 variables to Model 2.  
3.2.2. Model 1: return to walking at T1 in IWS group 
3.2.2.1. Univariate predictors of outcome at T1: demographics, and 
clinical impairment at T0 
Model 1 examined predictors of walking ability at T1. For this reason, only 
demographic variables, clinical impairment at T0, and radiological findings 
were considered as candidate predictors in this model. The modelling process 
began by examining univariate associations between possible predictors and 
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walking ability at T1. The most statistically significant univariate predictors 
were C-RMI score and MoCA score at T0 (p<0.0005) (Table 3.3). Age and 
OCSP clinical stroke syndrome (p=0.005), thrombolysis status (p=0.002), and 
gender (p=0.033) were also statistically significant univariate predictors. 
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Table 3.3. Univariate predictors of independent walking ability at T1.  
Predictors: age, gender, thrombolysis status, OCSP clinical stroke 
syndrome, and clinical impairment at T0. 
 
 N 
Missing 
(%) Mean 
(Range, SD) 
Sig OR 95% CI for OR 
     Lower Upper 
D
e
m
o
g
ra
p
h
ic
 v
a
ri
a
b
le
s
 
Age 438 0 
69.13 
(20-98, 12.874) 
0.005 0.978 0.964 0.993 
Gender 267  0 - 0.033 0.648 0.435 0.965 
Thrombolysis 109  
1 
(0.2%) 
- 0.002 0.479 0.299 0.769 
OCSP 438 0 - 0.005 - - - 
 TACS 145  - - 0.005 - - - 
 PACS 154) - - 0.013 1.839 1.138 2.973 
 POCS 43  - - 0.004 2.820 1.403 5.671 
 LACS 96 - - 0.005 2.164 1.264 3.706 
P
h
y
s
ic
a
l 
im
p
a
ir
m
e
n
t 
a
t 
T
0
 
C-RMI 438 
0 
2.25 
(0-6, 1.809) 
<0.0005 1.719 1.512 1.954 
 
MoCA 429 9 (2.1%) 
20.37 
(0-30, 6.268) 
<0.0005 1.076 1.039 1.114 
GHQ-12 422 
16, 
(3.7%) 
19.13 
(3-36, 6.842) 
0.475 0.990 0.962 1.018 
Any pain 180 
7 
(1.6%) 
- 0.654 0.914 0.618 1.352 
UL pain 82 
7 
(1.6%) 
- 0.786 1.070 0.656 1.745 
LL pain 120 
7 
(1.6%) 
- 0.045 1.572 1.010 2.449 
3.2.2.2. Univariate predictors of outcome at T1: radiological variables 
Univariate associations between walking ability at T1 and imaging findings are 
shown in Table 3.4. None of the imaging predictor variables tested attained 
statistical significance.  
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Table 3.4. Univariate models of ability to walk 10m or more independently at 
T1.  
Predictors: vascular territory of infarct; presence of old stroke, white 
matter lesions, or atrophy; infarct location; infarct size. 
 N (%) 
Missing 
(%) 
Sig OR 95% CI for OR 
     Lower Upper 
Any visible abnormality 379 (86.5%) 0 0.840 0.944 0.538 1.655 
Any acute infarct 225 (51.4%) 0 0.390 0.846 0.577 1.239 
Acute MCA infarct 180 (41.1%) 0 0.510 0.877 0.549 1.295 
Acute ACA infarct 8 (1.8%) 0 0.876 0.891 0.210 3.778 
Acute PCA infarct 16 (3.7%) 0 0.824 0.889 0.317 2.493 
Acute lacunar infarct 13 (3.0%) 2 (0.5%) 0.215 0.438 0.119 1.614 
Acute borderzone infarct 5 (1.1%) 2 (0.5%) 0.999 0.000 0.000 - 
Acute cerebellar infarct 4 (0.9%) 2 (0.5%) 0.072 3.048 0.903 10.28 
Acute brainstem infarct 12 (2.7%) 2 (0.5%) 0.192 4.535 0.468 43.954 
Old vascular lesion 119 (27.2%) 4 (0.9%) 0.615 1.116 0.727 1.713 
Any white matter lesions 189 (43.2%) 3 (0.7%) 0.926 0.982 0.667 1.445 
Atrophy 46 (10.5%) 9 (2.1%) 0.151 1.622 0.838 3.139 
Infarct location 437 1 (0.2%) 0.820 - - - 
 Cortical 89 (20.3%) - 0.514 0.845 0.509 1.402 
 Subcortical 90 (20.5%) - 0.716 0.911 0.552 1.505 
 Both 45 (10.3%) - 0.408 0.754 0.387 1.471 
 No visible infarct 213 (48.6%) - 0.820 - - - 
Infarct size 429 9 (2.1%) 0.951 - - - 
 Small 58 (13.2%) - 0.640 0.867 0.477 1.576 
 Medium 131 (29.9%) - 0.763 0.934 0.598 1.458 
 Large 32 (7.3%) - 0.681 0.851 0.395 1.833 
 No visible infarct 208 (47.5%) - 0.951 - - - 
Of the 225 patients with a visible acute infarct, 180 had a lesion in the MCA 
territory. The observed frequency of infarcts in other vascular territories was 
low. In addition, the proportion of cases with missing data (n=2 for lacunar 
infarcts, borderzone, brainstem, and cerebellum) was high as a proportion of 
the observed frequency of infarcts in these territories. Estimates for odds 
ratios for these variables are therefore likely to be significantly biased, as 
evidenced by their wide confidence intervals. 
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3.2.2.3. Model 1: construction of an initial model 
A multi-variate model was constructed using a forward stepwise approach. 
Based on the p-values outlined in Tables 3.3 and 3.4, C-RMI at T0 was entered 
in to the model first. With the entry of each subsequent variables, the 
contribution of all variables to the model was re-evaluated and predictors that 
did not make a significant overall contribution were removed. The first variable 
to be entered was C-RMI. This made a statistically significant contribution to 
the model (p<0.0005), explained between 17.5% and 23.7% of the variance 
in walking ability, and correctly classified 69.2% of cases as walking or not 
walking independently at T1. The addition of MoCA score at T0 made a 
statistically significant contribution to the model (p<0.017), but this 
combination explained only marginally more variance in outcome (19.6%-
26.4%) and there was no change in the proportion of cases correctly classified 
by the model (69.2%). When added sequentially to the model, age, gender, 
OCSP and thrombolysis status failed to attain statistical significance, nor was 
there any substantial increase in the proportion of cases correctly classified. 
The proposed final iteration model therefore comprised C-RMI and MoCA 
score at T0. 
3.2.2.4. Model 1: model evaluation and testing assumptions of logistic 
regression 
When the Hosmer and Lemeshow goodness-of-fit test was applied to this 
model, a value of p=0.017 was obtained, indicating inadequate fit to the 
observed data. Examination of standardised residuals for evidence of 
localised misfit revealed five participants with values >±2.58. Each of these 
cases was evaluated in turn. Participant 164 had a total SR-RMI score of 13 
at T1, which suggests that he was able to walk independently at this time. 
However, his dichotomised SR-RMI classified him as being unable to walk 
independently for 10m or more. This probably indicates that a response to 
question 7 was not provided: and since missing responses to this question 
were not imputed, he was classified as being unable to walk. Participants 173 
and 312 did not return a valid SR-RMI at T1, and were therefore assumed to 
be unable to walk independently. This may account for the discrepancy 
between their observed (unable to walk) and predicted (able to walk) status. 
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Participants 238 and 563 had a very low C-RMI and MoCA scores at T0, and 
yet were able to walk independently at T1. It is possible that both simply made 
a better-than-expected recovery in the face of profound initial impairment. 
However, their persistently low MoCA scores at T1 raise the possibility that 
cognitive impairment might have led them to over-estimate their physical 
abilities, and thus biased their SR-RMI score at T1. It is equally possible that 
communication impairment compromised their ability to complete the MoCA 
at T0, and thus led to a score that does not reflect their true cognitive ability. 
This could therefore have led the model to predict erroneously that they would 
be unable to walk at T1.  
3.2.2.5. Model 1: revision of model to improve fit 
This evidence of localised misfit prompted a re-evaluation of the variables 
included in the model. On re-evaluating model parameters, the MoCA score 
at T0 made a statistically-significant contribution to the model but its overall 
effect size was small (β=0.044). Removing this variable resulted in a 
univariate model which contained only C-RMI at T0. The Hosmer and 
Lemeshow goodness-of-fit test was non-significant (p=0.270), indicating 
acceptable overall fit. When assessing local model fit, there were no cases in 
which standardised residuals exceeded the threshold level of ±2.58. 
Examining the influence of individual cases, there were no cases in which 
Cook’s distance or values of DFBeta exceeded 1. Leverage values ranged 
from 0.00004 to 0.00962. Sixty-eight patients had leverage values in excess 
of the predicted value (1+1/438=0.00457). The Box-Tidwell test was 
performed to assess the assumption of a linear relationship between predictor 
variables and the natural log of the odds ratio of walking independently at T1. 
Prior to natural-log transformation, a score of 1 was added to all values of C-
RMI, to eliminate scores of 0. C-RMI score was then forced into a model which 
also contained the interaction terms (C-RMI+1*Ln[C-RMI+1]). The interaction 
terms did not make a significant contribution to the model, thus indicating that 
the assumption of linearity of the logit was met. 
3.2.2.6. Model 1: final version 
The final, univariate, iteration of Model 1 is summarised in Table 3.5.  
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Table 3.5. Final version of Model 1. 
Model contains only C-RMI at T0. 
 B S.E. Wald df Sig OR 95% CI for OR 
       Lower Upper 
C-RMI at T0 0.542 0.065 68.608 1 <0.0005 1.719 1.512 1.954 
Constant -1.666 0.189 77.922 1 <0.0005 0.189   
3.2.2.7. Model 1: summary of model characteristics 
This model correctly classified 69.2% of cases, and accounted for 17.5%-
23.7% of variance in outcome. Each one-point increase in C-RMI at T0 
increased the odds of walking independently at T1 by 71.9%. The observed 
versus predicted classification of patients by Model 1 is shown in Table 3.6. 
From this, the sensitivity, specificity, and positive and negative predictive 
values can be ascertained. 
Table 3.6. Classification table for Model 1. 
 Walking independently by T1 (predicted) % correct 
No Yes 
Walking independently 
by T1 (observed) 
No 232 30 88.5 
Yes 105 71 40.3 
Overall %   69.2 
The sensitivity of Model 1 was low (40.3%), but specificity was higher (88.5%). 
The positive predictive value of the model is 70.3%. The negative predictive 
value of model 1 is 68.8%.  
3.2.2.8. Model 1: testing assumptions made for missing data 
Model 1 was constructed on the basis of an assumption that patients who did 
not return a SR-RMI score at T1 were unable to walk independently. This might 
be termed the “default” assumption. To explore the impact of this assumption 
on model parameters, Model 1 was re-fitted with two alternative assumptions 
made. The first (assumption 1) was that patients who did not return a SR-RMI 
score at T1 were excluded from analysis. A total of 393 patients were therefore 
analysed under this assumption. The second (Assumption 2) was that all 
patients who did not return a SR-RMI score at T1 were able to walk 
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independently. The variation in the properties of Model 1 when re-fitted under 
these alternative assumptions are summarised in Table 3.7. 
Table 3.7. Properties of Model 1 when fitted under alternative assumptions 
for missing SR-RMI scores at T1. 
 Default Assumption 1 Assumption 2 
% correctly classified 69.2% 71.2% 67.6% 
Sensitivity 40.3% 62.5% 57.0% 
Specificity 88.5% 78.3% 78.3% 
Positive predictive value 70.3% 70.1% 72.8% 
Negative predictive value 68.8% 72.0% 66.7% 
% Variance  Cox&Snell R2 17.5% 21.2% 16.6% 
% Variance Nagelkerke R2 23.7% 28.3% 22.2% 
C-RMI at T0    
 B 0.542 0.623 0.531 
 OR 1.719 1.865 1.701 
 95% CI for OR 1.512 – 1.854 1.613 – 2.157 1.493 – 1.939 
Model properties changed considerably depending upon what assumptions 
were made for missing data. The possible range for the percentage of cases 
correctly classified is between 67.6% (assumption 2) and 71.2% (assumption 
1). The percentage increase in the odds of walking independently for each 
one-point change in C-RMI at T0 ranged from 70.1% (under assumption 2) to 
86.5% (under assumption 1). Values of sensitivity range from 40.3% (under 
the default assumption) to 62.5% (under assumption 1). Similarly, values of 
specificity range from 78.3% (assumptions 1 and 2) to 88.5% (default 
assumption). Positive predictive values ranged from 70.1% (assumption 1) to 
72.8% (assumption 2); negative predictive values lay between 66.7% 
(assumption 1) and 72.0% (assumption 2). The percentage of variance 
explained by the model ranges from 16.6% (Cox&Snell R2, assumption 2) to 
28.3% (Nagelkerke R2, assumption 1).  
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3.2.3. Model 2: return to walking at T2 in IWS group 
3.2.3.1. Univariate predictors of outcome at T2: demographics, and 
clinical impairment at T0 and T1 
Model 2 aimed to predict walking ability at T2, and thus considered 
demographic variables, clinical impairment at both T0 and T1, and radiological 
findings as possible predictors. Once again, univariate associations between 
these variables and walking ability at T2 were first established. The most 
strongly significant univariate predictors at T0 were age (p<0.0005), and C-
RMI score and MoCA score at T0 (p<0.0005). SR-RMI and MoCA score at T1 
were also highly significant (p<0.0005) (Table 3.8). 
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Table 3.8. Univariate predictors of independent walking ability at T2. 
Predictor variables: age, gender, receipt of thrombolysis, OCSP clinical 
stroke syndrome, impairment at T0, and impairment at T2. 
  N Missing (%) Mean 
(Range, SD) 
p OR 95% CI for OR 
     Lower Upper 
D
e
m
o
g
ra
p
h
ic
 v
a
ri
a
b
le
s
 
Age 438 0 69.13  <0.0005 0.962 0.947 0.978 
   (20-98, 12.874)     
Gender 267 0 - 0.027 1.544 1.049 2.273 
Thrombolysis 109 1 (0.2%) - 0.195 0.750 0.485 1.159 
OCSP 438 0 - 0.008 - - - 
 TACS 145 - - 0.008 - - - 
 PACS 154 - - 0.138 1.413 0.895 2.231 
 POCS 43 - - 0.001 3.557 1.691 7.482 
 LACS 96 - - 0.093 1.561 0.929 2.623 
P
h
y
s
ic
a
l 
im
p
a
ir
m
e
n
t 
a
t 
T
0
 
C-RMI 438 0 2.25  <0.0005 1.506 1.335 1.698 
   (0-6, 1.809)     
MoCA 429 9 (2.1%) 20.37  <0.0005 1.064 1.030 1.099 
   (0-30, 6.268)     
GHQ-12 422 16, (3.7%) 19.13  0.857 0.997 0.970 1.026  
   (3-36, 6.842)     
Any pain 180 7 (1.6%) - 0.238 0.794 0.541 1.165 
UL pain 82 7 (1.6%) - 0.907 0.972 0.601 1.572 
LL pain 120 7 (1.6%) - 0.099 0.700 0.458 1.069 
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SR-RMI 393 
45 
(10.3%) 
6.50  <0.0005 1.599 1.457 1.755 
   (0-15, 4.070)     
MoCA 392 46 (10.5%) 22.53  <0.0005 1.119 1.076 1.163 
   (0-30, 6.054)     
GHQ-12 393 
45 
(10.3%) 
16.94  0.004 0.958 0.930 0.986 
   (0-36, 6.993)     
FAS 393 
45 
(10.3%) 
25.24  0.135 0.980 0.955 1.005 
   (10-49, 7.874)     
Any pain 298 40 (9.1%) - 0.185 0.732 0.462 1.160 
UL pain 251 40 (9.1%) - 0.562 1.128 0.750 1.697 
LL pain 177 40 (9.1%) - 0.042 0.662 0.444 0.985 
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3.2.3.2. Univariate predictors of outcome at T2: radiological variables 
Univariate associations between walking ability at T2 and imaging findings are 
summarised in Table 3.9. None of the imaging variables was a statistically 
significant predictor of outcome, and estimates for odds ratios for some 
variables are likely to be biased by low observed event rates and relatively 
high proportions of missing data.  
Table 3.9. Univariate models of independent walking ability at T2. 
Predictors: vascular territory of infarct; presence of old stroke, white 
matter lesions, or atrophy; infarct location; infarct size. 
 N (%) Missing (%) Sig OR 95% CI for OR 
     Lower Upper 
Any visible abnormality 379 (86.5%) 0 0.949 1.018 0.588 1.763 
Any acute infarct 225 (51.4%) 0 0.928 1.107 0.699 1.480 
Acute MCA infarct 180 (41.1%) 0 0.873 0.969 0.663 1.419 
Acute ACA infarct 8 (1.8%) 0 0.167 0.321 0.064 1.609 
Acute PCA infarct 16 (3.7%) 0 0.970 0.981 0.362 2.663 
Acute lacunar infarct 13 (3.0%) 2 (0.5%) 0.753 0.837 0.277 2.532 
Acute borderzone infarct 5 (1.1%) 2 (0.5%) 0.203 0.240 0.027 2.163 
Acute cerebellar infarct 4 (0.9%) 2 (0.5%) 0.103 3.000 0.801 11.235 
Acute brainstem infarct 12 (2.7%) 2 (0.5%) 0.347 2.972 0.307 28.800 
Old vascular lesion 119 (27.2%) 4 (0.9%) 0.992 0.998 0.654 1.521 
Any white matter lesions 189 (43.2%) 3 (0.7%) 0.077 0.709 0.485 1.038 
Atrophy 46 (10.5%) 9 (2.1%) 0.005 0.392 0.203 0.758 
Infarct location 437 1 (0.2%) 0.954 - - - 
 Cortical 89 (20.3%) - 0.876 1.040 0.634 1.706 
 Subcortical 90 (20.5%) - 0.948 1.016 0.621 1.664 
 Both 45 (10.3%) - 0.623 0.851 0.447 1.620 
 No visible infarct 213 (48.6%) - 0.954 - - - 
Infarct size 429 9 (2.1%) 0.877 - - - 
 Small 58 (13.2%) - 0.948 0.981 0.548 1.756 
 Medium 131 (29.9%) - 0.798 1.059 0.684 1.640 
 Large 32 (7.3%) - 0.479 0.763 0.361 1.614 
 No visible infarct 208 (47.5%) - 0.877 - - - 
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3.2.3.3. Model 2: construction of an initial model 
A multi-variate model was constructed using a forward stepwise approach. 
Demographic variables and clinical impairment at T0 were entered first, in 
preference to impairment at T1. C-RMI at T0 made a statistically significant 
contribution to the model (p<0.0005). This variable alone explained 11.1%-
14.8% of variance in walking ability, and correctly classified 63.5% of cases 
as walking or not walking independently at T2. The addition of age explained 
marginally more variance (14.7%-19.6%), and correctly classified 68.5% of 
cases. The addition of MoCA score at T0 did not make a statistically significant 
contribution to a model containing C-RMI and age (χ2=2.687, p=0.101), and 
the resulting model explained only fractionally more variance than a model 
containing C-RMI and age alone (15.9%-21.1%). Nor was there any 
substantial increase in the proportion of cases correctly classified (68.3%). 
However, the prevalence of cognitive impairment after stroke, and its 
theoretical importance in motor learning, justify retention of this variable in the 
model. Neither gender nor OCSP clinical stroke syndrome made a statistically 
significant contribution to the model; and nor did their inclusion increase the 
proportion of variance explained or the percentage of patients classified 
correctly. Both of these variables were removed from the model. 
Having entered all predictor variables measured at T0, the model thus 
contained C-RMI and MoCA scores at T0 and age. Predictor variables 
measured at T1 were next entered. The SR-RMI score at T1 made a highly 
significant contribution to the model (p=<0.0005); in the presence of this 
variable the C-RMI score at T0 became non-significant, indicating that the 
ability of mobility at T0 to predict mobility outcomes at T2 is wholly mediated 
by mobility at T1. C-RMI at T0 was thus replaced in the model by SR-RMI at 
T1. The resulting model explained 38.3% to 51.2% of unexplained variance in 
outcome, and correctly classified 79.7% of cases. The MoCA score at T1 also 
made a significant contribution to the model (p=<0.003). Although MoCA 
scores at T0 retained statistical significance when fitted alongside scores at 
T1, the strong collinearity between scores collected at the two time points 
raised the possibility that model coefficients could be biased if both were 
included. MoCA scores at T0 were therefore removed from the model. GHQ-
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12 scores at T1 did not make a statistically significant contribution to the 
model, and were thus excluded.  
3.2.3.4. Model 2: modification to improve localised misfit 
The working “final” iteration of the model thus comprised age, and SR-RMI 
and MoCA scores at T1. This model correctly classified 80.1% of cases, and 
explained between 38.8% and 51.9% of unexplained variance in outcome. 
However, when the model was examined for evidence of localised misfit, 
twelve patients had standardised residuals of >±2.58. This amounted to 
2.74% of the analysis population. Whilst the percentage of cases affected did 
not exceed the 5% threshold (Field, 2013), the fact that seven cases had 
standardised residuals of >3 was nevertheless cause for concern. 
The variables included in the model were therefore re-evaluated, and an 
alternative model was constructed. Replacing SR-RMI at T1 with C-RMI at T0 
resulted in more acceptable model fit, with seven cases having standardised 
residuals of >±2.58. In this iteration, MoCA scores at T1 remained highly 
significant, and this variable was therefore considered for inclusion in the final 
model. However, in clinical practice the timeframe defined as T0 in DARS (5-
42 days after stroke) typically marks the most intense period of rehabilitation 
intervention. It is desirable to be able to predict medium-term outcomes using 
information that would be available to professionals in the early acute 
rehabilitation period (i.e. within six weeks of a stroke). It could be argued that 
such a model would be more useful in clinical practice than a model which 
incorporated predictor variables acquired at a later date, even if the model 
explains a lower percentage of the overall variance in outcome when 
compared with a model containing variables measured at T1. 
3.2.3.5. Model 2: model evaluation and testing assumptions of logistic 
regression 
Replacing MoCA scores at T1 with values measured at T0 thus resulted in a 
model containing age, and C-RMI and MoCA scores at T0. This model showed 
acceptable fit to the data (Hosmer and Lemeshow goodness-of-fit test 
p=0.488), and only two cases had standardised residuals of >±2.58. Neither 
patient returned a RMI score at T2, and both were therefore assumed to be 
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unable to walk independently at this time point. This may account for the 
discrepancy between their observed (unable to walk) and predicted (able to 
walk) status. The model was also examined for influential cases using Cook’s 
distance, leverage statistics, and DFBeta values for the constant and each of 
the predictors (Table 28). No cases had a Cook’s distance of >1. Leverage 
values ranged from 0.00291 to 0.0445. One hundred and fifty-seven patients 
had a leverage value greater than the expected value of 0.00913). No cases 
returned DFBeta values >1 for the constant or for any of the predictor 
variables. The assumption that a linear relationship exists between each 
predictor variable and the natural log of the odds ratio of walking 
independently at T2 was tested using the Box-Tidwell test. Prior to natural-log 
transformation, a score of 1 was added to all values of C-RMI and MoCA at 
T0, to eliminate scores of 0. The covariates C-RMI, age, and MoCA score were 
then forced in to a model which also contained the interaction terms (C-
RMI+1*Ln[C-RMI+1]), (age*ln[age]), and (MoCA+1*Ln[MoCA+1]). The 
natural-log interaction terms did not make a significant contribution to this 
model (p>0.05), indicating that the assumption of linearity of the logit was met 
for C-RMI, age and total MoCA score at T0.  
3.2.3.6. Model 2: final version 
The final iteration of Model 2 is summarised in Table 3.10.  
Table 3.10. Final version of Model 2 
Predictor variables: C-RMI, age, and MoCA at T0. 
 B S.E. Wald df Sig OR 95% CI for OR 
       Lower Upper 
C-RMI at T0  0.395 0.065 37.107 1 <0.0005 1.485 1.308 1.686 
Age -0.032 0.009 12.977 1 <0.0005 0.969 0.952 0.986 
MoCA at T0  0.029 0.018 2.659 1 0.103 1.029 0.994 1.065 
Constant 0.775 0.759 1.041 1 0.307 2.170   
3.2.3.7. Model 2: summary of model characteristics 
This model accounted for 15.9%-21.1% of the unexplained variance, and 
correctly classified 68.3% of cases. Each one-point increase C-RMI at T0 
increased the odds of walking independently at T2 by 48.5%. Each one-year 
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increase in age decreased the odds of walking independently at T2 by 3.2%. 
The smallest overall effect size was seen for MoCA scores at T0, with each 
one-point increase increased the odds of walking independently by only 2.9% 
at T2. The observed versus predicted classification of patients by Model 2 is 
shown in Table 3.11.  
Table 3.11. Classification table for Model 2 
 Walking independently by T2 (predicted) % correct 
No Yes 
Walking independently 
by T2 (observed) 
No 149 63 70.3 
Yes 73 144 66.4 
Overall %   68.3 
The sensitivity of Model 2 is 66.4%, with a specificity of 70.3%. Its positive 
predictive value was 69.6%, and its negative predictive value was 67.1%.  
3.2.3.8. Model 2: testing assumptions made for missing data 
The default assumption made for missing data in Model 2 was that all patients 
maintained the level of mobility they had reached at T1. Those who had not 
returned a SR-RMI score at T1 were assumed to be unable to walk 
independently at T2. To explore the impact of this assumption, Model 2 was 
re-fitted with three alternative assumptions. Assumption 1 excluded patients 
who did not return a SR-RMI score at T2 from analysis: data from only 364 
participants were fitted under this assumption. Assumption 2 was that all 
participants who did not return a SR-RMI at T2 were able to walk 
independently; conversely, Assumption 3 was that these patients were unable 
to walk independently at this time-point. The properties of the model under 
each of these assumptions are summarised in Table 3.12.  
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Table 3.12. Properties of Model 2 when fitted under alternative assumptions 
for missing SR-RMI scores at T2. 
 Default Assumption 1 Assumption 2 Assumption 3 
% correctly classified 68.3% 68.3% 66.0% 66.7% 
Sensitivity 66.4% 74.4% 85.3% 61.4% 
Specificity 70.3% 60.0% 30.0% 71.6% 
Positive predictive value 69.6% 72.0% 69.4% 66.8% 
Negative predictive value 67.1% 62.9% 52.3% 66.5% 
% Variance  Cox&Snell R2 15.9% 18.3% 11.5% 12.5% 
% Variance Nagelkerke R2 21.1% 24.6% 15.8% 16.7% 
C-RMI at T0     
 B 0.395 0.488 0.378 0.356 
 OR 1.485 1.628 1.460 1.428 
 95% CI for OR 1.308 – 1.686 1.396 – 1.899 1.273 – 1.674 1.264 – 1.613 
Age     
 B -0.032 -0.036 -0.025 -0.021 
 OR 0.969 0.965 0.976 0.980 
 95% CI for OR 0.952 – 0.986 0.946 – 0.985 0.958 – 0.993 0.964 – 0.996 
MoCA at T0     
 B 0.029 0.032 0.017 0.028 
 OR 1.029 1.033 1.017 1.028 
 95% CI for OR 0.994 – 1.065 0.994 – 1.072 0.983-1.053 0.994 – 1.064 
The percentage of cases correctly classified ranged from 66.0% (assumption 
2) to 68.3% (default assumption, and assumption 1). The percentage increase 
in the odds of walking independently for each one-point change in C-RMI at 
T0 ranged from 42.8% (assumption 3) to 62.8% (assumption 1). The 
percentage change in the odds of walking independently with each one-year 
increase in age ranged from 2.0% (assumption 3) to 3.6% (assumption 1). 
The percentage change in odds ratio for independent mobility with each one-
point increase in MoCA score was between 1.7% (assumption 2) and 3.3% 
(assumption 1). The sensitivity of Model 2 ranged from 61.4% (assumption 3) 
to 62.5% (under assumption 1). Values of specificity range from 78.3% 
(assumptions 1 and 2) to 85.3% (assumption 2). Positive predictive values lay 
between 66.8% (assumption 3) and 72.0% (assumption 1); negative 
predictive values between 52.3% (assumption 2) and 66.5% (assumption 3). 
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The percentage of variance explained by the model ranges from 11.5% 
(Cox&Snell R2, assumption 2) to 24.6% (Nagelkerke R2, assumption 1).  
153 
 
Part 3.3 Modelling walking ability in intracerebral 
haemorrhage 
3.3.1. Characteristics of the HWS group 
3.3.1.1. Defining the HWS group 
Models 3 and 4 were derived in the HWS group: a sub-group of 75 patients 
(47 men and 28 women) who had sustained a primary intracerebral 
haemorrhage. Of these patients, 58 (77.3%) had radiological evidence of a 
parenchymal haematoma with no infarct visible. However, it must be noted 
that the criterion for inclusion in the HWS group was that the patient had 
sustained a primary intracerebral haemorrhage as defined by the recruiting 
centre. For this reason, the group also contains eight patients who were 
thought by the scan review panel (JP and consultant neuroradiologist) to have 
a parenchymal haematoma clearly remote from a visible infarct, and two who 
were thought to have radiological evidence of haemorrhagic transformation of 
an underlying infarct. 
3.3.1.2. Determining how many variables might be fitted 
It must be acknowledged that the numbers of patients in the HWS group are 
small, and do not support anything other than an exploratory analysis. In 
particular, the number of observed outcome events at each time point limit the 
number of predictor variables which may be fitted. At T1, 36 patients (48.0%) 
were able to walk independently for 10m or more; 39 (52.0%) were unable to 
do so. If a guideline of ten patients per variable is applied to the smaller of the 
two outcome groups, then a maximum of 36/10=3 variables may be fitted to 
Model 3. By T2, 32 patients (42.7%) were able to walk independently, with 43 
(49.5%) unable to do so. Model 4 therefore supports a maximum of three 
predictor variables.  
3.3.2. Model 3: return to walking at T1 in HWS group 
3.3.2.1. Univariate predictors of outcome at T1 
Model 3 examined predictors of mobility at T1, using demographic details, 
clinical impairment at T0, and radiological predictors. Univariate associations 
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between these variables and walking ability at T1 are summarised in Table 
3.13. 
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Table 3.13. Univariate predictors of independent walking ability at T1. 
Predictor variables: age; gender; clinical impairment at T0; haematoma 
volume; presence of midline shift; haematoma location; presence of 
hydrocephalus; presence of intraventricular extension; white matter 
lesions; old stroke lesion. 
 N Missing (%) Mean 
(Range, SD) 
Sig OR 95% CI for OR 
     Lower Upper 
Age 75 0 
65.85 
(32-92 1.501) 
0.030 0.960 0.925 0.996 
Male gender 47 0 - 0.833 0.904 0.354 2.309 
C-RMI 75 0 
1.96  
(0-6, 1.664) 
0.001 1.934 1.312 2.849 
MoCA at T0 72 3 (4%) 
20.17  
(0-30, 5.891) 
0.035 1.102 1.007 1.205 
GHQ-12 at T0 71 4 (5.3%) 
20.84  
(8-36, 6.836) 
0.442 0.973 0.908 1.043 
Any pain at T0 (yes) 21 3 (4.0%) - 0.914 1.058 0.382 2.925 
UL pain at T0 (yes) 12 3 (4.0%) - 0.463 0.625 0.178 2.192 
LL pain at T0 (yes) 14 3 (4.0%) - 0.908 0.933 0.290 2.999 
ICH volume (mm3) 67 8 (10.7%) 
16.58  
(1-88, 17.023) 
0.091 0.973 0.942 1.004 
Midline shift (mm) 66 9 (12%) 
1.99 
(0-44, 5.700) 
0.635 1.025 0.926 1.134 
Haematoma location 64 11 (14.7%) -     
 Frontal 10 - - 0.711    
 Temporal 1 - - 1.000 0.000 0.000 - 
 Parietal 6 - - 0.058 11.667 0.922 147.5 
 Occipital 1 - - 1.000 >1000 0.000 - 
 Basal ganglia 38 - - 0.212 2.593 0.581 11.56 
 Internal 
capsule 
2 - - 0.590 2.333 0.107 50.98 
 Brainstem 0 - - - - - - 
 Cerebellum 6 - - 0.999 >1000 0.000 - 
Hydrocephalus 12 9 (12%) - 0.272 0.941 0.138 1.748 
Intraventricular extension 26 8 (10.7%) - 0.378 0.640 0.237 1.726 
Old vascular lesion 13 2 (2.7%) - 0.335 0.547 0.160 1.866 
White matter lesions 26 0 - 0.090 0.431 0.163 1.142 
Atrophy 5 2 (2.7%) - 0.580 0.593 0.093 3.774 
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The only statistically significant univariate predictors of mobility at T1 were 
age, and C-RMI and MoCA scores at T0. However, the HWS group contained 
only a small number of participants and had a relatively high proportion of 
missing data at T1. The high odds ratios and wide confidence intervals for 
some radiological parameters (in particular, occipital and cerebellar 
haematoma location) indicate that there are insufficient data to support robust 
conclusions about these predictors. Nevertheless, fitting a model to these data 
may generate hypotheses worthy of investigation in a larger data-set.  
3.3.2.2. Model 3: construction of an initial model 
With these caveats in mind, an initial model containing only C-RMI at T0 was 
fitted. This accounted for 18.7%-24.9% of the unexplained variance in 
outcome, and correctly classified 68% of cases. Age did not make a 
statistically significant contribution to the model, and was therefore removed. 
MoCA scores at T0 were of borderline statistical significance (p=0.079), and 
the resulting model accounted for little more variance in outcome (22.7%-
30.3%) than did C-RMI alone. The combination of the two variables correctly 
classified 73.6% of cases. It is therefore possible that this variable might have 
attained statistical significance in a larger sample size. It was therefore 
retained in the model. The proposed final iteration of Model 3 thus contained: 
C-RMI and MoCA scores at T0.  
3.3.2.3. Model 3: model evaluation and testing assumptions of logistic 
regression 
The Hosmer and Lemeshow test indicates acceptable overall model fit 
(p=0.536). No cases had standardised residuals of >±2.58: although this 
implies that there is no evidence of localised misfit, it does raise the possibility 
that Model 3 is over-fitted to the small sample available. The model was 
examined for influential cases using Cook’s distance, leverage statistics, and 
DFBeta values for the constant and each of the predictors. No cases had a 
Cook’s distance of >1. Leverage values ranged from 0.0191 to 0.189. Twenty-
six patients had a leverage value greater than the expected value of 0.04. No 
cases returned DFBeta values >1 for the constant or for either of the predictor 
variables. 
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The Box-Tidwell test was performed to test the assumption of a linear 
relationship between predictor variables and the natural log of the odds ratio 
of walking independently at T1. Prior to natural-log transformation, a score of 
1 was added to all values of C-RMI and MoCA, to eliminate scores of 0. The 
covariates C-RMI and MoCA score at T0 were then forced in to a model which 
also contained the interaction terms (C-RMI+1*Ln[C-RMI+1]) and 
(MoCA+1*Ln[MoCA+1]). The natural-log interaction terms did not make a 
significant contribution to this model (p>0.05), indicating that the assumption 
of linearity of the logit was met for all variables.  
3.3.2.4. Model 3: final version 
The final iteration of Model 3 is summarised in Table 3.14.  
Table 3.14. Final iteration of Model 3.  
Predictor variables: C-RMI and MoCA scores at T0. 
 B S.E. Wald df Sig OR 95% CI for OR 
       Lower Upper 
C-RMI at T0 0.643 0.206 9.704 1 0.002 1.901 1.269 2.849 
MoCA at T0 0.082 0.049 2.814 1 0.093 1.085 0.986 1.193 
Constant -2.721 1.076 6.399 1 0.011 0.066   
3.3.2.5. Model 3: summary of model characteristics 
This model explained 22.7%-30.3% of variance in outcome at T1, and correctly 
classified 73.6% of patients as walking or not walking at this time. Taken at 
face value, Model 3 indicates that each one-point increase in C-RMI score at 
T0 is associated with a 90.1% increase in the odds of walking independently 
at T1, and each one-point increase in MoCA score at T0 is associated with an 
85% increase in the odds of walking independently at T1. However, this 
apparently-impressive effect size is likely to reflect inflation of the coefficients 
due to the small sample size from which Model 3 was derived. Although 
mobility and cognitive function at T0 do seem to be of prognostic importance 
in ICH, these apparent associations must be confirmed in a larger sample 
size. 
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The observed versus predicted classification of patients with ICH as “walking 
independently”/“not walking independently” by T1 is shown in Table 3.15.   
Table 3.15. Classification table for Model 3. 
 Walking independently at T1 (predicted) % correct 
No Yes 
Walking independently  
at T1 (observed) 
No 25 9 73.5 
Yes 10 28 73.7 
Overall %   73.6 
The model had a sensitivity of 73.7% and a specificity of 73.5%. Its positive 
predictive value was 75.6%, and its negative predictive value was 71.4%.  
3.3.2.6. Model 3: testing assumptions made for missing data 
The default assumption made for missing outcome data in Model 3 was that 
patients who did not return a SR-RMI at T1 score were unable to walk 
independently. To explore the impact of this assumption, Model 3 was re-fitted 
with two alternative assumptions made. Assumption 1 was that those who did 
not return a SR-RMI score at T0 were excluded from analysis: this restricted 
the available population to only 60 participants. Assumption 2 was that all 
participants lost to follow-up were able to walk independently at T1. The 
properties of Model 3 under these alternative assumptions are outlined in 
Table 3.16.  
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Table 3.16. Properties of Model 3 when fitted under alternative assumptions 
for missing SR-RMI scores at T1. 
 Default Assumption 1 Assumption 2 
% correctly classified 73.6% 66.1% 70.8% 
Sensitivity 73.7% 81.6% 86.3% 
Specificity 73.5% 38.1% 33.3% 
Positive predictive value 75.6% 70.5% 75.9% 
Negative predictive value 71.4% 53.3% 50% 
% Variance  Cox&Snell R2 22.7% 24.6% 19.8% 
% Variance Nagelkerke R2 30.3% 33.7% 28.3% 
C-RMI at T0    
 B 0.643 0.841 0.904 
 OR 1.901 2.319 2.469 
 95% CI for OR 1.269- 2.849 1.331 – 4.041 1.329 – 4.380 
MoCA at T0    
 B 0.082 0.026 -0.021 
 OR 1.085 1.027 0.979 
 95% CI for OR 0.986 – 1.193 0.914 – 1.153 0.887 – 1.080 
 
The percentage of cases correctly classified ranged from 66.1% (assumption 
1) to 73.5% (under the default assumption). The percentage increase in the 
odds of walking independently for each one-point change in C-RMI at T0 
ranged from 84.9% (default assumption) to 146.9% (assumption 2). The 
coefficients for the MoCA score at T0 were unstable, remaining positive under 
the default assumption and assumption 1, but becoming negative under 
assumption 2. Hence, under assumption 1 each one-point change in MoCA 
score resulted in an increase in the odds of walking independently at T1 of 
2.7%; under assumption 2, each one-point increase in score resulted in a 
2.1% decrease in the odds of walking independently. This instability most 
probably reflects the small sample size in which these estimates were derived. 
The sensitivity of Model 3 ranged from 73.7% (default assumption) to 86.3% 
(under assumption 2). The range of possible values for specificity was broad: 
between 33.3% (assumption 2) and 73.5% (default assumption). Positive 
predictive values lay between 70.5% (assumption 1) and 75.9% (assumption 
2); negative predictive values between 50% (assumption 2) and 71.4% 
(default assumption). The percentage of variance explained by the model 
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ranges from 19.8% (Cox&Snell R2, assumption 2) to 33.7% (Nagelkerke R2, 
assumption 1).  
3.3.3. Model 4: return to walking at T2 in HWS group 
3.3.3.1. Univariate predictors of outcome at T2: demographics, and 
clinical impairment at T0 and T1 
Model 4 predicted return to independent walking at T2 in the HWS group. 
Univariate associations between walking ability at T2, and demographics and 
clinical impairment at T0 and T1 are shown in Table 3.17. 
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Table 3.17. Univariate models of independent walking ability at T2. 
Predictor variables: age; gender; clinical impairment at T0; clinical 
impairment at T2. 
 N Missing (%) Mean 
(Range, SD) 
p OR 95% CI for OR 
     Lower Upper 
Demographic predictor variables 
Age 75 0 
65.85 
(32-92 1.501) 
0.002 0.937 0.898 0.977 
Male gender 47 0 - 0.611 0.783 0.305 2.012 
Predictor variables at T0 
C-RMI 75 0 
1.96 
(0-6, 1.664) 
0.002 1.896 1.276 2.815 
MoCA 72 3 (4%) 
20.17 
(0-30, 5.891) 
0.006 1.148 1.041 1.267 
GHQ-12 71 4 (5.3%) 
20.84 
(8-36, 6.836) 
0.643 0.984 0.918 1.054 
Any MSK pain 21 3 (4.0%) - 0.307 0.587 0.211 1.634 
Upper limb pain 12 3 (4.0%) - 0.248 0.476 0.135 1.676 
Lower limb pain) 14 3 (4.0%) - 0.241 0.493 0.151 1.607 
Predictor variables at T1 
SR-RMI 60 15 (20%) 
8.12 
(0-15, 4.342) 
<0.0005 1.628 1.271 2.086 
MoCA 64 11 (14.7%) 
23.48 
(8-30, 4.694) 
0.002 1.250 1.084 1.442 
GHQ-12 59 16 (21.3%) 
15.71 
(3-30, 6.734) 
0.072 0.925 0.851 1.007 
FAS 59 16 (21.3%) 
24.23 
(11-40, 6.44) 
0.023 0.896 0.814 0.985 
Any MSKl pain 47 16 (21.3%) - 0.526 1.524 0.415 5.598 
Upper limb pain 33 16 (21.3%) - 0.512 1.437 0.486 4.251 
Lower limb pain 28 16 (21.3%) - 0.413 1.579 0.529 4.710 
3.3.3.2. Univariate predictors of outcome at T2: radiological variables 
Univariate associations between imaging variables and walking ability at T2 
are shown in Table 3.18. 
Table 3.18. Univariate predictors of independent walking ability at T2. 
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Predictor variables: haematoma volume; presence of midline shift; 
haematoma location; presence of hydrocephalus; presence of 
intraventricular extension; white matter lesions; old stroke lesion. 
 N 
Missing 
(%) 
Mean 
(Range, 
SD) 
Sig OR 95% CI for OR 
     Lower Upper 
ICH volume (mm3) 67 
8 
(10.7%) 
16.58 
(1-88, 
17.023) 
0.422 0.988 0.960 1.017 
Midline shift (mm) 66 9 (12%) 
1.99 
(0-44, 
5.700) 
0.492 1.052 0.911 1.214 
ICH location 64 
11 
(14.7%) 
- 0.996    
 Frontal 10 - - 0.996    
 Temporal 1 - - 1.000 0.000 0.000 - 
 Parietal 6 - - 0.790 1.333 0.161 11.075 
 Occipital 1 - - 1.000 >1000 0.000 - 
 Basal ganglia 38 - - 0.734 1.282 0.306 5.366 
 
Internal 
capsule 
2 - - 0.999 >1000 0.000 - 
 Brainstem 0 - - - - - - 
 Cerebellum 6 - - 0.697 0.667 0.087 5.127 
Hydrocephalus 12 9 (12%) - 0.041 0.250 0.066 0.942 
Intraventricular 
extension 
26 
8 
(10.7%) 
- 0.047 0.355 0.127 0.987 
Old vascular lesion 13 2 (2.7%) - 0.363 0.571 0.171 1.910 
White matter lesions 26 0 - 0.157 0.498 0.190 1.307 
Atrophy 5 2 (2.7%) - 0.115 0.165 0.017 1.553 
Once again, attention is drawn to the small overall sample size, and to the 
high proportion of missing data for some T1 predictor variables. As for Model 
3, the numbers of participants with certain radiological features (temporal, 
occipital, capsular, or cerebellar haematomas) were small, and as such 
confidence intervals for these lesions are either implausibly large or 
incalculable. It must again be stressed that models derived from these data 
are exploratory, and should thus be interpreted with caution. 
3.3.3.3. Model 4: construction of an initial model 
The modelling process began by fitting the strongest predictors measured at 
T0. The initial model containing C-RMI at T0 only explained 16.9%-22.8% of 
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variance in outcome, and correctly classified 65.3% of patients. The addition 
of age made a significant (p=0.010) contribution to the model; the combination 
of this and C-RMI accounted for 24.0%-32.3% of unexplained variance, and 
correctly classified 69.3% of patients. The addition of MoCA scores at T0 
resulted in a model that explained 29.9%-40.2% of variance in outcome, and 
correctly classified 75.0% of patients. 
Variables measuring clinical impairment at T1 were next fitted. The addition of 
SR-RMI at T1 was statistically significant (p<0.0005), but the contribution of C-
RMI at T0 was no longer statistically significant (p=0.955). This suggests that 
the effect of C-RMI at T0 are entirely mediated by that of SR-RMI at T1. A 
model containing SR-RMI at T1 explained more variance in outcome (49.0%-
67.9%) and correctly classified a greater percentage of patients (86.4%) than 
the previous iteration containing C-RMI at T0. However, there is a strong 
clinical rationale for including variables measured at T0 in preference to those 
measured at T1, since T0 marks the time at which patients would typically be 
engaged in their early rehabilitation. C-RMI at T0 was retained in the model, 
and SR-RMI at T1 was removed. MoCA score and FAS at T1 and two CT 
variables (presence of hydrocephalus and presence of intraventricular 
extension) all failed to make a statistically significant contribution to the model, 
and were thus removed. The resulting model contained MoCA and C-RMI 
scores at T0, and age. Although this model explained 29.9%-40.2% of 
variance in outcome, and correctly classified 75.0% of patients, the small 
sample size from which it was derived makes it desirable to fit the smallest 
number of predictor variables possible. The variable with the smallest effect 
size was age (coefficient -0.049; odds ratio 0.952). Removing this variable 
resulted in a model containing only MoCA and C-RMI scores at T0: a 
combination which still explained 25.1%-33.8% of variance in outcome, and 
classified 72.2% of patients correctly.  
3.3.3.4. Model 4: model evaluation and testing assumptions of logistic 
regression 
This model showed acceptable fit to the data (Hosmer and Lemeshow 
goodness-of-fit test, p=0.563). Only one case showed evidence of localised 
misfit (standardised residual -2.808). This patient had a comparatively high C-
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RMI score of 5 at T0, and was able to walk independently by T1. By T2 his 
mobility had deteriorated, with a SR-RMI score of 3. It is possible that he 
sustained a further stroke or an intercurrent illness in the intervening period. 
The model was examined for influential cases using Cook’s distance, leverage 
statistics, and DFBeta values for the constant and each of the predictors 
(Table 53). No cases had a Cook’s distance of >1. Leverage values ranged 
from 0.0202 to 0.181. Thirty-three patients had a leverage value greater than 
the expected value of 0.04. No cases returned DFBeta values >1 for the 
constant or for either of the predictor variables.  
The Box-Tidwell test was performed to assess the assumption of a linear 
relationship between predictor variables and the natural log of the odds ratio 
of walking independently at T2. Prior to natural-log transformation, a score of 
1 was added to all values of C-RMI and MoCA at T0, to eliminate scores of 0. 
The covariates C-RMI and MoCA score at  T0 were then forced in to a model 
which also contained the interaction terms (age*Ln[age]), (C-RMI+1*Ln[C-
RMI+1]) and (MoCA+1*Ln[MoCA+1]). The natural-log interaction terms did 
not make a significant contribution to this model (p>0.05), indicating that the 
assumption of linearity of the logit was met for all continuous variables 
included.  
3.3.3.5. Model 4: final version 
The final iteration of Model 4 is summarised in Table 3.19.   
 
 
 
 
Table 3.19. Final version of Model 4. 
Predictor variables: MoCA and C-RMI at T0. 
 B S.E. Wald df Sig OR 95% CI for OR 
       Lower Upper 
MoCA at To 0.127 0.053 5.778 1 0.016 1.135 1.024 1.259 
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C-RMI at To 0.616 0.214 8.305 1 0.004 1.852 1.218 2.816 
Constant -3.298 1.152 8.196 1 0.004 0.037   
3.3.3.6. Model 4: Summary of model characteristics 
Each one-point increase in C-RMI score at T0 appears to result in an 85.2% 
increase in the odds of walking independently at T2. The effect size for MoCA 
score at T0 is smaller, with each one-point increase resulting in a 13.5% 
increase in the odds of regaining independent mobility at T2. The apparent 
effect sizes for these variables are larger than those seen in Models 1 and 2. 
However, this is likely to reflect the smaller sample size in which Model 4 was 
derived. Once again, it must be stressed that the analysis presented here is 
exploratory in nature: the value of these variables in predicting prognosis 
requires confirmation in a larger sample.  
The observed versus predicted classification of patients with ICH as “walking 
independently”/“not walking independently” by T2 is shown in Table 3.20.   
Table 3.20. Classification table for Model 4. 
 Walking independently by T2 (predicted) % correct 
No Yes 
Walking independently 
by T2 (observed) 
No 18 12 60.0 
Yes 8 34 81.0 
Overall %   72.2 
Model 4 had a sensitivity of 81.0% and a specificity of 60.0%. The positive 
predictive value of this model was 73.9%, and its negative predictive value 
was 69.2%.  
3.3.3.7. Model 4: testing assumptions made for missing data 
The default assumption made for missing outcome data in Model 4 was that 
the mobility of patients who did not return a SR-RMI score at T2 was 
unchanged since the score at T1, if this was known. If no SR-RMI score had 
been returned at T1, patients were assumed to be unable to walk 
independently at T2. To explore the impact of this assumption, Model 4 was 
re-fitted with three alternative assumptions made for missing outcome data. 
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Assumption 1 excluded patients who did not return a SR-RMI at T2 from 
analysis, and was thus tested in only 56 of the 75 patients in the HWS group. 
Assumption 2 was that all patients who did not return a SR-RMI at T2 were 
able to walk independently, whilst assumption 3 was that those with missing 
data were unable to walk independently at T2. The properties of Model 3 when 
re-fitted under these alternative assumptions are summarised in Table 3.21. 
Table 3.21. Properties of Model 4 when fitted under alternative assumptions 
for missing SR-RMI scores at T2. 
 Default Assumption 1 Assumption 2 Assumption 3 
% correctly classified 72.2% 76.4% 76.4% 70.8% 
Sensitivity 81.0% 44.4% 98.1% 75.7% 
Specificity 60.0% 91.9% 11.1% 65.7% 
Positive predictive value 73.9% 77.3% 76.8% 70.0% 
Negative predictive value 69.2% 72.7% 66.7% 71.9% 
% Variance  Cox&Snell R2 25.1% 23.1% 9.7% 27.9% 
% Variance Nagelkerke R2 33.8% 32.2% 14.4% 37.2% 
MoCA at T0      
 B 0.127 0.112 0.042 0.160 
 OR 1.135 1.118 1.043 1.174 
 95% CI for OR 1.024 – 1.259 0.993 – 1.260 0.950 – 1.144 1.045 – 1.319 
C-RMI at T0     
 B 0.616 0.655 0.480 0.593 
 OR 1.852 1.926 1.616 1.809 
 95% CI for OR 1.218 – 2.816 1.156 – 3.208 1.034 – 2.525 1.221 – 2.679 
The percentage of cases correctly classified ranged from 70.8% (assumptions 
3) to 76.4% (assumptions 1 and 2). The percentage increase in the odds of 
walking independently for each one-point change in MoCA score at T0 ranged 
from 11.8% (assumption 1) to 17.4% (assumption 3). Each one-point change 
in C-RMI score at T0 resulted in an increase in the odds of walking 
independently at T2 of between 61.6% (assumption 2) and 92.6% (assumption 
1). The sensitivity of Model 4 ranged from 44.4% (assumption 1) to 98.1% 
(assumption 2). The range of possible values for specificity was also broad: 
between 11.1% (assumption 2) and 91.9% (assumption 1). Positive predictive 
values lay between 70.0% (assumption 3) and 77.3% (assumption 1); 
negative predictive values between 66.7% (assumption 2) and 72.7% 
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(assumption 1). The percentage of variance explained by the model ranges 
from 9.7% (Cox&Snell R2, assumption 2) to 37.2% (Nagelkerke R2, 
assumption 3).  
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Part 3.4 Modelling walking ability in the whole DARS sample 
3.4.1. Characteristics of the DARS sample 
3.4.1.1. What predictor variables were fitted to Models 5 and 6? 
Models 1-4 presented above were constructed using two sub-groups (IWS 
and HWS) of the DARS sample. The purpose of examining ischaemic stroke 
and ICH separately, and using only those patients for whom imaging was 
available, was to assesses the importance of imaging variables as predictors 
of mobility. However, none of the CT variables examined had a strong 
univariate association with outcome at T1 or T2. Two additional models were 
therefore constructed, this time utilising all 593 patients in the DARS sample. 
Model 5 predicted recovery of independent mobility at T1; Model 6 predicted 
mobility outcome at T2. Only demographic and clinical impairment recorded at 
T0 were utilised as predictors in these models. Although the inclusion of 
variables recorded at T1 may explain more variance in outcome and correctly 
classify a greater percentage of patients as mobile or immobile at T2, models 
that utilise only information available to the rehabilitation team at the time of 
the patient’s entry in to an acute rehabilitation programme are likely to be more 
useful in a clinical setting.   
3.4.1.2. Determining how many variables might be fitted 
At T1, 252 (42.5%) patients were able to walk independently for 10m or more; 
341 (57.5%) were unable to do so. If a guideline of ten patients per variable is 
applied to the smaller of the two outcome groups, then a maximum of 
252/10=25 variables may be fitted to model 5. Allowing for a more generous 
ratio of 20 patients per variable would allow up to 12 variables to be fitted 
(Stoltzfus, 2011). By T2, 311 (52.4%) patients were able to walk 
independently, with 282 (47.6%) unable to do so. If a ratio of 10 patients per 
variable is adopted, then 28 variables could be fitted to model 6. Allowing a 
more conservative 20 patients per variable would permit 14 variables to be 
fitted (Stoltzfus, 2011).  
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3.4.2. Model 5: return to walking at T1 in the whole DARS sample 
3.4.2.1. Univariate predictors of outcome at T1 
Model 5 sought to predict walking ability at T1 using demographic details and 
clinical impairment at T0. Univariate associations between predictor variables 
and this outcome are summarised in Table 3.22. 
Table 3.22. Univariate predictors independent walking ability at T1.  
Predictor variables: age; gender; OCSP clinical stroke syndrome; clinical 
impairment at T0. 
 
 N 
Missing 
(%) Mean 
(Range, SD) 
Sig OR 95% CI for OR 
     Lower Upper 
D
e
m
o
g
ra
p
h
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a
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b
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s
 
Age 593 0 
68.42 
(20-98, 
13.232) 
<0.0005 0.971 0.958 0.983 
Gender 
(male) 
364  0 - 0.015 1.542 1.085 2.140 
Infarct 
(versus ICH) 
508  0 - 0.020 0.578 0.364 0.918 
OCSP 592 1 (0.2%) - 0.001 - - - 
 TACS 161  - - 0.001 - - - 
 PACS 178  - - 0.008 1.836 1.172 2.877 
 POCS 52  - - 0.002 2.747 1.446 5.216 
 LACS 116  - - 0.011 1.913 1.163 3.147 
 ICH 85  - - 0.000 2.777 1.612 4.784 
P
h
y
s
ic
a
l 
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p
a
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m
e
n
t 
a
t 
T
0
 
C-RMI 593 0 
2.25  
(0-6, 1.791) 
<0.000
5 
1.714 1.533 1.916 
MoCA 580 
13 
(2.2%) 
20.23  
(0-30, 6.308) 
<0.0005 1.074 1.043 1.106 
GHQ-12 570 
23 
(3.5%) 
19.36 
(3-36, 
6.848) 
0.180 0.983 0.960 1.908 
Any pain 236  
10 
(1.7%) 
- 0.395 0.864 0.618 1.209 
UL pain 114  
10 
(1.7%) 
- 0.950 0.987 0.652 1.493 
LL pain 154  
10 
(1.7%) 
- 0.020 0.636 0.433 0.932 
3.4.2.2. Model 5: construction of an initial model 
The first variable to be fitted was age. Although highly statistically significant 
(p<0.0005), this explained only 3.6%-4.8% of variance in outcome and 
correctly classified 59.9% of participants. The addition of C-RMI to the model 
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explained a much greater percentage of the variance in outcome (18.3%-
24.6%), and correctly classified 70.5% of cases. The addition of MoCA score 
at T0 explained slightly more variance in outcome (19.2%-25.8%), but did not 
improve the classification rate (69.4%). The MoCA score was nevertheless 
retained in the model, due to the theoretical importance of this variable in 
learning processes. 
The OCSP classification was considered for inclusion in the model next. This 
was developed as a clinical classification of ischaemic stroke only (Bamford 
et al., 1991), and typically includes only four categories: TACS, PACS, POCS, 
and LACS. The inclusion of both ischaemic stroke and ICH in the DARS 
sample necessitated the creation of a fifth category, “ICH,” to allow this 
variable to be utilised in a model predicting outcome in a mixed sample of 
stroke patients. However, to enter OCSP with an additional “ICH” category 
alongside the dichotomised variable “infarct versus ICH” risked creating 
collinearity between the two variables. OCSP (with an ICH category) and 
stroke type dichotomised as “infarct versus ICH” were therefore entered in to 
separate models which also included age, C-RMI at T0, and MoCA at T0. 
A model incorporating OCSP with an “ICH” category explained 21.4%-28.8% 
of variance in outcome, and correctly classified 71.0% of cases. This was little 
different from a model including “infarct versus ICH” as a dichotomous 
variable, which accounted for 21.2%-28.5% of variance in outcome, and 
correctly classified 70.3% of cases. When OCSP (with an ICH category) and 
dichotomised “infarct versus ICH” were forced in to the model simultaneously, 
only “infarct versus ICH” retained statistical significance (p=0.001). This 
variable was therefore retained in the model, and OCSP was removed. The 
addition of both gender and the presence of lower limb pain failed to contribute 
significantly to the model, and they were therefore removed.  
3.4.2.3. Model 5: model evaluation and testing assumptions of logistic 
regression 
The final iteration of the model thus contained age, C-RMI and MoCA scores 
at T0, and infarct versus ICH. This model showed acceptable fit to the data 
(Hosmer and Lemeshow goodness-of-fit, p=0.529). Ten cases (1.69% of the 
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total sample) had standardised residuals of >±2.58. These cases were 
examined to explore possible reasons for misfit. Cases 164, 173, 238, 312, 
and 563 all previously showed misfit to Model 1, and the reasons for this have 
been examined above. Participants 28 and 555 both had an initial C-RMI of 
0, and were thus predicted to be unable to walk independently by T1. However, 
both made a better recovery than might be anticipated, with an SR-RMI scores 
at T1 of 10 and 7 respectively. In the case of participant number 28, this gain 
in motor function was sustained at T2 (SR-RMI=12). Patient number 555 
unfortunately failed to sustain this initial recovery, and by T2 had a SR-RMI of 
2. Participants 68 and 532 had a comparatively high C-RMI of 6 at T0, and 
might therefore have been expected to be walking independently at T1. 
However, neither returned an SR-RMI at T1, and both were therefore classified 
as being unable to walk. Patient number 99 had an initial C-RMI of 6, and 
MoCA of 27. Despite being predicted to walk independently at follow-up, his 
scores at T1 were unchanged. It is not possible to determine a reason for this 
with the available data. The model was examined for influential cases using 
Cook’s distance, leverage statistics, and DFBeta values for the constant and 
each of the predictors. No cases had a Cook’s distance of >1. Leverage values 
ranged from 0.00270 to 0.03903; 201 patients had leverage values greater 
than the expected value of 0.00843. No cases returned DFBeta values >1 for 
the constant or for any of the predictor variables.  
The Box-Tidwell test was performed to assess the assumption of a linear 
relationship between predictor variables and the natural log of the odds ratio 
of walking independently at T1. Prior to natural-log transformation, a score of 
1 was added to all C-RMI and MoCA scores, to eliminate scores of 0. The 
covariates age, C-RMI and MoCA score at T0 were then forced in to a model 
which also contained the interaction terms (age*Ln[age]), (C-RMI+1*Ln[C-
RMI+1]) and (MoCA+1*Ln[MoCA+1]). The categorical term “infarct versus 
ICH” was omitted from the model. The natural-log interaction terms did not 
make a significant contribution to this model (p>0.05), indicating that the 
assumption of linearity of the logit was met for age, C-RMI and total MoCA 
score.  
172 
 
3.4.2.4. Model 5: final version 
The final iteration of Model 5 is summarised in Table 3.23. 
Table 3.23. Final version of Model 5. 
Predictor variables: age, MoCA and C-RMI at T0, and infarct versus ICH. 
 B S.E. Wald df Sig OR 95% CI for OR 
       Lower Upper 
Age -0.017 0.007 5.179 1 0.023 0.983 0.969 0.998 
C-RMI at T0 0.530 0.060 77.358 1 0.000 1.699 1.509 1.911 
MoCA at T0 0.041 0.016 6.374 1 0.012 1.042 1.009 1.076 
Infarct (versus ICH) -0.805 0.268 9.028 1 0.003 0.447 0.264 0.756 
Constant -0.509 0.691 0.543 1 0.461 0.601   
3.4.2.5. Model 5: summary of model characteristics 
This model explained 20.5%-27.5% of variance in outcome, and correctly 
classified 70.3% of cases. Once again, the largest effect size seen was for C-
RMI. Each one-point increase in score at T0 was associated with an increase 
of 69.9% in the odds of walking independently at T1. The effect of cognitive 
impairment remained more modest, with each one-point increase in MoCA 
score at T0 increasing the odds of walking independently by 4.2% at T1. Each 
one-year increase in age resulted in a 1.7% decrease in the odds of walking 
independently at T1. Finally, at T1 those with an ischaemic stroke had a 44.7% 
reduction in the odds of being mobile when compared with those with 
intracerebral haemorrhage.   
The observed versus predicted classification of patients in the DARS sample 
as “walking independently”/“not walking independently” by T1 is shown in 
Table 3.24. 
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Table 3.24. Classification table for Model 5. 
 Walking independently by T1 (predicted) % correct 
No Yes 
Walking independently 
by T1 (observed) 
No 269 62 81.3 
Yes 110 139 55.8 
Overall %   70.3 
Model 5 had a sensitivity of 55.8% and a specificity of 81.3%. The positive 
and negative predictive values of this model were, respectively, 69.2% and 
71.0%.  
3.4.2.6. Model 5: testing assumptions made for missing data 
The default assumption made for missing outcome data in Model 5 was that 
patients who did not return a SR-RMI score at T1 were unable to walk 
independently. To explore the impact of this assumption, the model was re-
fitted with two alternative assumptions. Assumption 1 excluded patients who 
did not return a SR-RMI at T1 from analysis, and was thus tested in only 393 
of the original 593 participants. Assumption 2 was that all patients who did not 
return an SR-RMI at T1 were able to walk independently. The properties of 
Model 5 when fitted under these alternative assumptions are summarised in 
Table 3.25. 
174 
 
Table 3.25. Properties of Model 5 under alternative assumptions for missing 
SR-RMI scores at T1. 
 Default Assumption 1 Assumption 2 
% correctly classified 70.3% 71.7% 69.1% 
Sensitivity 55.8% 68.3% 72.0% 
Specificity 81.3% 74.5% 65.8% 
Positive predictive value 69.2% 71.7% 71.3% 
Negative predictive value 71.6% 71.6% 66.5% 
% Variance  Cox&Snell R2 20.5% 25.0% 19.3% 
% Variance Nagelkerke R2 27.5% 33.4% 25.8% 
Age    
 B -0.017 -0.017 -0.012 
 OR 0.983 0.983 0.989 
 95% CI for OR 0.969 – 0.998 0.967 – 0.999 0.974 – 1.003 
C-RMI at T0    
 B 0.530 0.609 0.518 
 OR 1.699 1.839 1.678 
 95% CI for OR 1.509 – 1.911 1.608 – 2.103 1.487 – 1.893 
MoCA at T0    
 B 0.041 0.041 0.031 
 OR 1.042 1.042 1.031 
 95% CI for OR 1.009 – 1.076 1.007 – 1.077 1.001 – 1.063 
Infarct versus ICH    
 B -0.805 -1.087 -1.063 
 OR 0.447 0.337 0.345 
 95% CI for OR 0.264 – 0.756 0.185 – 0.615 0.199 – 0.598 
The percentage of cases correctly classified ranged from 70.3% (default 
assumption) to 71.7% (assumption 1). The percentage decrease in the odds 
of walking independently at T1 with each one-year increase in age ranged from 
1.1% (assumption 2) to 7.7% (default assumption and assumption 1). Each 
one-point increase in C-RMI score at T0 resulted in an increase in the odds of 
independent mobility at T1 of between 67.8% (assumption 2) and 83.9% 
(assumption 1).  The odds of walking independently increased by between 
3.1% (assumption 2) and 4.3% (default assumption and assumption 1) for 
each one-point increase in MoCA score at T0. The odds of walking 
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independently for an infarct (versus ICH) were between 34.5% (assumption 
2) and 44.7% (default assumption). 
The sensitivity of Model 5 ranged from 55.8% (default assumption) to 72.0% 
(assumption 2). The range of values for specificity was between 65.8% 
(assumption 2) and 81.3% (default assumption). Positive predictive values lay 
between 69.2% (default assumption) and 71.7% (assumption 1); negative 
predictive values between 66.5% (assumption 2) and 71.6% (assumption 1). 
The percentage of variance explained by the model ranges from 19.3% 
(Cox&Snell R2, assumption 1) to 33.4% (Nagelkerke R2, assumption 1).  
3.4.3. Model 6: return to walking at T2 in the whole DARS sample 
3.4.3.1. Univariate predictors of outcome at T2 
Model 6 predicted recovery of walking ability at T2. Univariate associations 
between this outcome and predictor variables (demographics and impairment 
at T0) are summarised in Table 3.26. 
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Table 3.26. Univariate models of independent walking ability at T1. 
Predictor variable: age; gender; infarct (versus haemorrhage); OCSP 
clinical stroke syndrome; and clinical impairment at T0. 
 
 N 
Missing 
(%) 
Mean 
(Range, SD) 
Sig OR 95% CI for OR 
      Lower Upper 
D
e
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Age 593 0 
68.42 
(20-98, 13.232) 
<0.0005 0.957 0.944 0.970 
Gender 
(male) 
364  0 - 0.011 1.540 1.104 2.147 
Infarct 
(versus ICH) 
508  0 - 0.422 0.827 0.521 1.314 
OCSP  592 1 (0.2%) - 0.018    
 TACS 161  - - 0.018    
 PACS 178  - - 0.110 1.419 0.924 2.177 
 POCS 52  - - 0.001 3.127 1.591 6.146 
 LACS 116  - - 0.163 1.406 0.871 2.270 
 ICH 85  - - 0.066 1.644 0.968 2.793 
P
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C-RMI 593 0 
2.25 
(0-6, 1.791) 
<0.0005 1.519 1.367 1.688 
MoCA 580 
13 
(2.2%) 
20.23 <0.0005 1.080 1.050 1.111 
   (0-30, 6.308)     
GHQ-12 570 
23 
(3.5%) 
19.36 0.609 0.994 0.970 1.018 
   (3-36, 6.848)     
Any pain 236  
10 
(1.7%) 
- 0.246 0.822 0.590 1.145 
UL pain 114  
10 
(1.7%) 
- 0.973 1.007 0.669 1.518 
LL pain 154  
10 
(1.7%) 
- 0.042 0.681 0.471 0.986 
3.4.3.2. Model 6: construction of an initial model 
As for model 5, age made a statistically significant contribution (p<0.0005), 
but explained only a small percentage of the variance in outcome (7.3%-9.8%) 
and correctly classified 63.9% of cases. The addition of C-RMI made a 
statistically significant contribution (p<0.0005) to the model. Alongside age, it 
explained 15.7%-21.0% of the variance in outcome and correctly classified 
68.3% of cases. MoCA score at T0 was next fitted. The resulting model 
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explained 17.5%-23.4% of the variance in outcome and correctly classified 
69.0% of cases. Gender, OCSP clinical stroke syndrome, and lower limb pain 
all failed to reach statistical significance, and did not contribute any additional 
explicable variance. Nor did they improve the percentage of patients correctly 
classified.  
3.4.3.3. Model 6: model evaluation and testing assumptions of logistic 
regression 
The model therefore comprised age, and C-RMI and MoCA scores at T0. This 
model was an acceptable fit to the data (Hosmer and Lemeshow test 
p=0.606). Examination of residuals for individual cases demonstrated 7 cases 
(1.18% of the 593 cases included) in which standardised residuals were 
>±2.58 (Table 78). Two patients (68 and 173) had standardised residuals >3. 
Five participants (numbers 68, 84, 173,532, and 547) had relatively high C-
RMI scores at T0, but failed to return a SR-RMI at T2. All were classified as 
being unable to walk, despite relatively favourable C-RMI scores at T0. 
Participant number 99 had an initial C-RMI score of 6, but failed to achieve 
any improvement in mobility at either T1 or T2. It is not possible to establish a 
definite cause for this with the data available, although the fact that he 
developed both upper and lower limb musculoskeletal pain between the initial 
assessment at T0 and first follow-up at T1 may provide some indication of why 
he failed to progress in rehabilitation.  
The model was examined for influential cases using Cook’s distance, leverage 
statistics, and DFBeta values for the constant and each of the predictors 
(Table 79). No cases had a Cook’s distance of >1. No cases returned DFBeta 
values >1 for the constant or for any of the predictor variables. Leverage 
values ranged from 0.00215 to 0.0327: 202 participants had leverage values 
greater than the expected value of 0.00674.  
The Box-Tidwell test was performed to assess the assumption of a linear 
relationship between predictor variables and the natural log of the odds ratio 
of walking independently at T2. Prior to natural-log transformation, one point 
was added to all C-RMI and MoCA scores to eliminate scores of 0. The 
covariates age, C-RMI, and MoCA score at T0 were then forced in to a model 
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which also contained the interaction terms (age*Ln[age]), (C-RMI+1*Ln[C-
RMI+1]) and (MoCA+1*Ln[MoCA+1]). The natural-log interaction terms did 
not make a significant contribution to this model (p>0.05), indicating that the 
assumption of linearity of the logit was met for age, C-RMI and total MoCA 
score at T0.  
3.4.3.4. Model 6: final version 
The final iteration of Model 6 is summarised in Table 3.27. 
Table 3.27. Final version of Model 6 
Predictor variables: age, C-RMI, and MoCA at T0. 
 B S.E. Wald df Sig OR 95% CI for OR 
       Lower Upper 
Age -0.035 0.007 21.601 1 <0.0005 0.966 0.952 0.980 
C-RMI at T0 0.378 0.057 43.506 1 <0.0005 1.459 1.304 1.633 
MoCA at T0 0.046 0.015 9.219 1 0.002 1.048 1.017 1.079 
Constant 0.747 0.650 1.321 1 0.250 2.111   
3.4.3.5. Model 6: Summary of model characteristics 
This model explained 17.5%-23.4% of variance in outcome, and correctly 
classified 69.0% of patients as walking/not walking independently at T2. Each 
one-point increase in C-RMI at T0 resulted in a 45.9% increase in the odds of 
walking independently at T2. A one-point increase in the MoCA score at T0 
conferred a more modest 4.8% increase in the odds of walking independently 
at T2. Each one-year increase in age was associated with a 3.5% reduction in 
the odds of walking independently at T2. The observed versus predicted 
classification of patients in the DARS sample as “walking independently”/“not 
walking independently” by T2 is shown in Table 3.28.  
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Table 3.28. Classification table for Model 6. 
 Walking independently by T2 (predicted) % correct 
No Yes 
Walking independently 
by T2 (observed) 
No 185 89 67.5 
Yes 91 215 70.3 
Overall %   69.0 
Model 6 had a sensitivity of 70.3%, a specificity of 67.5%, a positive predictive 
value of 70.7%, and a negative predictive value of 67.0%.  
3.4.3.6. Model 6: testing assumptions made for missing data 
The default assumption under which Model 6 was fitted was that patients who 
did not return SR-RMI scores at T2 maintained the same level of mobility that 
had been recorded at T1. Those who had also failed to return a SR-RMI at T1 
were assumed to be unable to walk independently at T2. In order to test the 
robustness of model parameters, Model 6 was re-fitted using three alternative 
assumptions. The first excluded those who had not returned a SR-RMI at T2 
from analysis, and was tested in only 487 of the original 593 participants. The 
second was that all patients who did not return a SR-RMI at T2 were able to 
walk independently at this time. The third was that those who did not return a 
SR-RMI at T2 were unable to walk independently. The properties of Model 6 
when fitted under these alternative assumptions are summarised in Table 
3.29. 
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Table 3.29. Properties of Model 6 when fitted under alternative assumptions 
for missing SR-RMI scores at T2. 
 Default Assumption 1 Assumption 2 Assumption 3 
% correctly classified 69.0% 60.1% 68.6% 66.4% 
Sensitivity 70.3% 79.5% 88.9% 62.8% 
Specificity 67.5% 57.6% 27.2% 69.9% 
Positive predictive value 70.7% 71.6% 71.3% 67.3% 
Negative predictive value 67.0% 65.1% 54.7% 65.6% 
% Variance  Cox&Snell R2 17.5% 19.0% 11.7% 13.6% 
% Variance Nagelkerke R2 23.4% 25.7% 16.2% 18.1% 
Age     
 B -0.035 -0.036 -0.026 -0.022 
 OR 0.966 0.965 0.974 0.979 
 95% CI OR 0.952 – 0.980 0.948 – 0.982 0.959 – 0.989 0.965 – 0.992 
C-RMI at T0     
 B 0.378 0.461 0.356 0.336 
 OR 1.459 1.586 1.427 1.399 
 95% CI for OR 1.304 – 1.633 1.385 – 1.815 1.264 – 1.610 1.257 – 1.556 
MoCA at T0     
 B 0.046 0.050 0.030 0.046 
 OR 1.048 1.051 1.030 1.048 
 95% CI for OR 1.017 – 1.079 1.017 – 1.087 1.000 – 1.061 1.017 – 1.079 
The percentage of cases correctly classified ranged from 60.1% (assumption 
1) to 68.6% (assumption 2). The percentage decrease in the odds of walking 
independently at T2 with each one-year increase in age ranged from 2.1% 
(assumption 3) to 3.5% (assumption 1). Each one-point increase in C-RMI 
score at T0 was associated with an increase in the odds of independent 
mobility at T2 of between 39.9% (assumption 3) and 58.6% (assumption 1). 
The odds of walking independently increased by between 3.0% (assumption 
2) and 5.1% (assumption 1) for each one-point increase in MoCA score at T0. 
The sensitivity of Model 6 ranged from 62.8% (assumption 3) to 88.9% 
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(assumption 2). The range of values for specificity was between 27.2% 
(assumption 2) and 69.9% (assumption 3). Positive predictive values lay 
between 67.3% (assumption 3) and 71.6% (assumption 1); negative 
predictive values between 54.7% (assumption 2) and 65.6% (assumption 3). 
The percentage of variance explained by the model ranges from 11.7% 
(Cox&Snell R2, assumption 2) to 25.7% (Nagelkerke R2, assumption 1).  
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Chapter 4. Discussion 
Part 4.1 Summary of results 
4.1.1. The aims of this study 
This Thesis sought to develop a series of models to predict return to 
independent walking after stroke at T1 and T2 (roughly eight weeks and six 
months after stroke). Few models have been developed to predict mobility 
outcomes specifically. Those that have tend to rely upon an assessment of 
clinical impairment (van de Port et al., 2006a). Whether or not including an 
assessment of structural brain impairment using imaging variables offers any 
additional predictive value over and above an assessment of clinical 
impairment alone remains uncertain (Stinear and Ward, 2013, Dawes et al., 
2008). However the models derived here examined a series of predictor 
variables including limitation of activity and impairment in brain structure (of 
which CT imaging was a surrogate marker) in the hope of predicting recovery 
of the ability to walk 10m or more independently at up to six months after 
stroke. 
4.1.2. Summary of models 
4.1.2.1. Summary of key findings 
The most striking finding of the work presented here is that none of the brain 
imaging variables examined here predict walking ability at T1 and T2 (up to six 
months after stroke). Whilst the small sample size of the HWS group is 
acknowledged, this suggests that models based upon measures of clinical 
impairment alone might provide a more reliable prediction of rehabilitation 
potential than those incorporating imaging variables. With this in mind, it is 
worth examining in more detail the findings of models 5 and 6, which were 
developed in the whole DARS sample and did not incorporate radiological 
variables. In both of these models the strongest predictor variable was C-RMI. 
In model 5, this variable alone increased the percentage of explicable variance 
from 3.6-4.8% (for age alone) to 18.3-24.6% (for age and C-RMI). The 
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percentage of cases correctly classified increased from 59.9% (age alone) to 
70.5% (age plus C-RMI). Similarly, in model 6 the addition of C-RMI alongside 
age to the model increased the variance explained from 7.3-9.8% to 15.7-
21.0%, although there was a more modest rise in the percentage of cases 
correctly classified (from 63.9% with age alone to 68.3% of cases with age 
plus C-RMI). When additional variables were fitted (MoCA at T0 and infarct 
versus ICH for model 5, and MoCA at T0 for model 6) the final iterations of the 
models explained only marginally more variance than age plus C-RMI (20.5-
27.5% for model 5; 17.5-23.4% for model 6), and resulted in little or no 
improvement in the percentage of patients correctly classified (70.3% for the 
final iteration of model 5; 69.0% for the final iteration of model 6). This 
suggests that a clinician-scored RMI performed within eight weeks of stroke 
(defined here as “T0”, and representing the time window during which patients 
were randomised to DARS) is a useful predictor of independent walking ability 
at up to six months. Depending upon the assumptions that were made for 
missing data, model 5 had a sensitivity of between 55.8-72.0%, and a 
specificity of 65.8-81.3%; model 6 had a sensitivity of 62.8-88.9% and a 
specificity of 27.2-69.9%. 
4.1.2.2. Key predictor variables 
The variables that were most consistently predictive of outcome across all 
models were C-RMI and MoCA scores at T0. Of the two, the largest effect size 
was seen for C-RMI. In the IWS group, each one-point increase in this score 
increased the odds of walking independently at by 71.9% at T1, and 48.5% at 
T2. Estimates in the HWS group are derived from a much smaller sample, and 
must thus be treated with caution. Taken at face value, a one-point increase 
in C-RMI at T0 is associated with a 90.1% increase in the odds of walking 
independently at T1, and an 85.2% increase in the odds of walking 
independently at T2. In the DARS sample as a whole, each one-point increase 
was associated with a 69.9% increase in the odds of walking independently 
at T1, and a 45.9% increase in the odds of walking independently by T2. 
Cognitive function at T0 was also a significant predictor of outcome, albeit with 
a smaller effect size than C-RMI. In the IWS group, each one-point increase 
MoCA score at T0 increased the odds of walking independently by 2.9% at T2. 
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Findings in the HWS group must be viewed with caution, but a one-point 
increase in MoCA scores at T0 was associated with an 8.5% increase in the 
odds of regaining independent mobility by T1 and a 13.5% increase in the odds 
of walking independently at T2 in this group. In the whole DARS sample, a 
one-point increase in MoCA score at T0 was associated with a 4.2% increase 
in the odds of walking independently at T1, and a 4.8% increase in the odds 
of regaining independent mobility at T2. Age at stroke onset attained 
significance only in models 2, 5, and 6. In the IWS group, each one-year 
increase in age was associated with a 3.2% decrease in the odds of walking 
independently at T2. Similarly, in the DARS sample as a whole a one-year 
increase in age was associated a 1.7% reduction in the odds of walking 
independently at T1, and a 3.5% reduction in the odds of walking 
independently at T2. The type of stroke (infarct versus ICH) was a significant 
predictor variable only in Model 5 (outcome at T1 in the whole DARS sample). 
Here, those with an ischaemic stroke had a 44.7% reduction in the odds of 
being mobile at T1 when compared with those with intracerebral haemorrhage. 
4.1.2.3. Classification of patients and percentage variance explained  
The models presented here correctly classified between 68% and 73% of 
participants as walking/ not walking independently at the specified end-points: 
lower than that achieved by other models which successfully predicted RMI 
score to within ±2 points in 81% of patients (van de Port et al., 2006a). They 
also account for only around 20-30% of variance in outcome at best: lower 
than the 50% accounted for in other models (van de Port et al., 2006a). 
The success of the models in classifying patients as walking/not walking 
independently may be judged by examining how accurately an outcome might 
be predicted if no model were fitted at all. For example, in the DARS sample 
as a whole, 42.5% of patients were mobile at T1, and 57.5% were immobile. 
Without any further modelling, one can state that DARS participants have a 
higher prior probability of being immobile at T1 than of being mobile. Thus, if 
an individual were selected from the sample at random and a guess were 
made about their likely mobility at T1, it would be reasonable to predict that 
the participant would be immobile at that time. If the same assumption were 
made for every patient in the sample, then without any further modelling 
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walking ability at T1 would be correctly predicted in 57.5% of patients. Fitting 
Model 5 to the data increases the accuracy of prediction, and allows 70.3% of 
patients to be correctly classified. This sounds impressive: but in reality, only 
12.8% more participants are correctly classified by the model than would be 
the case using prior probability alone.  
Furthermore, a patient’s rehabilitation potential is currently estimated not by 
statistical models, but following an expert assessment by an experienced 
multi-disciplinary team. Little has been published about how such decisions 
are made, and what factors inform therapists’ prognostication. And yet, an 
apparent “educated guess” by skilled therapists may be as reliable in 
predicting recovery of walking ability as a regression model (Kwakkel et al., 
2000). In order to be useful in clinical practice, a prognostic model would not 
only need to result in a much higher rate of correct classification than has been 
achieved here: it must also be demonstrably superior to the judgement of 
experienced therapists.  
4.1.2.4. Sensitivity, specificity, and positive and negative predictive 
values 
If these models are to be used in clinical practice, one must also bear in mind 
the differing balances of sensitivity and specificity that each displays. Models 
1 and 5, both predictive of walking ability at T1, have relatively poor sensitivity 
(40.3% for Model 1, 55.8% for Model 5) but higher specificity (88.5% for Model 
1, 81.3% for Model 5). This implies that both are relatively poor predictors of 
who will return to walking by T1, but more reliably classify those who will not 
do so. Models derived to predict mobility outcomes at T2 (Model 2 and Model 
6) have moderate sensitivity (68.3% for Model 2; 70.3% for Model 6) and 
specificity (70.3% for Model 2; 67.5% for Model 6). They thus perform 
moderately well in predicting both positive (“walking”) and negative (“not 
walking”) outcomes. Models 3 and 4 were derived from a small sample of 
patients with ICH, and must therefore be interpreted cautiously. In Model 3, 
sensitivity and specificity are balanced (73.7% and 73.5% respectively); 
Model 4 has a higher sensitivity (81.0%) than specificity (60.0%), indicating a 
greater reliability in identifying those who will return to walking than those who 
will not. 
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4.1.2.5. Stability of models under alternative assumptions for missing 
data 
Estimates for the effect sizes of each of the predictors fitted changed 
considerably depending on the assumptions made for missing outcome data. 
The most worrying example of this was seen in Model 3, in which a one-point 
increase in MoCA score at T0 was associated with a 2.7% increase in the odds 
of walking independently at T1 under assumption 1, but a 2.1% decrease in 
the odds of independent mobility under assumption 2. This example is 
extreme, and reflects the small sample size from which these estimates were 
derived. Nevertheless, even models fitted to larger samples demonstrated 
changes in effect size when alternative assumptions were made for missing 
data. In Model 5, derived from the whole DARS sample, a single-point 
increase in C-RMI score at T0 was associated with a 67.8% increase in the 
odds of walking independently at T1 under assumption 2, but an increase of 
83.9% under assumption 1. In Model 6 (outcome at T2), effect size estimates 
for C-RMI ranged from 39.9% (assumption 3) to 58.6% (assumption 1). 
Furthermore, the sensitivity and specificity of the models also varied 
considerably when alternative assumptions for missing data were tested. The 
widest ranges were in models predicting outcome at T2, since a greater 
proportion of the sample had been lost to follow-up at this time than at T1. In 
Model 2, sensitivity ranged from 61.4% to 85.3%, whilst specificity lay between 
30.0% and 71.6%. In Model 6, sensitivity was 62.8%-88.9% and specificity 
27.2%-69.9%. Estimates of positive predictive value tended not to vary by 
more than a few percentage points. The greatest ranges of values observed 
was in Models 2 (66.8%-72.0%) and 3 (70.0%-77.3%). The greatest range in 
estimates of negative predictive values was in Model 6 (54.7%-65.9%).  
4.1.3. The need for formal validation of the models 
The models presented above all suggest that a patient’s level of mobility and 
cognitive function early after stroke might be useful in predicting walking 
ability. However, they show marked instability in both estimates of the effect 
sizes of covariates and of other key parameters such as sensitivity and 
specificity when alternative assumptions are made for missing data. This 
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raises concerns that the performance of the models derived here may also 
vary if applied to a different sample.  
Such instability might arise when the characteristics of the sample in which a 
model was developed are different from the population to which it is ultimately 
applied. For example, a model developed in a high-income country might later 
be applied in a low- or middle-income country (Vickers and Cronin, 2010), or 
a model developed in an adult sample might be extrapolated to children 
(Moons et al., 2015, Moons et al., 2009a).  
Over-fitting of a model may also result in the inclusion of predictors that have 
little value beyond the derivation sample or, conversely, exclusion of 
predictors that might be important in a different cohort (Moons et al., 2009a). 
It is therefore recommended that models undergo validation before 
introduction into clinical use. Ideally validation should be conducted in a 
sample different from the original (Altman and Royston, 2000). In practice 
however, validation is more usually performed by splitting the original data set, 
with half of the sample being used for model derivation and half for validation 
(Altman and Royston, 2000, Labarere et al., 2014, Moons et al., 2015). 
Although convenient, this practice is unsatisfactory. Firstly, the sample size 
available for derivation of the model is reduced, resulting in loss of statistical 
power (Altman and Royston, 2000, Labarere et al., 2014, Moons et al., 2015). 
Secondly, unless caution is exercised the characteristics of the “derivation” 
and “validation” samples may be virtually identical (Altman and Royston, 
2000). For these reasons, “split sample” validation was not performed for the 
models presented here. 
When considering whether it might be appropriate to undertake formal 
validation of the models presented here, one must consider what is already 
known about them and their possible clinical utility. The proportion of variance 
in outcome that they explain is relatively modest, and the classification rates 
they achieve are little better than prior probability alone and perhaps no better 
than the clinical judgement of a skilled multidisciplinary team. For these 
reasons, the models developed here cannot at present be recommended for 
use in clinical practice in their current form.  
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In clinical practice knowledge of the variables that might influence recovery, 
and an estimation of their possible effect sizes, might still provide useful 
information to inform the judgement of rehabilitation professionals and thus to 
guide discussions with patients and families. Although the findings presented 
above must be interpreted with caution, they do suggest that those with the 
most profound mobility impairment and cognitive dysfunction after stroke are 
less likely to recover the ability to walk. The development of reliable models 
to predict mobility will depend in part upon identifying the most crucial 
predictor variables. Examining the contribution of the variables included in the 
models presented here might be a starting point for this process. 
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Part 4.2 Comparing the findings of this study with previous 
literature 
As summarised above, the variables that were included in Models 1-6 were: 
C-RMI (mobility); MoCA (cognitive function); age; and type of stroke (infarct 
or ICH). Several variables that might have been expected to contribute to 
prediction of walking ability did not make a statistically-significant contribution 
to multivariate models. These included gender; OCSP clinical stroke 
syndrome; depression; fatigue; and musculoskeletal pain. Finally, none of the 
imaging predictor variables that were assessed were independent predictors 
of which patients might walk again. 
4.2.1. Variables that were predictors of walking ability in the 
models presented here 
4.2.1.1. Mobility early after stroke 
The variable with the largest effect across any of the models was C-RMI at T0. 
The finding that a patient’s level of mobility in the early stages after stroke is 
predictive of their later ability to walk again was noted previously by Shum et 
al. (2014) who used a modified version of the RMI (M-RMI) (Lennon and 
Johnson, 2000) administered at 3 days to predict walking ability at 28 days 
after stroke. Unlike the original RMI (Collen et al., 1991), which has 15 
questions with binary responses, the M-RMI has eight domains with 
polytomous responses ranging from 0 (unable to perform) to 5 (independent) 
(Lennon and Johnson, 2000). An M-RMI score of ≥18.5 at day 3 predicted 
independent walking ability at day 28 with a sensitivity of 85% and specificity 
of 75% (Shum et al., 2014).  
A patient’s initial level of mobility appears to be an important predictor of not 
only later independent mobility, but also of discharge destination after stroke 
(Sommerfeld and von Arbin, 2001, Brauer et al., 2008). Sommerfeld and von 
Arbin (2001) found that those achieving RMI scores of ≥4 at 10 days after 
stroke had a 29-fold increase in the risk of being discharged home within three 
months (relative to those with scores of <4). A similar pattern was noted by 
Brauer et al. (2008), who utilised a different measure of mobility, the Motor 
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Assessment Score (Carr et al., 1985). Each one-point increase on the “gait” 
sub-scale of this measure increased the odds of stroke survivors returning 
home 1.66-fold, and each single-point increase in the “balance” sub-scale 
increased the odds of discharge home by a factor of 1.28.  
If initial mobility is a useful indicator of long-term outcome, it is useful to ask 
what aspect of “mobility” is of greatest prognostic importance. The DARS trial, 
for example, enrolled only participants who had an initial C-RMI score of <7 at 
T0: and were thus initially unable to walk independently (Bhakta et al., 2014). 
Hence, although the effects of C-RMI in models 1-6 were quoted above as the 
percentage change in the odds of walking independently at follow-up 
associated with a one-point increase in C-RMI score, it is perhaps more 
accurate to specify that this prediction holds true only for values of C-RMI in 
the range of 0-6. Initial differences in low-level mobility functions (short of 
actually walking) may therefore have an important bearing on a patient’s 
subsequent outcome. 
If the RMI is examined more closely, then It could be argued that RMI values 
within the range of 2 (able to transfer from lying to sitting in bed) to 5 (ability 
to stand for 10 seconds unaided) (Collen et al., 1991) appear to measure the 
underlying construct of balance rather than mobility. Indeed, re-establishing 
adequate balance, first in sitting and then in standing, are necessary 
prerequisites for walking. Interestingly, a model constructed by van de Port et 
al. (2006a) to predict RMI scores at one year after stroke found sitting balance 
(measured using the trunk control test) to be a significant predictor of this 
outcome. Indeed, this accounted for 8% of observed variance in RMI scores 
at 12 months (van de Port et al., 2006a). Interestingly, the range of the metrics 
for the “gait” and “balance” sub-scales of the Mobility Assessment Scale (Carr 
et al., 1985), utilised by Brauer et al. (2008) as a predictor of discharge 
destination, do align with the lower-end scores of the RMI (Collen et al., 1991). 
Perhaps future modelling in patients who are initially immobile should include 
specific measures of balance, as opposed to more global measures of mobility 
such as the RMI. 
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4.2.1.2. Cognitive function after stroke 
As described in Chapter 1, the phenomenon of cognitive impairment after 
stroke is complex. It is a common consequence of stroke, both acutely and in 
the longer term (Gottesman et al., 2010). And given the importance of loop 
circuits between cortical and sub-cortical structures in motor learning (Doyon 
et al., 2009, Hikosaka et al., 2002, Penhune and Steele, 2012), and the 
potential for these pathways to become disrupted by both injury to particular 
structures as a result of the stroke itself (Schmahmann and Pandya, 2008, 
Schmahmann et al., 2009) and as a consequence of chronic microvascular 
disease (Iadecola, 2013, Wardlaw et al., 2013b), one might expect cognitive 
function to be a strong predictor of recovery of walking ability. However, 
although MoCA scores did indeed make a statistically significant contribution 
to the models, the effect observed for each one-point increase was relatively 
modest in comparison to C-RMI score. This suggests that any relationship 
between cognition and motor recovery is not straightforward.  
Cognitive dysfunction is associated with a decline in mobility at up to three 
years after stroke (van de Port et al., 2006c), but the precise relationship 
between motor and cognitive functions remains uncertain (Chen et al., 2013). 
Whether “cognition” can be regarded as a single underlying construct is 
debatable: several key cognitive domains are recognised including memory, 
executive function, praxis, and visuospatial function (Barker-Collo et al., 
2010). It is possible that mobility impairment after stroke is due in part to 
difficulty in allocating limited cognitive resources to a complex task such as 
walking, rather than to a failure of learning processes per se. The 
phenomenon of dual-task interference, in which performance of a motor task 
is compromised when the patient is asked to perform a cognitive task 
simultaneously, is well recognised (Chen et al., 2013). This was initially 
attributed to an inability to focus attention to two tasks at once, but there is 
now growing evidence that the underlying impairment is actually in executive 
function (Chen et al., 2013). Interestingly, impairment in motor function 
(measured using the Berg balance score, gait velocity, and “timed up-and-go” 
test) within the first six months after mild stroke also seem to predict the 
development of cognitive dysfunction at up to two years later (Ben Assayag 
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et al., 2015). Giving fewer correct answers to questions asked during walking 
(i.e. under dual-task conditions) also predicted subsequent cognitive decline 
(Ben Assayag et al., 2015). It is therefore possible that aspects of gait and 
motor task performance are influenced by subtle impairments in specific 
cognitive functions, with more florid cognitive dysfunction becoming apparent 
later on. The link between motor and cognitive dysfunction may therefore be 
mediated by impairment in specific cognitive domains such as executive 
function. The MoCA, which was designed as a brief screening test of global 
cognitive function (Nasreddine et al., 2005), may lack sensitivity for more 
subtle domain-specific impairments. Although the MoCA does contribute to 
the overall predictive ability of models 2-5, it is possible that more detailed 
tests of specific cognitive ability, such as executive function, could account for 
a greater proportion of observed variance in outcome. 
4.2.1.3. Age at stroke onset  
Age at stroke onset attained significance only in models 2, 5, and 6. Age has 
been shown to be a negative correlate of mobility at between one and five 
years in several models: (van de Port et al., 2006a, Meyer et al., 2015, 
Sanchez-Blanco et al., 1999) but, in keeping with findings above, its effect is 
modest. It accounts for only 3% of variance in motor outcome (van de Port et 
al., 2006a, Bagg et al., 2002), and each one-year increase in age is associated 
with an increase of only 0.08 points on the leg and trunk function sub-scale of 
the Rivermead Motor Assessment and a 0.13-point increase in the gross 
function subscale of this measure (Meyer et al., 2015). It is likely that the effect 
of age is mediated by other variables such as cognitive impairment or 
comorbidities (Bagg et al., 2002). For this reason, age must not be the only 
criterion in deciding whether a patient might benefit from rehabilitation (Bagg 
et al., 2002).  
4.2.1.4. Type of stroke 
The association between type of stroke and outcome is uncertain. Although 
the early mortality from ICH is high (Dennis, 2003), there have been 
suggestions that those who survive are more likely than those with ischaemic 
stroke to experience a favourable outcome. This was the case in Model 5, as 
discussed above. Several other studies also point to better outcomes following 
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ICH, although the association is by no means proven. A univariate analysis by 
van de Port et al. (2006a) found that the presence of intracerebral 
haemorrhage was associated with an increase of 0.176 points on the RMI at 
one year when compared to ischaemic stroke. Patients with ICH have also 
been shown to have higher RMI scores at discharge from a rehabilitation 
programme (mean RMI=6.57, SD ±4.33) compared with those with ischaemic 
stroke (mean RMI=5.42, SD ±3.90) (Paolucci et al., 2003), and to show a 
greater change in the motor subscale of the Functional Independence 
Measure at discharge from rehabilitation (ΔFIM-motor 22.7±1.1 for ICH; 
20.2±0.5 for ischaemic stroke) (Kelly et al., 2003). However, although these 
findings are all statistically significant it is debatable whether they meet the 
threshold for true clinically significant change. Also, Meyer et al. (2015) did not 
detect statistically significant differences between survivors of ischaemic 
stroke and ICH in Rivermead Motor Assessment (RMA) gross function and 
arm and trunk subscale scores at any time point. Although there was 
statistically significant gain of 1.82 points on the RMA arm function subscale 
for ICH when compared with ischaemic stroke, the clinical relevance of this 
finding is debatable (Meyer et al., 2015).  
A large prospective cohort study also found that patients with ICH were  more 
likely to be dead or dependent at three months and one year (Bhalla et al., 
2013). However, data collection in this cohort spanned a 16-year period 
between 1995 and 2011; hence, not all patients enrolled received what would 
today be regarded as “gold standard” care (Bhalla et al., 2013). For example, 
patients with ischaemic stroke were more likely to be managed in the 
community than those with ICH; a practice that is now regarded as outmoded. 
In short, the evidence that the type of stroke a patient sustains influences 
functional prognosis is mixed. Type of stroke therefore cannot at present be 
used to predict rehabilitation potential. 
4.2.2. Clinical predictor variables that did not make a contribution 
to models 1-6 
Several variables that could plausibly have been predictors of mobility 
ultimately failed to make an independent contribution to the models presented 
above. These will be examined below. 
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4.2.2.1. Gender 
Gender reached statistical significance as a univariate predictor of outcome in 
models 1, 2, 5, and 6, with men having more favourable odds of achieving 
independent mobility at eight weeks and six months than women. However, 
this variable was not statistically significant on multivariate analysis. These 
findings are in keeping with those of previous studies, which showed that 
female gender was associated with a reduction in one-year RMI score 
compared to male (van de Port et al., 2006a). Once again, this finding did not 
reach statistical significance in a multivariate analysis (van de Port et al., 
2006a). Meyer et al. (2015) failed to demonstrate a statistically significant 
influence of gender on outcome at any time point up to five years.  
4.2.2.2. OCSP clinical stroke syndrome 
Clinical stroke syndrome, defined using the OCSP classification (Bamford et 
al., 1991), was only fitted to models that included patients with ischaemic 
stroke but did not attain significance in any of these. The OCSP classification 
has been shown to be of prognostic relevance: but only in the distinction 
between TACS and other syndromes (PACS, LACS, POCS). At six months 
after stroke, those with TACS have lower mean RMA scores, a longer length 
of hospital stay, and greater mortality rates (Pittock et al., 2003). Compared 
with patients who sustain a LACS, at 3 months after stroke those with TACS 
are 3.27 (95% CI 2.30-4.66) times more likely to experience limitation of 
activities (Barthel index of 0-14), and 2.71 (95% CI 1.91-3.85) times more 
likely to be disabled (Rankin scale of 2-5) (Di Carlo et al., 2006). Although 
TACS carries clear prognostic implications, the distinction between PACS, 
LACS, and POCS is uncertain.  
4.2.2.3. Depression and fatigue 
Depression (GHQ-12) did not attain significance in any of the univariate 
analyses presented above. The interaction between mood and motor recovery 
is complex (Chen et al., 2013). Nannetti et al. (2005) found no difference in 
motor outcome (Fugl-Meyer Assessment Scale) three months after stroke 
between patients who had been depressed on admission versus those who 
were not. However, depression has been shown to be associated with long 
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term deterioration in mobility (defined as a fall of ≥2 points on the RMI) at one 
year (OR 3.44; 95% CI 1.57–7.54) (van de Port et al., 2006b) and at two years 
(OR 4.2; 95% CI 1.3-13.2) (van Wijk et al., 2006) after stroke. Fatigue reported 
at T1 (FAS) was a significant univariate predictor for model 4 (p=0.023), but 
failed to reach significance in the final multivariate model. Other studies, 
however, have found the presence of fatigue to be predictive of long-term 
deterioration in mobility: in both a univariate model (OR 3.30; 95% CI 1.09–
9.99) and as part of a multi-variate model (OR 3.30; 95% CI 1.09–9.99) 
alongside depression and cognitive impairment.(van de Port et al., 2006b) It 
is therefore possible that any effects of depression and fatigue on motor 
function are exerted on a timescale longer than the six months post-stroke 
considered here. 
4.2.2.4. Musculoskeletal pain 
In the DARS sample the proportion of patients reporting musculoskeletal pain 
in any locus increased from 39.8% at baseline, to 66.9% at eight weeks and 
63.2% at six months. The percentage reporting pain in any lower limb locus 
was 26.0% at baseline, 40.5% at eight weeks, and 43.2% at six months. This 
is somewhat higher than previous estimates, which indicate that the 
prevalence of any joint pain within two years of stroke is around 55.4% 
(Hettiarachchi et al., 2011). The presence of lower limb musculoskeletal pain 
was a significant univariate predictor in model 1 (assessment at T0; p=0.045), 
model 2 (assessment at T1; p=0.042); model 5 (assessment at T0; p=0.02), 
and model 6 (assessment at T0; p=0.042). However, it failed to achieve 
significance as part of multivariate models. None of the other musculoskeletal 
pain parameters assessed (presence of any pain, and presence of lower limb 
pain) made even a univariate contribution to predicting outcome. This is 
surprising, since previous studies have found that the presence of both stroke-
related impairment and hip pain increased the odds of reporting difficulties in 
standing and mobilising by a far greater magnitude than either of these 
impairments alone (Hettiarachchi et al., 2011). A possible reason for the 
discrepancy between the findings presented here and those of Hettiarachchi 
et al. (2011), may be that the latter study chose to classify pain by laterality 
and as specific loci; for example “left knee”, “right hip”. The absolute numbers 
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reporting pain in each locus are not presented, but the wide confidence 
intervals for some analyses indicate that some combinations of impairments 
included relatively few participants (Hettiarachchi et al., 2011). The present 
study, by contrast, chose to classify pain as “any musculoskeletal pain,” “any 
upper limb pain,” or “any lower limb pain.” This increased the number of 
patients available for analysis in each group, with commensurately narrower 
confidence intervals. However, it is possible that grouping pain loci in this way 
masked clinically significant differences in mobility resulting from pain in 
particular joints. 
4.2.3. Imaging predictor variables 
4.2.3.1. What imaging variables were evaluated? 
A number of imaging variables were considered as possible predictors of 
motor recovery. For ischaemic stroke, these included: the presence of any 
visible abnormality; the presence of visible acute ischaemic change; the 
location of infarcts (cortical, subcortical, or both); the size of an infarct (small, 
medium, or large); the presence of old stroke lesions; the presence of white 
matter lesions; and the presence of atrophy. The ASPECTS score, although 
associated with “death or dependency” outcome (Barber et al., 2000), makes 
no assessment of ischaemic change that lies outside of the MCA territory, or 
of ICH: groups that in total accounted for 69.6% of the DARS sample. For this 
reason, it was not utilised as a predictor here. For ICH, the variables examined 
were: haematoma volume and location; the presence of midline shift, 
intraventricular extension, and hydrocephalus; and the presence of atrophy 
and old stroke lesions. The protocol for image analysis used here was 
developed by Wardlaw et al, and has been used in the IST-3 trial (The IST 
collaborative group, 2015). The predictor variables utilised here for ischaemic 
stroke are therefore those used by Wardlaw et al in an analysis of imaging 
findings from the IST-3 data-set (The IST collaborative group, 2015). This 
presents an opportunity to compare imaging findings between the two data 
sets, before examining why imaging variables failed to make a significant 
contribution to predicting outcome in the present study.  
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4.2.3.2. Comparison of imaging findings in DARS with those of patients 
in the IST-3 trial 
Unlike DARS, the IST-3 trial enrolled only patients with ischaemic stroke, and 
thus resembles most closely the IWS group from which Models 1 and 2 were 
derived. It is to this sub-group of the main DARS sample that imaging findings 
from IST-3 (The IST collaborative group, 2015) will be compared. Firstly, there 
are striking differences in the sizes of ischaemic lesions reported in the two 
samples. In the DARS trial, 47.5% of the IWS group had no visible infarct; this 
was the case in a greater proportion (59%) of the IST-3 sample (The IST 
collaborative group, 2015). When comparing the size of visible infarcts 13.2% 
of the IWS group and only 7% of the IST-3 sample had a small infarct; 29.9% 
of the IWS group and 17% of the IST-3 group had medium infarcts (The IST 
collaborative group, 2015). In DARS, the frequency of “very large” infarcts (as 
defined by Wardlaw et al (The IST collaborative group, 2015)) was small, and 
this category was therefore amalgamated with “large” infarcts to give a total 
prevalence of “large” infarcts of 7.3%. In IST-3, “large” infarcts accounted for 
9% of the total, and “very large” infarcts 8% (The IST collaborative group, 
2015). In short, the IWS group had a greater proportion of small and medium-
sized infarcts, fewer large lesions, and fewer patients with no visible ischaemia 
than the IST-3 sample (The IST collaborative group, 2015). Several 
methodological differences between the two trials may account for these 
findings. Firstly, the DARS protocol utilised the first available imaging that had 
been collected for clinical indications, but did not specify when this should be 
acquired. By contrast, the IST-3 protocol required that imaging be performed 
within 6 hours of stroke onset (The IST collaborative group, 2015). Since early 
signs of early ischaemia on CT are often subtle and difficult to detect (Wardlaw 
and Mielke, 2005) it is possible that, in the IST-3 sample, large or very large 
lesions were more easily detectable from the outset whilst small and medium-
sized infarcts were less obvious and thus more likely to be interpreted as “no 
visible ischaemia”. Aside from radiological considerations the differences in 
size of infarcts could also be accounted for by the differing aims, and thus 
inclusion criteria, of the two studies. DARS randomised patients between five 
and 42 days after stroke (Bhakta et al., 2014). Only patients who were 
expected to survive for >2 months after stroke were recruited (Bhakta et al., 
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2014). By contrast, IST-3 randomised participants within 6 hours of symptom 
onset (Whiteley et al., 2006). The exclusion from DARS of those thought likely 
to die within 2 months, may have biased the DARS sample towards patients 
with more moderate impairment: and hence those with small-to-medium 
infarcts on CT. 
A further interesting and important difference between the two trials is that the 
prevalence of atrophy, previous strokes, and WML were much lower in the 
DARS IWS group than in IST-3. Atrophy was found in 10.5% of DARS 
participants, versus 77% of those randomised in to IST-3; 27.2% of DARS 
patients had evidence of a previous stroke, versus 43% of those in IST-3; and 
43.2% of DARS patients showed evidence of WML, compared with 52% of 
IST-3 patients (The IST collaborative group, 2015). In simple terms, DARS 
participants appeared to have “healthier” brains prior to the index event than 
those randomised in to IST-3. As noted for “infarct size” above, perhaps 
patients with advanced atrophy, multiple old strokes, and WML were excluded 
from the trial: either because they were deemed to have poor rehabilitation 
potential, or because it was thought unlikely that they would survive more than 
two months. However, this observation may also reflect in part differences in 
the age profile of the DARS IWS group, compared with participants enrolled 
in to IST-3. The DARS trial randomised a greater proportion of younger 
patients than IST-3 (8% versus 4% in the 18-50 age group, 16% versus 7% in 
the 51-60 group, 24% versus 12% in the 61-70 group). Peak enrolment for 
DARS was in the 71-80 age group (31% for DARS, versus 24% for IST-3). 
IST-3 by contrast specifically sought to expand the indications for thrombolysis 
beyond accepted parameters, and thus made active attempts to recruit a 
greater proportion of elderly patients in to the trial (Sandercock et al., 2012). 
Hence, 46% of those enrolled were in the age group 81-90 (17% for the DARS 
IWS group), and 7% were aged >90 (2% for DARS IWS group) (The IST 
collaborative group, 2015). The increasing prevalence of atrophy and WMLs 
with age may thus account for the different frequency of these findings in the 
two samples.  
200 
 
4.2.3.3. Other studies using imaging variables to predict outcome 
None of the imaging variables considered for inclusion in models 1-6 
contributed to their predictive ability. There is a long history in the stroke 
literature of utilising imaging in outcome prediction: but the most widely-used 
systems for classifying imaging findings were never intended to predict future 
walking ability. For example, the ASPECTS score was developed to decide 
upon eligibility for entry to a thrombolysis trial (Barber et al., 2000), but has 
since been found to predict good versus poor functional outcome (Dzialowski 
et al., 2006, Hill et al., 2003) and the risk of haemorrhagic transformation of 
an infarct following thrombolysis (Hirano et al., 2012). Models to predict 
outcome from ICH have typically focused upon identifying those who might 
benefit from aggressive intervention (Godoy et al., 2006, Ruiz-Sandoval et al., 
2007, Hemphill et al., 2001, Cheung and Zou, 2003, Cho et al., 2008), reliable 
prognostication (Tuhrim et al., 1991, Cheung and Zou, 2003), or stratification 
of patients for entry in to clinical trials (Broderick et al., 1993, Godoy et al., 
2006, Tuhrim et al., 1991, Hemphill et al., 2001, Cheung and Zou, 2003).   
Several studies have evaluated the use of imaging to predict outcome in 
ischaemic stroke. Many were published over ten years ago, and therefore 
utilised imaging technology that is now obsolete (Johnston et al., 2002, 
Wardlaw et al., 1998, Saver JL et al., 1999, Candelise L et al., 1991, Johnston 
et al., 2000). The majority use “death or dependency” as their primary 
outcome: an outcome measure that is too broad to be of genuine use in 
planning a rehabilitation programme. Even using such a general measure of 
outcome, the evidence that neuroimaging variables make a contribution to the 
model beyond that of clinical variables alone is mixed. Whilst some have found 
that the presence of any visible infarct on early imaging is associated with an 
adverse outcome (Wardlaw et al., 1998, Candelise L et al., 1991), more recent 
reports suggest that this variable confers no extra predictive power beyond 
that of clinical variables alone (Reid et al., 2010). Similarly, the volume of an 
infarct on DWI imaging has been shown to be a useful predictor by some 
(Johnston et al., 2000), but not all (Johnston et al., 2009a, Johnston et al., 
2002), studies.  
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4.2.3.4. Implications for the use of imaging in rehabilitation practice 
The role of imaging in predicting specific rehabilitation outcomes therefore 
remains far from certain, and a detailed evaluation of neuroimaging does not 
at present form a routine part of rehabilitation prognostication (Stinear and 
Ward, 2013). Whilst disappointing, the failure of neuroimaging to contribute to 
predicting the functional prognosis of stroke survivors does have important 
implications for how limited resources might be used most efficiently in low- 
and middle-income countries. These nations currently bear the greatest share 
of the global burden of stroke (Johnston et al., 2009b); and yet access to high-
quality acute stroke care is often limited by a combination of cost, lack of 
trained staff, and geographical centralisation of services in major cities that 
are inaccessible to the majority of the population (Mendis, 2010). In the 
absence of acute stroke services, rehabilitation intervention should be the 
mainstay of stroke management. In countries where access to imaging is 
restricted (Mendis, 2010), it is useful to note that a thorough clinical 
assessment of initial impairment, utilising standardised outcome measures, 
may allow prediction of a patient’s prognosis without the need for imaging.  
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Part 4.3 Limitations of this Thesis 
The models described above must be interpreted in the light of several major 
limitations. Crucial amongst these are: the post-hoc nature of the analysis 
presented here; the degree to which DARS participants may be regarded as 
representative of stroke survivors entering rehabilitation programmes in the 
UK or worldwide; the high rate of loss to follow-up in the DARS sample; and 
the nature of the outcome measures used and the manner in which they were 
analysed. All of these limitations will be discussed in the coming section. The 
analysis of scan findings will be considered separately in Part 4.4. Although 
all of these factors may ultimately restrict the use of these models in clinical 
practice, it is perhaps legitimate to regard the findings presented here as an 
exploratory analysis from which hypotheses worthy of future investigation 
might be generated.  
4.3.1. Analytical considerations 
4.3.1.1. Limitations of post-hoc analysis 
The first, and possibly the most crucial, limitation of the analysis presented 
here is that it was conducted post-hoc in a data set originally collected as part 
of a randomised controlled trial of the effects of administering co-careldopa on 
motor recovery from stroke. The dangers of such analyses are well 
recognised. Firstly, the statistical testing of large numbers of predictors 
increases the potential for type 1 errors to occur: i.e. that a false hypothesis is 
accepted as correct. This arises when tests of multiple hypotheses yield 
results that are statistically significant by chance alone (Rothwell, 2005). After 
all: a p-value of <0.05 merely implies that there is a 95% probability that the 
null hypothesis can be rejected. In some cases this can produce results for 
which there is no rational scientific basis: for example, that patients who were 
born under the star signs Libra or Gemini do not benefit from aspirin after 
myocardial infarction (p=0.02) (Collins and MacMahon, 2001). In other cases, 
the consequences for clinical practice can be more profound and even 
dangerous: for example, the spurious finding that men, but not women, derive 
benefit from aspirin in ischaemic stroke (Anonymous, 1978) led to the under-
treatment of women for at least a decade before new evidence emerged to 
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challenge this result (Rothwell, 2005). In order to guard against the possibility 
of type 1 errors a Bonferroni correction may be undertaken, in which the 
significance level that is accepted is adjusted for the number of hypotheses 
under test (Dunn, 1961). Such a correction was not undertaken here, and this 
could have led to variables being included in some models inappropriately. 
For example, when fitting Model 5, the variable “infarct versus ICH” was 
significant at the level p=0.02 in a univariate analysis. It was thus fitted to the 
model, where it achieved statistical significance at a level of p=0.003. And yet, 
as discussed above, there is scanty evidence at best to support a hypothesis 
that this variable is of clinical significance in predicting motor recovery from 
stroke (Bhalla et al., 2013, Meyer et al., 2015, van de Port et al., 2006a). 
Models that contain such variables are likely to be over-fitted to the data set 
in which they were derived, and may thus generalise poorly when applied to 
other groups.  
A second limitation of post-hoc analyses is that any sub-groups that are 
specified are almost always under-powered in relation to the main sample 
(Rothwell, 2005): a situation well-illustrated here by models 3 and 4, which 
were developed in the HWS group. This group consisted of 75 patients, or 
12.6% of the whole DARS sample. On univariate analysis, the small number 
of observed events for some parameters (for example, haemorrhage involving 
the parietal lobe), resulted in wide confidence intervals and unreliable 
estimates of their coefficients and odds ratios. Furthermore, instability was 
also seen in parameters for the final models: most markedly Model 3, in which 
the MoCA score was by turns both a negative and a positive predictor of 
walking ability depending upon the assumptions that were made for missing 
data. Such models may therefore be unreliable, and require formal validation 
before clinical use.    
The derivation of models post hoc from an existing data set also limits the 
variables that can be fitted to the model to those that have already been 
collected. These may not be the ones that best predict the outcome in 
question. This is illustrated well by considering the percentage of variance 
explained by the models derived above. The largest percentage of variance 
explained by any of the models above was seen for Model 4 (33.8%, 
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Nagelkerke R2); estimates for other models were more typically in the range 
of 15-25%. The fact that the majority of the variance in mobility outcome 
remains unexplained by these models indicates that key predictor variables 
have not been included. The models presented here ultimately included a 
combination of impairment in bodily functions (mobility, cognition, and type of 
stroke) and contextual factors (age), although other impairments in brain 
structure (radiological findings) and in bodily function (pain, fatigue, 
depression, OCSP), and contextual factors (gender) were also considered for 
inclusion. It is likely that other impairment-level variables that were not 
collected here might have been significant predictors of mobility. For example, 
initial severity of leg weakness (Sanchez-Blanco et al., 1999, Patel et al., 
2000, Veerbeek et al., 2011, Wandel et al., 2000),  the presence of 
hemianopia (Sanchez-Blanco et al., 1999, Patel et al., 2000), urinary 
incontinence (Wade and Hewer, 1987), impairment in sitting balance (Wade 
and Hewer, 1987, Veerbeek et al., 2011)  or standing balance (Kollen et al., 
2005), and time between stroke and mobility assessment (Preston et al., 
2011, Kwakkel et al., 2006), and activities-level measures such as the BI 
(Kollen et al., 2006, Paolucci et al., 2008)  have all been shown to be 
associated with limitation of walking ability at six months (Kollen et al., 2005, 
Patel et al., 2000, Sanchez-Blanco et al., 1999, Veerbeek et al., 2011, Wade 
and Hewer, 1987, Wandel et al., 2000) or at the time of discharge from 
inpatient rehabilitation (Paolucci et al., 2008). The National Institute of Health 
Stroke Scale (NIHSS) (Brott et al., 1989) is a measure of clinical impairment 
after stroke that is widely used in acute stroke services. It has been shown to 
be predictive of early mortality after ischaemic stroke (Fonarow et al., 2012) 
and ICH (Cheung and Zou, 2003), and of functional outcomes (measured 
using the mRS) (Saver and Altman, 2012). Its relationship to motor outcomes 
is less certain. A small study of 200 patients (114 of whom were non-ambulant 
at enrolment) has shown that a combination of age and NIHSS score predict 
both independent ambulation and recovery of upper limb function at six 
months (Kwah et al., 2013). The DARS trial might have presented an 
opportunity to examine the ability of the NIHSS to predict recovery of walking 
ability in a larger sample; but unfortunately this variable was not collected. 
Furthermore, in ICF terms recovery from stroke represents a complex 
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interaction between patients’ physical impairments and their 
environmental/societal contexts (Gutenbrunner et al., 2006, The World Health 
Organisation, 2011, Dahl, 2002). Although early physical impairment might be 
important in predicting recovery of mobility, it is likely that factors such as the 
support from a spouse or partner and family, friends, or carers that a patient 
is able to access, their home environment and financial situation, and the 
availability of community resources such as clubs and social groups ultimately 
have a much greater impact upon a person’s quality of life and independence 
(Meijer et al., 2004).  
A final limitation of post-hoc data analysis is that data sets obtained for other 
purposes may contain biases and can reflect poorly the characteristics of the 
population to whom a prognostic model might be applied. This issue will be 
discussed in detail below. 
4.3.1.2. Representativeness of the DARS sample 
The models developed here were developed in a data-set collected as part of 
the DARS trial: to date, the largest-ever trial of co-careldopa-augmented 
stroke rehabilitation. There is, however, a fundamental tension between the 
requirements of a randomised controlled trial and those of prognostic 
modelling. When designing a clinical trial, the imperative is to maximise the 
potential for a true treatment effect to be observed by rigorously controlling for 
possible confounding variables. For this reason, trials typically set rigid 
inclusion/exclusion criteria: for example, all DARS participants were expected 
to survive for more than two months after stroke, and be able to access 
ongoing rehabilitation on discharge (Bhakta et al., 2014). Practical constraints, 
such as the requirement for patients to be able to provide informed consent 
or to be able to swallow medication, further limited the pool of eligible 
participants. As a result the sample that was ultimately obtained may reflect 
poorly the whole population of stroke survivors in the UK or worldwide. This 
poses a problem when interpreting trial results (Rothwell, 2005), since the 
evidence base for an intervention does not encompass the patients or 
situations that are commonly encountered in clinical practice.  
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The lack of generalisability of such data sets also poses a problem for any 
prognostic models derived from them, since such models are most reliable 
when derived in samples whose characteristics closely resemble those of the 
population to which they will ultimately be applied. It is also difficult to control 
retrospectively for biases that might have been introduced at the time of data 
collection. In order to understand how useful (or otherwise) the models 
developed here might be in clinical practice, it is important to understand the 
DARS sample and how closely it might reflect the population of stroke 
survivors as a whole. 
Around 20-30% of patients who sustain a stroke will die within three months 
(Department of Health, 2007); and yet, in the DARS trial, all participants were 
expected to survive for >2 months after recruitment (Bhakta et al., 2014). Just 
as patients with severe life-limiting strokes were excluded, so those with more 
minor impairment were excluded by the protocol requirement that participants 
be unable to walk 10m or more independently at the point of entry in to the 
trial (Bhakta et al., 2014). The distribution of mRS scores at T0 indicates that 
36.1% of participants had a score of 3, and 29.0% had a score of 4. This 
indicates a sample with moderate initial impairment. Enrolment of patients with 
certain other impairments was also impractical. Although around 30% of 
patients experience cognitive impairment after stroke and 33% have aphasia 
(The Stroke Association, 2016), those with the most severe degrees of these 
impairments were excluded from DARS by their inability to give informed 
consent. Similarly, 45% of stroke survivors experience swallowing problems 
(The Stroke Association, 2016). In DARS, patients with dysphagia that did not 
resolve before the end of the recruitment window were excluded, since the 
trial drug could not be crushed for administration by a nasogastric or 
gastrostomy tube.  
Patients from certain ethnic groups (Afro-Caribbean and South Asian) are 
more likely to experience strokes at a younger age than those of Caucasian 
heritage, and are twice as likely to have risk factors for stroke such as diabetes 
or hypertension (The Stroke Association, 2016). Nevertheless, patients from 
ethnic minorities are often under-represented in stroke research trials (Cruz-
Flores et al., 2011). This is a cause for concern. Firstly, research findings or 
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prognostic models derived in samples with a non-representative ethnic mix 
may not be generalisable to patients from minority communities. Secondly, 
failure to collect data from those from certain communities/backgrounds may 
limit the ability of clinicians firstly to detect and secondly to understand and 
mitigate inter-racial differences in rehabilitation outcomes. In DARS, data on 
patients’ ethnic background was not collected: it is therefore not possible to 
ascertain whether patients enrolled fully represent the ethnic diversity of those 
who survive a stroke in the UK. 
In short, the DARS trial recruited a sample with moderate, predominantly 
motor, impairment. Patients with more severe degrees of aphasia, cognitive 
impairment, and dysphagia were not recruited. This sample is therefore not 
representative of the whole population of people who sustain a stroke 
worldwide. However, the population of patients who sustain a stroke each year 
is, perhaps, not an appropriate comparator for the DARS sample. In clinical 
practice, motor rehabilitation is neither appropriate nor necessary for all those 
who survive a stroke. For those who sustain a catastrophic stroke, palliative 
care or planning for discharge to a nursing home might be most appropriate. 
Conversely, those who sustain a minor stroke with little motor deficit and 
minimal loss of function will still require rigorous investigation and control of 
risk factors, but might recover with early supported discharge, without the 
need for a longer period of inpatient rehabilitation. Hence, although the DARS 
sample does not reflect the full spectrum of post-stroke impairment, it may 
more accurately reflect those who enter rehabilitation programmes in the UK. 
This is an important distinction, since the models developed here will 
ultimately be applied to patients on rehabilitation units: i.e., who are judged to 
have the potential to benefit from a period of predominantly physical inpatient 
rehabilitation. 
In DARS, the mean age at randomisation to the trial was 68 years (SD 13.23 
years). In a survey of four stroke rehabilitation services in Europe, the mean 
age of patients on admission to the UK centre was 72.0 (SD 9.5 years) (De 
Wit et al., 2007). In DARS, 85.7% of patients had an ischaemic stroke and 
14.3% of patients had an ICH. Survey data from other UK rehabilitation units 
indicate that ischaemic stroke accounts for 87% of admissions, and ICH 11% 
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(De Wit et al., 2007). At the time of enrolment, 13.8% of DARS participants 
had a mRS score of ≤2, indicating no to moderate disability; this is slightly 
greater than data from other UK centres, in which 7-11% of patients had a 
mRS score of ≤2 (Putman et al.). In DARS, all patients were unable to walk 
10m or more at baseline, with a mean RMI score of 2.25 (SD 1.791). The RMA 
Leg and Trunk subscale score for patients admitted to rehabilitation 
programmes in other UK centres is 4, and the mean RMA gross function 
subscale score was 2 (De Wit et al., 2007): these values indicate respectively 
an ability to transfer from sitting to standing (equivalent to an RMI score of 4-
5) and an ability to transfer from lying to sitting on the side of the bed 
(equivalent to an RMI score of 2). The baseline level of mobility impairment 
seen in DARS is therefore comparable to that seen at entry in to inpatient 
rehabilitation programmes in other UK centres.  
Although the baseline characteristics of the DARS sample do reflect those of 
samples drawn from other rehabilitation units, the proportion of DARS patients 
who regained independent mobility at T1 and T2 is somewhat lower than might 
be expected. In DARS, 42.5% of patients were walking independently at T1 
and 52.4% at T2; estimates from other studies indicate that 60%-80% of 
patients are independently mobile at six months post stroke (T2 in the DARS 
trial) (Kwakkel and Kollen, 2013). However, such estimates may be 
confounded by inclusion of patients who were ambulant at the time of 
enrolment (Preston et al., 2011). The DARS trial enrolled only patients who 
were unable to walk 10m or more at baseline (Bhakta et al., 2014). Systematic 
reviews which consider only patients who were non-ambulant at baseline have 
estimated the probability of walking independently as 0.39-0.60 at three 
months, and 0.65-0.69 at six months, depending upon whether the patient 
was managed in a rehabilitation unit or an acute stroke (Preston et al., 2011). 
The distinction between “acute” and “rehabilitation” units this Australian study 
makes does not reflect UK practice, in which patients typically receive both 
acute care and early rehabilitation on an acute stroke unit. Nevertheless, 
these estimates, derived in patients who were non-ambulant initially, indicate 
that the proportion of DARS patients who were able to walk independently at 
T2 is lower than one might expect. One possible reason for this discrepancy 
is the comparatively high proportion of DARS patients lost to follow-up at T2.  
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4.3.1.3. Loss to follow-up in the DARS sample 
DARS was the first trial of pharmacologically-augmented rehabilitation in 
which extended follow-up (up to one year) was attempted. However, the 
proportion of patients lost to follow-up at all end-points was higher than 
anticipated. By T1, 61 patients (10.3%) were lost to follow-up and a further 
eight did not return a SR-RMI score. Hence, the primary outcome measure 
was unavailable for 69 patients (11.6% of the total sample). By T2, the 
cumulative loss to follow-up was 101 patients (17.0%), and a further five did 
not return usable six-month SR-RMI scores. The total number for whom a SR-
RMI was not available at T2 was therefore 106 patients (17.9% of the total 
sample enrolled). The primary reasons cited for loss to follow-up at T2 were: 
withdrawal from the trial (n=45); death of a patient (n=20); inability of the trial 
team to contact the patient (n=15); and the patient moving to an area no longer 
covered by the trial team (n=8). 
The percentage of patients lost to follow-up in DARS is higher than in 
comparable rehabilitation trials. The FLAME trial (Fluoxetine for motor 
recovery after acute ischaemic stroke) (Chollet et al., 2011) examined the 
impact of fluoxetine upon motor recovery from stroke. In total 118 patients 
were randomised across both arms, with 113 remaining in follow-up by 90 
days. Only five patients (4.2%) were lost to follow-up (Chollet et al., 2011).  A 
second large multi-centre rehabilitation trial of very early mobilisation after 
stroke (AVERT) randomised 2104 participants across both arms, to either 
early mobilisation or usual care (Bernhardt et al., 2015). At three months, 181 
(8.6%) were lost to follow-up (Bernhardt et al., 2015). The mortality rates for 
DARS participants (7 patients (1.1%) at T1 and 20 patients (3.3%) at T2) are 
however lower than that seen in AVERT (160 patients, 7.6%, at 3 months) 
(Bernhardt et al., 2015). 
The DARS intervention was complex (Craig et al., 2008), in that for each 
participant its successful delivery depended upon an interaction between a 
number of individuals, spanning several professional disciplines and 
sometimes two or more services. It is therefore perhaps remarkable that the 
intervention was delivered successfully in the majority of cases. However, the 
impact of such high loss rates on the models presented here cannot be 
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ignored. In particular, the instability in model parameters that was seen when 
they were fitted under alternative assumptions for missing data has been 
highlighted above. 
4.3.1.4. Outcome measures used 
As has been alluded to above, the predictor variables utilised in these models 
were analysed under an assumption that they provide interval-level 
measurement: i.e. that a one-point change in their score equates to precisely 
the same magnitude of clinical change no matter where a patient is located 
on the metric. However, as illustrated in Chapter 2 using the example of the 
RMI, this assumption is illogical. This poses a particular problem for 
regression analysis. When the variables used here were fitted to the models, 
the output quoted was the change in odds of walking (versus not walking) for 
each one-point change in a covariate (Stoltzfus, 2011). However, if one cannot 
be sure that a one-point change in score measured in different patients 
represents the same magnitude of clinical change, then the face validity of 
such findings is called into question. Nor is it legitimate to perform 
mathematical operations on ordinal scales, such as the calculation of mean 
values and standard deviations. 
The fundamental difference between ordinal and interval-level measurement 
is perhaps not as widely appreciated as it should be. And yet, the 
consequences of making an unfounded assumption that an outcome measure 
provides interval-level measurement are profound for clinical practice, 
commissioning of rehabilitation services, and research. This is well illustrated 
in another field of rehabilitation practice: the management of chronic pain 
(Kersten et al., 2014). The Pain Visual Analogue Scale (VAS) is a widely-used 
method for documenting a patient’s experience of pain (Kersten et al., 2014). 
It consists of a line ten centimetres long, with each end of the scale typically 
anchored with statements such as “no pain” or “worst pain imaginable” 
(Kersten et al., 2014). Patients are invited to indicate the severity of their pain 
by placing a mark along the line. Pain severity is typically quoted as a score 
out of 100, which represents the distance along the scale in millimetres that 
the mark is positioned (Kersten et al., 2014). Since scores are quoted as a 
distance in millimetres, they are often assumed to have interval-level 
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properties and are therefore interpreted as such: for example in the calculation 
of “change” scores (the difference in VAS scores taken at two time points) 
(Kersten et al., 2014). The assumption that the pain VAS provides interval-
level measurement has recently been challenged. In particular, patients report 
difficulty in conceptualising their pain as a point on a linear continuum, and 
thus responses tend to be “clustered” rather than spread evenly along the 
length of the metric (Kersten et al., 2014). An analysis by Kersten et al. (2014) 
has recently confirmed that the pain VAS actually behaves as an ordinal scale. 
This fundamentally undermines the assumption that parametric statistics can 
be applied to this measure.  
This is more than just an arcane statistical argument. When results from two 
randomised controlled trials that had utilised the VAS as an outcome measure 
were re-analysed, the change in VAS scores quoted in the original papers 
were found to greatly over-estimate the true change observed when the VAS 
was first converted to an interval-level measure (Kersten et al., 2014). The 
impact of these findings cannot be over-stated. Firstly, a change in the VAS 
score of equal magnitude, but at different locations on the scale,  may have 
fundamentally different clinical implications (Kersten et al., 2012). Secondly, 
change scores calculated from the VAS may under- or over-estimate true 
clinical change (Kersten et al., 2012). Thirdly, if change in VAS scores do not 
reliably measure true clinical change, then the use of this measure to inform 
decisions about the commissioning of services is questionable (Kersten et al., 
2012). Fourthly, if estimates of clinical change derived from the VAS are 
unreliable, then utilising this measure in sample size calculations may result 
in under- or over-powered trials from which inappropriate conclusions may be 
drawn (Kersten et al., 2012).  
Caution must therefore be exercised when interpreting the output of Models 
1-6. Although the direction and magnitude of effects for each of the covariates 
fitted to the model may be indicative, they are likely to under- or over-estimate 
the magnitude of true clinical change. If models are to be derived that reliably 
predict true clinical change after stroke, then there is a pressing need for 
robust interval-level scales to measure both key rehabilitation outcomes and 
predictor variables. The means by which this might be achieved will be 
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discussed below in Section 5. First however, the limitations of the analysis of 
brain scans that is presented here will be considered. 
4.3.2. Imaging considerations 
This study sought to examine whether the characteristics of the stroke, as 
seen on imaging, contributed to the ability of models to predict motor recovery. 
Although centres of excellence in imaging research exist (notably the Brain 
Research Imaging Centre (BRIC) in Edinburgh: www.sbirc.ed.ac.uk), at the 
time the DARS protocol was under development there was surprisingly little 
in the published literature to guide non-radiologists who wished to include a 
secondary analysis of brain imaging in a trial. The Acute Stroke Imaging 
Research Roadmap (Wintermark et al., 2008), published in 2013, provides a 
helpful guide to some of the central methodological considerations of robust 
radiological research and is strongly commended to interested readers. 
However, it is clear in hindsight that a failure to address some basic 
considerations when writing the protocol for imaging analysis subsequently 
led to unanticipated difficulties. The following paragraphs will reflect upon 
some of the difficulties encountered in this work, and highlight its 
methodological flaws and their impact upon the models presented here. 
Although it may also serve as a useful guide to non-experts, those who wish 
to include an analysis of imaging in a trial are strongly advised to consult 
experienced academic neuroradiologists from the earliest stages of protocol 
design. 
4.3.2.1. Proportion of scans not available for analysis 
A delay in obtaining ethical approval for the centralised review of scans 
resulted in a failure to collect imaging from the first 24 participants randomised 
in to the trial. A further 36 scans could not be obtained for other reasons, and 
20 were excluded since only MRI imaging and not CT was sent. Hence, 80 
participants (13.5% of the DARS sample) did not have imaging available for 
analysis. Formal testing for differences in the clinical characteristics of those 
for whom imaging was and was not obtained revealed slightly higher mean 
SR-RMI scores at T1 and T2 in those for whom imaging was not available; 
however, there was no evidence of a statistically-significant difference in the 
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proportions of the two groups who were walking independently at eight weeks 
and six months. Nor were there any other statistically-significant differences 
in the characteristics of the two groups.  
4.3.2.2. The use of routinely-collected as opposed to protocol-specified 
imaging 
Perhaps the most fundamental decision to make when planning an analysis 
of imaging is whether to utilise scans acquired routinely for clinical purposes, 
or to stipulate the acquisition of additional imaging beyond that which would 
normally be considered to be clinically indicated. This will of course depend 
upon the research question (Wintermark et al., 2008). For example, MRI 
sequences that are known to have a greater sensitivity and specificity for white 
matter lesions and lacunes than CT (O'Brien et al., 2003). A study examining 
the prevalence of these lesions, or changes in them over time, would thus 
specify that MRI imaging be used. However, requesting additional imaging 
exclusively for trial purposes inevitably incurs additional costs, which must be 
included in any grant proposal. As a guide, in 2015-16 NHS England set a 
funding tariff of £77 for a non-contrast CT of one body area in an adult patient, 
with an additional £20 for reporting; the tariff for a non-contrast MRI was 
higher, at £123 plus £22 for reporting (NHS England, 2015). The costs of 
acquiring and reporting more complex sequences (such as angiography) are 
commensurately greater. The cost of radiographers’ time and patient transport 
or travelling expenses to and from the scanning facility must also be 
accounted for.  
In DARS, analysis was restricted to the first available CT scan acquired for 
routine clinical purposes. This pragmatic approach has several advantages: 
the costs of acquiring imaging specifically for trial purposes are mitigated, and 
no additional radiation exposure to patients is required. Furthermore, if the 
clinical utility of a model depends in part upon the predictor variables it utilises 
being readily collectable in practice (Altman and Royston, 2000), then it is 
advantageous to construct a model using scans that are already collected 
routinely. However there are also some clear disadvantages to this approach, 
including an inability to guarantee that the scanners on which images are 
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taken are appropriately calibrated, and difficulty in standardising the time at 
which imaging is acquired in relation to the onset of stroke symptoms.  
4.3.2.3. The timing of imaging acquisition 
Failing to standardise the time of acquisition of scans has crucial implications 
for the reliability of reporting, since any scan is only ever a static 
representation of what is a highly dynamic process. For example, early 
ischaemic changes on CT are subtle (Grotta et al., 1999, Wardlaw and Mielke, 
2005) and may easily be overlooked (Wardlaw et al., 2007). Re-scanning the 
same patient some weeks later is likely to reveal a mature area of hypodensity 
typical of an established infarct. Scans acquired within a few hours of stroke 
onset may thus under-estimate the true structural impairment. 
Just as it is difficult to predict the final extent of brain injury from an initial scan, 
so it may also be difficult to determine the nature of an initial lesion when 
presented with a scan taken some time after an event. For example, ICH 
initially returns a hyperdense appearance on CT, but later become hypodense 
and may closely resemble an old infarct (Macellari et al., 2014, Balami and 
Buchan, 2012). Similarly, small subcortical infarcts or haemorrhages may give 
rise to a range of final appearances including: no visible abnormality; a lacune; 
or white matter lesions (Wardlaw et al., 2013b). In the absence of previous 
imaging (for example, showing an intracerebral haemorrhage) or a 
corroborating clinical history (for example, suggesting a lacunar stroke 
syndrome), clinical judgement must be used to come to a view on the likely 
clinical significance of scan findings. In DARS, the fact that the timing of 
imaging in relation to stroke onset was not standardised raises the possibility 
that patients with very similar patterns of clinical impairment could have 
displayed markedly different scan findings, depending upon the timing of the 
imaging. Standardising the timing of imaging may have reduced some of the 
heterogeneity in this analysis: for example, the true extent of an infarct may 
have been more easily appreciated had delayed imaging been specified. 
4.3.2.4. Expert review of scans 
A key requirement for any trial data is that they be collected in a robust and 
reproducible manner (Wintermark et al., 2008). If scans are to be used to 
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determine eligibility for participation in a trial, then there may be insufficient 
time to obtain an expert centralised review by a consultant neuroradiologist. 
In such cases it may be acceptable to rely upon the interpretation of local 
stroke physicians, provided that adequate training is provided (Barber et al., 
2000). The use of a standardised template may help to improve the reliability 
of non-expert reports, by drawing the reviewer’s attention to each relevant 
area in turn (Wardlaw et al., 2007, Wardlaw et al., 2010). 
If imaging is to be used as a variable in a subsequent analysis, or if advanced 
imaging techniques are to be used, then reporting by an experienced 
consultant neuroradiologist is advisable. Centralised review of imaging is 
recommended, with radiologists blinded to clinical information and treatment 
allocation (Wintermark et al., 2008). In DARS, the initial grant proposal was 
for a Research Fellow to code scan findings using written reports from local 
radiologists. This procedure was later modified to specify centralised review 
of imaging, since it was recognised that written reports alone were unlikely to 
be sufficiently detailed to allow accurate coding of findings. However, the 
additional costs of radiology time had not been included in the original grant 
application. It was therefore necessary to divert funds from elsewhere in the 
grant to support this work. As a result, there was sufficient funding to allow 
scans to be reviewed by JP plus only one consultant neuroradiologist. 
Consensus reporting by a panel of experts, with formal arbitration 
mechanisms to settle disagreements between them, might have been more 
robust. The requirement for centralised reporting of scans also necessitated 
the establishment of secure procedures for the despatch of scans to CTRU. 
4.3.2.5. Data management and quality control 
Any systems put in place for receiving images at a centralised reporting facility 
must be secure, and subject to robust quality control mechanisms 
(Wintermark et al., 2008). The option of establishing a secure data link 
between recruiting centres and LTHT was considered, but was deemed 
impractical given the time taken to approve and establish such links with such 
a large number of sites. However, the despatch of scans using electronic 
storage media proved difficult to standardise, and presented several 
difficulties.  
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Firstly, a number of sites would only approve transfer of data in encrypted form 
despite this not being a protocol requirement. Obtaining passwords from sites 
therefore presented an additional administrative burden. However, the more 
crucial consideration was that the trial team were unable to implement robust 
verification procedures for images sent in anonymised form, and were 
therefore wholly reliant upon quality control procedures at local site to ensure 
that the correct imaging for the correct patients was downloaded. This had a 
number of important consequences. Once images had been redacted of 
patient-identifiable information, they were identifiable only by the participant’s 
trial identification number. There was no way for CTRU to verify that the 
images had been correctly identified at source. Indeed, a number of cases 
were noted in which obviously incorrect imaging had been sent. In one case, 
the same sequence of images was for the same patient was copied to two 
different CDs, each labelled with the trial identification number of a different 
participant: the error was noticed only because a distinctive necklace the 
patient was wearing appeared in the scout image. In a second case a CT of 
the thorax, performed on an earlier occasion for an indication unrelated to the 
patient’s presenting stroke, was sent.  
In patients who had had previous neuroimaging studies, the onus was upon 
the recruiting centre to ensure that only imaging relating to the index stroke 
(the event for which they were randomised in to the DARS trial) was sent. 
However, when the dates of image acquisition (as recorded on the images 
themselves) were compared to the dates of the index stroke, it was noted that 
in 32 participants the date of imaging pre-dated the index stroke. In 24 cases, 
the recorded scan date preceded the stroke by more than 7 days, with the 
longest recorded interval being 395 days pre-stroke. At the other extreme, 19 
patients had imaging that was apparently conducted >14 days after the index 
stroke, with the longest time interval being 163 days. The reasons for these 
discrepancies were impossible to determine. It is possible that, in some cases, 
the “date of stroke” entered on to the CRF is incorrectly stated, and in fact 
represents the date on which the patient was transferred from another 
hospital. It is equally possible that the “first available” imaging may not 
correspond with the “first imaging performed”: in cases where patients were 
transferred from a regional “hyperacute” stroke unit and subsequently 
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recruited on a local “acute” stroke unit, imaging performed at the hyperacute 
centre may not have been made available at the time of transfer. Finally, it is 
possible that recruiting centres interpreted the instructions to anonymise the 
images as requiring that all clinical information be redacted from the scans, 
and that a false date of image acquisition was substituted. Ultimately, this 
situation illustrates the need for robust quality control procedures in 
despatching and receiving imaging. 
4.3.2.6. Storage and archiving of images 
All data collected as part of a clinical trial must be archived securely. The 
archiving of scan images presented a particular challenge. Although LTHT 
has a secure Picture Archiving and Communications System, storage 
capacity for this server was limited and the cost of administrator time to upload 
images to it could not be met. The trial team were thus obliged to archive 
images on CDs: a format which may degrade over time. It was therefore 
agreed that completed radiology CRFs would also be archived as source data, 
to ensure that a contemporaneous paper-based record of scan findings was 
retained. However, if archiving of original images is required then the costs of 
doing so and of preserving the data in a usable format must be included in the 
initial grant application. 
Part 4.4 Directions for future work. 
4.4.1. The need for prognostic modelling in stroke 
The need for robust models to predict specific rehabilitation outcomes after 
stroke has, arguably, never been greater. In recent years, many major 
advances have been made in acute stroke care. In some cases, such as the 
introduction of thrombolysis for acute ischaemic stroke, the development of 
simple and reliable prognostic models has been crucial in differentiating those 
patients who might benefit from the intervention from those at risk of 
sustaining harm as a result of treatment (Barber et al., 2000).  
Although the benefits of acute interventions in stroke care are evaluated 
largely in terms of preventing death or dependency (Stroke Unit Trialists 
Collaboration, 2013, Early Supported Discharge Trialists, 2009, Wardlaw et 
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al., 2014b), such broad outcomes provide very little useful information about 
specific functional outcomes such as recovery of walking (Preston et al., 2011, 
Kwakkel and Kollen, 2013). And yet these are precisely the outcomes that are 
of greatest use when planning a rehabilitation intervention. 
4.4.1.1. The possible uses of prognostic models in clinical practice 
The development of models to predict specific rehabilitation outcomes may be 
useful in several respects. Firstly, a model that is able to predict reliably who 
might walk again could allow more accurate prognostic information to be 
provided to patients and their families (Craig et al., 2011). This could in turn 
facilitate goal-setting and discharge planning (Kwakkel and Kollen, 2013). 
However, in order to be truly useful in this setting any such model would need 
to offer predictive accuracy superior to that of the clinical judgement of a 
skilled multi-disciplinary team (Kwakkel et al., 2000), include predictor 
variables that can easily be collected (Altman and Royston, 2000), and have 
a scoring system that is simple to apply (Moons et al., 2015).  
A second important role for prognostic modelling in rehabilitation practice 
might be in tailoring the intervention that is delivered to the needs of individual 
patients. This might sound like an unusual, even counter-intuitive, point to 
assert: after all, rehabilitation by its nature consists of a “personalised” 
package of interventions aimed at achieving goals that are specific to an 
individual (Gutenbrunner et al., 2006). And yet, considerable uncertainty 
remains about what rehabilitation strategies are most appropriate for 
individual patients. A good example of such a controversy in stroke care is in 
deciding the intensity of rehabilitation that should be offered. Although more 
intensive rehabilitation is associated with shorter lengths of stay in hospital 
(Slade et al., 2002), recent evidence from a major randomised controlled trial 
has raised concerns that offering very intensive mobilisation within the first 48 
hours of stroke actually results in a reduction in the odds of a favourable 
outcome at three months, and no net benefit in terms of mobility outcome 
(Bernhardt et al., 2015). This finding is surprising, and merits further 
consideration. Since the trial enrolled participants with a range of initial clinical 
impairment from mild to severe (Bernhardt et al., 2015), it is plausible that 
those with mild initial impairment may in fact benefit from early intensive 
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mobilisation, whilst those with more severe impairment may be harmed by 
such an approach. A model to predict who might recover the ability to walk 
again could thus allow the intensity of rehabilitation that is offered to be 
tailored to the patient’s prior probability of regaining independent mobility. 
Thus, those with mild initial impairment and a high prior probability of walking 
again could be targeted for early intensive rehabilitation; those with an 
intermediate probability of walking and moderate impairment may still benefit 
from active rehabilitation, but at a lesser intensity; those with a low probability 
of walking (and the most profound impairment) may benefit from a focus upon 
compensatory rehabilitation strategies, with the aim of maximising 
participation by modification of contextual factors. An ability to predict future 
recovery reliably may thus allow the delivery of rehabilitation interventions to 
be tailored to a patient’s prior probability of attaining a specified level of 
functioning  (Steyerberg et al., 2013, Dorresteijn et al., 2011, Kwakkel and 
Kollen, 2013) thereby allowing resources to be used more efficiently 
(Steyerberg et al., 2013). 
4.4.1.2. Possible uses of prognostic modelling in rehabilitation 
research 
Perhaps the greatest potential of prognostic modelling in rehabilitation lies not 
in clinical practice, but in research. A number of promising novel rehabilitation 
strategies are now emerging, such as the use of robotic interventions to 
augment the intensity and frequency of task-specific practice that can be 
delivered by therapists (Kwakkel et al., 2008, Sivan et al., 2014), the use of 
electrical stimulation of peripheral nerves to enhance plasticity in the central 
nervous system (Dimyan and Cohen, 2011, O'Connor et al., 2014), or direct 
stimulation of the motor cortex either by magnets or by implanted electrodes 
(Dimyan and Cohen, 2011). The benefits of these strategies remain as yet 
unproven, and large-scale trials will ultimately be necessary to establish 
whether or not they have a place in clinical practice. Having models to predict 
rehabilitation outcomes such as walking ability might allow patients to be 
selected for these trials based on their prior probability of benefitting from the 
intervention. Prognostic modelling may also play a role in the design of future 
stroke research trials.  
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As was alluded to in Chapter 1, randomised controlled trials enrol a 
heterogeneous sample of participants (Dorresteijn et al., 2011). Inherent in 
the interpretation of their results are the assumptions that each participant has 
an equal probability of benefitting from the intervention, and that the 
magnitude of any effect size observed is, on average, uniform across the 
entire sample (Dorresteijn et al., 2011). End-points are often dichotomised in 
to favourable versus unfavourable outcomes, and are applied to the trial 
population as a whole. Doing so assumes that the population to which the 
intervention is applied is homogeneous, and that the direction and magnitude 
of any treatment effect will be roughly the same for the whole group. And yet, 
sub-groups within a sample may vary considerably: both in their baseline 
clinical characteristics and in their response to the intervention (Dorresteijn et 
al., 2011). Presenting results as an “average” effect size may therefore fail to 
account for clinically important differences in trial participants (Young et al., 
2005). For example, those with profound disability may consider even a 
modest improvement to be a “good” outcome, whereas those with minor 
impairment may be dissatisfied with anything less than complete recovery 
(Young et al., 2005). Furthermore, the existence of significant heterogeneity 
in a trial sample may compromise statistical power to detect the primary 
outcome (Makin et al., 2013). Sample size calculations are generally based 
upon an assumption about the baseline probability of patients developing the 
outcome of interest: if a sample contains a significant proportion of patients at 
one extreme of the prognostic spectrum (very good or very poor), then the 
statistical power to detect a treatment effect will be attenuated (Makin et al., 
2013). Perhaps a first step towards improving the design of future 
rehabilitation trials would be to account for the heterogeneity of trial 
participants (Dorresteijn et al., 2011). Prognostic models to predict key 
outcomes of interest (Steyerberg et al., 2013) such as mobility may be used 
to recruit in to trials only those patients who stand the best chance of 
benefitting from an intervention (Makin et al., 2013). Doing so may reduce the 
sample size required, but at the expense of decreased recruitment and 
prolongation of the study (Makin et al., 2013). An alternative approach would 
be to pre-specify a range of possible trial outcomes, and assign patients 
differential end-points dependent upon their prior probability of achieving a 
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specified level of function (Makin et al., 2013). This approach, though not 
presently used widely in stroke rehabilitation, has the potential to reduce the 
sample sizes required whilst not impacting upon recruitment (Makin et al., 
2013). It is, of course, reliant upon the development of reliable prognostic 
models.  
Models to predict outcomes such as walking may thus have a considerable 
impact upon both stroke rehabilitation in clinical practice, and rehabilitation 
research. However, this potential will only be realised if the models developed 
are able to reliably predict the outcome of interest with a high sensitivity and 
specificity. A striking, and perhaps important, finding of this study is that a 
combination of simple clinical measures of impairment that one might expect 
to find in use on UK stroke units actually explained comparatively little 
variance in outcome, and correctly classified only marginally more patients as 
walking/not walking at T1 and T2 than prior probability alone. This raises two 
important questions. Firstly: what might the implications be for the way in 
which teams arrive at a rehabilitation prognosis? Secondly: what variables 
might prove to be better predictors of motor outcome? 
4.4.1.3. Is statistical modelling any more reliable than “team opinion” in 
predicting recovery? 
As discussed above, if a model is to be useful in clinical practice then it must 
offer a more reliable prediction of outcome than the opinion of an experienced 
multi-disciplinary team. It has been suggested previously that models to 
predict walking ability after stroke offer no greater predictive value than a 
therapist’s assessment (Kwakkel et al., 2000). And yet, the same study 
revealed that physiotherapists accurately predicted a patient’s future walking 
ability only 48% of the time (Kwakkel et al., 2000). Around 26% of predictions 
made at five weeks about a patient’s walking ability at six months were over-
optimistic, whilst 26% underestimated the final level of mobility achieved 
(Kwakkel et al., 2000). Recovery of arm function was more reliably predicted, 
with 63.6% of physiotherapists and 59.1% of occupational therapists 
accurately predicting six-month prognosis on the basis of an assessment at 
five weeks (Kwakkel et al., 2000). However, this apparent improvement in 
reliability relative to prediction of walking ability is most likely due to the well-
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recognised tendency for arm function to recover incompletely (Kwakkel et al., 
2000). It therefore appears that neither existing prognostic models nor clinical 
judgement alone are reliable predictors of future prognosis. One possible 
explanation for this finding is that both prognostic models and a professional’s 
clinical judgement depend, either explicitly or implicitly, upon a combination of 
measures of physical impairment that themselves explain comparatively little 
variance in outcome. There is therefore a need to understand better the basis 
upon which a team’s prognostic decisions are made and how reliable those 
decisions might be in predicting key outcomes.  
There is also a need to identify variables that might explain a greater 
proportion of variance in outcome. It is possible that measures focusing upon 
very specific impairments such as balance (van de Port et al., 2006a) or of 
executive function might yield more accurate predictions than scales that 
measure the broader constructs of “mobility” and “cognition”. However, the 
identification of constructs that might be predictive of key rehabilitation 
outcomes is merely a first step towards model development. Perhaps a more 
fundamental and urgent imperative is for robust scales with which to measure 
these constructs. 
4.4.1.4. What is the future role of brain imaging in predicting 
rehabilitation outcomes? 
This study aimed to evaluate whether variables derived from early CT imaging 
made a contribution to models predicting walking ability beyond that achieved 
by measures of clinical impairment alone. The choice of CT imaging was a 
pragmatic one, since this modality is already routinely used to guide a patient’s 
acute management, is cheap and quick to acquire in comparison with MRI 
modalities, and has fewer contra-indications than MRI imaging. However, CT 
is an imperfect surrogate for a patient’s functional impairment (Kobayashi et 
al., 2009). Nor does structural imaging provide useful information about how 
different brain structures interact to shape recovery (Dayan and Cohen, 2011). 
It is therefore perhaps unsurprising that CT findings do not contribute to the 
prediction of a specific functional outcome (recovery of walking ability). 
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Functional MRI provides a dynamic picture of brain metabolic activity that is 
assumed to reflect activation of brain structures (Arthurs and Boniface, 2002). 
This may offer some insight in to the biological basis of recovery from stroke, 
by elucidating how network interactions between spatially-distributed brain 
structures facilitate learning. However, although much work has already been 
done to understand the processes that underpin motor learning (Doyon et al., 
2009, Hikosaka et al., 2002, Penhune and Steele, 2012), theoretical models 
developed in healthy participants cannot be assumed to translate directly to 
those recovering from stroke. At present, functional imaging remains largely 
a research tool, and is not performed routinely in clinical practice. 
If this modality is to prove useful in predicting rehabilitation outcomes, then 
the key questions for research are perhaps: what brain structures interact to 
facilitate motor learning in healthy individuals; how do these processes differ 
in those with structural brain injury as a consequence of stroke; do specific 
patterns of disruption of network interactions between brain structures 
correlate with limitation of motor recovery; does functional MRI imaging allow 
a more accurate prediction of prognosis to be made than would be obtained 
using clinical judgement alone or models based on robust measures of clinical 
impairment; and what are the costs versus benefits of using this technique 
more widely in clinical practice.     
4.4.2. The need for robust outcome measurement in stroke 
research 
4.4.2.1. Why is outcome measurement important? 
The need for robust outcome measurement in stroke is urgent and pressing: 
both for research, prognostic modelling, and for clinical practice. 
Rehabilitation interventions are, by their nature, complex (Craig et al., 2008): 
they depend upon a team of professionals working together to restore physical 
function and modify a patient’s social and environmental context, with the 
overall aim of mitigating disability (a construct defined in terms of limitation of 
activities and restriction of participation) (Gutenbrunner et al., 2006). 
However, the efficacy of particular elements of a rehabilitation programme 
may be hard to discern. Randomised controlled trials, long regarded as the 
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gold standard of scientific evidence, are by their nature a reductive process 
that seek to isolate and examine one component part of a wider package of 
measures (Gutenbrunner et al., 2006). Any genuine effect of such 
interventions may be small, and difficult to differentiate from that of the wider 
rehabilitation programme. The ability to detect reliably small changes in 
function is therefore crucial to evaluating novel rehabilitation interventions. 
The development of new rehabilitation interventions will also depend upon an 
understanding of how different physical impairments may interact to influence 
recovery. Utilising modelling techniques to explore the process of recovery 
may allow the identification of key variables that strongly influence outcome. 
This might, in turn, provide information that will be of value in planning a 
rehabilitation programme, and also in the development of new interventions 
that specifically target key components of recovery. Models that are 
developed in order to predict prognosis may not only enable more reliable 
information to be provided to patients and families, but could also allow the 
stratification of patients in to research trials or the differential selection of end-
points for trials based upon a patient’s prior probability of attaining a specified 
level of functioning. However, the interpretation of such models depends upon 
knowing the magnitude of true clinical change that such models are able to 
predict.     
In clinical practice, the ability to detect true clinical change is important not 
only in planning a package of rehabilitation interventions for individual 
patients, but also for the commissioning of services. Rehabilitation is known 
to be effective in reducing physical dependency after stroke (O'Connor et al., 
2011). However, demonstrating the cost-effectiveness of such services 
depends upon the ability to detect change in a patient’s level of functioning. 
Robust outcome measurement is, once again, critical for this process. For 
example, some scales such as the Barthel Index are known to be insensitive 
to true clinical change in patients with the highest and lowest scores (Quinn 
et al., 2011). Such “floor” and “ceiling” effects mean that, in the most- and 
least-disabled patients, it is possible for clinically-significant changes in 
performance to occur despite minimal or no change on the BI score (Quinn et 
al., 2011). The ability to evaluate the success of a rehabilitation intervention, 
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and its cost-effectiveness, may therefore be compromised if outcome 
measures are used that do not appropriately target the population in question. 
The ability to detect small changes in function, both in rehabilitation trials and 
in clinical practice, depends upon the use of sensitive, psychometrically-
robust outcome measures that are appropriately applied, analysed, and 
reported. Here, unfortunately, much work remains to be done.  
4.4.2.2. The current status of outcome measurement in stroke research 
A bewildering array of outcome measures exists, measuring a wide variety of 
constructs. A recent systematic review found 47 different outcome measures 
used in 126 stroke trials (Quinn et al., 2009b). The numbers of measures in 
use for specific impairments (upper limb function, aphasia, and cognition) is 
larger still (Ali et al., 2013). Despite several calls for standardisation of 
outcome measurement (Langhorne et al., 2009, Lees et al., 2012), no 
consensus has been reached on which measures are the most appropriate 
and standards for a minimum data-set for rehabilitation trials have not been 
agreed (Lees et al., 2012, Ali et al., 2013). In 2012 the European Stroke 
Outcomes Working Group (Lees et al., 2012) suggested that the mRS be 
adopted as the primary outcome measure in stroke trials. Unfortunately this 
measure is far too broad in scope to be of use in rehabilitation trials. The wide 
variety of outcome measures used in stroke trials greatly impedes meta-
analysis and comparison of trial data (Ali et al., 2013). Worse still, the scales 
themselves are often arbitrarily changed with scant regard for the impact of 
those changes on their properties.  
A good example of the confusion that surrounds outcome measurement in 
stroke is the Barthel Index (BI). This is a measure of global physical 
functioning, covering a number of activities. Since its first publication in 1965 
(Mahoney and Barthel, 1965), it has become one of the most widely-used 
outcome measures in clinical practice (Quinn et al., 2011). Although designed 
neither for clinical trials nor specifically for stroke, its adaption in to stroke 
research has been enthusiastic with only the mRS proving more ubiquitous 
(Quinn et al., 2009b). The original version described ten items: feeding, 
dressing, grooming, bathing, bladder and bowel continence, toileting, 
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transfers, mobility, and stair use (Quinn et al., 2011). Each item is scored 
according to a weighted scale: total scores are out of 100, with higher scores 
denoting greater independence (Quinn et al., 2011). The BI has been modified 
several time, including changes to the weighting of items, or alterations to the 
definitions of items (Quinn et al., 2011). There are presently at least four 
versions which return summary scores out of 100, all of which are referred to 
in the literature as the “Barthel Index” (Quinn et al., 2011). A number of 
expanded versions have been suggested which incorporate items not 
included in the original score (such as tracheostomy management or cognitive 
function), apparently in response to local needs (Quinn et al., 2011). Attempts 
have also been made to derive “short-form” indices, by removing all but the 
most discriminating items. Interestingly, the items chosen for inclusion or 
removal seem to vary (Quinn et al., 2011). The construct validity and clinical 
utility of these “modified” versions cannot be assumed (Quinn et al., 2011). 
Versions of the BI have been developed for administration by face-to-face 
interview, direct observation, by telephone, or by self-report (including by 
post).(Quinn et al., 2011, Gompertz et al., 1994) There is no consensus about 
which version is the most appropriate for use in stroke trials (Quinn et al., 
2011).  
4.4.2.3. What are the key properties of a rehabilitation outcome 
measure? 
As we have discussed above rehabilitation outcome measures seek to define 
a construct, to develop a list of items that range in order from “easiest” to 
“hardest” or “less” to “more”, and then to determine the position of a patient 
along the metric according to the location of the items that they endorse 
(Hobart and Cano, 2009). If the output of such scales is represented as a 
summary score, then it cannot be assumed that such scores provide interval 
level measurement.  
Furthermore, unless all items contained within a scale measure a common 
underlying construct, the legitimacy of deriving a summary score from them 
may be called in to question. This property is termed unidimensionality. 
Attempts to measure rehabilitation outcomes may be further compounded by 
the inter-dependence of the scale used, and the characteristics of the people 
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in the sample it seeks to measure (Hobart and Cano, 2009). The apparent 
performance of a group of patients may change depending upon the scale 
that is used to measure them. For example, when measuring physical 
functioning in Multiple Sclerosis, a sample of moderately-disabled patients will 
return a high score on the BI, a mid-range score on the Multiple Sclerosis 
Impact Scale physical functioning subscale, and a low score on the Medical 
Outcomes Study 36-item Short Form Health Survey physical functioning 
dimension (Hobart and Cano, 2009). The apparent performance of an 
individual patient on any given scale will also depend upon the characteristics 
of the other patients in the sample. If measured within a sample containing 
predominantly severely-disabled patients, a person with moderate disability 
will score within the higher percentiles for physical functioning; conversely the 
same patient, measured using the same scales but this time amongst a mildly-
disabled sample, will score within the lower percentiles (Hobart and Cano, 
2009). Put simply, the apparent performance of an individual depends upon 
the properties of the scale used to measure them, and on the characteristics 
of the sample of which they are part (Hobart and Cano, 2009). This poses a 
problem for outcome measurement in rehabilitation practice: unless a means 
can be found to isolate genuine change in the performance of individual 
patients from variation in the characteristics of a scale, one cannot be 
confident that true clinical change has been measured. Ideally, the 
performance of an individual should be independent of the scale used to 
measure them, and the properties of a scale should not vary depending upon 
the characteristics of the sample it is used to measure. This concept is termed 
invariance. Interval-level measurement, unidimensionality, and invariance are 
sometimes referred to as the key tenets of measurement (Hobart and Cano, 
2009). Fortunately, it is possible to evaluate scales systematically to establish 
whether they meet these requirements. 
4.4.2.4. Methods for the formal evaluation of outcome measures 
The science of measuring rehabilitation outcomes, a field termed 
psychometrics, has developed enormously in recent years. Traditionally, the 
validation of a new outcome measure would focus upon three domains: 
reliability (the extent to which measurements are influenced by random error); 
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validity (whether a scale actually measures the property it purports to 
measure); and responsiveness (whether a scale reliably detects clinical 
change) (Hobart and Cano, 2009). However, classical methods for evaluating 
scales offer no means of determining whether an outcome measure provides 
interval-level measurement or displays invariance (Hobart and Cano, 2009). 
They also depend upon the scale satisfying several assumptions which in fact 
cannot be mathematically tested, and are therefore considered to be met for 
most data-sets (Hobart and Cano, 2009). 
More recently, a range of rigorous methods have been developed for the 
evaluation of outcome measures. Amongst them are a series of models 
proposed by Georg Rasch, and Item Response Theory (Hobart and Cano, 
2009). A detailed discussion of these models is beyond the scope of this 
thesis: interested readers are referred to a comprehensive monograph by 
Hobart and Cano (2009). Suffice to say that Rasch proposed a set of 
mathematically-testable hypotheses which, if satisfied, indicate that a scale 
can be assumed to fulfil the key tenets of measurement (Hobart and Cano, 
2009). Unlike Item Response Theory, which seeks to derive models from 
observed data, Rasch analysis gives primacy to the model itself (Hobart and 
Cano, 2009). The data obtained from a rating scale are fitted to the Rasch 
model, and the observed fit is then compared to what would be expected if the 
scale fulfilled the criteria for optimum measurement (Hobart and Cano, 2009). 
Any misfit between observed and expected values prompts not a re-evaluation 
of the model, but a further examination of the data to determine why an item 
(or set of items) is not performing as expected (Hobart and Cano, 2009). 
Rasch analysis allows for the systematic examination of scales to establish if 
they fulfil the criteria of unidimensionality and invariance. It also allows the 
appropriateness of the order in which items are arranged in a scale to be 
evaluated, and for items that do not fit the model to be identified (Tennant and 
Conaghan, 2007). Bias that arises as a result of differences in the response 
to individual items between different patient groups within the sample 
(differential item functioning) can also be evaluated (Tennant and Conaghan, 
2007). Crucially, the location of items on an ordinal scale can be mapped to a 
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logarithmic scale: thereby providing true interval-level measurement (Tennant 
and Conaghan, 2007).  
4.4.2.5. The Virtual International Stroke Trials Archive: an opportunity 
to evaluate outcome measures used in stroke?  
Rasch analysis may be used to build scales de novo, or to evaluate the 
properties of existing scales (Tennant and Conaghan, 2007). The systematic 
evaluation of rehabilitation scales that are commonly used in stroke would be 
of enormous value, since having available a battery of validated outcome 
measures that are proven to fulfil the key tenets of measurement would 
provide a solid foundation from which research and modelling could then 
proceed. Such work would, of course, rely upon the existence of a large bank 
of data derived in stroke patients and covering a variety of relevant outcome 
measures. The VISTA archive may be such a resource.  
VISTA was set up in 2007 to bring together data from major clinical trials, in 
the hope that doing so would facilitate exploratory analyses of existing data-
sets.(Ali et al., 2007)  By 2013, its rehabilitation trials offshoot (VISTA-Rehab) 
contained data-sets from 38 trials, enrolling a total of 10,244 participants (Ali 
et al., 2013). A total of 44 different outcome measures are included, 
encompassing both impairment and activities/ participation levels of the ICF 
(Ali et al., 2013). Unfortunately, the promise of this resource has yet to be 
realised. Differences in characteristics of the samples from which these 
measures were recorded confounds any meta-analysis of these data (Ali et 
al., 2013). If, however, it could be established that the outcome measures 
contained within VISTA-Rehab display invariance, then exploratory analyses 
and statistical modelling using pooled data from the VISTA-Rehab bank could 
proceed with confidence. Furthermore, if the outcome measures contained 
within VISTA-Rehab could be proven to provide interval-level measurement, 
then the result would be a large bank of scales for which the magnitude of 
change can be measured quantitatively. This would be an enormously 
powerful resource for the design of future rehabilitation trials, since the 
appropriate measure could be selected from a battery of scales with known 
psychometric properties and proven validity. The ability to provide interval-
level measurement would also allow more accurate power calculations to be 
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made, since the number of patients enrolled could be tailored to the magnitude 
of true change anticipated to result from an intervention. This may ultimately 
reduce the cost of clinical trials: either by preventing the wastage of resources 
on under-powered trials that are likely to return inconclusive results, or in 
some cases by allowing the reduction of sample sizes (thereby minimising the 
time and costs of recruitment). The systematic application of Rasch methods 
to scales in the VISTA-Rehab bank and the DARS data-set therefore offers a 
means to establish whether the most commonly used stroke outcome 
measures fulfil the key tenets of measurement. This work could be completed 
using existing data; yet its possible impact is substantial. 
Part 4.5 Concluding remarks 
4.5.1. Potential future uses of outputs from this Thesis 
4.5.1.1. Reflections on a complex trial 
At the time of its inception DARS was the largest-ever multi-centre 
randomised controlled trial of a pharmacological intervention to enhance 
physical recovery after stroke. Delivery of the DARS intervention (a single 
dose of co-careldopa 45min to 1hour before the start of each therapy session) 
seems straightforward when set down as a short paragraph in the trial 
protocol. As Bipin Bhakta himself, ever the optimist, might have said: “How 
hard can it be?”. 
In reality, ensuring the reliable delivery of this ostensibly-simple intervention 
turned out to be a major challenge for the trials team. There is no absolute 
definition of what constitutes a “complex” intervention, but the Medical 
Research Council have suggested that the characteristics of a such an 
intervention include: a large number of interacting components within the 
experimental and control groups; the number and difficulty of behaviours 
required by those delivering or receiving the intervention; and the degree of 
tailoring or flexibility of the intervention permitted (Craig et al., 2008). In the 
case of DARS, ensuring that the medication was delivered in accordance with 
the trial protocol required an unprecedented degree of liaison and interaction 
between ward nurses and therapy teams (for in-patients), or between 
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community therapy teams and patients or carers (for those discharged from 
hospital before their course of treatment was completed).  
This required an unprecedented level of training in trial procedures for hospital 
and community staff who would be involved in delivering the intervention. This 
was conducted by me and the DARS trial monitor, Lorna Barnard, at a series 
of face-to-face site initiation visits. The provision of face-to-face training in trial 
procedures was felt to be the only way to ensure that staff were trained in trial 
procedures to the standard required for them to deliver the intervention per 
protocol requirements. This was, however, a costly and time-consuming 
exercise that was only compounded by the number of centres that ultimately 
collaborated with DARS. 
It was initially intended that the trial would be conducted across a small 
number of centres within the Yorkshire area. However, when feasibility 
assessments were requested from potential recruiting centres in the early 
stages of trial setup, it became apparent that anticipated per-centre monthly 
recruitment was lower than expected. This led to an initial expansion in the 
number of centres to 20. Once the trial opened to recruitment, even the 
modest estimates of 1-2 patients recruited per centre each month were found 
to be optimistic. This necessitated a further expansion to a final total of over 
50 centres. Ultimately, the initial recruitment target was met and exceeded; 
but maintaining currency in trial procedures for staff at centres that rarely 
recruited patients was a significant challenge. This was compounded by the 
tendency of junior therapists to rotate to different posts every 4-6months. 
DARS was an ambitious trial, which overcame a number of significant 
challenges to deliver a robust answer to an important clinical question. In this 
respect, it stands not only as a lasting tribute to Bipin, but also as a benchmark 
for other complex rehabilitation trials. Although the process of setting up and 
running the DARS trial has not been discussed in detail previously in this 
Thesis, it is clear that a reflective paper setting out the challenges that were 
faced by DARS and how they were overcome has much to offer the design of 
future complex rehabilitation trials.  
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4.5.1.2. Incorporating analysis of imaging in to a trial  
It is not unusual for randomised controlled trials to include an analysis of 
imaging. This might be as a direct inclusion/exclusion criterion (as for trials of  
thrombolysis in stroke), or as an outcome measure in itself (for example 
measuring tumour regression in cancer chemotherapy trials). In DARS, the 
incorporation of an analysis of brain imaging in to the protocol stemmed 
initially from a desire to explore the mechanism by which co-careldopa might 
influence recovery. Although centres of excellence in brain imaging research 
do exist, there is surprisingly little published literature to guide non-radiologists 
looking to include imaging analysis in a trial. When designing the DARS 
protocol, several important radiological considerations were therefore 
overlooked. For example, the cost of centrally collating imaging and 
subsequent expert review by experienced neuroradiologists was not 
incorporated in to the original grant application. Due to the limited funding 
available, reporting was performed by a single expert plus JP, not by a panel 
of experts. Information that might have been useful to the radiologists when 
interpreting scans (for example, the laterality of stroke symptoms) was not 
collected, as trial paperwork and procedures had been largely finalised by the 
time the need to do so was identified. Nor were quality control procedures for 
ensuring that the correct scans were sent to CTRU as robust as they ought to 
have been. A paper laying out the basic considerations when including 
imaging analysis in a grant proposal would be useful in the design of future 
trials.  
4.5.1.3. Rasch analysis of outcome measures from the DARS data-set 
This Thesis sought to develop a series of models to predict walking ability at 
up to six months after stroke. However, any such models must be founded 
upon the rock of robust outcome measurement, rather than the shifting sands 
of ordinal scales. An enormous variety of outcome measures are currently 
used in stroke medicine, few of which have been validated using modern 
psychometric techniques. The manner in which these measures are then 
analysed and interpreted, for example in the derivation of mean scores or in 
quoting changes in scores over time, is questionable. This situation is an 
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impediment to the design, interpretation, and meta-analysis of high quality 
rehabilitation trials. 
There is a need in stroke research and in clinical practice for robust outcome 
measures that fulfil the key tenets of measurement: interval-level 
measurement, unidimensionality, and invariance. The use of scales that are 
proven to be interval-level would allow more efficient linear regression models 
to be fitted: and their output could legitimately be expressed as the change in 
the value of an outcome variable for each unit change in a predictor variable. 
Interval-level outcome measurement will also allow more reliable estimation 
of effect sizes: when fitting predictor variables statistical models, and when 
measuring the impact of rehabilitation interventions in clinical practice.  
The DARS trial acquired outcome measures covering a variety of impairments 
and activity limitations at four time points (baseline, eight weeks, six months, 
and one year after stroke). The systematic application of rigorous 
psychometric techniques such as Rasch analysis to such a rich data-set would 
allow a series of outcome measures to be made available that are proven to 
fulfil the key tenets of measurement.   
4.5.2. The implications of this Thesis for clinical practice and 
research 
4.5.2.1. Implications for clinical practice 
Although brain imaging findings may have a role in predicting broad outcomes 
such as death or dependency following stroke, the models presented above 
cast doubt upon the ability of CT imaging to predict more specific rehabilitation 
outcomes such as ability to walk independently; at least as far as ischaemic 
stroke is concerned (models 1 and 2). The models presented for ICH (models 
3 and 4) are derived in a smaller sample, with commensurately wide 
confidence intervals for some imaging variables. By contrast models 5 and 6, 
based on clinical impairment assessed within the first few weeks after stroke, 
correctly classified up to 70.3% at T1 and 69.0% of patients at T2. This implies 
that, in clinical practice, a reasonably accurate estimation of prognosis may 
be made based on initial clinical impairment alone. Although plain CT imaging 
remains crucial in guiding the acute management of stroke patients, it cannot 
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at present be deemed useful for rehabilitation prognostication. This finding is 
of potential significance in low-resource settings, in which brain imaging might 
not be readily available. 
Advanced imaging techniques such as fMRI have been used to explore the 
interactions that take place between brain structures during the learning 
process. However so-called “functional” imaging actually detects an increase 
in blood oxygen diffusion in to tissues, a finding that is purported to correlate 
with an increase in neuronal metabolic activity. The actual “function” of those 
brain areas and how they actually interact to shape learning remains a matter 
for inference and speculation. Nor is it necessarily legitimate to assume that 
learning processes in a healthy volunteer under experimental conditions are 
analogous to those of a stroke patient participating in a rehabilitation 
programme. Functional imaging therefore remains at present primarily a 
research tool with little role in routine rehabilitation practice.   
The models presented here would certainly require validation in an 
independent sample prior to clinical use. However, models that are to be used 
in clinical practice must also be easy to apply, and deliver an output that is 
readily interpretable by staff. Although binary logistic regression modelling 
gives some indication of the relative importance of each predictor variable (as 
measured by the percentage of variance that each predictor explains and the 
change in odds of the outcome of interest for each one-point change in a 
predictor variable), the output that they deliver is neither intuitive for a clinician 
nor easily applicable to an individual patient. A “decision tree”, in which each 
node is a binary choice and the output is the odds of walking independently at 
T1 and T2, might allow outcome predictions to be made in a more readily 
interpretable manner. 
4.5.2.2. Implications for research 
Perhaps the greatest potential of the models presented here is in rehabilitation 
research. A model that is able to correctly classify around 70% of patients as 
able or unable to walk at T1 and T2 with a sensitivity of 55.8-72.0% at T1 and 
62.8-88.9% at T2 might allow patients recruited in to future rehabilitation 
research trials to be assigned different end-points at the time of 
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randomisation, based on their prior probability of walking again. There are 
several advantages to such an approach. Firstly, the sample size required to 
detect a treatment effect could be reduced, thereby reducing the cost of 
setting up and running trials. Secondly, accounting for differences in 
anticipated prognosis would allow researchers to assign outcome measures 
that are of practical importance to patients. For example, a patient who is 
unlikely to return to walking might consider achieving independent sitting 
balance to be an important goal, whereas for those patients who are expected 
to be able to walk 10m or more an outcome centred around higher levels of 
mobility (such as walking outdoors, climbing stairs, or running) might be pre-
specified. Ultimately such an approach would allow trials to adopt a range of 
outcome measures that are of direct relevance to pre-specified sub-groups of 
patients. This approach may also allow detection of more subtle treatment 
effects than would be apparent if results are analysed based on a single 
dichotomous outcome. 
A further implication of this Thesis is that it calls in to question how useful brain 
imaging is in predicting rehabilitation potential. Although models incorporating 
imaging variables are of value in predicting mortality or broad categories such 
as “independent”/”dead or dependent”, the findings of routinely-acquired CT 
imaging appear to add nothing beyond an assessment of clinical impairment 
when predicting more nuanced rehabilitation outcomes such as walking 
ability. Is it reasonable to continue to fund studies aiming to predict 
rehabilitation outcomes using imaging variables, when clinical impairment 
alone appears to be a more reliable predictor of rehabilitation potential? 
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List of abbreviations 
ACA Anterior cerebral artery territory 
Act FAST Facial drooping, Arm weakness, Speech slurred - time to call 999 
(public health campaign) 
AF Atrial Fibrillation 
AISCT Acute ischaemic stroke classification template 
ASPECTS Alberta Stroke Program Early CT Score 
BI Barthel Index 
BOLD Blood oxygen level dependent signal 
BRIC University of Edinburgh Brain Research Imaging Centre 
CD Compact Disc 
CE-CT Contrast-enhanced computerised tomography scanning 
CLRN Comprehensive local research network 
C-RMI Clinician-completed Rivermead Mobility Index 
CT Computerised tomography scanning 
CTRU The Clinical Trials Research Unit, University of Leeds 
DALY Disability-Adjusted Life Year 
DARS Dopamine Augmented Rehabilitation in Stroke (clinical trial) 
DICOM Digital Imaging and Communication in Medicine 
DMEC Data monitoring and ethics committee 
DTI Diffusion tensor imaging 
DWI Diffusion-weighted imaging 
FAS Fatigue assessment scale 
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fMRI Functional Magnetic Resonance Imaging 
GCS Glasgow Coma Scale 
GHQ General Health Questionnaire 
GHQ-12 Twelve-item version of the General Health Questionnaire 
GOS Glasgow Outcome Scale 
HWS "Haemorrhage with scan available" (analysis sub-group) 
ICF The World Health Organisation International Classification of 
Functioning, Disability, and Health 
ICH Intracerebral haemorrhage (here used specifically in reference to 
primary haemorrhage, not traumatic haemorrhage) 
ISRCTN International standard randomised controlled trial number database 
IWS "Primary infarction, with scan available" (analysis sub-group) 
JMP Dr Jeremy Macmullen-Price, consultant neuroradiologist, Leeds 
Teaching Hospitals NHS Trust 
JP Dr John Pearn, Clinical Research Fellow to the DARS trial 
LACS Lacunar stroke syndrome 
LTHT Leeds Teaching Hospitals NHS Trust 
MCA Middle cerebral artery 
MMSE Mini mental-state examination 
MoCA Montreal cognitive assessment 
MRI Magnetic resonance imaging 
M-RMI Modified version of the Rivermead Mobility Index 
mRS Modified Rankin scale 
MSK-SSP Musculoskeletal signs, symptoms, and pain manikin 
NEADL Nottingham extended activities of daily living scale 
271 
 
NHS National Health Service (United Kingdom) 
NIHSS National Institute of Health Stroke Scale, 
NOAC Non-vitamin K oral anticoagulants 
OCSP Oxford Community Stroke Project clinical classification of stroke 
syndromes 
PACS Partial anterior circulation stroke syndrome 
pBI Postal version of the Barthel Index 
PCA Posterior cerebral artery 
PI Principle Investigator 
POCS Posterior circulation stroke syndrome 
PSF Post-stroke fatigue 
RMA Rivermead Motor Assessment 
RMI Rivermead Mobility Index 
RS Rankin scale (original version) 
SBP Systolic blood pressure 
SR-RMI Patient self-reported Rivermead Mobility Index 
STICH Surgical Trial in Intracerebral Haemorrhage (clinical trial) 
TACS Total anterior circulation stroke syndrome 
TP Dr Tufail Patankar, consultant interventional neuroradiologist, Leeds 
Teaching Hospitals NHS Trust 
TSC Trial steering committee 
UK United Kingdom 
USB Universal Serial Bus 
VAS Visual Analogue Scale 
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VBM Voxel-based morphometry 
VCI Vascular cognitive impairment 
VIF Variance Inflation Factor 
VISTA Virtual International Stroke Trials Archive 
VISTA-Rehab Stroke rehabilitation trials sub-section of the Virtual International 
Stroke Trials Archive, 
WHO World Health Organisation 
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Appendix A. Table summarising prognostic models for 
predicting outcome following ICH 
Table A.1. Summary of prognostic models for predicting outcome following 
ICH. 
Author Type of ICH Outcome 
predicted 
Predictors included in 
multivariate model 
Results 
Hemphill et 
al. (2001) 
Supratentorial 
and 
infratentorial 
haemorrhage 
30-day 
mortality 
ICH Score: GCS (score 
3-4, 5-12, 13-15); age 
(<80, ≥80); haematoma 
volume (<30ml, ≥30ml); 
intraventricular 
haemorrhage (yes/no) 
30-day mortality was 13% 
for score of 1; 26% for 
score of 2; 72% for score of 
3; 97% or score of 4 
p<0.0005 for trend). No 
patients with a score of 0 
died. No patient attained 
the maximum score of 6. 
Cho et al. 
(2008) 
Basal ganglia 
haemorrhage 
Six-month 
mortality, 
and Glasgow 
Outcome 
Scale and 
Barthel Index 
at one year 
Modified ICH Score 
(MICH): GCS (score 13-
15, 5-12, 3-4); 
haematoma volume 
(≤20ml, 21-50ml, 
≥50ml); presence of 
intraventricular 
haemorrhage or 
hydrocephalus (yes/no) 
For prediction of good 
functional outcome: score 
≥2.  
At score of 0-1, conservative 
management achieved a 
better functional outcome 
than surgical intervention. 
Score 3-4: six-month 
mortality was higher for 
conservative treatment 
than surgical management. 
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Lisk et al. 
(1994) 
Hemispheric 
haemorrhage 
Model 1: 
good 
outcome 
(mRS 0-2) 
Model 2: 
poor 
outcome 
(mRS 5 and 
death) 
Model 1: age; 
haemorrhage 
diameter; presence of 
intraventricular 
haemorrhage 
Model 2: GCS; age; 
gender; haemorrhage 
volume  
Both models generated 
a predicted probability 
of achieving the 
specified outcome. 
Model 1: predicted 
probability of ≥0.32 results 
in a sensitivity of 100% and 
specificity of 91% for good 
outcome. 
Model 2: predicted 
probability of >0.60 results 
in a sensitivity of 62.1% 
and specificity of 95% for 
poor outcome. 
Ruiz-
Sandoval et 
al. (2007) 
Supratentorial 
and 
infratentorial 
haemorrhage 
Glasgow 
Outcome 
Scale at 30 
days. 
In-hospital 
and 30-day 
mortality 
ICH Grading Scale (ICH-
GS): Age (<45, 45-64, 
≥65); GCS on admission 
(13-15, 9-12, 3-8); ICH 
location (supratentorial 
or infratentorial); 
haematoma volume 
(for supratentorial ICH: 
<40ml, 40-70ml, 
>70ml); for 
infratentorial ICH: 
<10ml, 10-20ml, 
>20ml); intraventricular 
extension (yes/no). 
Model explained 44.2% of 
variance in in-hospital 
mortality, 43.8% of 
variance in 30-day 
mortality, and 33.2% of 
variance in functional 
outcome.  
Sensitivity for in-hospital 
mortality 78.2%, and 30-
day mortality 78.5%. 
Tuhrim et 
al. (1991) 
Supratentorial 
haemorrhage 
30-day 
survival. 
Barthel 
Index, 
Activities of 
Daily Living 
Score 
Pulse pressure (≤40, 
41-65, ≥65); GCS (≤8, 
≥9); volume of 
haematoma (<27cc, 27-
72cc, >72cc); 
intraventricular 
extension (yes/no) 
Model correctly classified 
94% of patients as dead or 
alive at 30 days, and 95% 
of patients as having a 
good or poor outcome. 
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Cheung and 
Zou (2003) 
Supratentorial 
and 
infratentorial 
haemorrhage 
30-day 
mortality. 
30-day 
Modified 
Rankin Scale 
score 
Model 1 (30-day 
mortality): NIHSS score; 
pulse pressure; 
subarachnoid 
extension; 
intraventricular 
extension. 
Model 2 (favourable 
outcome): low 
admission 
temperature; low 
NIHSS   
For 30-day morality: 
sensitivity of model 91.3%, 
specificity 72.7%. Positive 
predictive value 50.0%, 
negative predictive value 
96.6% 
For favourable outcome: 
sensitivity 70.0%, 
specificity 91.7%, positive 
predictive value 84.8%, 
negative predictive value 
82.1%. 
Godoy et al. 
(2006 
Supratentorial 
and 
infratentorial 
haemorrhage 
30-day 
mortality. 6-
month 
Glasgow 
Outcome 
Scale score. 
Two modified ICH 
(mICH) scores were 
created: 
Version A: GCS (13-15, 
5-12, 3-4); ICH volume 
(≥30cc, <30cc); 
intraventricular 
haemorrhage (yes/ 
no); Graeb’s score (1-
4, 5-8, ≥9); 
infratentorial origin 
(yes/ no); age (<80, 
≥80). 
Version B: as above, 
but excluding 
“infratentorial origin” 
item. 
Version A: cutoff score of 4 
best predicted mortality 
(sensitivity 0.79, specificity 
0.80, positive predictive 
value 0.68, negative 
predictive value 0.88). 
Score of 3 best predicted a 
good outcome (sensitivity 
0.85, specificity 0.73, 
positive predictive value 
0.62, negative predictive 
value 0.9). 
Version B: cut-off score of 
3 was optimum for 
predicting both mortality 
(sensitivity 0.85, specificity 
0.73, positive predictive 
value 0.62, negative 
predictive value 0.90) and 
good outcome (sensitivity 
0.70, specificity 0.90, 
positive predictive value 
0.92, negative predictive 
value 0.66). 
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Berwaerts 
et al. (2000) 
Any ICH 
related to use 
of oral 
anticoagulants 
(included post-
traumatic ICH) 
In-hospital 
mortality; 
functional 
recovery by 
time of 
discharge 
(none, 
partial, full). 
Model 1: predicts in-
hospital mortality. 
Variables included: 
type of haemorrhage 
(presumably refers to 
supratentorial/ 
infratentorial location, 
but the authors do not 
specify what is meant 
by this); admission 
within 12 hours of 
onset of symptoms; 
and GCS score <14. 
Model 2 (radiological 
predictors of in-
hospital mortality). 
Variables included: 
diameter of ICH 
(continuous variable); 
presence of ischaemic 
change (yes/ no). 
Model 3 (in-hospital 
mortality): presence of 
ischaemia on CT; 
intraventricular 
haemorrhage; 
displacement of 
midline; location in 
posterior fossa; 
haemorrhage diameter 
(10mm, ≤30mm, 30-
50mm, >50mm). 
GCS score alone predicted 
in-hospital mortality with 
sensitivity of 46% and 
specificity of 83%. 
Model 1: sensitivity of 
74%, specificity of 100% 
for prediction of in-
hospital mortality. 
Model 2: predicted in-
hospital mortality with a 
sensitivity of 73%, 
specificity of 89%, positive 
predictive value of 80%, 
negative predictive value 
of 85%. The sign for the 
categorical predictor 
“presence of ischaemic 
change” was negative, 
suggesting that in this 
sample the presence of 
ischaemic change 
protective against 
mortality. 
Values of sensitivity/ 
specificity were not 
presented for model 3. 
Odds ratios (with 95% CI) 
were: ischaemia on scan 
OR 0.053 (0.003-0.979); 
intraventricular blood OR 
10.21 (0.49-211.81); 
displacement of midline 
OR 2.89 (0.04-212.98); 
location in posterior fossa 
OR 1.71 (0.06-45.39); 
haemorrhage diameter OR 
93 (OR 0.70-5.33). 
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Fogelholm 
et al. (1997) 
First-ever 
supratentorial 
ICH 
28-day 
survival 
Level of consciousness 
(alert, somnolent/ 
disorientated, 
unconscious/ 
comatose); mean 
arterial pressure on 
first day (continuous 
variable); spread of 
haemorrhage in to the 
subarachnoid space 
(yes/no); shift of 
midline structures 
(yes/no); blood glucose 
level on admission 
(continuous variable); 
vomiting on admission 
(yes/no). 
Model predicted 28-day 
survival with a sensitivity 
of 78%, specificity of 90%, 
positive predictive value of 
80%, and a negative 
predictive value of 85%. 
Hallevy et 
al. (2002) 
Spontaneous 
supratentorial 
ICH 
mRS at 
discharge 
(cut-off score 
of ≤3 for 
good 
outcome and 
≥4 for poor 
outcome). 
Age (<60, ≥61); severity 
of hemiparesis (none-
moderate [Medical 
Research Council grade 
3-5/5]; severe [grade 0-
2/5]); level of 
consciousness (alert 
versus drowsy or 
comatose); presence of 
mass effect (yes/ no); 
size of 
haematoma(small 
versus medium or large 
according to radiology 
opinion); presence of 
intraventricular 
extension (yes/ no). 
Percentages of patients 
achieving good outcome: 
82% for score of 0-1; 53.7% 
for a score of 2; 23.3% for 
a score of 3; 0% for a score 
of 4-6. 
Mase et al. 
(1995 
Primary ICH 30-day 
mortality 
Intraventricular 
extension of 
haemorrhage (yes/no); 
haematoma “size” 
(used in this context to 
refer to volume, not 
Model correctly identified 
93% of patients who 
survived and 88% of 
patients who died. 
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maximal dimension: 
<8.3cc, 8.3-20.4cc, 
20.5-47.7cc, >47.7cc); 
GCS score 
Nilsson et 
al. (2002) 
Primary ICH 30-day and 
one-year 
mortality 
Model 1 (30-day 
mortality): level of 
consciousness on 
admission (alert, [GCS 
14-15] drowsy [GCS 8-
13], comatose (GCS 3-
7]); haematoma 
volume (<30cc; 30-
60cc; >60cc); history of 
heart disease prior to 
ICH (yes/no). 
Model 2 (one-year 
mortality): level of 
consciousness on 
admission (alert, [GCS 
14-15] drowsy [GCS 8-
13], comatose (GCS 3-
7]); age (0-54; 55-74; 
≥75); haematoma 
location (lobar, central, 
cerebellar, brainstem). 
Patients who were drowsy 
on admission had a 5.2-
fold increase in the odds of 
death at 30days compared 
with those who were alert 
(95% CI 2.3-11.6). Those 
who were unconscious had 
a 42-fold increase in the 
odds of death at 30days 
(95% CI 15.6-113.3). 
Haematoma volume of 
>60cc conferred a 3.2-fold 
increase in the odds of 30-
day mortality compared 
with haematomas of 
<30ml (95% CI 1.5-9).  
At one year, patients who 
were drowsy on admission 
had a 3.6-fold increase in 
the hazard of death 
compared with those who 
were alert (95% CI 2.1-6.1). 
Those who were 
unconscious had a 15.2-
fold increase in the hazard 
of death at 30days (95% CI 
8.8-26.3). Age of ≥75 
conferred a 3.3-fold 
increase in the hazard of 
death compared with 
those in the 0-54 age 
group (95% CI 1.6-6.9). 
Passero et 
al. (2002) 
Primary 
intraventricular 
haemorrhage 
In-hospital 
mortality 
GCS (≤8, >8); early 
hydrocephalus 
(yes/no). 
Odds of death were 4.67-
fold greater for patients 
with GCS ≤8 compared 
with those with GCS >8 
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(95% CI 1.22-17.92). Odds 
of death were increased 
4.93-fold for those with 
hydrocephalus versus 
those without (95% CI 
1.13-21.59) 
Phan et al. 
(2000) 
Deep ICH. 
Divided in to: 
caudate/ 
thalamic ICH 
(“medial” 
group) and 
putaminal ICH 
(“lateral” 
group) 
30-day 
mortality 
mRS (good 
outcome <2; 
moderate to 
poor 
outcome 2-4; 
dependency 
5; death 6) 
Model 1 (30-day 
mortality for both 
medial groups): GCS 
(≤8, >8); presence of 
hydrocephalus on 
visual inspection 
(yes/no). 
Model 2 (30-day 
mortality in medial 
group): only GCS (≤8, 
>8) was a significant 
predictor variable. 
Model 3 (30-day 
mortality in lateral 
group): GCS (≤8, >8); 
presence of 
hydrocephalus on 
visual inspection 
(yes/no). 
Model 1: sensitivity of 55% 
and specificity of 90%. 
Positive predictive value 
70%, negative predictive 
value 83%. 
Model 2: sensitivity and 
specificity not quoted. 
Patients with GCS≤8 had 
16.5-fold increase in the 
odds of 30-day mortality 
compared with patients 
with GCS>8 (95% CI 3.7-
73.4). 
Model 3: sensitivity of 57% 
and specificity of 91%. 
Positive predictive value 
73%, negative predictive 
value 84%. 
Portenoy et 
al. (1987) 
Spontaneous 
supratentorial 
ICH 
Good 
outcome (no 
deficit to 
moderately 
dependent) 
versus poor 
outcome 
(severely 
dependent, 
persistent 
vegetative 
state, or 
death). 
Model for prediction of 
good (versus poor) 
outcome: GCS; size of 
haematoma (a 
calculated index value 
based on maximal 
haematoma 
dimensions. 
Categorised as: 4-19; 
20-28; 29-44; 45-81); 
intraventricular 
extension (yes/no). 
Model correctly identified 
87% of patients with good 
outcomes and 88% of 
patients with poor 
outcomes. 
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Qureshi et 
al. (1995) 
Spontaneous 
ICH 
Deterioration 
from an 
initial GCS of 
>12 by ≥4 
points within 
the first 24 
hours of 
admission; 
in-hospital 
mortality. 
Model 1 (prediction of 
early deterioration): 
presence of 
intraventricular 
extension (yes/no); ICH 
volume (<30cc, ≥30cc). 
Model 2 (prediction of 
mortality): presence of 
intraventricular 
extension (yes/no); ICH 
volume (<30cc, ≥30cc); 
initial GCS (≤12, >12). 
Model 1: odds ratio for 
early deterioration with 
(versus without) 
ventricular extension was 
4.67 (95% CI 1.30-16.72). 
Odds ratio early 
deterioration with ICH 
volume ≥30cc (vesus 
<30cc) 6.78 (95% CI 1.89-
24.35). 
Model 2: odds ratio for 
death with (versus 
without) intraventricular 
extension 4.23 (95% CI 
1.82-9.82); odds ratio for 
mortality with ICH volume 
≥30cc (vesus <30cc) 6.66 
(95% CI 2.85-15.58); odds 
ratio for mortality with 
initial GCS ≤12 (versus >12) 
3.23 (95% CI 1.46-7.14) 
Razzaq and 
Hussain 
(1998) 
Spontaneous 
ICH 
30-day 
mortality 
Model 1 (clinical 
predictors): GCS score 
(≥12, 9-11, ≤8); paresis 
(yes/no); 7th nerve 
palsy (yes/no). 
Model 2 (CT 
predictors): ventricular 
enlargement (yes/no); 
haematoma size 
(<3cm, >3cm); 
intraventricular 
extension of 
haemorrhage (yes/no). 
Model 3 (combined 
clinical and CT 
predictors): GCS score 
(≥12, 9-11, ≤8); history 
of hypertension 
Model 1: patients with GCS 
≤8 had 7.6-fold increase in 
the odds of dying 
compared with patients 
with GCS ≥12. 
Model 2: patients with 
intraventricular extension 
of the haemorrhage had a 
3.5-fold increase in the 
odds of death compared 
with those without. Those 
with ventricular 
enlargement had a 2.6-fold 
increase in the odds of 
death compared with 
those without. 
Model 3: patients with GCS 
≤8 had 11-fold increase in 
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(yes/no); pulse 
pressure (continuous); 
haematoma size (<3cm, 
>3cm); intraventricular 
extension of 
haemorrhage (yes/no). 
the odds of death 
compared with patients 
with GCS ≥12. Patients 
with hypertension had a 3-
fold increase in the odds of 
death compared with 
those without. Each unit 
increase in pulse pressure 
conferred a 1.3-fold 
increase in the odds of 
death. Those with a 
haematoma size of >3cm 
had a 2.9-fold increase in 
the odds of death 
compared with those with 
a haematoma of <3cm. 
Patients with 
intraventricular extension 
of the haemorrhage had a 
2.9-fold increase in the 
odds of death compared 
with those without. 
Schwarz et 
al. (2000) 
Spontaneous 
supratentorial 
ICH 
Glasgow 
Outcome 
Scale at 72 
hours. Poor 
outcome 1-2; 
moderate or 
favourable 
outcome 3-5 
Model for prediction of 
poof outcome: 
ventricular 
haemorrhage (yes/no); 
haematoma 
enlargement or 
secondary 
haemorrhage (yes/no); 
initial GCS (14-15; 8-13; 
3-7); haematoma 
volume (<25ml; 25-
60ml; >60ml); duration 
of elevation in blood 
pressure (<24hrs; 24-
48hrs; >48hrs); 
duration of elevated 
blood glucose levels 
>11mmol/l (never; 
<24hrs; >24hrs); 
duration of 
Presence of ventricular 
haemorrhage conferred a 
five-fold increase in the 
odds of a poor outcome. 
Haematoma expansion 
increased the odds of a 
poor outcome seven-fold. 
An initial GCS of 3-7 
increased the odds of an 
unfavourable outcome by 
a factor of 18.34 compared 
with an initial GCS of 14-
15. A haematoma volume 
of 25-60ml increased the 
odds of an unfavourable 
outcome by a factor of 
1.75 compared with a 
volume of <25ml; 
haematoma volumes of 
>60ml conferred a 13.9-
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temperature >37.5C 
(<24hrs; 24-48hrs; 
>48hrs). 
fold increase in the odds of 
an unfavourable outcome. 
Elevation in blood pressure 
for >48hrs conferred an 
8.42-fold increase in the 
risk of an unfavourable 
outcome compared to a 
rise in blood pressure of 
<24hrs duration. Elevated 
blood glucose levels for 
>48hrs increased the odds 
of an unfavourable 
outcome by a factor of 
13.53 compared with 
those who had never had 
high blood glucose levels. 
A body temperature of 
>37.5C for >48hrs 
conferred a 13.52-fold 
increase in the odds of an 
unfavourable outcome 
when compared with 
those who had an elevated 
body temperature for 
<24hrs.   
Shaya et al. 
(2005) 
Non-traumatic 
first-time ICH. 
Glasgow 
Outcome 
Scale at 6 
months 
Haematoma volume 
(<20ml 1 point; 20-
50ml 2 points; >50ml 3 
points); hydrocephalus 
(1 point if present); 
focal neurological 
deficit (1 point if 
present) 
Score derived from model 
was used to predict six-
month GOS (no detail 
provided on how this was 
accomplished). Spearman 
correlation coefficient 
between observed and 
predicted values was 0.76 
(p=0.0001). 
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Appendix B. The AISCT template for coding ischaemic stroke 
lesions 
The Acute Ischaemic Stroke Classification Template (AISCT) was developed 
by Professor Wardlaw et al, of the University of Edinburgh Brain Research 
Imaging Centre (BRIC), Neuroimaging Sciences, Edinburgh 
(www.bric.ed.ac.uk) (Wardlaw and Sellar, 1994). The BRIC is part of the 
SINAPSE (Scottish Imaging Network–A Platform for Scientific Excellence) 
collaboration (www.sinapse.ac.uk) funded by the Scottish Funding Council 
and the Chief Scientist Office. The AISCT is available to download from: 
http://www.bric.ed.ac.uk/research/imageanalysis.html#ais 
The AISCT was used in DARS with the permission of Professor Wardlaw 
(private communication with author). 
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B.1. AISCT template for coding acute ischaemic change in 
the MCA territory  
The AISCT classifies acute ischaemic change within the MCA territory using 
the eight template diagrams shown below (© Professor J.M. Wardlaw, 
University of Edinburgh, Brain Research Imaging Centre; reproduced here 
with permission). 
 
Table B.1. Key for template images coding ischaemic change in the MCA 
territory  
Template Finding represented 
1 Small cortical infarct 
2 Basal ganglia infarct (>2×2×2cm) 
3 Infarct of the white matter lateral to the ventricle (>2×2×2cm) 
4 Infarct of anterior half of the peripheral MCA territory 
5 Infarct of the posterior half of the peripheral MCA territory 
6 Infarct of whole of peripheral MCA territory 
7 Infarct of posterior half of MCA territory plus lateral part of basal ganglia 
8 Infarct of whole MCA territory 
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B.2. AISCT template for lacunar lesions and border zone 
ischaemia  
The AISCT classifies lacunar lesions and border-zone ischaemia using the 
template diagrams shown below (© Professor J.M. Wardlaw, University of 
Edinburgh, Brain Research Imaging Centre; reproduced here with 
permission). 
 
Table B.2. Key for template images coding lacunar lesions and border-zone 
ischaemic change 
Template Finding represented 
9 Lacune in internal capsule/ lentiform nucleus 
10 Lacune in internal border zone 
11 Lacune in centrum semiovale 
12 Lacune in thalamus 
13 Lacune in brainstem, including pons (not shown) 
14 Anterior border zone infarction 
15 Posterior border zone infarction 
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B.3. AISCT template for tissue swelling  
The AISCT classifies the extent of tissue swelling in acute ischaemic stroke 
using the template diagrams shown below (© Professor J.M. Wardlaw, 
University of Edinburgh, Brain Research Imaging Centre; reproduced here 
with permission). 
 
Table B.3. Key for template images coding extent of tissue swelling in acute 
ischaemic stroke 
Template Finding represented 
0 No swelling 
1 Effacement of sulci overlying the infarct 
2 1+minor effacement of adjacent lateral ventricle 
3 1+complete effacement of lateral ventricle 
4 1+effacement of lateral and third ventricle 
5 4+shift of midline away from the side of the ventricle 
6 5+effacement of basal cisterns (not shown) 
287 
 
Appendix C. Summary of standardised outcome measures 
used in the DARS trial 
A range of measures were used in the DARS trial, to capture not only the 
primary outcome (mobility) but also other functional outcomes (such as upper 
limb function and independence in activities of daily living), general disability, 
and other variables that could modify a patient’s response to rehabilitation 
(such as musculoskeletal pain, fatigue, and depression). These outcome 
measures are summarised below in Table C.1. 
Abbreviations used in this table: 
PO:  Primary Outcome 
EM:  Effect modifier 
SO:  Secondary outcome 
A/P:  Activities/participation 
I:  Impairment 
SR:  Patient self-report 
CR:  Clinician report 
RI:  Researcher interview 
Y: Yes 
N: No 
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Table C.1. Standardised outcome measures used in the DARS trial. 
Outcome measure Analysis Construct ICF 
domain 
Method T0 T1 T2 T3 
Rivermead Mobility 
Index (RMI) (Collen 
et al., 1991) 
PO Mobility A/P SR, CR Y Y Y Y 
General Health 
Questionnaire, 12-
item version (GHQ-
12) (Goldberg and 
Hillier, 1979) 
EM Psychological 
morbidity 
I SR Y Y Y Y 
Musculoskeletal 
signs/ symptoms 
and pain manikin 
(MSK-SSP) 
(Keenan et al., 
2006) 
EM Musculoskeletal 
pain 
I SR Y Y Y Y 
Fatigue 
Assessment Scale 
(FAS) (Michielsen 
et al., 2003) 
EM Fatigue I SR N Y Y Y 
Montreal Cognitive 
Assessment 
(MoCA) 
(Nasreddine et al., 
2005) 
EM Cognitive 
function 
I RI Y Y Y Y 
Postal version of 
the Barthel Index 
(Gompertz et al., 
1994) 
SO Independence in 
activities of daily 
living 
A/P SR Y Y Y Y 
Nottingham 
Extended Activities 
of Daily Living Scale 
(NEADL) (Nouri and 
Lincoln, 1987) 
SO Independence in 
activities of daily 
living 
A/P SR Y Y Y Y 
ABILHAND scale 
(Penta et al., 1998) 
SO Hand function A/P SR Y Y Y Y 
EuroQol EQ-5D 
(Rabin and de 
Charro, 2001) 
SO Health-related 
quality of life 
A/P SR Y Y Y Y 
Modified Rankin 
Scale (mRS) 
(Bonita and 
Beaglehole, 1988) 
SO Global disability A/P RI N Y Y N 
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Appendix D. The Rivermead Mobility Index 
The RMI (Collen et al., 1991), reproduced in full below, was both an inclusion/ 
exclusion criterion and the key outcome measure for DARS. The RMI was 
used here as both a professionally-completed (C-RMI) and as a patient self-
report (SR-RMI) measure. Both were identical in every respect, other than the 
manner in which they were completed.   
At the time of enrolment, all patients had a C-RMI score of ≤6, and had 
answered “no” to question 7 (highlighted below in red). When used as an 
outcome measure, the SR-RMI was dichotomised as “able to walk 10m or 
more with an aid if necessary but no standby help” (“yes” or “no”). 
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1. Do you turn over from your back to your side without help? 
2. From lying in bed, are you able to get up to sit on the edge of the bed on 
your own? 
3. Could you sit on the edge of the bed without holding on for 10 seconds? 
4. Can you (using hands and an aid if necessary) stand up from a chair in less 
than 15 seconds, and stand there for 15 seconds 
5. Observe patient standing for 10 seconds without any aid. 
6. Are you able to move from bed to chair and back without any help? 
7. Can you walk 10 metres with an aid if necessary but with no standby 
help? 
8. Can you manage a flight of steps alone, without help? 
9. Do you walk around outside alone, on pavements? 
10. Can you walk 10 metres inside with no calliper, splint or aid and no standby 
help? 
11. If you drop something on the floor, can you manage to walk 5 metres to 
pick it up and walk back? 
12. Can you walk over uneven ground (grass, gravel, dirt, snow or ice) without 
help? 
13. Can you get in and out of a shower or bath unsupervised, and wash 
yourself? 
14. Are you able to climb up and down four steps with no rail but using an aid 
if necessary? 
15. Could you run 10 metres in 4 seconds without limping? (A fast walk is 
acceptable.) 
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Appendix E. Flow diagram summarising the process of 
image analysis 
Figure E.1. Summary of the process of imaging analysis in the DARS trial. 
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Image quality 
1. All images normal? 
2. Any acute ischaemia? 3. Side of ischaemia 
4. Classify features 
of early ischaemia 
5 Size and site 
of acute infarct 
5a Tissue swelling 
5b MCA ischaemia 5c Size and site 
of MCA lesion 
5d ACA ischaemia 
5e PCA ischaemia 
5f Lacunar infarcts 
5g Border zone infarcts 
5h Cerebellar infarcts 
5h Brainstem infarcts 
6 ASPECTS score 7 Abnormal vessel 
sign 
8 Any haemorrhage 
(indicate location) 
9 Volume, hydrocephalus, 
intraventricular extension, midline shift 
10 Type and maximum diameter 
11 Does haemorrhage contribute 
to overall burden of brain injury? 
12 White matter lesions 
13 Second (minor) acute infarct 
14 Old vascular lesion 
15 Non-stroke lesion 
End 
Yes Yes 
Yes 
No 
No 
No 
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Appendix F. CT Image Interpretation Case Report Form 
The CT Image Interpretation Case Report Form. One form was completed for 
every scan analysed. This protocol was developed by Wardlaw et al for use 
in the Third International Stroke Trial (Wardlaw and Sellar, 1994). 
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“Job done.” 
- Bipin Bhakta 
